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Abstract 
Impulsivity is a pathological feature of drug addiction. Amphetamine is a highly addictive drug 
that is amongst the most harmful recreational drugs abused within the UK (Nutt, King, & 
Phillips, 2010). Interestingly, however, amphetamine has a paradoxical relationship with 
impulsivity and can both alleviate and induce impulsive behaviour depending on pre-baseline 
levels of impulsivity and the dimension of impulsivity that is being measured. The current 
thesis sought to investigate the relationship between different patterns of amphetamine 
administration and impulsivity in the form of behavioural inhibition, and the neural substrates 
of amphetamine induced behavioural disinhibition, using the symmetrically reinforced Go/No-
go task in rats (Harrison, Everitt, & Robbins, 1999). To assess the effects of different patterns 
of amphetamine administration on behavioural inhibition, separate groups of rats were 
treated with subchronic (4-day) and chronic (11-day) amphetamine and were tested on the 
Go/No-go task during drug treatment and drug withdrawal. Following two weeks of drug 
withdrawal, sensitivity to the acute effects of amphetamine in rats was tested with acute drug 
challenges. To assess the role of nucleus accumbens core D2 and GABAA receptors in the 
mediation of behavioural inhibition and amphetamine-induced behavioural disinhibition, 
separate groups of rats were also treated with intra-nucleus accumbens core infusions of the 
D2 antagonist eticlopride and GABAA agonist muscimol. Results revealed that short duration 
and high frequency binge-like amphetamine administration produced longer term increases in 
behavioural disinhibition than longer term and less frequent but overall higher dosing of 
amphetamine in rats. However, neither the binge-like (4-day) or longer term amphetamine 
regimes (11-day) caused any enduring changes in sensitivity to the acute disinhibitory effects 
of amphetamine in rats. Infusions of either eticlopride or muscimol into the NAcb core had no 
effect on behavioural inhibition assessed under baseline conditions, however, eticlopride 
infusions produced full behavioural reversal of amphetamine induced behavioural disinhibition 
and muscimol infusions produced partial reversal of amphetamine induced behavioural 
disinhibition. Taken together, these results demonstrate that different patterns of 
amphetamine administration produce different effects on the duration of behavioural 
disinhibition in rats, and further, that amphetamine induced activation of the D2 receptors 
within the nucleus accumbens core mediates amphetamine induced behavioural disinhibition 
on the symmetrically reinforced Go/No-go task. Results additionally support the possibility of 
dopamine-GABA interactions in the mediation of amphetamine induced behavioural 
disinhibition on the symmetrically reinforced Go/No-go task in rats.  
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Chapter 1 General Introduction 
1.1The global problem of Drug Addiction 
Drug addiction is a wide-spread global health pandemic. Approximately 230 million people 
world-wide (accounting for 5% of the global population) have been estimated to use illicit 
drugs whilst approximately 12% of this figure, equating to 27 million, are dependent on illegal 
drugs (World Drug Report (WDR), 2012). The cost associated with treating this level of drug 
use and dependency amongst users has been placed at between £128-160 billion (WDR, 2012) 
and within the UK the social economic cost of addiction has been estimated at 15.4 billion 
(National Treatment Agency for Substance Misuse (NTA), 2012). More specifically, the costs 
associated with treatment of drug dependence within the NHS are estimated at £488 million 
per year, whilst every drug user not gaining treatment costs the tax payer roughly £26,074 per 
year in crimes (NTA, 2012).  
The health consequences of drug use and dependence span a range of severe mental and 
physical health problems including depression, anxiety, psychosis, infectious diseases and 
cancer. Co-morbidity of mental health problems and drug use is extremely high, with 70% of 
patients in drug treatment services, and 86% of patients in alcohol treatment services, 
diagnosed with an additional mental health problem in the UK (NTA, 2012). Drug addiction also 
feeds mortality rates associated with leading global health burdens including cardiovascular 
disease, pulmonary disease, cancers and blood borne infections (HIV/AIDS, Hepatitis B/C, 
Tuberculosis (TB), Ineffective endocarditis) (Global Burden of Disease Study (GBD), 2010). The 
impact of drug use on mortality is demonstrated by figures reporting an increase in drug use 
globally of approximately 50 million alongside an increase in global drug related deaths by 
191.2% between 1990-2010 (WDR, 2004; 2012; GBD, 2010). 
In addition to the severe health impact of drug use, the illegal setting surrounding the misuse 
of addictive drugs, places drug use and dependence intrinsically with criminal activity. 
Maintaining drug use during dependence is often fuelled through criminal activity including 
robbery, theft and fraud. The magnitude of criminal activity associated with drug use and 
dependence is illustrated by statistics reporting that within the UK 90% of the social economic 
costs of drug abuse are accountable to the costs of drug related crimes, estimated at 
approximately £13.9 billion (NTA, 2012). Illicit drug use and dependence therefore poses a 
huge monetary, health and social burden within the UK, and throughout the world.  
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1.1.1 The problem of Amphetamine and Amphetamine-Type-Stimulant (ATS) 
Misuse and Dependence: Global and UK statistics 
Amphetamine type stimulants (ATS) (excluding ecstasy (MDMA)) are the second most 
frequently used illicit drug group after cannabis world-wide, with up to 1.2% of the adult 
population (15-64 years) consuming ATS (WDR, 2012). Over the past 20 years amphetamine 
and ATS use has grown to equalise the use of cocaine and opiates combined world-wide, 
raising concerns that amphetamine and ATS use may exceed cocaine and opiate use in the 
future (WRD, 2004; 2009; 2010; 2012). This would prospectively place amphetamine and ATS 
use above two of the world’s largest drug markets combined. Corresponding with this 
increased use, global seizures of ATS have increased from 2002-2010, with methamphetamine 
(MA) showing the steepest recent increase from 2007-2010 (WDR, 2012). In addition, a 44% 
increase in amphetamine laboratories was detected in Europe from 2009 to 2010 (WDR, 
2012), indicating that the production of amphetamine in Europe nearly doubled within one 
year.  
Amphetamine and ATS are amongst the most commonly misused illegal drug groups in 
England. In 2011, 800,000 adults reported use of amphetamines and 300,000 young people 
aged between 16-24 reported use of amphetamine and ATS (both figures inclusive of MDMA) 
(Crime Survey for England and Wales (CSEW), 2012). Outside of household surveys, The Drug 
Treatment Research Outcomes Study (DTORS) surveying 1,796 drug users seeking treatment 
within community based services found that that ‘unprescribed amphetamines’ were the 5th 
most prevalent drug of primary use at baseline, and were the 6th most prevalent problem drug 
at baseline (Donmall et al., 2012). Injection of amphetamine is also prevalent amongst 
problem drug users with crack cocaine and heroin dependence. Hope et al., (2008) found that 
from a sample of crack and heroin users 13% reported injecting amphetamine. Amphetamine 
use is also highly prevalent within the UK prison population. A large sample of 1009 male adult 
prisoners found that amongst the 55% of this sample that reported drug use in prison, 
amphetamine use was the most prevalently misused drug with 75% of this sample reporting 
use of amphetamine, followed by cocaine at 69% and heroin at 58% (Strang et al., 2006). 
Dependence and illegal use of ATS is also highly prevalent within the UK. The CSEW found that 
out of the 800,000 adults reporting use of amphetamines 500,000 of this figure represent 
MDMA use, and out of the 300,000 young people aged between 16-24 reporting use of 
amphetamine and ATS’s, 200,000 of this figure represents MDMA (CSEW, 2012). Furthermore, 
club drug clinics within the UK that treat dependence to ATS’s such as, MDMA, MA and 
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methadrone, have also reported an increase in the number of young adults and adults in 
treatment for club drug dependence between 2005-2012 (Club Drugs Report, NTA, 2012).  
In addition to the misuse of illegal street amphetamine and ATS’s, misuse and diversion of 
prescription amphetamines and ATS’s is also rising globally and within the UK. Misuse of 
prescription amphetamines and ATS’s within the USA is highly prevalent, with 13% of young 
adults (18 – 25 years) in the USA using prescription stimulants for non-medical purposes 
(National Survey on Drug Use and Health, 2011). This trend is most prevalent amongst college 
students and the magnitude of this problem is demonstrated by one study reporting that 
amongst a sample of 9,161 American college students the misuse of prescription 
amphetamines used to treat ADHD (Adderall, Ritalin) actually exceeded the use of prescription 
amphetamines amongst students with ADHD (McCabe, Teter, & Boyd, 2006). There is also 
evidence of rising amphetamine and ATS misuse within the UK. Sumnall et al. (2008) refer to 
an unpublished survey conducted by the authors finding a lifetime prevalence of illicit 
methylphenidate (MPH; Ritalin) use amongst 31% young people, second only to cannabis 
misuse. These findings therefore illustrate trends in diversion and misuse of prescription 
amphetamine and ATSs globally and within the UK, and highlight potential pathways to 
amphetamine misuse and dependence.  
Collectively, the literature reviewed in this section demonstrates that amphetamine 
dependence and misuse of ATS’s is a current problem globally. Amphetamine dependence is a 
severely debilitating syndrome that has been likened to heroin and crack cocaine dependence 
(Churchill et al., 1993; Kramer, Fischman, & Littlefield, 1967). The withdrawal syndrome 
associated with psychostimulant dependence is typically defined by depression, tiredness, 
lethargy, insomnia, paranoia, psychosis and increase the risk of suicide (Barr, Markou, & 
Phillips, 2002). Consequently, amphetamine withdrawal is very difficult to treat and half of 
amphetamine users go into remission within the first year of abstinence (Calabria et al., 2010). 
Despite the prevalence and deleterious health consequences of amphetamine use, there 
remains no effective treatment for amphetamine dependence, defined by successful relapse 
prevention. Consequently, there is a demand to explore the consequences of amphetamine 
use and dependence that may render drug users more vulnerable to relapse and poor 
abstinence rates. Furthermore, exploration of the neural systems underlying amphetamine 
dependence is a clear research priority in order to identify targets of potential pharmacological 
treatment.   
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1.2Amphetamine: Definitions and Pharmacology 
1.2.1.1 Structural properties 
Amphetamine is a synthetic psychostimulant containing a phenyl ring bonded to a three-
carbon side chain substituted with an amine group at the 2-carbon (IUPAC: 1-phenylpropan-2-
amine). The core presence of a phenyl ring, two-carbon side chain and amine group at the 2-
carbon represents the molecular structure of β-phentylamine. Amphetamine is therefore 
classified as a β-phenthylamine and can also be defined as a β-phenthylamine containing an α-
methyl group (α-methylphenthylamine). The 2-carbon in amphetamine is chiral and created 
two enantiomers of amphetamine; (S) dextro- and (R) levo- amphetamine. 
1.2.1.2 Overview of amphetamine pharmacology  
Amphetamine induces feelings of euphoria, increased energy, alertness, anorexia, insomnia 
and, at high doses, can cause auditory and visual hallucinations known as ‘amphetamine 
psychosis’ (Curran, Byrappa, & Mcbride, 2004; Leonard, 2004). These symptoms are a 
consequence of increased synaptic dopamine (DA), noradrenaline (NA) and serotonin (5-HT), 
that in turn increase signal activity within these neurotransmitter circuits. The primary 
molecular targets of amphetamine that elevate synaptic catecholamine concentration are 
plasma membrane transporters responsible for the reuptake of dopamine (DAT), noradrenalin 
(NAT) and serotonin (SERT), and vesicular monoamine transporters (VMAT). Amphetamine 
binds competitively to reuptake transporters and consequently inhibits the reuptake of DA, NA 
and 5-HT and increases synaptic neurotransmitter levels (Kuczenski & Segal, 1989; Segal & 
Kuczenski, 1994; Sulzer et al., 2005). Acting as a substrate at reuptake transporters also allows 
amphetamine to receive direct passage through reuptake transporters from the synapse into 
the nerve terminal in place of DA, NA and 5-HT. Additionally amphetamine is lipophillic and 
can diffuse across the cell membrane, creating two direct pathways to enter the cytosol (Kahlig 
et al., 2005; Sulzer et al., 1995). Once inside the nerve terminal, amphetamine competitively 
binds to VMAT1 and VMAT2 (Peter et al., 1994), inhibiting the packaging of cytosolic DA, NA 
and 5-HT into vesicles. Alongside additional molecular actions of amphetamine, including 
vesicle rupture, MAO inhibition, DAT and NA trafficking, and enhanced DA synthesis, 
collectively, these molecular actions ultimately lead to a high concentration of unpackaged 
neurotransmitter within the nerve terminal. This concentration coupled with changes in 
membrane transporter permeability drives the release of DA, NA and 5-HT from the nerve 
terminal into the synapse via membrane transporters, and is termed amphetamine induced 
‘reverse transport’. Consequently, amphetamine is termed a catecholamine ‘releaser’.  
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1.2.1.3 Binding affinity 
D-amphetamine has a high affinity for the DAT and NAT, and a weak affinity for SERT (for 
review see Heal et al., 2013). L-amphetamine has a much lower affinity for DAT in comparison 
to d-amphetamine and has no significant affinity for SERT. L-amphetamine however has a 
greater affinity for NET than d-amphetamine (Heal et al., 2013). Due to l-amphetamine 
showing low affinity for DAT, it has a low potential for abuse and induction of addictive 
behaviours (Jasinski, 1991; Schechter & Rosecrans, 1973; Schechter, 1978). For the remainder 
of this section, the pharmacology of d-amphetamine will be considered due to d-amphetamine 
being the focus of this thesis and of greater abuse potential to l-amphetamine. Unless 
otherwise stated, ‘amphetamine’ henceforth refers to d-amphetamine. 
1.2.2 Amphetamine-type Stimulants: Definitions and pharmacology 
‘Amphetamine-type stimulants’ (ATS) is a collective term for stimulants that are substituted 
amphetamines. Amphetamine can be substituted at the aromatic ring, the α and β carbons 
and the amine terminal. This consequently enables a range of structural combinations that ATS 
can form. Due to amphetamine and ATS containing the same structural core, all ATS act as 
central and peripheral nervous system stimulants via activating DA, NA and 5HT release. The 
affinity of ATS at catecholamine receptors, however, varies between ATS depending on their 
structural substitution. All ATS therefore act as psychostimulants to increase wakefulness and 
alertness; however the strength of these stimulatory effects varies between ATS. Structural 
changes between ATS also produce differences in the effects of ATS. For example, ring-
substituted amphetamines such as MDMA and methylenedioxyamphetamine (MDA) are 
associated with low stimulant effects but high empathogenic and hallucinogenic effects, whilst 
substitutions at the N-terminus, such as methamphetamine (MA) and cathinone, are 
associated with similar psychomotor and anorectic effects to amphetamine (Carvalho et al., 
2012). 
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1.3Key stages of drug addiction 
Drug addiction has been conceptualised as a ‘chronically relapsing disorder’, whereby as drug 
use increases, a transition from impulsive to compulsive drug use emerges, driving a state of 
uncontrollable and chronic relapse (Koob & Le Moal, 2008). The transition into this state is 
thought to occur through distinct stages that include initiation, acquisition, maintenance, 
escalation, abstinence and relapse.  
 
Initiation refers to the first time engagement with a drug and acquisition marks the transition 
from this stage in a phase of regular drug use, such as weekly use (Perry, 2008). Following 
acquisition maintenance marks a phase of steady and regular drug use (Perry, 2008). In 
contrast, escalation refers to increased frequency and quantity of drug use that is reflective of 
a loss of control over drug use. This stage marks the transition from controlled to uncontrolled 
levels of drug use (Perry, 2008). Following the cessation of drug use, a phase of abstinence 
begins. This stage in addiction marks the period where users refrain from engaging in drug use, 
which may be of short or long duration. Subsequently, relapse defines the transition from 
abstinence to the engagement with drug use again (Perry, 2008).  
 
A variety of biological (genetics, neuroadaptive changes), psychological (psychopathology, 
personality traits) and social (stressful life events, environmental cues, socioeconomic status) 
risk factors can interact with any or all of these stages of addiction to increase vulnerability to 
the development of drug addiction. One of the most prevalent risk factors throughout all 
stages of addiction however is stress (Miczek et al., 2004; Piazza & Le Moal, 1996; Ramsey & 
Van Ree, 1993; Shaham, Erb, & Stewart, 2000; Stewart, 2000). In addition, common risk factors 
of relapse during the later stages of addiction include intense drug craving, greater sensitivity 
and reactivity to drug cues and the aversive state of drug withdrawal (Cook et al., 2010; Koob 
& Le Moal, 2008; Marra et al., 1998; Niaura et al., 1988; Robinson & Berridge, 1993; Rohsenow 
et al., 1991). Alongside these common risk factors, greater levels of impulsivity can increase 
vulnerability to addiction through reducing inhibitory control over the magnitude of these 
highly emotive states (Jentsch & Taylor, 1999). 
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1.4Theories of Addiction 
1.4.1 Incentive-Sensitisation Theory of Addiction 
The incentive-sensitization theory of addiction (Robinson & Berridge, 1993) addresses central 
facets of addiction involving craving, relapse and drug induced neural adaptations. Robinson 
and Berridge (1993) propose that all drugs of abuse share a common neural target of the 
mesolimbic dopamine system that is responsible for controlling motivation and reward 
processes. The mesolimbic dopamine system is also proposed to mediate the subjective 
experience of ‘wanting’, but not ‘liking’, of drugs and associated stimuli (cues) via elevating the 
incentive value attached to these stimuli. Drugs and drug cues are therefore rendered highly 
attractive due to enhanced incentive value. It is proposed that the continuous activation of this 
pathway through repeated drug use produces neural adaptations that render this system 
‘hypersensitive’, or ‘sensitized’, to the incentive value of drug reward and drug cues. 
Consequently, sensitization of the mesolimbic dopamine system leads to a pathological state 
of drug ‘craving’, whereby increased attractiveness (salience) of drugs and conditioned drug 
stimuli drives pathological ‘wanting’. Sensitization to the incentive value of rewards is 
proposed to persist long-term due to enduring alterations in brain reward and motivation (DA) 
circuitry. Consequently, enduring neural alterations that cause heightened sensitivity to the 
incentive value of drugs and drug cues are proposed to underlay relapse even after a 
prolonged period of drug abstinence (See Fig. 1.1). Incentive-sensitization is also proposed to 
interact with drug induce changes in fronto-striatal systems that can compromise inhibitory 
control over drug cravings (Jentsch & Taylor, 1999) and compromise cognitive choice that 
renders drug users biased to disadvantageous decision-making when coupled with 
pathological drug cravings (Bechara, Dolan, & Hindes, 2002; Robinson & Berridge, 2008) 
The central component to the ‘incentive-sensitization’ theory of drug addiction is that drugs of 
abuse sensitize the incentive value of drugs and drug related stimuli. Consequently, evidence 
for this theory is taken principally from the investigation of behavioural and neural 
sensitization to drug and drug related cues. 
  
8 
 
Drug use activates the mesolimbic dopamine 
system. This system mediates the incentive value, 
or ‘wanting’, of drugs and associated stimuli (cues).
Increased dopamine release during  drug 
intoxication leads to an increase in the incentive 
value or ‘wanting’ of the drug and drug cues.
Repeated dug use leads to neuroadaptations 
within the mesolimbic dopamine system that 
render the system ‘sensitized’ to the incentive 
value of drugs and drug cues.
Sensitization of the mesolimbic dopamine system 
heightens the incentive value of drugs and drug 
cues . This creates a pathological state of ‘wanting’ 
drugs, and is observed as craving  amongst addicts.
Drug induced neuroadaptive changes in the form 
of a sensitised mesolimbic dopamine system 
elevates the incentive value , or ‘wanting’, of drugs. 
These neuroadaptations are the underlying neural 
basis of drug craving and relapse observed 
amongst addicts , fuelling the addiction cycle.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.1.1 Sensitization in Humans 
Evidence of behavioural and neural sensitization as a consequence of drug use in humans has 
been demonstrated by Boileau et al., (2006, 2007). Boileau et al., (2006) found that repeated 
amphetamine exposure in healthy volunteers produced increased eye bink reactions and 
increased dopamine release in the striatum in response to amphetamine up to 1 year 
following their first amphetamine dose. This study therefore demonstrates that repeated 
amphetamine treatment in healthy subjects can cause enduring behavioural and neural 
sensitization. More specifically, neurochemical sensitivity within dopaminergic circuitry 
supports drug induced sensitization of the mesolimbic dopamine system. In addition, cues 
Figure 1.1: Flow diagram summarising key points in the incentive-sensitization theory of 
addiction. 
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associated with amphetamine can increase dopamine transmission within the ventral striatum 
and putamen within healthy controls (Boileau et al., 2007), expanding evidence of dopamine 
sensitivity to drug cues as well as the acute pharmacological effect of drugs.  
The mesolimbic dopamine system is also assumed to mediate the psychomotor effects of 
drugs, such as enhanced locomotor activity, rotational behaviour and stereotyped patterns of 
behaviour (Wise & Bozarth, 1987). Consequently, a common indirect method of assessing 
sensitization of addictive drugs in animal models is through measuring psychomotor 
sensitization following drug exposure. Increased locomotor and stereotypy in response to 
repeated drug exposure is a well established phenomenon amongst psychomotor stimulants, 
including amphetamine, cocaine, methylphenidate, methamphetamine, nicotine, MDMA 
(Benwell & Balfour, 1992; Kalivas, Duffy, & White, 1998; Kuczenski & Segal, 1997; Pierce, Bell, 
Duffy, & Kalivas, 1996; Pierce & Kalivas, 1997; Segal & Kuczenski, 1997; Segal & Mandell, 1974; 
Shuster et al., 1982) and amongst non-stimulant drugs including morphine and alcohol (Crow, 
McWilliams, & Ley, 1979; Kalivas & Duffy, 1987). However, more direct evidence for incentive-
sensitization comes from animal models measuring the incentive value of drug paired stimuli 
(cues) following repeated drug exposure. Assessment of behavioural motivation to seek and 
respond for drug paired stimuli allows for investigation of the incentive properties caused by 
primary drug reinforcement.  
1.4.1.2 Behavioural sensitization to reward cues: Animal Studies 
There is a wealth of evidence demonstrating that repeated administration of psychostimulants 
including amphetamine, cocaine and nicotine leads to increased pavlovian conditioned 
approach behaviour and increased sign-tracking of stimuli associated with the delivery of food 
reward  (Doremus-Fitzwater & Spear, 2011; Hall & Gulley, 2011; Palmatier et al., 2013; Shiflett, 
2012; Taylor & Jentsch, 2001). Amphetamine sensitization can also increase pavlovian-
instrumental transfer (PIT) in comparison to saline treated animals. Wyvell & Berridge (2001) 
found that amphetamine sensitization can increase instrumental responding for a food-
associated cue under extinction conditions in comparison to saline treated animals. This 
demonstrates that amphetamine can boost the incentive value of a natural reward cue to 
produce elevated instrumental responding for the cue even under extinction conditions. 
Amphetamine sensitization can also impair out-come specific pavlovian-instrumental transfer 
(Hall and Gulley, 2011; Shiflett, 2012). These findings have been interpreted to represent an 
amphetamine induced increase in transfer of general pavlovian associated incentive 
motivation of reward, such that specific PIT is superseded (Shiflett, 2012) Additionally, animals 
treated with a sensitizing regime of cocaine alongside conditioning with a cocaine-paired 
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stimulus, can acquire a novel instrumental procedure quicker than saline treated animals (Di 
Ciano, 2007). This indicates that drug cues can act as conditioned reinforcers in their own right 
to aid learning of novel instrumental behaviour. These studies collectively demonstrate that 
sensitisation to stimulants, and in particular amphetamine, can increase the incentive value, or 
‘wanting’, for reward cues. 
Rats treated with a methamphetamine regime that reliably induces locomotor sensitisation, 
however, do not increase sign-tracking behaviour for water reward (Michaels, 2012), and 
repeated administration on MDMA in rats does not increase approach behaviour for food 
reward (Taylor & Jentsch, 2001). These findings contrarily demonstrate that not all stimulants 
induce increasing ‘wanting’ for natural reward cues.  
1.4.1.3 Dopaminergic sensitization to reward cues: Animal studies  
A central component of the incentive-sensitization theory of addiction is that addictive drugs 
induce sensitisation towards the incentive value of drug reward through increasing the 
dopamine releasing properties of addictive drugs and drug related cues. In support of this, 
increased transmission of dopamine within the ventral striatum, and specifically the nucleus 
accumbens (NAcb), has been detected alongside locomotor and cue elicited behavioural 
sensitisation (Bassareo et al., 2013; Benwell & Balfour, 1992; Robinson et al., 1988). Direct 
elevation of dopaminergic transmission within the NAcb via intra-accumbens amphetamine 
administration has also been shown to increase the incentive value of a conditioned sucrose 
cue in comparison to saline treated animals (Wyvell & Berridge, 2000), and 6-
hydroxydopamine lesions to the NAcb can severely impair acquisition, and to a lesser extent 
impair performance, within an appetitive pavlovian approach behaviour procedure (Parkinson 
et al., 2002). More recently, Bassareo et al., (2013) found that rats treated with a sensitizing 
regime of morphine developed increased approach behaviour for a drug-CS and non-drug-CS 
(food-CS), however, only increased dopamine release within the NAcb core and shell was 
simultaneously recorded during drug-CS approaches, and not non-drug-CS, demonstrating that 
only drug-CS developed increasing dopamine releasing properties. These findings draw 
attention to potential differences in dopamine evoked response in animal models measuring 
the incentive value of non-drug related cues 
1.4.1.4 Transcriptional mechanisms of enduring neural sensitization 
A further prediction of the incentive-sensitisation theory is that drugs of abuse cause enduring 
neural changes within reward circuitry that can facilitate heightened drug sensitivity even after 
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long periods of drug abstinence. Molecular changes in the induction of transcription factors, 
such as ∆FosB, within targets of the mesolimbic dopamine system have been proposed to 
underlay enduring changes in neural sensitisation (Renthal & Nestler, 2008). Chronic 
administration of stimulants and opioids induce accumulation of ∆FosB mRNA within the 
nucleus accumbens (Murphy et al., 2003; Nye et al., 1995; Nye & Nestler, 1996; Pich et al., 
1997), and due to the long-lasting half-life of the ∆FosB isoform, this induction of ∆FosB is 
suggested to act as a molecular neural mechanism of prolonged sensitization to drugs (Renthal 
& Nestler, 2008). In addition, transgenic mice with over expression of ∆FosB in the nucleus 
accumbens show increased locomotor activity in response to cocaine (Kelz et al., 1999) and 
show greater sensitivity to the reinforcing effects of cocaine (Colby et al., 2003). These studies 
demonstrate drug induced alterations at the molecular level that can produce both long-term 
neural and behavioural sensitization. 
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1.4.2 Opponent Process Theory of Addiction 
The opponent process theory of drug addiction (Koob et al., 1997; Koob & Le Moal, 2008) 
alternatively considers how neural adaptations acting to neutralise (oppose) the effects of 
drugs might lead to addiction. Conceptually, Koob and Le Moal (2008) propose that from 
initiating drug use a transition from impulsive to compulsive drug use emerges that drives a 
chronic state of drug relapse. The motivational framework of this theory builds upon Solomon 
& Corbit's (1974) proposition that opponent processes, in the form of negative feedback loops, 
are in place to regulate a normal homeostatic range of motivation. Koob and LeMoal (2008) 
expand upon this principle by proposing that an ‘antireward’ system is in place to limit 
excessive activity of reward circuitry within the central nervous system (CNS). An ‘antireward’ 
system is therefore recruited in response to drugs that directly elevate activity of the 
dopamine reward pathway. Activation of the ‘antireward’ system consequently counteracts 
the intensity of excessive dopamine activity, and therefore reward, within the CNS.  
Neuroadaptations that limit reward are proposed to manifest via ‘within-system’ and 
‘between-system’ adaptations. Within-system neuroadaptations desensitise the dopamine 
reward pathway in attempt to counter act excessive dopamine activity at a cellular level. 
Between-system adaptations recruit neural stress and emotion systems in attempt to further 
limit reward through the production of negative reinforcement. Recruitment of the antireward 
system however comes with a homeostatic pay off that is an elevation in the brains reward 
‘set point’. Elevation in reward ‘set point’ consequently means that a larger quantity of a drug 
is required in order to achieve the threshold for experiencing reward. This is commonly 
observed as tolerance during the escalation and maintenance of drug dependence amongst 
addicts. Continuous use of drugs is therefore proposed to drive a feed-forward shift from a 
homeostatic to an allostatic reward ‘set point’ (See Fig. 1.2). The persistence of an allostatic 
reward state, alongside increased sensitivity of stress and affective circuitry consequently 
creates a highly aversive affective state and persistent change in motivation that drives 
compulsive drug seeking and taking behaviour in the attempt to alleviate this highly aversive 
state of drug dependence (Koob and LeMoal, 2008). In following, the opponent process theory 
addresses how hallmark features of addiction such as tolerance, and the negative affective 
state of drug withdrawal, contribute towards the compulsive state of drug dependence. 
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Drug use increases reward levels within the CNS.
Repeated drug use induces excessive elevations in reward 
levels that activates the ‘antireward’ system. This system 
limits reward within a normal homoeostatic range.
The antireward system limits reward through ‘within-
system’ and ‘between system’ changes.  Within-system 
changes are physiological changes that counteract 
excessive activity within the neural system directly 
targeted by drug use, for example dopamine. Between-
system changes are changes in the function of systems not 
directly targeted by drug use in order to reduce reward 
elevations, for example stress systems.
The threshold of activation to experience reward in the 
brain is known as the brain reward ‘set point’. In order to 
limit  excessive drug induced reward levels an upwards 
shift in reward ‘set point’ occurs. 
Continuous activation of the brains antireward system 
over the course of repeated drug use drives an upwards 
shift in reward set point and leads to an ‘allostatic’ reward 
set point. This state represents a chronic deviation in the 
threshold of activation to experience reward . The 
development of this state means that drug users require 
higher drug doses to experience reward. This is observed 
as the development of tolerance amongst addicts.
The development of an allostatic reward state creates a 
negative affective state and persistence change in 
motivation that drives compulsive drug seeking and taking 
behaviour amongst drug addicts.  
Conceptual Framework: Opponent processes exist within the CNS that counteract excessive affective and hedonic activity. 
  
 
 
1.4.2.1 Within-system neuroadaptations: Human literature 
There is considerable evidence from human literature that chronic use of addictive drugs can 
downregulate activity of the mesolimbic dopamine system, and that such downregulation can 
persist long-term. For example, cocaine dependent subjects show blunted alpha-methyl-para-
tyrosine (AMPT) induced increase in binding of the D2/3 antagonist raclopride in comparison to 
controls (Martinez et al., 2009) indicating that cocaine dependent users have reduced 
endogenous dopamine transmission at the D2/3 receptors within the striatum. Cocaine 
dependent subjects also show a blunted response to amphetamine induced reductions in 
raclopride binding within the striatum in comparison to controls (Martinez et al., 2007) 
indicating reduced drug induced pre-synaptic dopamine release within the striatum amongst 
cocaine users. Downregulation of the dopamine D2/3 receptors within the striatum and ventral 
striatum is also prevalent amongst stimulant dependent users and detoxified abstinent users. 
Methamphetamine dependent subjects also show reduced D2/3 receptors binding within 
ventral striatum using the D2/3 antagonist fallypride (Lee et al., 2009). In addition, there is a 
positive correlation between D2/3 receptor availability in the ventral striatum and craving in 
smokers (Fehr et al., 2008) linking reduced activity at the D2/3 receptors within the ventral 
striatum with an important motivational variable in the maintenance of drug use.  
Figure 1.2: Flow diagram summarising key points in the opponent process theory of drug 
addiction. 
14 
 
Ex-cocaine and methamphetamine users also continue to display reduced D2/3 receptor 
availability into protracted drug withdrawal and into long-term abstinence, supporting that 
within-system hypo-functioning dopamine is an observable long-term neuroadaptations in 
drug addicts. Detoxified cocaine subjects display reduced cocaine uptake and a blunted 
dopamine response within the striatum following MPH (Volkow et al., 1996, 1997). Abstinent 
methamphetamine subjects (abstinence range 2 weeks up to ~ 3 years) also display reduced 
D2/3 receptor availability within the striatum in comparison to healthy controls (McCann et al., 
1998; Volkow et al., 2001), supporting long-term downregulation of the D2/3 receptors within 
the striatum amongst stimulant addicts. However, there is also evidence of some functional 
dopamine recovery following long-term drug abstinence, for example, abstinent 
methamphetamine users display increased striatal DAT density at 12-17 months of abstinence 
in comparison to 1 month of abstinence (Volkow et al., 2001). Striatal DAT recovery was also 
correlated with duration of methamphetamine abstinence (Volkow et al., 2001) and reduced 
striatal DAT density has been correlated with years of methamphetamine use (Volkow et al., 
2001). Such abstinence associated recovery, and striatal DAT association with years of 
methamphetamine use, supports the notion that downregulation of dopamine function is a 
long-term neuroadaptation in association with drug exposure and is not necessarily a 
consequence of a pre-disposing neural state. Collectively, these studies support, firstly, 
downregulation of the mesolimbic dopamine pathway amongst chronic drug users, and 
secondly, the persistence of such dopaminergic downregulation long-term. 
1.4.2.2 Within-system neuroadaptations: Animal literature 
Evidence for the recruitment of neural opponent processes that can counteract drug induced 
reward is largely supported by animal models of intracranial self-stimulation (ICSS). 
Administration of many drugs of abuse can lower reward thresholds during drug treatment 
and elevate reward thresholds following the termination of drug treatment (Harrison and 
Markou, 2001; Kornetsky & Esposito, 1979; Markou & Koob, 1991; Paterson, Myers, & 
Markou, 2000; Schulteis et al., 1995; Wise & Munn, 1995). Drug induced reductions in reward 
thresholds are thought to reflect the high rewarding properties of the administered drug, 
resulting in reduced demand for ICSS. Elevated reward thresholds during drug abstinence are 
believed to be the result of opposing neuroadaptive responses to excessive drug induced 
reward, thus producing reduced sensitivity to previously reinforcing levels of electrical brain 
stimulation. Such changes therefore indicate a change in reward ‘set point’ as predicted by the 
opponent-process theory. Animals treated with long-access (11 hours) to drug self-
administration also show reduced sensitivity to the reinforcing effects of the administered 
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drug long-term, indicating persistent changes in reward ‘set point’ following long access to 
drug self-administration (Ahmed & Koob, 1999). In addition, animals exposed to long-access (6 
hours) drug self-administration develop an increase in break point during progressive ratio 
procedures (Paterson & Markou, 2003) and continue to self-administer more drug than 
controls even when this is paired with an aversive outcome, such as foot shock, (Ahmed, 
Walker, & Koob, 2000) indicating that drugs cause significant increases in the motivation to 
gain drug reward.  
In addition to ICSS, measurement of neural adaptations following chronic drug exposure can 
now be measured using animal PET scans. Such methods are also useful for providing more 
direct comparisons between animal and human studies investigating drug induced 
neuroadaptations. Chronic methamphetamine treatment in monkeys has shown reduce D2/3 
receptor and DAT binding in the striatum for up to seven weeks and reduced DAT bingeing in 
the ventral striatum for up to two weeks following drug termination (Groman et al., 2012) 
similar to reduced D2/3 receptor and DAT downregulation reported in the striatum of abstinent 
human methamphetamine users (Volkow et al., 2001; 2001). Such findings therefore support 
the hypothesis that repeated use of drugs can induce persistent neuroadaptations in 
dopamine transmission within the striatum. Interestingly, mice bred with gene knockout of 
arrestin3, a protein responsible for the internalisation of the D2 receptor, and G protein-
coupled receptor associated sorting protein (GASP-1), a protein responsible for moving 
internalised D2 receptors to lyosomes, have been shown to display increased D2/3 receptor 
binding throughout drug abstinence in comparison to wild-type mice (Skinbjerg et al., 2010; 
Thompson, Martini, & Whistler, 2010) suggesting that a physiological mechanism underlying 
reduced D2/3 receptor binding might be increased internalisation of the D2 receptor. These 
findings therefore support that downregulation of the D2 receptors persist within dopamine 
nerve cells under conditions of increased dopaminergic tone. 
1.4.2.3 Transcriptional mechanisms of enduring neural desensitization 
Changes in the expression of transcription factors in dopamine cells provide molecular 
evidence of neuroadaptations in response chronic drug use. The induction of ΔFosB via chronic 
drug administration has been linked to the induction of epigenetic changes in chromatin 
packaging in individual cells within the nucleus accumbens (Robison & Nestler, 2011). One 
example of how an epigenetic mechanism might produce long lasting changes within the 
mesolimbic dopamine pathway, and that may contribute towards the long-lasting changes in 
drug desensitisation (tolerance), is through ΔFosB desensitisation of c-fos transcription. 
Induction of ΔFosB following chronic amphetamine has been found to decrease c-fos 
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transcription via recruitment of the histone deacetylase 1 (HDAC1) to the promoter region of 
the c-fos gene (Renthal et al., 2008). The authors interpreted the behavioural significance of 
this finding in relation to tolerance of drug reward, in consideration of mutant c-fos mice 
displaying reduced sensitivity to drug induced reward (Zhang et al., 2006). In following, ΔFosB 
induced suppression of c-fos transcription via an epigenetic mechanism involving histone 
methylation within chromatin structure, may serve as an example of how nerve cells mediating 
reward within the nucleus accumbens adapt to produce long-term alterations that can limit 
reward in response to chronic drug exposure. These molecular changes therefore illustrate 
how drugs might limit the reinforcing value of drugs following chronic exposure and how these 
changes persist at a molecular level long-term.  
1.4.2.4 Between-system neuroadaptations 
Between-system adaptations are proposed to exist in the form of sensitised stress systems 
within the brain (Koob and LeMoal, 2008). Chronic drug use and withdrawal are associated 
with increased activation of the HPA axis measured by with increased plasma cortisol and 
adrenocorticotropic hormone (ACTH) in drug users (Bannan et al., 1984; Contoreggi et al., 
2003; Schluger et al., 2001). Similarly, chronic administration of many drugs can lead to an 
increase in corticotrophin-releasing factor (CRF) within the amygdala during drug 
administration and drug withdrawal in rats (Ambrosio, Sharpe, & Pilotte, 1997; Heinrichs et al., 
1995; Koob et al., 1994; Pich et al., 1995; Richter & Weiss, 1999; Sarnyai et al., 1995). Systemic 
administration of CRF antagonists can also block increased cocaine and heroin self-
administration (Goeders & Guerin, 2000; Greenwell et al., 2009) and stress (foot-shock) 
induced relapse in animal models (Koob, 2010; Le et al., 2000; Shalev, Erb, & Shaham, 2010). 
These findings therefore collectively highlight the motivational and affective value of CRF 
activity and the relationship between HPA axis activation with drug use, withdrawal and 
relapse. 
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1.4.3 Impulsivity: Definitions and Measures 
Impulsivity can broadly be defined as acting upon internal urges without forethought for the 
long-term or detrimental consequences. The converse of impulsivity has been suggested to be 
‘self-control’ (Monterosso & Ainslie, 1999), conceptualising impulsive behaviour as a lack of 
self-control to suppress internal urges in consideration of long-term or detrimental 
consequences. Whilst occasional behaviour that acts on impulsive urges can serve to produce 
positive behavioural outcome, continuous selection to act upon impulsive urges in spite of the 
associated negative consequences can lead to a state of maladaptive and dysfunctional 
behaviour, during which risky decisions and behaviours are maintained through a lack of 
impulse control and restraint. This maladaptive state of behavioural control is prominent 
amongst substance dependent individuals that are continually driven to seek out and take 
harmful drugs despite the aversive and negative consequences of such decisions and 
behaviours (Bechara et al., 2002; Goldstein & Volkow, 2002; Jentsch & Taylor, 1999). The 
clinical relevance of impulsivity to substance dependence is highlighted by the inclusion of 
several criteria relating to dysfunctional behavioural control within the ICD 10 codes, these 
include, ‘a strong desire or sense of compulsion to take the substance’, ‘difficulties in 
controlling substance-taking behaviour in terms of its onset, termination, or levels of use’ and 
‘persisting with substance use despite clear evidence of overtly harmful consequences’ (ICD-10 
Codes, 4th edition). These codes not only highlight the diagnostic relevance of impulsivity to 
addiction, but also draw attention to the importance of understanding impulsive behaviour in 
relation to the aetiology and pathology of substance dependence. Understanding the 
relationship between impulsivity and drug dependence may therefore create a pathway to 
novel treatment options for substance dependence. 
1.4.3.1 Trait Impulsivity: Self-reported Impulsivity 
Impulsivity is a prominent dimension of personality which is reflected through the prevalence 
of impulsive traits within all major models of personality (Five-factor model; Eysencks E-N-P; 
Tellegens 3 factor model). The most common measure of trait impulsivity in humans is the 
Barratt Impulsivity Scale (BIS) (Barratt & Patton, 1983).The BIS-11 is a 30 item questionnaire 
that probes for an overall score of trait impulsivity through the assessment of impulsive 
responses within three distinct sub-traits of impulsivity, these are, motor impulsivity (acting 
without thinking), non-planning impulsivity (lack of ‘futuring’ or forethought) and attentional 
impulsivity (attention and cognitive instability) (Patton & Stanford, 1995). BIS has been found 
to detected differences in trait impulsivity between current, former and recreational drug 
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users across a range of different drugs (Balodis, Potenza, & Olmstead, 2010; Clark et al., 2006; 
Lee et al., 2009; Mitchell, 1999; Moreno et al., 2012). 
Trait impulsivity is also commonly assessed by the Impulsivity Venturesomess Extraversion 
Questionnaire (IVEQ; I₇) (Eysenck et al., 1985). This questionnaire measures impulsivity as a 
two component structure placing impulsivity as a constituent trait of psychoticism and 
extraversion. The I₇ is therefore related to Eysencks three factor model of personality and 
locates trait impulsivity within psychoticism and extraversion dimensions of personality. The 
dichotomy of impulsivity aligning with psychoticism and extraversion within the I₇ broadly 
related to sub-factors of the BIS measuring for non-planning and motor impulsivity, 
respectively. However, unlike the BIS, there is no measure within the I₇ that assesses cognitive 
inflexibility (attention impulsivity). Similar to BIS, the I7 is sensitive to trait impulsivity within 
current, former and recreational drug users across a range of ages and different drugs (Clark et 
al., 2009; Morgan, 1998; Parrott, Sisk, & Turner, 2000; Sher, Bartholow, & Wood, 2000; 
Thompson et al., 2006). 
More recently, Whiteside & Lynam, (2001) proposed a four-factor model of impulsivity 
incorporating measures of impulsivity through; ‘Urgency’ (negative urgency), ‘Premeditation’ 
(lack of premeditation), ‘Perseverance’ (lack of perseverance) and Sensation seeking, 
constituting the UPPS Impulsive behaviour scale.  This four-factor model was derived from 
conducting factor analysis of ten self-report measures of trait impulsivity with 437 subjects, 
following which the ‘UPPS’ factors emerged. Negative urgency relates to the tendency to 
engage in impulsive behaviour under conditions of negative affect in order to alleviate such 
negative emotion despite potentially harmful consequences. Lack of premeditation refers to 
difficulty in thinking and reflection of the consequences of an act before engaging in an act, 
this definition maps onto personality dimensions relating to ‘impulsive choice’. Lack of 
perseverance refers to the ability to remain focused on a task that may be difficult of boring, of 
which definition can be mapped on to personality dimensions relating to ‘behavioural 
inhibition’. Sensation seeking refers to the pursuit of activities that are exciting and that may 
be dangerous and can broadly map onto other personality measures of impulsivity such as 
‘venturesomeness’. Additionally, ‘Positive Urgency’ was added to the UPPS scale to form the 
UPPS-P scale to assess impulsive behaviour related to rash and risky behaviours as a 
consequence of heightened and positive mood (Cyders et al., 2007). The UPPS is a powerful 
predictive tool of frequency and patterns of drug use across a range of different drugs 
(Coskunpinar, Dir, & Cyders, 2013; Moreno-López et al., 2012; Verdejo-García et al., 2010; 
Verdejo-García et al., 2007; Zapolski, Cyders, & Smith, 2009). 
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1.4.3.2 Behavioural Dimensions and Measures of Impulsivity 
Impulsive behaviour spans a range of behaviours that are categorised by impulsive reflection, 
relating to the ability to gather and evaluate information before making a decision (Kagan, 
1966), impulsive choice, relating to choice preference between immediate over delayed 
reward (Ainslie, 1975) and impulsive action, relating to volitional action restraint usually 
manifested through the ability to ‘wait’ to receive reward and the ability to ‘stop’ an behaviour 
once initiated.  
1.4.3.2.1 Impulsive Reflection 
Reflection impulsivity refers to the tendency to gather and evaluate information before making 
a decision (Kagan, 1966; Clark et al., 2006). Failure to sample all information before making a 
decision can bias decision making towards immediately rewarding or salient options without 
evaluation of all information (Clark et al., 2006). This bias can speed up the decision making 
process and result in rash or risky decision making based upon poor reflection of all available 
information. This dimension of impulsivity can be measured through the Matching Familiar 
Figures Test (MFFT) (Kagan, 1966) whereby subjects are required to identify an image from 
within 6 similar images that identically matches a template image. Impulsivity within this test is 
indexed through the speed to match images and accuracy, with more impulsive subjects 
producing quicker reaction times and reduced accuracy to match images due to poor 
information sampling before decision making. Children with hyperactive disorders make more 
errors on the MFFT (Sandoval, 1977) and stimulant treatment for ADHD children reduces 
errors within the MFFT reflecting improved impulsivity within child populations of poor 
inhibitory control (Brown & Sleator, 1979). 
More recently, the Information Sampling Task (IST) was developed by Clark et al., (2006) to 
measure reflection impulsivity within the adult population. The IST presents subjects with a 5 x 
5 square grid within which they must open up boxes to reveal the colour inside the box. 
Subjects are required to make a judgement on which colour is predominant throughout the 
whole grid. Within ‘fixed win’ (FW) trials subjects can open as many boxes as they wish within 
the grid before making a decision without losing points, however, within ‘decreasing win’ (DW) 
trials points correspondingly decrease as subjects select boxes to open, creating a low 
certainty to reward and high certainty to low reward condition. Consequently, the IST does not 
depend upon the speed of responding as does the MFFT, which may relate to executive or 
visual processes, in order to index impulsivity. Reflection impulsivity is assessed through the 
average number of boxes opened before making a decision of overall grid colour and the 
number of incorrect judgements, of which demonstrate a subjects requirement for sourcing 
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information before making a decision and the consequence of poorly evaluated decisions in 
relation to performance.  
1.4.3.2.2 Impulsive Choice 
Impulsive choice refers to the preference between receiving a small immediate reward or a 
large delayed reward (Ainslie, 1975). Decline in the perceived value of delayed reward over 
time can be termed ‘temporal discounting’. Greater preference for immediate reward over 
delayed reward is termed ‘impulsive’ as this choice reflects greater discounting of delayed 
reward value in preference for reward immediacy (Monterosso & Ainslie, 1999). This 
dimension of impulsivity is interlinked with cognitive decision-making processes and the 
valuation of reward based on temporal dynamics. Amongst humans and animals, temporal 
discounting functions in a hyperbolic curve (Madden et al., 1997; Mazur, 1987; Petry, 2001; 
Richards et al., 1999), whereby steep discounting exists during initial/ early intervals of time, 
reflecting generalised human and animal motivation bias to gain immediate reward, and 
shallow discounting exists through longer time delays, reflecting the existence of some long-
term reward magnitude and preference but generally to a lesser extent than immediate 
reward magnitude (Monterosso & Ainslie, 1999). Human and animal measures of impulsive 
choice can be employed through delayed reward and delay discounting task whereby the 
individual or animal is given a choice of receiving a small fixed reward immediately or a large 
delayed reward over varying delays (eg. 10, 20, 40, 60 seconds in an animal model). Impulsive 
choice can be accessed through measuring the proportion of choice for delayed reward in 
comparison to choice for immediate reward (Cardinal, Robbins, & Everitt, 2000; Evenden & 
Ryan, 1996). Another assessment of impulsive choice is through adjusting the delay (Mazur, 
1987) or adjusting the amount (magnitude) of fixed delay reinforcers (Richards, Zhang, et al., 
1999) until subjects choose both immediate and delayed reinforces equally. This point is 
referred to as the ‘indifference point’ and represents the difference, in either delay or 
reinforcer magnitude, between which choice preference is equal between immediate and 
delayed reward.  
1.4.3.2.3 Impulsive Action 
‘Impulsive action’ refers to poor behavioural restraint. Examples of this dimension of impulsive 
behaviour include acting prematurely, behaving inappropriately, and difficulty in stopping and 
changing inappropriate behaviour. This dimension of impulsivity, also termed behavioural 
disinhibition, can be assessed in humans and animals through measuring a subject’s ability to 
withhold from making a prepotent response, assessing action restraint in the form of ‘waiting’, 
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and through measuring a subject’s ability to inhibit or cancel an on-going behaviour, assessing 
restraint of initiated action in the form of ‘stopping’.  
Behavioural inhibition is commonly measured in humans using one of the following tasks: 
continuous performance task (CPT) (Cornblatt et al., 1988; Rosvold et al., 1956), the immediate 
memory task/ delayed memory task (IMT/ DMT) (Dougherty, Marsh, & Mathias, 2002), go/no-
go task (Go/No-go) (Newman, Widom, & Nathan, 1985), stop-signal task (SST) (Logan & 
Cowan, 1984).  
The CPT (Rosvold et al., 1956) assesses a subject’s ability to continuously track and respond to 
target stimuli, and appropriately inhibit responding to non-target stimuli. This task therefore 
requires both sustained attention and inhibitory control over prepotent responding for target 
stimuli. Stimuli usually consist of a series of letters of numbers (eg. AB) that are presented 
individually across trials. Following the presentation of target stimuli, for example ‘X’, subjects 
must make a correct response, recorded as a ‘correct detection’. A response made to non-
target stimuli is recorded as a ‘commission error’. Failure to respond to a trial is recorded as an 
‘omission error’. Within this task, impulsivity is indexed according to commission errors and 
attention is indexed according to omission errors.  
The IMT/DMT is a more complex variation of the CPT that was developed for use amongst non-
clinical populations with higher cognitive capacities than clinical populations with impaired 
processing (Dougherty et al., 2002). This task maintains the same framework of a CPT in that 
subjects must respond to target stimuli and inhibit responding to non-target stimuli, however, 
additional task parameters create greater memory, attention and inhibitory demands on 
subjects than a CPT. Within the IMT/DMT 2- 7 digits (eg. 20417) are presented individually 
across trials. In the IMT subjects are required to respond when the numbers currently 
presented on screen match the numbers presented in the preceding trial, this reflects a 
‘target’ (eg. 20417-20417 = target). In the DMT, three distracter stimuli are presented between 
target stimuli (eg. 20417 – 12345 – 12345- 12345 – 20417 = target). This therefore extends the 
length of time subjects must remember initial target stimuli, sustain attention and inhibit 
inappropriate/ early responding. Within both the IMT and DMT, stimuli that closely resemble 
the target stimuli are presented, termed ‘catches’ (eg. 20417-20415). Similarly to the CPT, 
impulsivity in this task is indexed according to commission errors.  
Go/No-go tasks have a similar framework to continuous performance tasks in that subjects 
must make active and passive responses depending on the presentation of particular targets. 
However, a Go/No-go task requires passive responding when signalled by specific No-go 
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stimuli, as opposed to a non-target that may span multiple stimuli. Subjects must respond as 
fast as possible to ‘Go’ stimuli and inhibit responding following the presentation of ‘No-go’ 
stimuli. In order to bias active responding in subjects, the proportion of presented Go trials is 
usually greater than that of No-go trials, to enforce prepotent responding for Go trials. Go and 
No-go stimuli may consist of numbers, letters or colours. Correct and incorrect responses are 
usually reinforced through written ‘correct’/‘incorrect’ or auditory feedback between trials 
(Fillmore et al., 2003; Verdejo-García, Perales, & Pérez-García, 2007). The proportion of 
responses made following No-go stimuli (commission errors) is used as a behavioural index of 
response disinhibition. High levels of commission errors within Go/No-go tasks therefore 
represent poor prepotent response inhibition.  
In contrast to the CPT, IMT/DMT and Go/No-go tasks, the stop-signal task (Logan & Cowen, 
1984) measures a subject’s ability to stop or cancel an on-going action. This dimension of 
behavioural inhibition is hypothesised to function in a ‘race model’ where inhibitory control 
processes that control ‘stopping’ on-going behaviour compete against ‘go’ processes driving 
initiated behaviour in order to determine the outcome of behaviour (Logan & Cowan, 1984; 
Logan, 1994). ‘Stop’ and ‘Go’ response mechanisms are assumed to be independent processes 
meaning that when both processes are activated a race to reach the end point of each process 
begins before the outcome behaviour can be selected by the organism. The Stop process is 
assumed to be quicker than the Go process, allowing for inhibitory control mechanisms to 
successfully inhibit an initiated behaviour under conditions where enough time is available for 
the inhibitory process to finish before the Go process. The stop-signal theory therefore builds a 
model of action cancellation whereby if an inhibitory signal is presented at close temporal 
proximity to the signal to respond stimulus it is likely that the signal to respond action will be 
successful inhibited and the signalled action ‘cancelled’, however the further away the stop 
signal is presented from the signal to respond stimulus the harder the action will be to inhibit 
because the Go process will finish before the Stop process can be fully executed. Within this 
paradigm impulsivity can therefore be indexed as an estimation of speed of the internal 
inhibitory Stop process based on the speed of responding during signal to response trials 
where no Stop signal is present and the probability of inhibition at any given delay. This 
calculation is known as the stop-signal reaction time (SSRT) and can be calculated as a function 
of Go reaction time (RT) and the probability distribution of inhibition at the stop signal delay 
(SDD). Impulsive behaviour within the stop signal paradigm is reflected in long SSRT which 
represents a slow internal inhibition processes indicating that it is difficult to inhibit or cancel 
an initiated behaviour.   
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Within the stop-signal task for humans, subjects are presented with a series of Go and Stop 
trials cued by specific stimuli. For example, a dot (•) and letter ‘X’ may represent Go and stop 
trials, respectively. Around two thirds of the trials are usually Go trials and one third Stop 
trials. During a Go trial, the Go stimulus (•) will appear on screen for brief duration of (1- 2 s) 
during which time subjects must make an active response. This encourages fast prepotent 
responding to Go trials. During a Stop trial, the Go stimulus will appear on screen (•) followed 
by the Stop stimulus (X) presented at varying delays from the presentation of the Go stimulus 
in milliseconds (eg. 100, 200, 300, 400, 500 ms). Using the Go RT and SSD, subjects SSRT can be 
calculated to index behavioural control of action cancellation. 
Behavioural inhibition in animals can be measured using operant based tasks that are 
conducted in skinner boxes. Many of these tasks employ comparable parameters to that of 
human behavioural inhibition tasks. The five choice serial reaction time task (5CSRTT) originally 
designed to measure attention (Carli et al., 1983) has been the most frequently employed in 
animal studies to measure behavioural inhibition and is comparable to continuous 
performance tasks. During this task animals are required to constantly scan an array of five 
apertures during a five second inter-trial interval (ITI) period prior to the random brief 
illumination (0.5 s) of one of the apertures. The animals then have to respond in the 
illuminated aperture to receive a food reward. Inappropriate premature responding in the 
apertures prior to the presentation of the visual stimulus is a measure of the animals 
behavioural restraint or waiting ability. High levels of premature responding indicates poor 
levels of behavioural inhibition. In addition, nose pokes made in an aperture immediately after 
a correct response are recorded as perseverative responses. This type of behaviour is thought 
to reflect an inability to stop an action despite no programmed consequence, reflecting 
compulsive repetition. 
Another method of assessing behavioural inhibition in the form of ‘waiting’ is through the 
differential reinforcement of low rates schedule (DRL) (Evenden, 1999). In this task 
reinforcement is gained through low levels of behavioural responding. Animals are required to 
nose poke an active hole following a fixed internal of time, requiring animals to successfully 
employ timing accuracy and behavioural inhibition during the fixed interval. This interval is 
called the inter-response time (IRT), and can vary according to the particular demands of an 
experiment. For example, a DRL30 schedule represents a 30 s schedule of reinforcement 
whereby nose pokes must be separated by at least 30 s. Responses made during the IRT (30 s) 
represent non-rewarded responding and are therefore used as an index of behavioural 
inhibition. Responses made during the IRT can be separated in to bins per second and used to 
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assess the distribution of premature responding as a function of time. This enables assessment 
of differential patterns of premature responding over time.  
Animal versions of the Go/No-go task are also frequently used to assess behavioural inhibition. 
Within this task animals are trained to discriminate between Go and No-go stimuli and 
respond (nose poke/ lever response) or inhibit responding, respectively. The presentation of a 
Go stimulus constitutes a Go trial and presentation of No-go stimuli constitutes a No-go trial. 
Trials are usually cued via a light stimulus, for example, light stimulus on and light stimulus off 
for Go and No-go trials, respectively (Fletcher, 1993). Reinforcement can be delivered either 
asymmetrically (food reward following correct Go trials only) (Fletcher, 1993), or symmetrically 
(food reward following correct Go and No-go trials) (Harrison et al., 1999). Go and No-go trials 
are usually presented equally across the total number of trials. Animals are initially trained to 
respond under Go trial conditions before receiving No-go trial training, consequently, 
responding during Go trials is considered the prepotent response behaviour within this task, 
and thus successful inhibition during No-go trials represents inhibition of a prepotent 
response. Impulsive behaviour within Go/No-go tasks is therefore indexed by responses made 
during No-go trials.  
Action cancellation can also be measured in rats using a rodent version of the stop-signal task 
(Eagle & Robbins, 2003). Within this task, animals are required to respond rapidly during Go 
trials and to cancel an initiated response following the presentation of a stop signal (Stop trial). 
Stop trials are presented during 20% of the stop-signal task to ensure that animals do not 
develop an inhibitory response strategy that may invalidate calculation of the SSRT. To initiate 
a Go trial animals must make a nose poke in a central food well that subsequently presents a 
lever on the left hand-side of the chamber and illumination of a light above the lever. Animals 
are required to press the left lever following which the lever is retracted and light 
extinguished. A lever on the right-hand side of the chamber is then presented and light above 
the lever is illuminated. Animals must quickly press the right lever to complete the Go trial and 
receive a food reward, representing a correct go trial. The response speed from left lever press 
to right lever press is controlled by a limited hold period. The limited hold is calculated per 
animal in relation to the time required to make a fast Go response and successful action 
cancellation, for example 1.1- 1.4 s (Eagle et al., 2011) During Stop trials animals initiate the 
trial in the same manner as a Go trial; however, following left lever press a stop-signal tone is 
presented. The delay at which the tone is presented varies depending on animals individual 
GoRT. Subsequently individual SSRT for each rat can be calculated based on individual GoRT 
and SSD.   
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1.4.3.3 Correlation between dimensions of impulsivity 
These dimensions highlight the complexity of impulsivity, such that impulsivity has been 
defined as a multidimensional construct (Evenden, 1999). The relationship between self-
report, choice and action probing measures of impulsivity has produced contrasting evidence 
over whether these dimensions are related or not. BIS and I₇ scores correlate with delay and 
probability discounting, and false alarm rate within the IMT/DMT (Richards et al., 1999; Swann 
et al., 2002) and delay discounting to loads on to overall BIS scores (Meda et al., 2009). 
However, BIS and I₇, have also been found to produce no correlation with behavioural 
measures of impulsive action and choice, including the SST, delay and probability discounting 
and IMT/DMT (Broos et al., 2012; Dougherty et al., 2009; Lane et al., 2003; Reynolds et al., 
2006). A recent meta-analysis of studies exploring the relationship between self-report and 
behavioural measures of impulsivity in humans identified a small overall correlation (r=0.097) 
between self-report and behavioural measures impulsivity in humans (Cyders & Coskunpinar, 
2011). Authors, however, concluded that generally self-report and behavioural measures do 
not correlate and that any correlation observed is usually small (Cyders & Coskunpinar, 2011).  
The relationship between different behavioural forms of impulsivity has also been found to be 
unrelated. Delay discounting and SSRT is uncorrelated in humans (Broos et al., 2012; Reynolds, 
2006) and delay discounting is uncorrelated with premature responding on the 5CSRTT within 
the same cohort of rats (Broos et al., 2012) suggesting that impulsive choice and action are 
independent behaviours. Interestingly, animals displaying high levels of impulsivity in the 
5CSRTT do not show longer SSRT in comparison to less impulsive animals (Robinson et al., 
2009), indicating that not only are impulsive choice and action dissociable, but also sub-
dimensions of impulsive action are behaviourally independent. Additionally, treatment of 
amphetamine reduces impulsive choice whilst increasing premature responding, and 
atomoxetine produces an increase in impulsive choice and decreases impulsive action within 
the same cohort of rats (Broos et al., 2012), indicating that impulsive choice and action might 
be both behaviourally and pharmacologically dissociable. Global serotonin depletion has also 
been shown to preferentially disrupt premature responding whilst remaining undisruptive to 
delay discounting in rats (Harrison, Everitt, & Robbins, 1997; Winstanley et al., 2004), 
collectively indicating that impulsive choice and action are neurally dissociable within 
dopamine, noradrenalin and serotonin systems in rats. However, Robinson et al., (2007) 
reported that atomoxetine reduces delay discounting, premature responding and stop-signal 
reaction time in separate cohorts of rats, suggesting a possible underlying noradrenalin 
relationship between these behavioural measures of impulsivity in rats. Additionally, Robinson 
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et al., (2009) reported that highly impulsive rats on the 5CSRTT also showed steeper 
discounting of delayed reward than less impulsive animals, suggesting that there might be 
some overlap in impulsive action and choice in animals that are impulsive at baseline. In 
conclusion, there appears to be support for orthogonal dimensions of impulsivity, most 
convincingly between impulsive choice and action; however, there is also evidence for some 
pharmacological overlap in animal models and behavioural overlap in animals that are highly 
impulsive. 
 
  
Figure 1.3: Diagram to depict the multi-dimensional concept of impulsivity and the tasks 
used to assess these dimensions in both humans and animals. 
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1.4.4  Impulsivity and Drug Addiction: The Relationship 
1.4.4.1 Initiation and Acquisition of Drug use 
A wealth of evidence has reported that dependent and recreational drug users have elevated 
trait impulsivity, suggesting that impulsivity might act as a predated risk factor for drug use. 
However, there is also evidence that drug use can predict changes in trait impulsivity (Quinn, 
Stappenbeck, & Fromme, 2011) therefore suggesting that drug use per se might contribute 
towards the differences in trait impulsivity observed in drug users. Longitudinal studies are 
therefore required to identify whether trait impulsivity is a pre-disposing risk factor for the 
initiation and acquisition of drug use.  
Trait impulsivity at 13 years can longitudinally predict alcohol, cigarette and illicit drug use at 
18 years and the age that alcohol, cigarette and illicit drug use was initiated within a sample of 
777 adolescent subjects (Hartman et al. 2013). More specifically, high scores of self-reported 
novelty seeking, defined as self-reported impulsive behaviour and thrill seeking, were 
associated with a younger age of first time alcohol, cigarette, illicit drug use, and greater 
experimentation with illicit drugs reported at 18 years  (Hartman et al. 2013). This indicates 
that trait impulsivity in young adolescents can increase the risk of earlier initiation with drugs 
and the likelihood of initiating experimentation with more than one drug through adolescence. 
Self-reported novelty seeking was also found to be the best predictor of reported alcohol, 
cigarette and illicit substance use at 18 years relative to personality traits that can also predict 
substance use, including, harm avoidance, reward dependence and lack of perseverance 
(Hartman et al. 2013).  
Trait impulsivity predating the initiation and acquisition of drug use can also be exemplified 
through the relationship between childhood ADHD and the risk of substance use. Adolescents 
with a diagnosis of ADHD report greater illicit drug use and daily smoking than non-ADHD 
controls and childhood symptoms of ADHD are associated with the age of first cigarette and 
illicit drug use (Molina & Pelham, 2003), indicating both greater initiation and acquisition of 
drug use amongst a population with increased impulsivity. A ten year follow up of children 
with ADHD also recently reported that ADHD at 10 years predicts cigarette smoking at 20 years 
(Wilens et al., 2011). Symptoms of hyperactivity and impulsivity, but not inattention, in 
children with ADHD at 14 years has also been found to increase the odds ratio for nicotine, 
alcohol and illicit substance use at the age of 18 years (Elkins, McGue, & Iacono, 2007). These 
studies therefore support that impulsive traits in children can longitudinally increase the 
chance of initiating drug use and risk of acquisition repeated/ daily drug use. 
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In addition to evidence that trait impulsivity can predict the initiation and acquisition of drug 
use, impulsive behaviour has also been linked to these early stages of addiction. Steep 
discounting of hypothetical monetary reward correlates with the age of first alcohol, cigarette 
and marijuana use, and the total number of illicit drugs used within a student population 
(Kollins, 2003). This suggests that the chance of initiating and experimenting with drugs might 
increase as a result of insensitivity to future rewards that might act as an incentive to prevent 
drug use initiation. Steep reward discounting in rats also predicts faster acquisition of cocaine 
self-administration in comparison to less impulsive rats (Perry et al. 2005; Perry et al. 2008) 
similarly suggesting that reduced value of delayed reward might increase the likelihood of 
acquiring drug use. However, rats that are screened for high impulsivity (HI) within delay 
discounting procedures do not differ in comparison to less impulsive rats in acquiring cocaine 
or nicotine self-administration (Broos et al. 2012b; Diergaarde et al. 2009). This suggests that 
discounting of future rewards may predispose vulnerability towards faster acquisition of drug 
use, whilst greater delay discounting per se may not be involved in this early stage of 
addiction. 
Rats displaying trait impulsivity on the 5CSRTT, defined by high levels of premature responding 
within this task, acquire nicotine and cocaine self-administration faster than rats displaying low 
levels of premature responding (Dalley et al., 2007; Diergaarde et al., 2009) suggesting that 
low levels of behavioural inhibition at baseline might increase the risk of acquiring drug use. 
Rats displaying this high impulsivity phenotype on the 5CSRTT, however, do not show any 
difference in the acquisition of MDMA self-administration in comparison to less impulsive rats 
(Bird & Schenk, 2012) and similarly, trait impulsivity measured by BIS in subjects categorised 
‘at risk’ of MDMA use does not longitudinally predict MDMA use in these subjects (de Win et 
al., 2006). This suggests that reduced behavioural inhibition might increase vulnerability to the 
acquisition of stimulants that have a high, but not low, abuse potential in humans. Subjects 
with reduced action restraint on the SST also report greater ‘satisfied’ and ‘want more’ feelings 
following acute nicotine (Perkins et al., 2008), additionally suggesting that individual 
differences in behavioural inhibition may predict greater sensitivity to nicotine following 
initiation, increasing the chance of acquisition.  
In summary, these studies support that greater trait impulsivity, impulsive choice, and 
impulsive action that predates drug use might increase the chance of initiating and acquiring 
drug use during these early stages of the addiction. 
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1.4.4.2 Maintenance 
A pattern of drug use that might be considered exemplary of the ‘maintenance’ stage is 
smoking. Smokers typically maintain a steady and regular level of nicotine intoxication 
throughout waking hours. As mentioned within the initiation/ acquisition section, ADHD status 
and impulsive symptoms amongst children with ADHD can longitudinally predict daily smoking 
and nicotine dependence (Elkins et al., 2007; Wilens et al., 2011) suggesting that greater levels 
of trait impulsivity can predict maintained drug use. Smokers from non-clinical samples also 
report greater levels of trait impulsivity than never smokers (Mitchell, 1999) and display higher 
levels hypothetical monetary discounting than ex smokers and non-smokers (Bickel, Odum, & 
Madden, 1999) suggesting that maintained drug use in non-clinical populations might also be 
associated with impulsivity.  
Animal models examining the relationship between impulsivity and maintenance have, 
however, generally indicated that higher levels of impulsive action and choice at baseline do 
not affect maintained drug self-administration. Animals screened for high and low trait 
impulsivity on the 5CSRTT do not show any difference in the number of cocaine infusions 
earned during self-administration when access to cocaine is low, for example when cocaine 
infusions are limited to phases of 40 minute access over 2.75 hours (Belin et al. 2008). 
Similarly, animals screened for high and low levels of impulsive choice within an adjusting 
delay procedure do not differ in the number of cocaine infusions earned when self-
administration is limited to 20 infusions or a limit of 2 hours (Anker et al. 2009; Perry et al., 
2005). This suggests that individual differences in impulsive action and choice might not affect 
drug use that resembles relatively controlled drug use.  Interestingly, however, rats with low 
trait impulsivity that have limited access (20 infusions per self-administration session) to 
cocaine self-administration for 14 days become more impulsive (Anker et al., 2009) suggesting 
that low levels of maintained drug use might actually increase impulsivity in low impulsive rats. 
Taken together these might suggest that whilst differences in baseline levels of impulsivity do 
not affect maintained drug use, maintained drug use itself might increase impulsivity, possibly 
in relation to baseline levels of impulsivity. 
1.4.4.3 Escalation 
Trait impulsivity measured by the I₇ and BIS can predict binge drinking and the development of 
alcohol dependence, of which both outcomes represent escalated and uncontrolled drug use 
(Carlson, Johnson, & Jacobs, 2010; Moreno et al., 2012; Sher, Bartholow, & Wood, 2000; 
Verdejo-García et al. 2007). The motor sub-scale within BIS has been found to specifically 
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correlate with the number of drinks consumed per drinking session and was found to be the 
best predictor of binge drinking within these studies (Carlson et al., 2010; Moreno et al., 2012). 
This suggests that high self-reported impulsive action, rather than forethought or attention 
measured by BIS, might act as a risk factor for escalating alcohol consumption. Similarly, a 
recent meta-analysis by Coskunpinar et al., (2013) found that ‘lack of perseverance’ within the 
UPPS scale predicts the quantity of alcohol consumed whilst all other personality dimensions 
measured by UPPS predict the frequency of drinking. This suggests that whilst overall scores of 
‘trait impulsivity’ measured by both BIS and UPPS can predict frequent drinking, escalation in 
the quantity of alcohol consumed once drinking is initiated is specifically related to reduced 
action restraint. Alcohol intoxication also acutely reduces behavioural inhibition measured by 
Go/No-go and SST tasks (Caswell, Morgan, & Duka, 2013; de Wit, Crean, & Richards, 2000; 
Fillmore & Vogel-Sprott, 1999; Ramaekers & Kuypers, 2005) but does not affect more cognitive 
dimension of impulsivity including reflection impulsivity and delay discounting procedures 
(Caswell et al., 2013; George, Rogers, & Duka, 2005; Ortner, MacDonald, & Olmstead, 2003; 
Richards, Zhang, et al., 1999). These findings again support impulsive action rather than 
cognitive dimensions of impulsivity in escalating alcohol consumption, and demonstrate that 
the acute effects of alcohol might also increase the chance of escalating alcohol consumption 
once drinking is initiated. Both increased trait impulsivity and drug induced effects on 
impulsivity might therefore increase vulnerability to escalate alcohol use. 
‘Negative Urgency’ has also been identified as a pathway to problematic drinking and 
substance dependence. Negative urgency acts as a mediator in the development of high 
quantity uncontrolled alcohol consumption that is harmful to subjects (Adams et al., 2012) and 
can predict alcohol, methamphetamine and cocaine dependence (Verdejo-García et al., 2007). 
Whilst other measures within UPPS were found correlate with and predict problem drinking 
and substance dependence, negative urgency was identified as the greatest mediator and 
predictor of both these outcomes. This indicates that escalation of alcohol and stimulant use 
to harmful and uncontrollable levels can also result through reduced impulse control that is 
driven by a negative emotional state.  
Impulsivity measured by the I₇ are is also associated with ‘heavier’ MDMA use (30- 1000 
occasions) whilst subjects that report less frequent MDMA use (0- 30 occasions) or no MDMA 
use have lower I₇ scores than subjects reporting heavy MDMA use (Parrott et al., 2000). This 
indicates that even though both these groups initiate and engage with repeated MDMA use, 
subjects with greater trait impulsivity actually escalate the frequency of their usage. Frequent 
monthly (heavy) MDMA use also correlates with reduced behavioural inhibition within the 
IMT/DMT (F Gerard Moeller et al., 2002) suggesting that subjects with reduced behavioural 
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inhibition might be more likely to escalate to heavier monthly drug use than subjects with 
better inhibitory control. Similarly, behavioural disinhibition amongst recreational cocaine 
users correlates with lifetime cocaine use (Colzato, van den Wildenberg, & Hommel, 2007) and 
the severity of cocaine use measured as a composite of years, frequency per month and dosing 
per usage is associated with more errors of commission on a Go/No-go task and can predict 
more errors on the stroop task ( erdejo-Garc  a et al., 2005; Verdejo-García et al., 2007). 
Subjects that report heavy MDMA use also have reduced reflection capacity within the MFFT 
in comparison to healthy controls, that also correlates with peak lifetime does of MDMA 
(Quednow et al., 2007). This suggests that subjects that make faster and less informed 
decisions are more likely to administer greater quantities of MDMA per dose (pill) taken.  
Greater frequency of illicit drug use and quantity of poly drug use amongst substance users 
also correlates with disadvantageous decision making within the IGT (Hanson, Luciana, & 
Sullwold, 2008). This suggests that amongst subjects that have all acquired drug use, those 
that escalate their use to a greater frequency and greater level of polydrug use, make more 
bad decisions than subjects will less frequent drug use and polydrug use. Similarly, Bechara et 
al., (2001) found that the severity of dependence calculated using a composite index of: days 
abstinent, years of dependence, episodes of treatment and employment status, correlates 
with poor performance on the IGT. This indicates that drug users that make more 
disadvantageous decisions also show more severe escalation of dependence than drug users 
with lower dependence severity. Subjects that engage in more frequent drug use, poly-drug 
use and report more severe dependence, of which all circumstances are symptomatic of 
escalated drug use, are therefore associated with poor decision making capacity relative to 
other drug users. Disadvantageous decision making during phases of escalation (increased 
frequency, quantity and duration of drug use and dependence) might then render drug users 
more likely to make choices that are associated with negative or detrimental outcomes 
resulting in fast escalation of drug use.  
Animal studies addressing the predictive role of trait impulsivity in the escalation of drug use 
have identified that rats with trait impulsivity on the 5CSRTT escalate stimulant, but not opiate, 
use at faster rate than less impulsive animals (Dalley et al., 2007; McNamara et al., 2010). Rats 
displaying this high impulsivity phenotype also display higher break point to earn stimulant 
reward during progressive ratio (PR) schedules in comparison to low impulsive animals (Belin 
et al., 2008; Diergaarde et al., 2009). Taken together, these studies might suggest that highly 
impulse rats escalate cocaine self-administration faster than low impulsive animals due to 
increased sensitivity to the reinforcing effects of cocaine. In addition, rats with trait impulsivity 
on an adjusting delay task also escalate cocaine self-administration under extended access 
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conditions at a faster rate than rats that are less impulsive at baseline (Anker et al., 2009). This 
high impulsivity phenotype within impulsive choice models can also predict amphetamine 
induced conditioned place preference (CPP) and inelastic demand for cocaine and nicotine 
(Koffarnus & Woods, 2013; Yates et al., 2012). Inelastic demand is an index of ‘essential’ value 
of a reward that is measured by consumption and not responding of reward. This further 
suggests that highly impulsive rats have greater sensitivity to the reinforcing effects of 
stimulants, and associate greater ‘essential’ value with drugs that may both leads to faster 
escalation in drug use. 
However, it is also possible that increased impulsivity observed during phases of escalation in 
dependent and non-dependent drug users is a consequence of direct disinhibitory effects of 
drugs. Administration of stimulants including amphetamine and cocaine can acutely increase 
impulsive action in stimulant dependent subjects (Fillmore, Rush, & Hays, 2002; Fillmore, Rush, 
& Marczinski, 2003) suggesting that the acute effects of these drugs in dependent subjects 
might directly contribute to reduced inhibitory control during phases of escalation or 
‘bingeing’.  Acute amphetamine also increases premature responding in rats performing the 
5CSRTT, increases SSRT and decreases No-go trial accuracy within a symmetrically reinforced 
Go/No-Go task in rats (Eagle & Robbins, 2003; van Gaalen et al., 2006; Harrison et al., In prep). 
Similarly, acute administration of cocaine and nicotine increases premature responding within 
the 5CSRTT and decreases No-go trial accuracy within a symmetrically reinforced Go/No-go 
task in rats (Kolokotroni, Rodgers, & Harrison, 2011; van Gaalen, Brueggeman, et al., 2006). 
Acute nicotine also increases impulsive choice within delayed reward and adjusting delay 
procedures in rats (Dallery & Locey, 2005; Kolokotroni et al., 2011), indicating that nicotine can 
acutely increase both impulsive action and choice. Similarly, acute morphine administered to 
rats increases behavioural disinhibition within the 5CSRTT and increases impulsive choice 
within delayed reward and adjusting amount procedures (Kieres et al., 2004; Pattij et al., 
2009). 
Such disinhibitory effects of drugs may therefore fuel greater escalation of drug use specifically 
during phases of bingeing. These drug induced effects might be particularly relevant to 
patterns of dependence typical of stimulant and opiate dependence, where the binge phase of 
the addiction cycle is very intense and significant to this pattern of drug use and dependence 
(Koob & Le Moal, 2008). However, it is noteworthy that not all stimulants increase impulsivity, 
but can acutely reduce impulsivity. Amphetamine, methamphetamine and methylphenidate 
acutely improve impulsive choice (Pitts & McKinney, 2005; Richards, Sabol, & de Wit, 1999; 
van Gaalen et al., 2006b). The direct drug induced effects in relation to impulsivity during this 
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phase of addiction is therefore particularly complex amongst stimulant drugs that exert both 
acute inhibitory and disinhibitory actions on subjects.  
In addition to the acute effects of drugs, the effects of repeated drug administration can also 
lead to direct effects on impulsivity in subjects. Long access (6 hrs) to 0.3 mg/kg infusions of 
amphetamine self-administration over 21 days reduces the mean adjusted delay (MAD) in rats 
during this phase in comparison to rats receiving short access self-administration, and these 
rats also escalated amphetamine self-administration during this phase (Gipson & Bardo, 
2009a). Non-contingent repeated cocaine administration also lowers indifference points in rats 
(Paine, Dringenberg, & Olmstead, 2003) and chronic nicotine administration increases 
impulsive action and choice in rats (Dallery & Locey, 2005; Kolokotroni, Rodgers, & Harrison, 
2012). This indicates that repeated exposure to stimulants can increase impulsive action and 
choice during phases of drug administration during which escalation of drug use takes place. 
Such disinhibitory actions following acute and chronic exposure to drugs might therefore lead 
to reduced behavioural control following initial phases of drug acquisition and might 
subsequently increase the chance of escalating drug use due to reduced control over limiting 
drug intake. 
The acute and chronic effects of drugs on impulsivity have also been shown to interact with 
baseline levels of inhibitory control, particularly amongst stimulants. This suggests that the 
combination of both baseline impulsivity and drug induced inhibitory/ disinhibitory actions 
might contribute towards escalation of drug use. For example, acute amphetamine reduces 
behavioural inhibition in subjects that exhibit low behavioural inhibition at baseline but does 
not affect inhibitory control in subjects with displaying ‘normal’ behavioural control at baseline 
(de Wit, Enggasser, & Richards, 2002; Fillmore, Kelly, & Martin, 2005). Conversely, 
amphetamine administered to stimulant users, a subject group that are more impulsive than 
controls (Clark et al., 2006), increases impulsivity in these subjects (Fillmore et al., 2003). A 
possible interpretation of amphetamine induced impulsivity amongst stimulant users and 
amphetamine induced behavioural control amongst healthy controls, is that prior drug 
exposure may alter the pharmacological-neural relationship underlying amphetamine induced 
impulsivity. This would mean that the acute effect of amphetamine might not impact the 
acquisition of amphetamine use in healthy subjects, but may be involved in disinhibited 
control during phases of bingeing (or escalation) in subjects that have already entered the 
acquisition or maintenance phases of addiction and thus have a different neural 
pharmacological-neural relationship following previous amphetamine intoxication. The acute 
effects of cocaine on impulsivity in cocaine dependent subjects also produce contrasting 
results. Low dosages of cocaine (50- 150 mg) can reduce inhibitory control in cocaine 
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dependent subjects (Fillmore et al., 2002) whilst higher dosages of 300 – 400 mg can improve 
inhibitory control in this group (Fillmore, Rush, & Hays, 2006; Garavan, Kaufman, & Hester, 
2008). These studies therefore show that the acute effect of stimulants that might contribute 
towards escalation and ‘bingeing’ within this drug group and ‘bingeing’ may relate both to 
baseline inhibitory control, prior to drug exposure, and the effects of the drug and dose 
consumed.  
In combination with elevated impulsivity predicting drug escalation, these studies suggests 
that both high impulsivity phenotypes and drug induced effects on impulsivity during phases of 
repeated drug use might act as risk factors for escalation. This suggests that both disinhibited 
behavioural control at baseline and drug induced disinhibition during phases of extended and 
repeated drug exposure may act as risk factors for escalating drug use. 
1.4.4.4 Abstinence/ Relapse 
Trait impulsivity has been reported during both short and long term abstinence amongst 
former substance users in comparison to healthy controls. Higher BIS and I₇ scores have been 
reported by alcohol, cocaine and heroin dependent subjects tested at or below 1 month of 
drug abstinence (Coffey et al., 2003; Nielsen et al., 2012; Petry, 2001) and former 
amphetamine and MDMA use tested at 1 year of drug abstinence similarly report greater 
levels of impulsivity within these questionnaires in comparison to healthy controls and report 
levels of impulsivity comparable to that reported by current amphetamine and MDMA users 
(Clark et al., 2006; 2008). Taken together, these findings suggest that self-reported reduced 
inhibitory control during early and late stages of drug abstinence may reduce the chance of 
entering into longer-term or maintaining abstinence.  
Former drug users also display impulsive and disadvantageous decision making during short 
and long-term abstinence. Cocaine and heroin dependent subjects make more 
disadvantageous choices within the IGT in comparison to healthy controls when tested at 15 
days of drug abstinence (Verdejo-García, Perales, & Pérez-García, 2007) indicating that drug 
users in this early stage of abstinence are more prone to making bad decisions. Similarly 
methamphetamine, alcohol and cocaine dependent subject tested 14, 39, 46 and days of 
abstinence show steeper discounting of delayed reward in comparison to healthy controls 
(Heil et al., 2006; Hoffman et al., 2008; Petry, 2001) indicating that former substance users bias 
disadvantageous choices due to insensitivity to long-term reward. In addition, cocaine 
dependent subjects that are less responsive to contingency management techniques, and 
therefore have steep discounting of the value of future monetary rewards, do not achieve 
35 
 
protracted abstinence during drug treatment, whilst cocaine users that that do respond to 
contingency management treatment and are  more sensitive to future rewards reach 
protracted abstinence (Martinez et al., 2011; Washio et al., 2011). Former methamphetamine 
dependent subjects tested at an average of 6 months of abstinence also display steeper 
discounting of delayed reward in comparison to healthy controls (Hoffman et al., 2006). These 
findings therefore indicate that former stimulant users continue to bias immediate 
disadvantageous decisions over advantageous decisions that require tolerance to receiving 
reward. This might mean that subjects entering drug abstinence that bias gratification of 
immediate drug reward are more likely to relapse due to insensitivity to the long-term 
advantages of drug abstinence. In addition, evidence that subjects reaching longer-term 
abstinence continue to display increased impulsive decision making indicates that bias for 
immediate gratification may be responsible for triggering relapse even when subjects comply 
with abstinence. 
Former amphetamine and heroin dependent subjects tested at 1 year of drug abstinence also 
report reduced reflection capacity. Former amphetamine users show comparable deficits on 
the IST relative to current amphetamine and opiate users and greater deficits in comparison to 
healthy controls (Clark et al., 2006). Similarly, former heroin users more errors on a porteus 
maze test in comparison to healthy controls (Lee & Pau, 2002). This suggests that alongside 
steeper discounting of future rewards during drug abstinence reduced ‘in the moment’ 
reflection capacity might also bias fast and disadvantageous decision making amongst former 
stimulant and opiate users. 
Cocaine users in short term abstinence (≥15 days) also display more errors of commission 
within a Go/No-go task (Verdejo-García et al., 2007) but do not at 8 months of drug abstinence 
(Bell et al., 2013). Cocaine users tested at a minimum of 14 days abstinence, however, do not 
show any differences to healthy controls in SSRT (Li et al., 2007). These studies might therefore 
suggest that behavioural inhibition during abstinence differs between specific dimensions of 
impulsivity and the time point measures However, heroin users in both short and long-term 
abstinence do not differ from healthy controls or current opiate users in error of commission 
of Go/No-go tasks (Constantinou et al., 2010; Verdejo-García et al., 2007). This suggests 
deficits in impulsive and disadvantageous decision making reported above might be more 
involved in the initiation of relapse amongst opiate users rather that reduced action control. 
Animal that display trait impulsivity on a DRT show greater resistance to stimulant extinction 
and relapse within self-administration models. Male rats expressing this behavioural 
phenotype on the DRT show greater resistance to nicotine and cocaine extinction, and greater 
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cue and context induced reinstatement in comparison to rats that are less impulsive on this 
task (Broos et al., 2012b; Diergaarde et al., 2009). These findings map onto human literature 
identifying that greater discounting of future rewards amongst substance users entering 
abstinence is associated with a greater chance of relapse during treatment (MacKillop & 
Kahler, 2009; Martinez et al., 2011; Wang et al., 2011). Male rats with low MAD scores, 
however, do not show greater resistance to cocaine extinction or drug induced reinstatement 
of self-administration (Perry et al., 2008) suggesting that impulsive decision making relating to 
the delay intolerance rather reward intolerance might be related to animal models of 
abstinence and relapse. In contrast, female rats with high MAD scores (low impulsivity) display 
greater resistance to cocaine extinction and reinstatement (Perry et al., 2008). This indicates 
potential gender differences in how trait impulsivity might interact with this stage of the 
addiction. Interestingly, female cocaine dependent subjects show greater sensitivity to cocaine 
associated cues and greater disruption in cortical-striatal activation than male cocaine users 
(Volkow et al., 2011) additionally supporting the prevalence if gender differences in triggers of 
relapse (cue sensitivity) in human drug users.  
Rats displaying trait impulsivity on the 5CSRTT have also been shown to display greater 
resistance to nicotine extinction in comparison to less impulsive rats, although this effect was 
not as strong as that seen with highly impulsivity rats screened by the DRT (Diergaarde et al., 
2009). Trait impulsive rats on the 5CSRTT also show greater cocaine relapse in comparison to 
less impulsive rats following repeated periods of punishment induced abstinence (Economidou 
et al., 2009). Interestingly, rats with both high and low trait impulsivity on the 5CSRTT relapse 
following an initial phase of punishment induced cocaine abstinence, however, only highly 
impulsive rats continue to relapse following a second abstinence phase (Economidou et al., 
2009). This pattern of relapse between rats with high and low trait impulsivity maps on to 
human studies reporting that subjects with higher levels of behavioural disinhibition do not 
reach protracted abstinence as quickly as subjects that are less disinhibited (Krishnan-Sarin et 
al., 2007).  In addition, trait impulsive rats performing the 5CSRTT show increased cocaine 
seeking in comparison to less impulsive rats (Belin et al., 2008) a behaviour that is believed to 
represent the motivational incentive to relapse (Stewart, 2010). 
The effects of drug withdrawal on impulsivity might also affect vulnerability to relapse during 
drug abstinence. Withdrawal from short access cocaine self-administration (2 hours) has been 
shown to lead to a transient increase in premature responding in rats (Winstanley et al., 2009), 
suggesting that greater levels of disinhibited behaviour during short-term drug abstinence 
might increase the chance of relapse due to reduced behavioural control. In contrast, 
intermittent withdrawal from 5-day long-access (8 hours) amphetamine self-administration 
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and withdrawal from 21-day long access amphetamine, methamphetamine and MDMA self-
administration does not produce any effects on premature responding during short or long-
term withdrawal (Dalley et al., 2005; Dalley et al., 2007b). Taken together, these studies 
suggest that the relationship between drug withdrawal and impulsivity might relate specifically 
to the pattern of drug treatment employed. 
1.4.5 Summary 
In summary, there is evidence that impulsivity can interact with all stages of the addiction to 
increase the chance of drug use though a loss of inhibitory control over behaviour. From the 
literature reviewed, however, amphetamine appears to have a have a particularly paradoxical 
relationship with impulsivity in that amphetamine can both increase and decrease impulsivity.  
These effects also appear to differ across different dimensions of impulsivity (choice vs. action) 
and in relation to baseline levels of impulsivity.  
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1.5Neuroanatomical framework of Impulsivity 
Impulsivity has been proposed to manifest as a consequence of poor ‘top-down’ frontal 
control over subcortical striatal and midbrain regions (Aron et al., 2007; Dalley et al., 2008; 
Jentsch & Taylor, 1999). Indeed, circuits connect the orbitofrontal cortex (OFC), dorsolateral 
prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) to subcortical regions of the 
basal ganglia including the dorsal and ventral striatum and to midbrain targets including the 
globus pallidum, substantia nigra and thalamus (Alexander & Crutcher, 1990; Alexander, 
DeLong, & Strick, 1986; Alexander, 1994). These circuits can therefore regulate ‘top-down’ 
signalling from frontal cortical regions to subcortical targets via direct passageway between 
higher cortical to subcortical regions. In contrast, subcortical circuits originating in the spinal 
cord, hindbrain and midbrain regions, such as the mesolimbic dopamine (DA), noradrenalin 
(NA) and serotonin (5-HT) systems, project ascending fibres to striatal and prefrontal regions 
and drive ‘bottom-up’ processing of primary motivation, reward and affect (Ikemoto, 2010; 
Leonard, 2004; Moore & Bloom, 1979; Moore, Halaris, & Jones, 1978). Activity through these 
ascending pathways can bias processing of primary motivational states through weakening the 
strength of descending ‘top-down’ frontal control systems. This bias can subsequently 
compromise ‘top-down’ frontal control leading to disinhibited behaviour. The major neural site 
of convergence between these circuits occurs within the striatal complex. Within the striatum, 
cortical, limbic and midbrain projections can converge on the same inhibitory medium spiny 
neuron (MSN) (Sesack & Pickel, 1990) allowing multiple cortical and subcortical activity to give 
rise to a single output. Hypothetically, disruption at any stage of these circuits that can alter 
the balance of ‘top-down’ processing of inhibitory control in favour of ‘bottom-up’ processing 
that might cause a behavioural output of increased impulsivity. ‘Impulsivity’ can therefore be 
conceptualised as a neural balancing act between ‘top-down’ and ‘bottom-up’ activity within 
these circuits.  
1.5.1 Neural correlates of inhibitory control 
fMRI studies have demonstrated that successful inhibition of a prepotent responding 
frequently activates the right DLPFC and right inferior frontal gyrus (IFG) in healthy subjects 
performing Go/No-go tasks (Garavan et al., 2002; 1999; Kelly et al., 2004; Liddle, Kiehl, & 
Smith, 2001; McNab et al., 2008; Menon et al., 2001). Activation of right prefrontal regions 
during No-go trials has also been detected when increasing and reducing inhibitory demand 
within No-go trials (Garavan et al., 2002; Kelly et al., 2004), proportionally distributing No-go 
trials with Go trials (Chikazoe, 2010; Steele et al., 2013) and when implementing low working 
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memory demand during a Go/No-go task (Steele et al., 2013). These studies therefore 
demonstrate that the right frontal cortex is involved in successful No-go trial inhibition 
regardless of alterations in stimulus frequency, salience or attentional demand. However, 
lesions to the left inferior frontal gyrus have also recently been found to impair performance 
with a Go/No-go task (Swick, Ashley, & Turken, 2011). In addition, activation the OFC has also 
been found during No-go trials as well as DLPFC activation (Horn et al., 2003).   
Alongside the involvement of right frontal regions, successful response inhibition during 
Go/No-go procedures also activates the ACC, inferior parietal cortex (IPC), pre supplementary 
motor area (preSMA), and sub-cortical regions including the caudate nucleus and putamen. 
Activation of the ACC has been linked to error and conflict monitoring during challenging No-
go trials (Garavan et al., 2002; Kelly et al., 2004) but has also been shown to activate during 
both Go and No-go trials, suggesting a role for the ACC in general response monitoring (Liddle 
et al., 2001). Sub-divisions of the ACC have however been found to differentially activate 
during successful inhibition (dorsal anterior ACC) and unsuccessful inhibition (rostral right ACC) 
(Menon et al 2001), suggesting that distinct regions of the ACC may be differentially involved 
in response inhibition and error monitoring. Activation of the IPC and preSMA are commonly 
reported during successful No-go trial inhibition, and as such fronto-parietal networks have 
been associated with successful response inhibition (Garavan et al., 1999; Steele et al., 2013). 
Activation of sub-cortical regions, mainly the caudate nucleus and putamen, during successful 
inhibition of No-go trials (Kelly et al., 2004; Steele et al., 2013), however, is also indicative of 
frontal-striatal networks in the regulation of inhibitory control. The fronto-parietal network is 
known to modulate attention in humans whilst fronto-striatal networks have been more 
closely associated with inhibitory control (Dalley et al., 2008; Ptak, 2012). Consequently the 
recruitment of fronto-parietal simultaneous to fronto-striatal activation might represent 
interaction of both these networks at a cortical level.    
Successful action cancellation in healthy controls during the SST is also associated with 
activation of the right IFG and patients with damage to the right IFG show specific impairments 
in performing the SST (Aron et al., 2003). Similarly, transcranial magnetic stimulation (TMS) 
applied over the pars opercularis region of the right IFG produces a specific impairment in the 
ability of healthy subjects to perform stop trials within the SST but does affect Go reaction 
time (Chambers et al., 2006). Furthermore, a ‘hyperdirect’ frontal-subcortical pathway 
originating in the right IFG and projecting to the preSMA and subthalamic nucleus (STN) has 
been identified in regulating action cancellation. Diffusion-weighted imaging (DWI) conducted 
in addition to fMRI imaging identified a direct frontal trajectory of white matter axons 
originating in the right IFG and projecting directly to the preSMA and STN in subjects 
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performing the SST (Aron et al., 2007). Within this study, regional brain activity collected from 
fMRI scans during stop trials was found to overlap with frontal-subcortical trajectories 
identified during DWI. These findings therefore provide insight into the circuitry underlying 
activation of the right IFG during fMRI scans. In addition these findings provide evidence for 
direct fronto-subcortical circuits in the regulation of response cancellation.  
 
The neural correlates of delay discounting in healthy subjects have also been associated with 
activation of frontal, striatal and parietal structures. Activation of the medial and lateral 
prefrontal cortex has been differentially associated with choice of immediate and delayed 
reward, respectively. The medial orbitofrontal cortex (mOFC), medial prefrontal cortex (mPFC) 
and medial posterior cingulate cortex (mPCC) are activated during choice for immediate 
reward, whilst the lateral OFC (lOFC), DLPFC, ventrolateral prefrontal cortex (VLPFC) and 
posterior parietal cortex (PPC) are activated during choice for large delayed reward (Ballard & 
Knutson, 2009; McClure et al., 2004). Volumes of the dorsolateral and inferiolateral prefrontal 
cortex have also been found to negatively correlate with choice for small immediate reward 
(Bjork, Momenan, & Hommer, 2009), indicating that increased lateral prefrontal activity is 
associated with preference for delayed reward.  
 
In addition to lateral prefrontal regions (McClure et al., 2004) reported activation of separate 
cortical and sub-cortical neural systems for choice of immediate vs delayed reward. Choice of 
small immediate rewards was found to correlate with limbic-striatal activity whilst choice off 
large delayed reward correlated with lateral prefrontal and parietal activation (McClure et al., 
2004). Similarly, striatal-basal ganglia regions are activated during learning of trials that deliver 
immediate reward whilst activation of the DLPFC and IFC are activated during learning of 
delayed reward trials (Tanaka et al., 2004). These studies therefore support that greater 
prefrontal activity is associated with impulse control whilst greater sub-cortical striatal activity 
is associated with impulsive choice. A recent study using tract-based diffusion tensor imaging 
also found that high diffusion and low fractional anisotropy (FA) frontal-striatal white matter, 
representing reduced tract integrity, predicted high rates of discounting in healthy subjects 
(Peper et al., 2013). These results expand upon the fMRI studies conducted by McClure et al., 
(2004) and Tanaka et al., (2004) to further implicate reduced connectivity and processing 
between frontal to sub-cortical striatal structures in impulsive choice. Collectively these 
studies support fronto-subcortical systems, and most frequently fronto-striatal systems, in the 
regulation of behavioural control.  
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1.5.2 Neural correlates of inhibitory control in substance users 
Neuroimaging studies of substance users have typically demonstrated a reduction in the 
volume of frontal cortical regions (Goldstein & Volkow, 2002). Reduced frontal grey matter 
volume has been found in stimulant, opiate and alcohol dependent users (Daumann et al., 
2011; Jernigan et al., 1991; Koester et al., 2012; Liu et al., 1998; Pfefferbaum et al., 1997). 
More specifically, reduced grey matter volume has been found in frontal regions including the 
OFC, ACC and insula in cocaine, amphetamine and methamphetamine users (Ersche et al., 
2011; Matochik et al., 2003; Thompson et al., 2004). In addition, volume reductions have been 
reported in temporal and parietal regions is cocaine and amphetamine users (Ersche et al., 
2011; Daumann et al., 2011). Female cocaine users also show hypoactivity within frontal, 
cingulate, parietal cortical regions and subcortical regions of the thalamus during exposure to a 
cocaine-cue video indicative of hypoactive ‘control circuits’ (Volkow et al., 2011). 
Conversely, cocaine and methamphetamine dependent subjects show increased grey matter 
volume in the striatum and other sub-cortical regions of the basal ganglia including the globus 
pallidus (Chang et al., 2005; Ersche et al., 2012; Jernigan et al., 2005; Thompson et al., 2004). 
However, greater duration of cocaine use and greater cumulative methamphetamine use has 
been correlated with reduced volume of the putamen and globus pallidus (Chang et al., 2005; 
Ersche et al., 2011) and stimulant dependent subjects show reduced substantia nigra volume 
(Todd et al., 2013). This suggests that greater stimulant exposure may actually reduce, not 
enlarge, the volume of grey matter within components of the basal ganglia. The enlargement 
of striatal volume commonly reported in stimulant dependent users has been proposed to act 
a consequence of reactive glial inflammation following heavy stimulant intoxication (Chang et 
al., 2005) and does not necessarily reflect long-term enhancement of striatal regions. In 
following, shrinking of both frontal and subcortical areas may represent volumetric changes 
within neural circuits that contribute towards drug maintenance. This neural hypoactivity in 
drug users maps on to fronto-striato-thalamic circuits and suggests that multiple nodes of 
inhibitory processing may be disrupted in addicts at both the cortical and subcortical level. 
Whether or not volume reduction in cortical and subcortical grey matter is specifically 
disruptive to inhibitory circuitry can be better elucidated via DWI and diffusion-tract imaging 
(DTI) imaging studies that explore the connectivity of white matter tracts between particular 
brain regions. Reduced FA in frontal white matter tracts connecting cortical to sub-cortical 
regions has also been reported in stimulant dependent subjects (Ersche et al., 2012) and 
reduced FA in white matter tracts originating in the right frontal sub-gyrus negatively 
correlates with the duration of heroin use in subjects (Liu et al., 2008). Reduced FA in the 
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anterior corpus callosum (genu) connecting frontal and striatal structures has been reported in 
alcohol and methamphetamine dependent subjects (Alhassoon et al., 2012; Salo et al., 2009). 
Interestingly, these studies specifically identify compromised white matter tracts connecting 
higher order prefrontal and cortical regions to subcortical regions via the anterior corpus 
callosum in substance dependence. However, to establish whether hypoactivity within frontal 
regions and thinning of white matter tracts from frontal to subcortical regions is directly linked 
to a loss of inhibitory control in substance users, assessment of these areas whilst performing 
inhibitory control tasks in required.  
Stimulant users performing tasks of action inhibition typically display reduced activity in 
comparison to controls within the ACC and insula (Hester & Garavan, 2004; Kaufman et al., 
2003; Li et al., 2008). Hypoactivity of the ACC has been linked to poor behavioural and error 
monitoring whilst the insula has been linked to reduced self-reflection (Modinos, Ormel, & 
Aleman, 2009). Consequently, hypoactivity of both these areas could lead to reduced 
awareness of poor behavioural monitoring in stimulant users. Both the ACC and insula 
constitute nodes of fronto-striatal connectivity, therefore hypoactivity at both of these 
locations in fronto-striatal connections may impair behavioural control via deleterious effects 
on top-down behavioural monitoring of sub-cortical structures. However, given that the ACC 
and insula are nodes in numerous neural circuits relating to executive control and attention 
processes that are additionally engage during the go/no-go and SSRT (Dosenbach et al., 2008) 
the specific contribution of these regions to poor inhibitory control is difficult to certify. Li et 
al., (2008) addressed this issue by controlling for ‘attention’, ‘post-error processing’ and ‘task 
frustration’ during the correlation analysis of neural activation and SST performance and a 
measure of emotional regulation (Difficult in Emotional Regulation Scale). Li et al., (2008) 
reports that hypoactivity of the ACC and preSMA after controlling for attention, post error 
processing and task frustration were correlated with emotional inhibitory control and short 
SSRT, respectively in cocaine users. These findings provide a useful insight into the specific 
contribution of hypoactive cortical brain regions in substance users in relation to reduced 
behavioural inhibition, and suggest that functional activity of the ACC may specifically regulate 
‘inhibitory control’ whilst activity of the preSMA may specifically regulate ‘motor inhibitory 
control’ (Li et al., 2008). In addition, commission errors within the IMT/DMT task negatively 
correlate with FA in the anterior corpus callosum (Moeller et al., 2004) and long SSRT correlate 
with reduced FA in white matter IFG and preSMA tracts (Ersche et al., 2012). These findings 
therefore confirm that poor frontal-striatal tract integrity is directly related to poor prepotent 
inhibitory control.  
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Within delay discounting procedures, MA users display reduced activity within regions of the 
right prefrontal cortex, ACC and parietal regions including the precuneus and inferior parietal 
sulcus whilst making more impulsive decisions within ‘hard’ temporal discounting choices 
(Hoffman et al., 2008; Monterosso et al., 2007). Cocaine dependent subjects with HIV also 
have reduced right prefrontal activity within the DLPFC, VLPFC and OFC whilst making more 
impulsive decisions during ‘hard’ temporal discounting choices in comparison to men 
diagnosed with HIV with no reported drug use (Meade et al., 2011). These studies suggest that 
impulsive decision making in stimulant users is correlated with reduced activity of prefrontal 
and parietal regions.  
Reduced activity of subcortical regions including the right caudate nucleus have also been 
reported during impulsive choices made by MA dependent subjects (Hoffman et al., 2008), 
indicating that hypoactivity of both frontal cortical and subcortical regions are involved in 
impulsive choice decision in MA users. Amphetamine dependent subjects also show decreased 
activity within the ventral striatum in anticipation of reward (Schouw et al., 2012), and area 
linked to the processing of reward value in temporal discounting procedures (Ballard & 
Knutson, 2009). In following, the combination of reduced cortical frontal activity (Monterosso 
et al., 2007; Hoffman et al., 2008; Meade et al., 2011) coupled with reduced ventral striatal 
sensitivity to reward (Schouw et al., 2012) reported in stimulant dependent subjects may drive 
and bias behaviour in favour to sub cortically processing to receive immediate reward. This 
interpretation is consistent with correlations between limbic-striatal activity and preference 
for immediate reward, and lateral prefrontal activity and preference for delayed reward, 
reported by McClure et al., (2004).  
From human literature reviewed it is clear that fronto-striatal and fronto-thalamic circuits are 
involved in the regulation of impulsivity and drug induced impulsivity. The following sections 
will further explore the more specific functional involvement of fronto-striato-thalamic circuits 
in the mediation of impulsivity and drug induced impulsivity through reviewing animal models 
of drug addiction and impulsivity.  
1.5.3 Neuroanatomical framework of Impulsivity in Animal Models 
1.5.3.1 Ventral Striatum 
The ventral striatum contains the nucleus accumbens (NAcb), consisting of the core and shell 
sub-divisions, and the olfactory tubercle. The NAcb contains two subregions, the medial and 
dorsal region named the core, and the lateral and ventral region named the shell. The NAcb 
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core receives afferent connections from prefrontal regions including the dorsal prelimbic 
cortex and lateral OFC, limbic regions including the rostral amygdala, midbrain regions 
including the ventral tegmental area (VTA), ventral pallidum and medial thalamus, and sends 
efferent connections to the dorsal subcommissural ventral pallidum, the entopeduncular 
nucelus and substantia nigra pars reticular (Basar et al., 2010; Brog et al., 1993; Ikemoto, 
2010). The dorsal ventral pallidum is in reciprocal connection with the dorsomedial 
subthalamic nucleus that in turn projects to the entopeduncular nucelus and substantia nigra 
pars reticular. Consequently the entopeduncular nucelus and substantia nigra pars reticular 
are under both direct and indirect control from the core. The entopeduncular nucelus and 
substantia nigra pars reticular send efferent projections to the ventromedial subthalamic 
nucelus and mediodorsal thalamic nucelus, respectively (Basar et al., 2010; Brog et al., 1993; 
Ikemoto, 2010). At the most caudal region of this circuit, the ventromedial subthalamic 
nucelus and mediodorsal thalamic nucleus are in reciprocal connection with the medial 
prefrontal cortex that in turn sends efferent projections to the core, thus creating a ventral 
striato-pallido-thalamo-cortical circuit. In contrast, the NAcb shell receives afferent 
connections from prefrontal regions including the subgenual ACC and the medial OFC, limbic 
regions including the caudal amygdala and hippocampus, midbrain regions including the VTA 
and paraventricular thalamic nucleus, and projects efferent connections to the ventromedial 
ventral pallidum, lateral hypothalamus, VTA and dorsal substantia nigra (Basar et al., 2010; 
Brog et al., 1993; Ikemoto, 2010). The ventromedial ventral pallidum projects to the 
mediodorsal thalamic nuclei that in turn projects to the medial prefrontal cortex and insula, 
thus creating a ventral striato-pallido-thalamo-cortical circuit incorporating the shell (Basar et 
al., 2010; Ikemoto, 2010). 
The NAcb core therefore receives prefrontal input predominantly from dorsal prefrontal 
regions and can target a multiple number of midbrain regions via output to the ventral 
pallidum. The NAcb shell in contrast predominately receives input from ventral prefrontal 
regions and receives dense innervation from the hippocampus. The shell is also in direct 
reciprocal connection with the VTA and substantia nigra meaning that the output from the 
shell can directly regulate ascending mesolimbic and mesocortical dopamine release. In 
contrast, the core does not directly project to the VTA but has greater control over regions of 
the midbrain, such as the subthalamic nucelus. All output signals sent from the core will 
ultimately reach the thalamus and affect thalamo-cortical signalling. A lesser proportion of 
shell output reaches the thalamus to influence the processing of thalamo-cortical signals but 
the shell will have a greater impact on the regulation of cortical and limbic DA release than the 
core. In following, the NAcb core is anatomically located to enable indirect processing of 
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behavioural output through interaction with multiple midbrain regions, whilst the shell is 
anatomically located to enable fast and direct processing of behavioural output through direct 
connection with the VTA and substantia nigra and more direct pathway to the thalamus than 
the core (See Fig. 1.4).  
1.5.4 Behavioural Literature examining the involvement of cortical-subcortical 
structures in impulsivity 
1.5.4.1 The Basal Ganglia and Midbrain 
Lesions to the NAcb can produce changes in both impulsive action and choice. Although lesions 
to the NAcb core or shell do not affect premature responses made under normal test or 
behavioural challenge conditions within the 5CSRTT, core lesions potentiate amphetamine 
induced premature responding whereas shell lesions attenuate this elevation in premature 
responding (Murphy et al., 2008). This supports a role for the core in processing inhibited and 
controlled behaviour and the shell in processing disinhibited and immediate response 
behaviour following stimulant treatment and is consistent with the involvement of the ventral 
striatum in impulsivity amongst stimulant users (Lee et al., 2009). In addition lesions to the 
NAcb core have been shown to increase impulsive responding measured by DRL task 
(Pothuizen et al., 2005). 
However, lesions to the NAcb core do not affect the SSRT or stop signal accuracy under normal 
test conditions in rats, and neither do they affect SSRT or stop trials in rats treated with 
amphetamine (Eagle and Robbins, 2003). These findings therefore draw an anatomical 
distinction between stimulant induced prepotent inhibition and action cancellation in animal 
models and further support human literature demonstrating that action cancellation does not 
involve processing via ventral striatal regions but direct pathways from frontal regions to the 
thalamus (Aron et al., 2007b). 
Lesions to the NAcb core have also been found to increase preference for immediate over 
delayed reward in rats (Cardinal et al., 2001), implicating a role for the core in processing delay 
discounting. These findings have been interpreted to represent a role for the core in mediating 
tolerance to delayed reinforcement (Cardinal et al., 2001). These findings are therefore 
consistent with human literature identifying the involvement of striatal activation during delay 
discounting procedures in healthy subjects (McClure et al., 2004). 
In contrast to the lack of effect that core lesions have on SSRT, lesions to the medial striatum in 
rats performing the SST produces an increase in SSRT whilst causing no change in the accuracy 
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of Go or Stop trial performance (Eagle and Robbins, 2003). Lesions to the medial striatum also 
reduces amphetamine induced elevations in SSRT at a low amphetamine dose (0.3 mg/kg) and 
an increase in amphetamine induced elevated SSRT at a high amphetamine dose (1.0 mg/kg) 
(Eagle and Robbins, 2003) indicating that the medial striatum is not only involved in mediating 
action cancellation under normal conditions but is also a potential target of stimulants that can 
alter action cancellation.  
Lesions to the subthalamic nucleus (STN) can increase premature responding in the 5CSRTT 
and reduced Stop trial accuracy in the SST (Baunez & Robbins, 1999; Chudasama & Muir, 2001; 
Eagle et al., 2008) linking this region with the regulation of behavioural disinhibition and action 
cancellation similar to that observed during imaging studies in humans performing Go/No-go 
and SST (Steel et al., 2013; Aron et al., 2007b). However, STN lesions do not affect SSRT (Eagle 
et al., 2008) suggesting that lesions to this region of the midbrain produces a generalised 
disruption in the ability to perform stop trials and inability to wait but not the processing of the 
stopping response that would be reflected in the SSRT. This therefore suggests that the STN 
might be involved in the final output of stopping an on-going action. In following, reduced stop 
trial accuracy in STN lesioned animals supports the existence of an action cancellation pathway 
to the STN, within which the STN is the circuitry node mediating behavioural execution (Aron 
et al., 2007b). Collectively, the involvement of the STN in both waiting and stopping behaviour 
supports involvement of thalamo-cortical loops as well as fronto-striatal loops in the regulation 
of behavioural inhibition.   
1.5.4.2 Prefrontal Cortex 
Lesions to the medial prefrontal cortex do not affect SSRT or performance in rats performing 
the SST (Eagle and Robbins, 2003). However, temporary inactivation of the ACC and dorsal 
prelimbic cortex increase SSRT (Bari et al., 2011) linking dorsal prefrontal regions to action 
cancellation in rats. Lesions to the OFC have also been found to increase SSRT in rats but 
inactivation of the OFC via gaba agonists does not affect SSRT (Eagle et al., 2008; Bari et al., 
2011) suggesting that specific involvement of the OFC in action cancelation remains slightly 
unclear. In following, the involvement of specific prefrontal regions in action cancelation is not 
wholly clear from animal models, however, inactivation of the ACC and dorsal prelimic cortex 
increasing SSRT is consistent with the involvement of the right IFG and ACC in action 
cancelation and error detection reported in human imaging studies (Aron et al., 2003; Garavan 
et al., 2002).  
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In contrast to specific prefrontal lesions in the involvement of action cancellation, lesions to 
the ACC, infralimbic and prelimbic have all been found to increase premature responding in 
the 5CSRTT (Chudasama & Muir, 2001; Muir, Everitt, & Robbins, 1996). However more dorsal 
prefrontal regions do not appear related to premature responding in the 5CSRTT (Chudasama 
& Muir, 2001), suggesting that more ventral regions are involved in processing of behavioural 
waiting signals. These findings are consistent with human literature implicating the inferior 
frontal gyrus and ACC in CPT and Go/No-go tasks (Garavan, 2000; 2002; Kelly, 2004; Steele et 
al., 2013). 
Lesions to the OFC have also been associated with temporal discounting. Lesions to the OFC 
however have been found to both increase and reduce impulsive choice, depending on the 
presence of delay to reward cues (Mobini et al., 2002; Rudebeck et al., 2006; Winstanley et al., 
2004). These discrepancies between results have been suggested to represent differences in 
the activation of the OFC that is related to environmental cues (Winstanley, 2007; Zeeb, 
Floresco, & Winstanley, 2010). Although the exact role of the OFC remains elusive, the OFC is 
activated during presentation of drug cues and seeking behaviour, and environmental cues 
associated with reward (Hutcheson & Everitt, 2003; Zeeb et al., 2010). This suggests that the 
OFC might contribute towards impulsive decision making and behavioural disinhibition in the 
5CSRTT in relation to processing of environmental cues that signal reward. These studies also 
expand on human literature reporting hypofunctioning within OFC of stimulant users that also 
discount delayed reward and display disinhibited behaviour (Coffey et al., 2003; Colzato et al., 
2007; Kirby & Petry, 2004; Volkow et al., 2001). 
In summary, lesions to specific nodes of inhibitory circuitry in rats confirm a relationship 
between fronto-striato-thalamic activity in the regulation of impulsivity. Inhibitory control over 
a prepotent response appears to engage more ventral prefrontal regions, whilst action 
cancelation engages more dorsal prefrontal regions. This might be because action cancellation 
utilises a direct hyper direct pathway to the thalamus, thus recruiting only a specific prefrontal 
region to initiate this hyperdirect pathway. In contrast, waiting behaviour recruits more ventral 
regions, comparable to the DLPFC and ACC circuits that have been linked to behavioural 
disinhibition in humans. In regards to delay discounting the OFC and NAcb core appear to be 
involved in this choice paradigm but the direction of this involvement in relation to the OFC 
might relate to differences in chemical circuitry or the extent of cues that can guide delay. This 
again maps onto human OFC circuits in decision making and impulsivity. 
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Figure 1.4 Cortical and sub-cortical afferent and efferent connections of the nucleus accumbens core and shell. Abbreviations: BLA, basolateral 
amygdala; dSNR dorsal substantia nigra pars reticular; dmSNR, dorsomedial substantia nigra pars reticular; dVP, dorsal ventral pallidum; 
dmSTN dorsomedial subthalamic nuclei; Hipp, hippocampus; IL, Infralimbic cortex; ILN, Intralaminar thalamic nuclei; iGP, internal segment 
globus pallidum; lHYP, lateral hypothalamus; lOFC, lateral orbitofrontal cortex; mOFC, medial orbitofrontal cortex; mPFC, medial prefrontal 
cortex; mdTN, mediodorsal thalamic nuclei; PL, prelimbic cortex; VTA; ventral tegmental area.  , glutamate; , dopamine; , GABA. , 
direct; - -> indirect; , hyperdirect. 
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1.6Neurochemical framework of impulsivity 
1.6.1 Neurochemical Connections of the Nucleus Accumbens Core and Shell 
The NAcb core and shell receive dense dopaminergic innervation from the A10 cell group in 
the VTA, 5-HT innervation from the median raphé nucleus and NA innervation from the locus 
coeruleus (Ikemoto, 2010; Leonard, 2004; Moore & Bloom, 1979; Moore, Halaris, & Jones, 
1978). The NAcb core and shell also receive GABA afferents from the VTA (Van Bockstaele & 
Pickel, 1995) meaning that both subregions receive excitatory and inhibitory afferents from 
the midbrain. In addition, both regions receive excitatory glutamate afferents from limbic and 
prefrontal regions. Within the NAcb, GABAergic medium spiny projection neurons and aspiny 
interneurons are the predominant cell type and make up 95% of accumbal cells (Gloria E 
Meredith, Pennartz, & Groenewegen, 1993). Excitatory D1 and inhibitory D2 receptors within 
the NAcb are located post-synaptically on medium spiny projection neurons (Albin, Young, & 
Penney, 1989; Surmeier et al., 2007) and there is evidence to suggest that the D2 receptors are 
located on presynaptic glutamate terminals innervating the accumbens (Goto & Grace, 2005). 
D1-like receptors (D1 and D5) are located on GABAergic interneurons (Centonze et al., 2002, 
2003). Consequently dopamine release into the NAcb can ‘gate’ converging afferent 
connections and efferent projections within the NAcb through actions at the D1 and D2 
receptors (Goto & Grace, 2005; Groenewegen & Trimble, 2007).  
1.6.2 Serotonin and Impulsivity 
Reduced 5-HT activity has historically been linked to impulsivity and clinical impulse control 
disorders (Hollander & Rosen, 2000; Soubrie, 1986). Low levels of circulating 5-HT has an 
established relationship with impulsive aggression (Seo, Patrick, & Kennealy, 2008) and 
selective serotonin reuptake inhibitors (SSRI) can reduce impulsive choice in violent male 
offenders (Cherek et al., 2002; Cherek & Lane, 2000), a population known to have reduced CSF 
levels of 5-HT metabolite 5-hydroxyindoleactic acid (5-HIAA) (Virkkunen et al., 1994). 
Polymorphisms in the 5-HT transporter gene (5HTT) and genes that encode for 5-HT receptors 
are also associated with impulsivity and aggression. The 5-HT transporter promoter gene, 
5HTTLPR, is associated with ADHD (Davidge et al., 2004) and the S allele of the 5HTTLPR also 
interacts with childhood adversity to predict emotional impulsivity in children (Carver et al., 
2011). Adolescent psychiatric patients expressing the t/t allele combination of the HTR2a gene, 
an allele combination associated with increased binding of the 5-HT2a receptors, are less 
impulsive and aggressive than patients with the t/c allele (Zalsman et al., 2011). These findings 
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therefore collectively support the involvement of 5-HT systems in impulsivity in clinical 
populations with co-morbid with mood related symptoms such as aggression. 
The role of 5HT activity in impulsivity within healthy subjects has produced mixed results. 5-HT 
transmission does not appear to be involved in the mediation of action cancellation. Increasing 
5-HT transmission via administration of the SSRI citalopram, and decreasing 5-HT transmission 
via acute tryptophan depletion, the amino acid precursor to 5-HT, both have no effect of SSRT 
in healthy subjects (Chamberlain et al., 2006; Clark et al., 2005). However, acute tryptophan 
depletion increases errors in a CPT and reduces right OFC activation during No-go trials in 
healthy subjects (Rubia et al., 2005; Walderhaug et al., 2002), suggesting that reduced 5-HT 
transmission might be involved in inhibition of prepotent responding. However, the CPT is 
primarily a task of attention, therefore, whether 5-HT is specifically involved in response 
inhibition in non-clinical populations remains inconclusive. The most convincing evidence for 5-
HT involvement in impulsivity therefore comes from clinical populations that have 
dysfunctional impulse control comorbid with emotional symptoms such as aggression.  
Central 5-HT depletion can lead to disinhibited behaviour on the 5CSRTT and symmetrically 
reinforced Go/No-go task in rats (Harrison et al., 1997, 1999). 5-HT has also been shown to 
interact with amphetamine induced elevations in premature responding and reductions in 
impulsive choice, indicating serotonin-dopamine interaction in impulsivity (Harrison et al., 
1997; Winstanley et al., 2003). Administration of 5-HT2a and 5-HT2c receptors antagonists both 
systemically and centrally into the NAcb have also been found to mediate changes in ipulsivity 
on the 5CSRTT (Robinson et al., 2007; Winstanley et al., 2004). Blockade of the 5-HT2a and 5-
HT2c receptors however produces opposing effects on impulsivity (Robinson et al., 2007; 
Winstanley et al., 2004), indicating that activation of the 5-HT2a and 5-HT2c receptors might 
lead to opposing effects on impulsivity. Animal studies therefore implicate a role for reduced 
5-HT tranismission in mediating impulsivity, which might function through indirect effects on 
dopamine activity. 
1.6.3 Noradrenalin and Impulsivity 
There is a clear relationship between NA transmission and impulsivity that is highlighted by the 
therapeutic success of NA reuptake inhibitors (NARI) for the treatment of ADHD. Atomoxetine, 
a NARI, and guanfacine, a noradrenalin α2a agonist, both increase release of NA and 
successfully reduce ADHD symptoms in adolescents and adults (Michelson et al., 2003; Sallee 
et al., 2009). Atomoxetine also improves action cancellation and increases right inferior frontal 
gyrus activity during stop trials in adults with ADHD performing the SST (Chamberlain et al., 
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2007, 2009), suggesting that increasing NA release into prefrontal regions can improve 
regulation of behavioural inhibition. In addition, the dopamine-noradrenalin reuptake inhibitor 
MPH reduces delay discounting in children with ADHD (Shiels et al., 2009) and has been found 
to occupy a significant number of NA reuptake transporters at clinically therapeutic dosages 
(Hannestad et al., 2010). These findings collectively suggest that reduced NA transmission 
might increase impulsivity, and more specifically, that hypoactive NA in the right inferior 
frontal gyrus might contribute towards behavioural disinhibition in subjects with ADHD.  
Unlike clinical groups with ADHD, healthy subjects that are acutely administered with 
atomoxetine become more impulsive. The α2a adrenoreceptor antagonist yohimbine that 
presynaptically blocks the α2a receptors and increases NE transmission similarly increases 
commission errors within IMT/DMT and Go/No-go tasks (Graf et al., 2011; Swann et al., 2005). 
In addition, yohimbine induced behavioural disinhibition in the IMT correlates with increased 
NA metabolites in healthy subjects, demonstrating that the increased impulsivity observed is 
related to an increase in NA transmission (Swann et al., 2013). Furthermore, the P300 event-
related-potential amplitude that has been proposed to reflect LC-NA activity (Nieuwenhuis, 
Aston-Jones, & Cohen, 2005) increases during No-go trials in a Go/No-go task and stop trials in 
the SST (Enriquez-Geppert et al., 2010; Falkenstein, Hoormann, & Hohnsbein, 1999), linking  
NA activity to behavioural inhibition. In addition, the NA β-blocker propanolol, reduces 
discrimination between the magnitude of wins and losses within a laboratory gambling task in 
healthy subjects (Rogers et al., 1999). This would suggest that NA signalling in involved in 
information processing of reward value under conditions of arousal.  
In summary, subjects taken from clinical populations with impaired inhibitory control appear 
to have hypo-functioning NA and treatment of this via NARI can produce positive clinical 
effects on symptoms. However, increasing NA in healthy controls appears to increase 
behavioural disinhibition and increase risky decision making amongst these subjects. These 
findings therefore support the involvement of NA in inhibitory control in both clinical and 
healthy populations. 
Interestingly, systemic administration of atomoxetine has been found to reduce impulsivity in 
rats when measured by the 5CSRTT, SSRT and DRT (Robinson, Eagle, et al., 2007) indicating the 
possibility of common neural substrate of impulsive action and choice being NA. Central 
administration of atomoxetine has also been shown to reduce impulsivity on the 5CSRTT when 
infused into the NAcb shell, but not the NAcb core (Economidou et al., 2012). These studies 
therefore support a relationship between reduced NA transmission and impulsivity in animal 
models. 
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1.6.4 Dopamine and Impulsivity 
Impulsivity in healthy subjects has been associated with fronto-striatal dopamine activity. SSRT 
in healthy subjects negatively correlates with D2/3 receptor availability within the striatum and 
subjects with short SSRT show greater activation of frontal structures in comparison to 
subjects with a long SSTT (Ghahremani et al., 2012). This demonstrates that subjects with 
greater difficulties in action cancellation have lower D2/3 availability within the striatum and 
reduced frontal activation. Trait impulsivity also negatively correlates with D2/3 availability in 
the VTA, and positively correlates with DA release in the ventral striatum following acute 
amphetamine (Buckholtz et al., 2010). This additionally indicates that differences in dopamine 
transmission in midbrain regions are related to impulsivity. Although still limited, these studies 
support a relationship between DA and impulsivity in healthy subjects. 
The relationship between DA and impulsivity has also been demonstrated, similarly to NA, 
through the therapeutic success of dopaminergic treatment of impulse control disorders, such 
as ADHD. Drugs that successfully treat impulsive symptoms amongst ADHD patients, such as 
Adderall (Mixed D- and L-amphetamine salts), Dexedrine (D-amphetamine) and Ritalin (MPH), 
all act either as a substrate at, or bind to and block, the DAT, indicating that changes in 
synaptic DA can alleviate impulsive symptoms. Furthermore, MPH administered to subjects 
with ADHD increases activity within neural regions associated with impulsivity, including 
frontal (right PFC, dmPFC, right and left IFG, vmPFC) and striatal (caudate nucleus, putamen) 
regions whilst patients perform inhibitory tasks (Cubillo et al., 2012; Lee et al., 2010; Rubia et 
al., 2009; Rubia et al., 2011) and activation of frontal and striatal areas following MPH has also 
been observed alongside a reduction in impulsive errors within Go/No-go tasks (Epstein et al., 
2007; Vaidya et al., 1998). These findings therefore indicate that changes in dopamine within 
fronto-striatal regions can improve impulse control in a clinical population with increased 
levels of impulsivity. 
Downregulation of dopamine synthesis, the DAT and the D2/3 receptors are common features 
of addiction pathology observed amongst stimulant, opiate and alcohol addicts (Lee et al., 
2009; Martinez et al., 2004, 2009; McCann et al., 1998; Volkow et al., 1997; Volkow et al., 
1993, 2002; Volkow et al., 2001; Volkow et al., 2001; Wang et al., 1997). These changes in 
dopamine function have been found to exist primarily in the striatum (Lee et al., 2009; 
Martinez et al., 2004, 2009; McCann et al., 1998; Volkow et al., 1997; Volkow et al., 1993, 
2002; Volkow et al., 2001; Volkow et al., 2001; Wang et al., 1997) and in cocaine and 
methamphetamine users downregulation of striatal D2 receptors has been observed alongside 
reduced frontal metabolism (Volkow et al., 1993; Volkow et al., 2001) demonstrating that 
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downregulation of dopamine function occurs within fronto-striatal regions relating to 
impulsivity amongst drug addicts. 
Increased impulsivity observed amongst addicts (Coffey et al., 2003; Colzato, van den 
Wildenberg, & Hommel, 2007; Fillmore & Rush, 2002; Hoffman et al., 2006; Kirby & Petry, 
2004; Madden, Petry et al., 1999; Monterosso et al., 2005; Petry & Bickel, 1999; Petry, 2001; 
Verdejo-García et al., 2007) might then relate to the wealth of evidence demonstrating 
changes in dopaminergic function within regions of inhibitory control. Studies directly 
assessing the relationship between dopamine and impulsivity amongst drug addicts have 
identified that reduced D2/3 receptor availability within the striatum is associated with 
increased levels of trait impulsivity and delay discounting in stimulant dependent subjects (Lee 
et al., 2009; Martinez et al., 2011; Wang et al., 2011) and furthermore that this reduction in 
D2/3 receptor availability can predict earlier relapse in cocaine and methamphetamine subjects 
(Martinez et al., 2011; Wang et al., 2011). In addition, increasing dopamine levels amongst 
cocaine addicts via administration of methylphenidate can reduce SSRT in these subjects 
alongside increasing frontal activity in the vmPFC and inhibition-related activation of the 
middle frontal cortex (Li et al., 2010). This demonstrates that changes in prefrontal dopamine 
are also associated with impulsivity in cocaine addicts. These studies therefore collectively 
confirm that changes in dopamine activity in frontal and striatal regions are associated with 
increased levels of trait impulsivity, impulsive choice and impulsive action observed in drug 
addicts, and furthermore that the extremity of these changes can predict relapse in drug 
addicts.  
Animal studies that have explored the neurochemical substrates of impulsivity and drug 
induced impulsivity have identified that dopamine depletion within the NAcb can reduce 
behavioural inhibition (Cole & Robbins, 1989) and drug induced changes in behavioural 
inhibition and delay discounting in rats (Cole & Robbins, 1989; Winstanley, Theobald, Dalley, & 
Robbins, 2005). Evidence that direct manipulation of dopamine transmission within the NAcb 
can change impulsivity therefore confirms a relationship between ventral striatal dopamine 
and impulsivity and supports human literature implicating a relationship between striatal 
dopamine and impulsivity in addicts (Martinez et al., 2009; Volkow et al., 1997). Confirmation 
that NAcb dopamine can mediate impulsivity in rats (Cole & Robbins, 1989; Winstanley et al., 
2005) alongside evidence that reduced D2/3 receptor availability within the ventral striatum is a 
common pathology of drug addiction (Martinez et al., 2004; Volkow et al., 1993, 2002; Volkow 
et al., 2001) and impulsivity amongst addicts (Lee et al., 2009; Martinez et al., 2011; Wang et 
al., 2011) has led to investigation into the roles of the dopamine sub-receptors in mediating 
impulsivity and drug use in animal models.  
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Similar to that observed in human PET studies, reduced D2/3 receptor availability within the 
ventral striatum, specifically within the NAcb, has been identified in highly impulsive rats that 
escalate cocaine use faster than less impulsive rats (Dalley et al., 2007). This overlap between 
human and animals literature therefore further confirms that neurochemical changes in the 
dopamine system at the level of the NAcb are involved in impulsivity and drug use. Direct 
manipulation of the D1, D2 and D3 receptors within the NAcb core and shell has further 
elucidated the specific functions of these dopamine sub-receptors within the ventral striatum 
in mediating impulsivity. The D1 receptors within the NAcb core and shell have been found to 
mediate impulsivity in rats that display normal levels of inhibitory control at baseline, but do 
not mediate drug induced impulsivity (Pattj et al., 2007). In contrast, the D2 receptors within 
the NAcb core, but not shell, have been found to mediate impulsivity in highly impulsive rats 
and drug induced impulsivity, but not ‘normal’ levels of impulsivity in rats (Moreno et al., 2013; 
Pattij et al., 2007). The D3 sub-receptor within the NAcb core, similarly to the D1 sub-receptor, 
does not mediate high levels of impulsivity in rats, but the D3 receptors in the NAcb shell do 
mediate hyperactivity in highly impulsive rats (Moreno et al., 2013). These findings therefore 
implicate a specific role for the D2 sub-receptor within the NAcb core in mediating high levels 
of impulsivity, and suggest that the functional sub-receptor mediating impulsivity in PET 
studies reporting reduced ventral striatal D2/3 receptor availability in highly impulsive addicts 
and rats might be the D2 sub-receptor. Consequently, evidence from animal studies to date has 
most convincingly implicated a role for the D2 sub-receptor within the NAcb core in the 
mediating elevated impulsivity in rats. 
1.6.5 Summary  
Literature reviewed in the ‘neurobiology of impulsivity’ section of this thesis has demonstrated 
the involvement of fronto-striatal-thalamic circuits in mediating both the normal expression of 
impulsivity and drug induced impulsivity. What is clear from human literature examining the 
neuroanatomical and neurochemical systems involved in impulsivity is that changes in the D2/3 
receptors within striatal regions, and particularly the ventral striatum, are associated with drug 
use and impulsivity. In addition, animal literature has similarly identified that changes in the 
D2/3 receptors within the ventral striatum are associated with impulsivity in rats and in the 
escalation of drug use, further supporting a relationship between D2/3 receptor activity in the 
ventral striatum with impulsivity and addiction.  
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1.7General Summary 
Drug addiction is a global monetary, health and social burden. Amphetamine is amongst the 
most harmful and prevalent of recreationally abused drugs both within the UK and throughout 
the world (Nutt, King, & Phillips, 2010; WDR, 2010; 2011; 2012). Consequently, research efforts 
aimed at elucidating this disease process are required. To date, two large theories have been 
the focus of addiction research; these are the ‘incentive-sensitisation’ and ‘opponent process’ 
theories of drug addiction, both of which address how central facets of addiction, including 
craving, drug seeking, tolerance, withdrawal and relapse, develop pathologically (Robinson & 
Berridge, 1993; Koob & Le Moal, 2008). However, more recent conceptualisations of addiction 
as a disorder of impaired impulse control has lead to theories proposing that changes in 
impulse control systems that heighten levels of ‘impulsivity’ are involved to the development 
and maintenance of addiction (Bechara, Dolan, & Hindes, 2002; Jentch & Taylor, 1999). 
Previous research attempting to test the hypothesis that reduced impulse control is involved in 
addiction has found substantial evidence that drug users and addicts have greater levels of 
both trait and behavioural forms of impulsivity in comparison to healthy subjects (Clark et al., 
2006; 2008; Coffey et al., 2003; Ersche., 2008; Fillmore & Rush, 2002; Hoffman et al., 2006; 
2008; Kirby & Petry, 2004; Kjome et al., 2010; Madden et al., 1997; Mitchell, 1999; Moeller et 
al., 2002; Monterosso et al., 2005; Morgan, 1998; 2002; Parrott et al., 2002; Petry & Bickel, 
1999; Quednow et al., 2007; Verdejo-Garcia et al., 2007). Animal research, that can more 
directly assess the cause and effect relationship of impulsivity and addition, has found that 
animal’s displaying greater levels if impulsivity at baseline acquire drug use, escalate drug use 
and relapse earlier than animals with lower levels of impulsivity at baseline (Anker et al., 2009; 
Broos et al., 2012b; Dalley et al., 2007; Diergaarde et al., 2009; Economidou et al., 2009; Perry 
et al., 2005; 2008). These findings suggests that greater levels of trait impulsivity predating 
drug use can increase the chance of developing addiction, supporting a causal relationship 
between pre-existing levels of impulsivity and addiction. However, acute and chronic 
administration of drugs can also increase impulsive behaviour in animals and humans (Blondel 
et al., 2000; Dallery & Locey, 2005; Fillmore, Rush & Hays, 2002; Fillmore, Rush & Marczinski, 
2003; Harrison, Everitt & Robbins, 1997; Kolokotroni, Rodgers & Harrison, 2011; 2012; Paine et 
al., 2003; Richards, Sabol & de Wit, 1999; Setlow et al., 2009; Simon, Mendez & Setlow, 2007; 
Winstanley et al., 2009). These studies alternatively suggest that elevations in impulsivity 
observed in addicts might be a direct consequence of drug use.  
Interestingly, amphetamine has been found to both increase and decrease impulsive 
behaviour in both animals and human studies. These effects appear to specifically depend on 
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baseline levels of impulse control within the subject group, with amphetamine reducing 
impulsive behaviour in subjects displaying poor impulse control at baseline (de Wit, Crean & 
Richards, 2000). Additionally, the effects of amphetamine on impulsivity appears to depend on 
the dimension of impulsivity measured, for example, acute amphetamine administration in 
rats can reduce impulsive choice but increase behavioural disinhibition in rats (Cardinal, 
Robbins & Everitt, 2000; Harrison, Everitt & Robbins, 1997; Harrison et al., In prep; Eagle et al., 
2009; van Gaalen et al., 2006; 2006b). These studies therefore suggest that the relationship 
between amphetamine use and impulsivity might be paradoxical based on the dimension of 
impulsivity measured. 
Investigations into the neurobiology of impulsivity has found that fronto-striato-thalamic 
regions are recruited by healthy subjects when performing tasks requiring inhibitory control 
(Aron et al., 2007; Chikazoe, 2010; Garavan et al., 2002; Kelly et al., 2004; Liddle, Kiehl & Smith, 
2001; McClure et al., 2004; McNab et al., 2008; Menon et al., 2001; Steele et al., 2013; Tanaka 
et al., 2004). Interestingly, changes in the volume of frontal (prefrontal cortex, orbitofrontal 
cortex, cingulate cortex, insula cortex) and striatal (caudate and putamen) regions have been 
observed in addicts in comparison to healthy controls (Chang et al., 2005; Daumann et al., 
2011; Ersche et al., 2011; 2012; Jernigan et al., 1991; Koester et al., 2012; Liu et al., 1998; 
Matochik et al., 2003; Pfefferbaum et al., 1997; Thompson et al., 2004). Addicts also tend to 
display lower prefrontal activation in comparison to controls when performing tasks requiring 
behavioural inhibition and delay discounting (Hester & Garavan, 2004; Hoffman et al., 2008; 
Kaufman et al., 2003; Li et al., 2008) indicating that changes in the activation of frontal control 
systems connected with striatal regions are linked to impulsive behaviour observed in addicts.  
Investigations into the neurochemical mediators of impulsivity has implicated changes in 
dopamine, serotonin and noradrenalin transmission to changes in impulsive behaviour 
amongst healthy subjects (Rubia et al., 2005; Chamberlain et al., 2007; Graff et al., 2011; 
Swann et al., 2005; Ghahremani et al., 2012; Buckholtz et al., 2010). PET studies conducted 
with drug addicts have more specifically identified hypoactive dopamine transmission and 
reduced D2 receptor availability within the striatum of addicts in comparison to healthy 
controls (Lee et al., 2009; Martinez et al., 2004; 2009; McCann et al., 1998; Volkow et al., 1993; 
1997; 1999; 2002; Wang et al., 1997). Reduced D2 receptor availability within the ventral 
striatum has also been found to correlate with trait impulsivity reported by addicts, and can 
predict treatment outcome amongst addicts engaged in contingency management therapy, 
where successful treatment outcome is reflective of reductions in impulsive choice behaviour 
(Lee et al., 2009; Martinez et al., 2011; Wang et al., 2012). These findings have subsequently 
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led to the recent proposition that the D2 receptors within the striatum are biomarker of 
impulsivity in drug addiction (Trifilieff & Martinez, 2013). 
1.7.1 Future Research Directions and Thesis Aims 
Whilst a clear relationship exists between impulsivity and drug addiction, breaking this 
relationship down to establish its direction (eg. cause vs. consequence) remains the focus of 
much research. To date, previous research that has investigated the direct effects of repeated 
amphetamine administration on impulsivity has found that amphetamine produces 
paradoxical effects on impulsivity depending on the dimension of impulsivity being measured 
(action vs. choice paradigm). More specifically, repeated amphetamine has been found to 
increase impulsive choice behaviour but does not produce any effects on behavioural 
inhibition in rats when tested with the 5CSRTT (Dalley et al., 2005; Dalley et al., 2007b; Gipson 
et al., 2009).  
The 5CSRTT is predominantly an animal model of attention and as such is known to rely on 
attentional mechanisms (Carli et al., 1983). This primary measure of the 5CSRTT can handicap 
the potential to measure behavioural inhibition in rats since changes in attention can produce 
behaviour similar to that observed as behavioural disinhibition. For example, reduced 
attention on the 5CSRTT might increase premature responses (the index of response 
disinhibition) due to the inability to employ the attention required to monitor light cues 
signalling correct response behaviour, as opposed to a change in the ability to inhibit a 
premature response. An additional caveat of the 5CSRTT for measuring behavioural inhibition 
is that premature responding on the 5CSRTT does not have a specific consequence in relation 
to the reinforcement parameters of the task. For example, if an animal increases premature 
responding in the 5CSRTT there is not necessarily a change in the amount of overall food 
reward gained. This means that an animal can make more premature responses without 
receiving any significant change in reinforcement. Consequently, the actual significance of 
changes in premature responding is difficult to ascertain from the 5CSRTT. In consideration of 
these factors, it is unclear whether repeated amphetamine exposure does not directly affect 
response inhibition in rats, or whether any amphetamine induced changes in response 
inhibition are not detected from this paradigm. Future research investigating the effects of 
repeated amphetamine exposure on response inhibition paradigms that are more direct 
measures of behavioural inhibition are therefore required. Research targeted at this area will, 
firstly, help to further disentangle the complex relationship between amphetamine and 
impulsivity, and, secondly, give a clearer picture of how repeated amphetamine specifically 
affects response inhibition.  
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The current thesis aims to address this research objective through assessing the effects of 
repeated amphetamine in rats on response inhibition measured by the Go/No-go 
symmetrically reinforced task. In the Go/No-go symmetrically reinforced task, response 
inhibition results in the direct gain of food reward whilst behavioural disinhibition results in 
the direct loss of food reward. This task also employs continual light cues guiding behaviour 
enabling low attentional demand. These parameters consequently allow for a more direct 
assessment of response inhibition in rats, where increases in response disinhibition can be 
interpreted as a motivationally significant change in prepotent inhibitory control. 
Previous research conducted into the neurobiology of impulsivity and addiction has implicated 
changes in fronto-striatal systems in drug addiction and impulsive behaviour (Chang et al., 
2005; Daumann et al., 2011; Ersche et al., 2011; Jernigan et al., 1991; Koester et al., 2012; Lee 
et al., 2009; Liu et al., 1998; Matochik et al., 2003; Martinez et al., 2004; 2009; McCann et al., 
1998; Pfefferbaum et al., 1997; Thompson et al., 2004; Volkow et al., 1993; 1997; 1999; 2002; 
Wang et al., 1997). The ventral region of the striatum has been identified as an important 
neuroanatomical site in relation to impulsivity and drug induced impulsivity in both human and 
animal research (Lee et al., 2009; Cardinal et al., 2001; Murphy et al., 2008). The ventral 
striatum is a site of neural convergence where prefrontal, limbic and midbrain neurons can 
synapse onto a single interneuron, allowing integration of prefrontal, limbic and midbrain 
processing to take place. Changes in the balance of this ‘prefrontal-midbrain’ integration can 
consequently weaken prefrontal top-down control over ‘impulsive urges’ originating from 
midbrain activity. Neurochemically, the ventral striatum is heavily innervated with dopamine 
nerve terminals and predominantly consists of GABAergic medium spiny interneurons; 
consequently, an important aim of future research will be to elucidate the specific role of both 
of dopamine and GABA systems within the ventral striatum in impulsivity and addiction.  
In order to address this research objective, investigating the role of system (dopamine and 
GABA) sub-receptors within the ventral striatum in impulsivity and drug induced impulsivity 
will be essential for establishing how neurochemical changes manifest at the level of the 
ventral striatum to affect impulse control. To date, human research has identified that reduced 
D2 receptor availability within the ventral striatum is associated with increased impulsivity and 
a greater tendency to discount future rewards associated termination of drug use in addicts 
(Lee et al., 2009; Martinez et al., 2009; Wang et al., 2011). Whilst such findings clearly indicate 
the involvement of the D2 receptors in impulsivity and addiction, it is difficult to establish from 
human research what the specific role of the D2 receptors within the ventral striatum is in 
relation to impulsive behaviour observed in addicts. Consequently, future research assessing 
the effects of direct D2 receptor manipulation within the ventral striatum on specific 
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behavioural dimensions of impulsivity and drug induced impulsivity is required. This thesis 
aims to address these research objectives by investigating the effects of D2 receptor 
antagonism within the ventral striatum, specifically within the nucleus accumbens core, on 
impulsivity and amphetamine induced impulsivity within the Go/No-go symmetrically 
reinforced task. Furthermore, given that GABA constitutes a major neurochemical network 
within, and projecting from, the ventral striatum, future research assessing the involvement of 
GABA within the ventral striatum in impulsivity and drug induced impulsivity is required. This 
thesis aims to address these research objectives by investigating the effects of GABAA receptor 
agonism within the ventral striatum, specifically within the nucleus accumbens core, on 
impulsivity and amphetamine induced impulsivity within the Go/No-go symmetrically 
reinforced task. Conducting these research aims will help to build up a more specific (sub-
receptor) and broader (systems) understanding of the neurochemical changes within the 
ventral striatum involved in impulsivity and addiction. 
1.7.2 Aims and Hypotheses 
In consideration of the future research directions discussed, this thesis has three main 
research aims: 
1) To further disentangle the relationship between repeated amphetamine use and 
response inhibition through testing the effects of subchronic (4-day) and chronic (11-
day) amphetamine treatment on a task that more directly measures response 
inhibition in rats. This aim sought to test the hypothesis that repeated amphetamine 
treatment affects response inhibition in rats performing the Go/No-go symmetrically 
reinforced paradigm. 
 
2) To assess the role of the D2 receptors within the ventral striatum in response inhibition 
and amphetamine induced response disinhibition in rats. This aim sought to test the 
hypothesis that the D2 receptors within the nucleus accumbens core mediate 
amphetamine induced response disinhibition in rats measured by the Go/No-go 
symmetrically reinforced paradigm. 
 
3) To assess the involvement of GABA within the ventral striatum in response inhibition 
and amphetamine induced response disinhibition in rats. This aim sought to test the 
hypothesis that the GABAA receptors within the nucleus accumbens core mediate 
amphetamine induced response disinhibition in rats measured by the Go/No-go 
symmetrically reinforced paradigm.  
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Chapter 2 General Methodology 
 
The following methodology was employed across all behavioural experiments in this thesis. 
Any adaptations of the below methods adopted for specific experiments are highlighted in the 
method section at the beginning of each experimental chapter.  
2.1.1 Ethics 
All animals were treated in accordance with the UK Animals (Scientific Procedures) Act 1986. 
Home Office training modules 1-4 were undertaken at The University of Leeds prior to the 
initiation of experimentation. All experiments were conducted under the author’s personal 
licence (PIL 40/9836) and under the project licence of Dr. Amanda Harrison (PPL 40/2711). 
2.1.2 Subjects 
All experiments employed male lister hooded rats (Charles River, UK) weighing between 300-
320 grams (g) upon arrival into the laboratory. An initial habituation week was implemented to 
familiarise animals to holding rooms and daily handling. All animals were housed in pairs 
received free feeding in their home cages until animals reached full adult body weight (320-
340g). Prior to behavioural training in the operant chambers animals were habituated to 
sucrose food pellets (Sandown Scientific, Middlesex, UK), used as food reward during operant 
training and testing. During behavioural training and testing animals were maintained on a 
mild food restriction schedule (15-20 g per day), to induce motivation for the food reward. The 
animals were weighed daily throughout behavioural studies to monitor healthy growth. Water 
was available ad libitum in their home cages throughout all behavioural studies.  
Animals were housed under a 12 hour light/ dark (LD) cycle (lights on at 0700hrs; lights off at 
1900hrs), in a temperature (21°C ± 2°C) and humidity (50% ± 5%) controlled environment. 
During the light phase artificial lights (193 lux) illuminated holding rooms.   
2.1.3 Apparatus (Operant Chambers) 
Two sets of 8 operant chambers (Med Associates  Inc., St Albans, VT, USA) and one set of 4 
operant chambers (Campden Instruments Ltd, Lafayette, IN, USA) were employed to conduct 
the symmetrically reinforced go/no-go paradigm (dimensions: 30.5 X 24.1 X 29.2cm, 30.5 X 
24.1 X 21 cm). All chambers were enclosed in wooden sound attenuating cubicles (63.5 x 49.1 
x 39.4 cm, Med Associates Inc., USA) and were air ventilated via an 115V AC wall fan. 
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Chambers consisted of aluminium panels at the front and rear of the chamber with clear 
polycarbonate joining walls, one of which was hinged making a door to place animals in the 
chamber. The front panel of the chamber contained two stainless steel levers located 
symmetrically on the left and right hand side of the panel. Each lever protruded 1.9 cm from 
the front panel when activated. Flat lens circular stimulus lights (2.5 cm diameter) were 
located symmetrically on the left and right of the front panel 6 cm below the top of the 
chamber. Stimuli lights were illuminated by 100 mA bulbs. Food pellets were dispensed into a 
central hole in the front panel referred to as the magazine which was equipped with an 
infrared bean across the front of the magazine to record head entries made into the magazine. 
The magazine (5.1 cm x 5.1 cm) was located 2.5 cm from the bottom of the front panel and 
could be illuminated by a light located at the top of the magazine. Each chamber was 
illuminated by a house light (100 mA) located centrally at the top of the rear chamber panel. 
All apparatus was controlled, and data recorded, from chambers using MED-PC IV software 
(Med Associates Inc., USA).   
2.1.4 Symmetrically reinforced Go/No-go conditional visual discrimination task 
Behavioural training commenced with magazine training which occurred in two stages. Initially 
animals were placed into test chambers whilst the magazine was illuminated and contained 
food pellets. The second stage of magazine training involved a continuous reinforcement 
schedule (CRF) whereby the magazine light was illuminated every 10 or 15 seconds (s) for a 
duration of 5 s across a 20 minute test session. Animals were required to nose poke the 
magazine upon illumination in order to receive the delivery of a single food pellet. CRF 
magazine training continued until animals collected a pellet on more than 80 trials during two 
consecutive test sessions.  
Upon successful completion of magazine training, animals began CRF lever training. Animals 
were required to make a lever response in order to illuminate the magazine for a duration of 
5s, during which time animals could nose poke the magazine to receive a food reward. All 
animals were assigned to either a left or right lever in a counterbalanced design and were 
required to make at least 100 lever responses over the course of 30 minutes. Upon completion 
of lever training, usually two consecutive sessions, animals progressed onto the full 
symmetrically reinforced Go/No-go conditional visual discrimination task. 
The symmetrically reinforced Go/No-go conditional visual discrimination task consisted of 80 
trials, within which there are 40 go and 40 no-go trials. The visual discriminanda were fast (0.1 
s pulses presented at 5 Hz) and slow (0.4 s pulses at 0.83 Hz) flashes of light made in temporal 
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synchrony via both the left and right light stimulus lights. Animals therefore, were exposed to 
one of two contingencies; 1) Go(fast)/ No-go(slow), or, 2) Go(slow)/ No-go(fast). Go and No-go 
trials were subsequently presented in a random sequence during each test session.  
Upon initiation of the task, the house light was illuminated and an inter-trial interval (ITI) of 5 s 
began. During each trial, either fast or slow flashing lights were presented for a period of 11.2 
s. During the first 1.2 s of this stimulus presentation (prediscrimination period) it is difficult to 
discriminate between the two visual stimuli, therefore any lever response made within this 
period is recorded as an early anticipatory response, but had no further consequence. All 
correct or incorrect behavioural responses were consequently registered during the following 
10s (discrimination period) of stimulus presentation. Magazine entries made prior to making a 
correct lever response, or prior to the termination of No-go discriminanda, were registered as 
inappropriate panel responses, and resulted in a 5 s time out period during which the 
houselight was extinguished, this was followed by the start of the same trial. 
During Go trials, a lever response made during the discrimination period of Go visual 
discriminanda, resulted in the stimulus lights being switched off, and the illumination of the 
magazine light for 5 s, during which time a magazine entry resulted in the delivery of a food 
reward and a correct go trial was recorded. Correct Go response latencies were measured from 
the end of the prediscrimination period of the stimulus presentation, to the time of lever 
response. After the delivery of a food pellet an ITI began, the duration of which was calculated 
from adding the standard ITI length of 5 s to the residual number of seconds of stimuli 
presentation after a lever response was made (5 s + (10 s – correct response latency) = ITI). Go 
trial magazine latencies were recorded from the time of the lever response to the time of the 
magazine entry. If an animal failed to enter the illuminated magazine to collect a food reward, 
a Go trial magazine omission was recorded. Following no lever response during a go trial, the 5 
s ITI began prior to the next trial and an incorrect go trial was recorded. Lever responses made 
within the prediscrimination period were recorded as Go trial anticipatory responses.  
During No-go trials, animals were required to withhold from making a lever response during 
the 10s stimulus presentation of No-go visual discriminanda. Following successful behavioural 
inhibition, the magazine light was illuminated for 5 s during which time a magazine entry 
resulted in the delivery of a food reward and the trial was recorded as a correct No-go trial. 
After the delivery of a food pellet an ITI of 5 s began before the start of the next trial. A lever 
response made within the 10 s discrimination period of a No-go trial resulted in immediate 
termination of the trial and the initiation of a time out period of 5 s during which the house 
light was extinguished and the trial was recorded as an incorrect No-go trial. Incorrect No-go 
63 
 
Behavioural Measure Dependent Variable
Accuracy of
Responding(%)
Totalpercentage correct
Totalpercentage correct Go trials
Totalpercentage correct No-go trials
Speed of
Responding (cs)
Go-trialcorrect response latency
No-go incorrect response latency
Go magazine latency
No-go magazine latency
Anticipatory
Responding
No. of Go trials with an anticipatory response
No. of No-go with an anticipatory response
No. of Go trials with an inappropriate panel responses
No. of No-go trials with an inappropriate panel response
Omissions No. of magazine omissions following correct Go-trials
No. of magazine omissions following correct No-Go trial
latencies were measured from the end of no-go prediscrimination period to the time of lever 
response. No-go magazine latencies were recorded from the cessation of the stimulus 
presentation to the time of the magazine entry. All response latencies were recorded in 
centiseconds (cs). Lever responses made within the prediscrimination period of No-go trials 
were recorded as No-go trial anticipatory responses. For a full outline of dependent variables 
measured during performance of the task see Table 2.1.  
2.1.5 Statistical Analysis 
All data was formatted in Microsoft Office Excel 2007 and was input into Statistical Package for 
the Social Sciences (SPSS) version 18 for analysis. 
All data was initially checked for homogeneity of variance and normality before conducting the 
main experimental analysis. Homogeneity of variance was assessed via Mauchly’s test of 
sphericity and the normality of data was assessed though Shapiro-Wilk and Kolmogorov-
Smirnov tests. Any data deviating from normality were appropriately transformed with square 
root, log10 or inverse transformations. All data expressed as a percentage values (proportional 
data) were subject to arcsine transformations. Due to rarity, omissions were not analysed and 
are therefore not included in this thesis. 
 
 
 
 
 
 
  
Table 2.1: Behavioural measures of the symmetrically reinforced 
Go/No-go conditional visual discrimination task 
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Chapter 3 The effects of amphetamine on food intake, water intake 
and body weight 
3.1Introduction 
Amphetamine is an anorexigenic agent that has historically been administered for the 
treatment of obesity. Amphetamine induced alterations in appetite are biphasic in nature, 
manifesting initially through reducing food intake (hypophagia) and more longer term through 
increases in food intake (hyperphagia), also known as the ‘rebound’ effect (Jones & Caul, 
1989). The switch between hypo- and hyperphagia has been suggested to mimic the initial 
stimulant and later withdrawal phases of amphetamine where alterations in motivation are 
markedly pronounced (Barr & Markou, 2005a; Der-Avakian & Markou, 2010). Specifically, 
hypophagia appears to predominantly occupy the early stimulant phase and hyperphagia more 
closely occupies the later ‘withdrawal’ phase. However, a secondary phase of hypophagia has 
also been reported to occur between 13- 27 hours following acute amphetamine 
administration (White, Sherrill, & White, 2007) suggesting that amphetamine induced 
hypophagia manifests during both early and more long term phases following amphetamine 
administration. The relationship between amphetamine and appetitive behaviours therefore 
appears to reflect at least several different motivational states following amphetamine 
administration.   
The co-occurrence of amphetamine-induced hypophagia and stereotypy has led to theories of 
early hypophagia (1-3 hrs following drug) which incorporate mechanisms of both anorexia 
(reducing motivation for food) and stereotypy (increasing behavioural competition with 
feeding). Animals receiving milk through intraoral cannulas, thus removing the demand to 
recruit consummatory eating behaviours, show a 50% increase in milk intake in comparison to 
bottle fed animals following amphetamine (2 mg/kg), suggesting that the amphetamine 
induced disruptions in the recruitment of consummatory behaviour affects food intake 
(Wolgin, 2000). However, cannulated animals also showed an increase in hypophagia as the 
amphetamine dose increased (up to 16 mg/kg) in spite of behaviourally un-restricted access to 
food, indicating that high dosages of amphetamine reduce food intake by reducing appetite 
(Wolgin, 2000). Similarly, amphetamine has been shown to disrupt feeding within the 
behavioural satiety sequence (BSS) in rats (Blundell & McArthur, 1981). More specifically, 
amphetamine disrupts the BSS via increasing locomotor activity that subsequently delays the 
rest phase in the BSS. It has therefore been suggested that satiety is not a primary mechanism 
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of amphetamine-induced hypophagia, but is impacted in-directly following the inability to 
engage in the eating phase of the BSS (Blundell & McArthur, 1981; Halford, Wanninayake, & 
Blundell, 1998). Alternatively, amphetamine has also been suggested to induce hypophagia via 
lowering the body weight ‘set point’ in rats (Levitsky, Strupp, & Lupoli, 1981; Stunkard, 1982; 
Wolgin, 1983). This view proposes that the reduction in food intake observed following 
amphetamine administration is the result of a homeostatic mechanism that is recruited to 
achieve a lower body weight set point. 
Longer-term hypophagia that may continue following the termination of amphetamine 
treatment has been less extensively studied. Interestingly, a secondary phase of hypophagia 
has been observed at 13-27 hrs following acute amphetamine administration (1 and 2 mg/kg)  
(White et al., 2007) indicating that hypophagia can continue to occur well past the clearance of 
amphetamine in rats (Fuller, Baker, & Molloy, 1977; Hutchaleelaha, Sukbuntherng, Chow, & 
Mayersohn, 1994). Time to consume food did not differ between saline and amphetamine 
animals when animals were required to lever press once to receive six pellets representing low 
response cost to receive reward. Interestingly, therefore, the influence of consummatory 
behaviours and appetitive motivation appear to be less implicated in the mechanisms 
underlying the secondary phase of hypophagia (White, Hundley, & White, 2010; White et al., 
2007). However, animals treated with a 4-day escalating dose regime of amphetamine exhibit 
lower break points in progressive ratio self-administration paradigms in comparison to saline 
controls up to withdrawal day three following drug treatment (Barr & Phillips, 1999; Orsini, 
Koob, & Pulvirenti, 2001) and a lower break point on food reward progressive ratio tasks for up 
to four weeks following drug termination (Der-Avakian & Markou, 2010) suggesting a 
reduction in appetitive motivation to gain food reward through these withdrawal phases. 
However, it was also found that animals did not differ in their consumption of freely available 
sucrose solution (Barr & Phillips, 1999) highlighting that this reduction in the animals 
motivation for food reward is only apparent when the response cost is high, such as during 
later stages of progressive ration schedules of reinforcement.  
Repeated administration of amphetamine leads to a slow reversal of amphetamine-induced 
hypophagia whereby animals gradually increase their food intake demonstrating tolerance to 
this drug effect. Tolerance to amphetamine-induced hypophagia however is contingent on 
preprandial administration of amphetamine (Carlton & Wolgin, 1971). The absence of this 
effect following postprandial administration of amphetamine has led to the suggestion that 
such tolerance is in part modulated by contingent drug-induced conditioning (Poulos, 
Wilkinson, & Cappell, 1981) accounting for the build up of tolerance only when feeding follows 
amphetamine. Tolerance to amphetamine’s hypophagic effects has also been suggested to 
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reflect instrumentally learnt suppression of stereotypic behaviour that is controlled via the 
prevailing contingencies of reinforcement (Wolgin, Thompson, & Oslan, 1987). In other words, 
animals learn to suppress stereotypic behaviours that are interfering with their ability to eat 
and gain food. Alternatively, Stunkard (1982) has argued that tolerance to amphetamine 
induced hypophagia reflects a method of homeostatic regulation to meet the new body weight 
settling point. This argument is supported by data demonstrating that whilst animals become 
tolerant to the hypophagic effects of amphetamine and subsequently increase food intake, 
body weight remains significantly lower than saline controls throughout the ‘tolerance’ phase  
(Wolgin, 1983). Furthermore, animals receiving chronic amphetamine over the course of 7 
days demonstrate increased motivation to obtain food reward through increased break points 
in a progressive ratio task to receive sucrose pellets whilst simultaneously displaying reduced 
body weight in comparison to saline controls (Der-Avakian & Markou, 2010). These findings 
support suggestions that alterations in the appetitive motivational state of animals receiving 
chronic amphetamine co-exist with a significant reduction in body weight. However, White et 
al., (2010) recently found that tolerance to the longer-term hypophagic effects (13- 27 hrs) is 
only produced by repeated administration of 1 mg/ kg of amphetamine and not an alternating 
1 and 2 mg/ kg regime, suggesting that tolerance to is less likely to develop under unstable 
drug dose administration regimes. The lack of tolerance displayed under alternating 
amphetamine regimes may reflect a deficit in learning due to the unpredictable drug regime. It 
could be, therefore, that it is harder for animals to learn how to suppress amphetamine 
induced hypophagia when the hypophagic effect of amphetamine is unpredictable.  
Alongside amphetamine-induced alterations in food intake, amphetamine is also known to 
alter water intake. Typically animals exhibit a reduction in water intake (hypodipsia) for around 
1- 2 hrs following amphetamine administration which is later compensated for via increases in 
water intake (hyperdispsia) at 2- 5 hrs, and subsequently becomes normalised after 
approximately 5 hrs (Camanni & Nencini, 1994). Repeated intermittent administration of 
amphetamine however leads to an increase in water intake in rats (Badiani & Stewart, 1993; 
Camanni & Nencini, 1994). Amphetamine induced hyperdispsia appears to be independent of 
the hypophagic effects of amphetamine. Amphetamine treated animals have been shown to 
drink the same amount of water when receiving free access to food as they do in the absence 
of food, suggesting that the excessive drinking following amphetamine administration is not 
related to the concomitant reduction in food intake (Rowland, Antelman, & Kocan, 1981). 
It is clear that amphetamine exerts substantial effects upon eating and drinking behaviour in 
animals, both in the short and longer term, subsequently altering the motivational state of 
animals. Due to the nature of operant tasks employing food reward as a behavioural 
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reinforcer, the possibility arises that amphetamine induced changes in primary motivation may 
directly impact behaviour observed in these operant tasks. Studies investigating the effects of 
pre-feeding on performance of the 5CSRTT have indicated that reducing the motivational state 
of animals prior to behavioural testing increases the latencies to respond and omitted trials, 
and significantly reduces premature responses (Grottick & Higgins, 2002; Harrison et al., 1997). 
Food intake has also been found to correlate with premature responding in the 5CSRTT, 
whereby the more food consumed by animals prior to operant testing the less number of 
premature responses were observed (Harrison et al., 1997). Animals maintained at 90 and 95 
% of their free feeding body weight (reduced motivation) display significantly lower levels of 
premature responding in comparison to animals maintained at 80 % (increased motivation) 
and to amphetamine treated animals (Bizarro & Stolerman, 2003). Motivational changes have 
also been shown to affect performance on the symmetrically reinforced Go/No-go tasks. 
Animals that received pre-feeding prior to operant testing (reduced motivation) failed to 
collect the food rewards during no-go trails more frequently than during baseline testing, 
whereas animals that received a 50% reduced feed 24 hours prior to operant testing 
(increased motivation) displayed a reduction in no-go trial incorrect response latencies in 
comparison to baseline, whilst causing no effect on go and no-go trial performance accuracy 
(Kolokotroni et al., 2011). Such studies highlight the importance of understanding the 
motivational state of animals prior to proceeding with operant food reward tasks.  
The current thesis aims to investigate the effects of acute and chronic amphetamine on 
behavioural disinhibition via a symmetrically reinforced Go/No-go task, within which impulsive 
behaviour is measured as increased inappropriate responding within no-go trials which results 
in the loss of food reward. The effects of the employed acute and chronic drug regimes on 
food intake, water intake and body weight have not yet been extensively studied. Thus, in 
order to effectively interpret the behavioural effects of amphetamine on impulsivity it is 
important to directly measure and identify the motivational state of animals following acute 
and 4-day amphetamine. 
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3.1.1 Objectives 
In order to investigate potential alternations in the motivational state of animals following 
acute and repeated (4-day) amphetamine administration, the objectives of Experiments 1a and 
1b were:  
i) To determine the effect of acute amphetamine on food intake, water intake and 
body weight in rats (Experiment 1a) 
ii) To determine the effect of  4-day amphetamine and withdrawal on food intake, 
water intake and body weight in rats (Experiment 1b) 
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3.2Method 
3.2.1 Subjects 
Subjects were 21 male Lister Hooded rats (Charles River, UK). Upon arrival animals weighed 
between 300-320g and were housed in pairs for experiment 1 and singly housed in experiment 
2 under a light/dark cycle of 12 hrs (lights on 07:00 hrs, lights off 19:00 hrs) in a temperature 
(21 +/- 2°C) and humidity (50 +/- 10%) controlled environment. Following habituation to the 
laboratory animals were separated and housed independently. Animals were maintained on a 
free-feeding schedule receiving unlimited access to rodent chow (Sandown Scientific, UK) 
within home cages for the duration of experimental procedures. Water was available ad 
libitum. 
3.2.2 Drugs 
Amphetamine (Sigma Aldrich, UK) was dissolved in 0.9% NaCl and was injected i.p. in a volume 
of 1 ml/kg body weight. 
3.2.3 Experiment 1a: The effect of acute amphetamine on primary motivation 
3.2.3.1 Procedure 
Upon reaching adult body weight (320- 340g) animals (n=8) entered the experiment. Animals 
received 0, 0.2, 0.4, 0.8, and1.2 mg/kg of amphetamine in a latin-square design, constituting 
five test sessions with seven days between each session.  
Prior to each test session animals’ were food restricted for 12 hours. On the morning of each 
test day animals were weighed before receiving amphetamine injections. 15 minutes prior to 
the test, and were subsequently placed back into their home cages and transported to the test 
room. Water bottles were removed from home cages for 15 minutes pre-test to ensure that 
test sessions captured water intake following amphetamine absorption. Pre-weighed rodent 
chow was placed into cage hoppers, and pre-weighed water bottles were placed in animals 
cages at the start of each test session. Each 1 hour test session took place between 12:00- 
13:00 hrs. At the end of each test session animals were weighed again and all food and water 
was re-weighed. Animals were then transported back to holding rooms where they received 
free access to food and water. 
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Food intake, water intake and body weight were all measured via change in grams from the 
beginning to the end of a test session. 
3.2.4 Experiment 1b: The effects of 4-day amphetamine on primary motivation 
3.2.4.1 Procedure 
Upon reaching adult body weight (320- 340g) animals entered the experiment and were 
assigned to either the amphetamine (n=7) or saline (n=6) treatment group. Animals were 
assigned to the group based on their body weight, food intake and water intake during the 
week prior to the study, to ensure that prior to drug treatment the groups were evenly 
matched across baseline in each dependent variable. Intake of rodent chow, water intake and 
body weight were subsequently recorded across 31 days containing the following four test 
phases: baseline (7 days), drug administration (4 days), withdrawal week one (7 days), 
withdrawal week two (7 days) and withdrawal week three (7 days). Food and water intake 
were measured from animals’ home cages. Following baseline, amphetamine was 
administered three times a day (0800 hrs/ 1400 hrs/ 2000 hrs) over the course of four days in a 
rising dose regime. A total of 50mg/kg of amphetamine was administered per animal at the 
following doses; Day 1 (1, 2, 3 mg/kg), Day 2 (4, 5, 5 mg/kg), Day 3 (5, 5, 5 mg/kg), Day 4 (5, 5, 
5 mg/kg). Control animals followed the same administration regime receiving three saline 
injections a day (0800 hrs/ 1400 hrs/ 2000 hrs) over 4 days. All measures were recorded at the 
same time daily, prior to the first amphetamine injection, during the administration phase. The 
data for baseline day 7 was recorded prior to the first drug treatment, on drug day 1, and 
therefore represents the final baseline measure of the dependent variables. On Figures 3.4 – 
3.6 drug day 1 therefore represents changes in food intake, water intake and body weight 
following amphetamine administration of 1, 2, 3 mg/kg or saline treatment on the previous 
day (baseline day 7). 
3.2.5 Statistical Analysis  
Before conducting the main analysis, all data were checked for normality and homogeneity of 
variance via Shaprio-Wilk tests and Mauchley’s test of Sphericty. Any data found to be 
abnormally distributed was subsequently transformed via log10, square root or inverse 
transformations (Field, 2005). Data violating sphericity was adjusted via Greenhouse-Geisser 
correction.  
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Acute amphetamine data (Experiment 1a) was analysed in a 1 x 5 repeated measures ANOVA, 
with amphetamine dose entered as the within-subjects factor and test dosages (0, 0.2, 0.4, 0.8, 
1.2 mg/kg) constituting 5 dose levels. Further analyses of main effects of dose were conducted 
using Bonferroni post-hoc analyses. Data was analysed as the change in grams from the 
beginning to the end of test sessions. 
Chronic amphetamine data was split into baseline, drug treatment, withdrawal week 1, 
withdrawal week 2 and withdrawal week 3 phases, and was subsequently analysed 
independently via 5 independent analyses. A 2 x 7 repeated measures ANOVA was conducted 
to analyse baseline data with treatment group entered as the between-subjects factor and 
baseline day entered as the within subjects factor. All remaining drug treatment and 
withdrawal data were analysed via ANCOVA with the subjects average baseline data acting as 
the covariate. Homogeneity of regression between the covariate and treatment groups, and 
the significance of the covariate were checked before proceeding with ANCOVA. In summary, 
one 2 x 3 repeated measures ANCOVA was conducted to analyse drug treatment (although 
there were four days of drug treatment the drug day 1 data was recorded prior to any drug 
treatment and was therefore represented during baseline (drug free), three 2 x 7 repeated 
measures ANCOVAs were conducted to analyse withdrawal week 1, withdrawal week 2, and 
withdrawal week 3 for each dependent variable. Interaction effects were further analysed via 
simple effects analysis of between and within subjects-effects utilising the pooled error term 
(Howell, 2010). Between-subjects effects on individual test days were analysed using a 
Univariate ANCOVA with the subject’s average baseline entered as the covariate. Within-
subjects effects were analysed using two 1-way repeated measures ANCOVA (one ANCOVA 
performed for each group). Significant F-Values resulting from within-subjects simple effects 
analyses were further investigated using post hoc comparisons between within-subject levels 
(drug days/ withdrawal days).  
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3.3Results 
3.3.1 Experiment 1a: The effect of acute amphetamine on primary motivation 
3.3.1.1 Food Intake 
Acute amphetamine was found to significantly affect food intake in rats (F(4, 28) = 15.946, 
p<0.001). Post hoc bonferroni analysis of this main effect revealed a significant reduction in 
food intake at 0.8 (p<0.05) and 1.2 mg/kg (p<0.01) in comparison to the saline control 
treatment. Furthermore, animals ate significantly less food after 1.2mg/kg in comparison to 
both 0.2 (p<0.05) and 0.4 mg/kg (p<0.05) and ate significantly less food after 0.8 mg/kg in 
comparison to 0.4 mg/kg (p<0.05). There was no difference in food intake between 0.8 mg/kg 
and 1.2 mg/kg (p>0.05) (Fig. 3.1). 
 
 
 
 
 
 
 
  
Figure 3.1: Effects of acute amphetamine on food intake. 
**p<0.01, *p<0.05 vs saline dose. Values represent means and 
error bars represent the SEM. 
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3.3.1.2 Water Intake 
Acute amphetamine significantly reduced water intake (F(4, 28)= 9.774, p<0.001). Post hoc 
Bonferroni analysis of this main effect revealed a significant reduction in water intake 
following 0.8 mg/kg (p<0.05) and 1.2 mg/kg amphetamine (p<0.001) in comparison to the 
saline control. 1.2 mg/kg of amphetamine was also found to produce significantly lower water 
intake in comparison to 0.2 mg/kg amphetamine (p<0.05) (Fig 3.2). 
. 
 
 
 
 
 
 
 
 
 
3.3.1.3 Body Weight 
Analysis of body weight data revealed that acute amphetamine significantly affected body 
weight in rats (F(4, 28) = 9.383, p<0.001), however post hoc bonferroni analysis revealed only 
an approaching significant difference between 0 mg/kg and 1.2 mg/kg (p=0.051, NS) (Fig. 3.3). 
  
Figure 3.2: Effects of acute amphetamine on water intake. 
**p<0.01, *p<0.05 vs saline dose. Values represent means and 
error bars represent the SEM. 
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3.3.2 Experiment 1b: The effects of 4-day amphetamine on primary motivation 
Homogeneity of regression was violated within body weight data during withdrawal weeks two 
and three. In following this data was analysed using ANOVA. Homogeneity of regression was 
confirmed for all remaining variables employing ANCOVAs (covariate x treatment group, p > 
0.05, NS) and the baseline covariate was found to significantly affect treatment groups (p > 
0.05), confirming the need to control for baseline differences between groups in food intake.  
3.3.2.1 Food Intake  
3.3.2.1.1 Baseline 
Analysis of food intake during baseline revealed a main effect of baseline day on food intake 
(F(6, 66) = 2.611, p<0.05), however post hoc bonferroni analysis revealed no significant 
differences in food intake between baseline days 1-7 (p>0.05) (Fig. 3.4). No main effect of 
group (F(1, 11) = 0.404, NS), or baseline day x treatment group interaction was found in the 
analysis of food intake during baseline (F(6, 66) = 0.942, NS) (Fig. 3.4).  
3.3.2.1.2 Amphetamine treatment 
Analysis of food intake during drug treatment revealed no main effect of drug day (F(2, 20) = 
2.324, NS), however, a main effect of drug group indicated that amphetamine treated animals 
ate less food during drug treatment in comparison to saline treated animals (F(1, 10) = 
Figure 3.3: Effects of acute amphetamine on body weight. 
Values represent means and error bars represent the SEM. 
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336.916, p < 0.001) (Fig. 3.4). In addition, analysis of food intake produced a significant drug 
day x drug treatment group interaction (F(2, 20) = 336.916, p < 0.001), with post hoc simple 
effects analysis revealing that amphetamine treated animals ate less food relative to the 
controls on day 1 (F(1, 30) = 78.960, p < 0.001), day 2 (F(1, 30) = 196.423, p < 0.001), and day 3 
(F(1, 30) = 254.316, p < 0.001) (Fig. 3.4). Analysis of within-subjects simple effects revealed no 
main effect of drug treatment day in either saline (F(8, 20) = 0.284, NS) or amphetamine 
animals when analysed independently (F(10, 20) = 0.662, NS) (Fig. 3.4).  
3.3.2.1.3 Withdrawal week 1 
Analysis of food intake during withdrawal week one revealed no main effect of withdrawal day 
(F(6, 60) = 0.638, NS), however, a main effect of drug treatment indicated that amphetamine 
treated animals continued to demonstrate less food intake in comparison to controls during 
withdrawal week one (F(1, 10) = 66.652, p < 0.001). In addition, a significant withdrawal day x 
drug treatment group interaction was detected (F(6, 60) = 40.627, p < 0.001) with simple 
effects analysis revealing that amphetamine treated animals ate less food than controls 
following 12 (F(1, 70) = 229.625, p < 0.001), 36 (F(1, 70) = 6.735, p < 0.001) and 60 hours of 
amphetamine withdrawal (F(1, 70) = 16.440, p =< 0.001) (Fig. 3.4). Simple effects analysis of 
withdrawal day effects however revealed no main effect of withdrawal day on food intake in 
either saline treated animals when analysed independently (F(24, 60) = 0.872, NS) or 
amphetamine treated animals (F(30, 60) = 0.907, NS) (Fig. 3.4). 
3.3.2.1.4 Amphetamine Withdrawal Week Two 
Analysis of food intake during withdrawal week two revealed no main effect of withdrawal day 
(F(1, 60) = 1.007, NS) and no difference in food intake was found between amphetamine and 
saline treated animals throughout this later phase of withdrawal (F(1, 10) = 1.693, NS). A 
significant withdrawal day x treatment group interaction was however detected during 
withdrawal week two (F(1, 60) = 2.561, p < 0.05). Within-subjects simple effects however failed 
to detected a main effect of withdrawal day within either amphetamine (F(30, 60) = 1.451, NS) 
or saline treated animals (F(24, 60) = 0.203, NS). In addition between-subjects simple effects 
revealed no differences in food intake between amphetamine treated animals at specific 
withdrawal days (df = 1, 70, all F ≤ 4.804, NS) (Fig. 3.4).  
3.3.2.1.5 Amphetamine Withdrawal Week Three  
Analysis of food intake during withdrawal week three revealed a main effect of withdrawal day 
(F(1, 60) = 3.283, p = 0.01) with post hoc bonferroni analysis indicating that animals ate more 
food on withdrawal day 21 in comparison to both withdrawal day 16 (p<0.01) and withdrawal 
day 18 (p<0.05) (Fig. 3.4). No difference in food intake however was found between 
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amphetamine and saline treated animals (F(1, 10) = 1.152, p = 0.308, NS) and no interaction 
between withdrawal day x treatment group was by the analysis of food intake during this late 
withdrawal period (F(1, 60) = 0.656, NS) (Fig. 3.4). 
 
 
 
 
3.3.2.2 Water Intake 
3.3.2.2.1 Baseline 
Analysis of water intake during baseline revealed no main effect of baseline day (F(1.614, 
17.753) = 1.760, NS), drug treatment group (F(1, 11) = 2.762, NS) and no baseline day x 
treatment group interaction (F(1.641, 17.753)  = 0.549, p = 0.550) (Fig. 3.5).  
3.3.2.2.2 Amphetamine treatment 
Analysis of water intake during drug treatment revealed no main effect of drug treatment day 
(F(2, 20) = 1.214, NS), drug treatment group (F(1, 10) = 0.120, NS)  or drug day x drug 
treatment group interaction (F(2, 20) = 2.012, NS) (Fig. 3.5).  
3.3.2.2.3 Amphetamine Withdrawal Week One 
Analysis of water intake during withdrawal week one revealed no main effect of withdrawal 
day (F(6, 60) = 0.767, NS), drug treatment group (F(1, 10) = 1.018, NS) and no withdrawal day x 
treatment group interaction (F(6, 60) = 0.260, NS) (Fig 3.5). 
 
Figure 3.4: Effects of 4-day amphetamine and amphetamine withdrawal on food 
intake. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant 
difference between amphetamine and saline groups. Values represent means and 
error bars represent the SEM. 
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3.3.2.2.4 Amphetamine Withdrawal Week Two  
Analysis of water intake during withdrawal week two revealed a main effect of withdrawal day 
(F(6, 60) = 2.427, p < 0.05), however, post hoc bonferroni analysis revealed no significant 
differences in water intake between individual withdrawal days 7-14 (all p > 0.05) (Fig. 3.5). In 
addition, analysis revealed no main effect of drug treatment group on water intake (F(1, 10) = 
0.008, NS) and no withdrawal day x drug treatment group interaction was detected (F(6, 60) = 
1.018, NS) (Fig. 3.5). 
3.3.2.2.5 Amphetamine Withdrawal Week Three 
Analysis of water intake during withdrawal week three revealed no main effect of withdrawal 
day (F(6, 60) = 0.887, NS), drug treatment group (F(1, 10) = 0.103, NS) or withdrawal day x drug 
treatment group interaction (F(6, 60) = 0.603, NS) (Fig. 3.5). 
 
 
 
3.3.2.3 Body Weight 
3.3.2.3.1 Baseline 
Analysis of body weight during baseline revealed a main effect of baseline day was (F(1.243, 
13.674) = 53.097, p < 0.001) (Fig. 3.6). Post hoc bonferroni analysis revealed a significant 
increase in body weight across all baseline days 1-7 (all p<0.05). There was, however, no 
difference in body weight between treatment groups (F(1, 11) = 0.008, NS) and no baseline day 
x drug treatment group interaction was detected (F(1.243, 13.674) = 0.162, NS) (Fig. 3.6). 
 Figure 3.5: Effects of 4-day amphetamine and amphetamine withdrawal on water intake. 
◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant difference 
between amphetamine and saline groups. Values represent means and error bars 
represent the SEM. 
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3.3.2.3.2 Amphetamine treatment 
Analysis of body weight during drug treatment revealed no main effect of drug day (F(2, 20) = 
0.016, NS), however, amphetamine treated animals were found to have lower body weight 
throughout drug administration (F(1, 10) = 22.026, p < 0.001). In addition, analysis revealed a 
significant drug day x treatment group interaction (F(2, 20) = 69.314, p < 0.001). Within-
subjects simple effects revealed no main effect of drug day in either amphetamine (F(10, 20) =  
0.03, NS) or saline (F(8, 20) = 0.017, NS) during drug administration, however, between-
subjects simple effects analysis revealed that amphetamine treated animals had lower body 
weight than saline treated animals on drug days 1 (F(1, 30) = 9.140, p < 0.01), 2 (F(1, 30) = 
33,948, p < 0.001), and 3 (F(1, 30) = 58.889, p < 0.001) (Fig. 3.6).   
3.3.2.3.3 Withdrawal Week One 
Analysis of body weight during withdrawal week one revealed no main effect of withdrawal 
day (F(2, 60) = 0.509, NS), however, amphetamine treated animals maintained a lower body 
weight than saline treated animals during withdrawal week one (F(1, 10) = 20.119, p < 0.001). 
In addition, a withdrawal day x treatment group interaction was detected (F(2, 60) = 3.457, p < 
0.05). Within-subjects simple effects analysis detected no main effect of withdrawal day within 
amphetamine (F(6, 23) = 0.007, NS) or saline (F(6, 23) = 0.009, NS) treated animals, however, 
between-subjects simple effects analysis revealed that amphetamine treated animals had 
lower body weight relative to controls at the following hours post drug termination: 12hrs (F(1, 
33) = 11.978, p < 0.01), 36 hrs (F(1, 33) = 10.381, p < 0.01), 60 hrs (F(1, 33) = 10.752, p < 0.01), 
84 hrs (F(1, 33) = 8.417, p < 0.01), 108 hrs (F(1, 33) = 8.018, p < 0.01), 132 hrs (F(1, 33) = 7.002, 
p < 0.05), and 156 hrs (F(1, 33) = 6.380, p < 0.05) (Fig. 3.6). 
3.3.2.3.4 Withdrawal Week Two 
Analysis of body weight during withdrawal week two revealed a main effect of withdrawal day 
(F(1.339, 14.733) = 11.618, p < 0.01) with post hoc bonferroni analysis revealing that animals 
increased body weight across all days (p < 0.05) apart from withdrawal day 11 (p > 0.05) (Fig. 
3.6). Analysis revealed no main effect of drug treatment group (F(1, 11) = 4.762, NS) or 
withdrawal day x drug treatment group interaction on body weight during withdrawal week 
two (F(1.339, 14.733) = 2.339, NS) (Fig. 3.6). 
3.3.2.3.5 Withdrawal Week Three 
Analysis of body weight during withdrawal week three revealed no main effect of withdrawal 
day (F(6, 60) = 3.622, NS) or drug treatment group (F(1, 10) = 2.531, NS) and no withdrawal day 
x drug treatment group interaction (F(6, 60) = 0.806, NS) (Fig. 3.6). 
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Figure 3.6 Effects of 4-day amphetamine and amphetamine withdrawal on body 
weight. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant 
difference between amphetamine and saline groups. Values represent means and 
error bars represent the SEM. 
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3.4Discussion 
Animals treated with acute amphetamine demonstrated amphetamine-induced hypophagia 
and hypodipsia following 0.8 and 1.2 mg/kg amphetamine alongside a general reduction in 
body weight. This suggests that dosages at and above 0.8 mg/kg are required to induce short 
term hypophagia of up to 1 hour following acute amphetamine. These findings mimic previous 
studies reporting a reduction in food intake acutely following amphetamine dosages at or 
above 0.5 mg/ kg (Wellman, Davis, Clifford, Rothman, & Blough, 2009; White et al., 2010, 
2007; Wolgin, Oslan, & Thompson, 1988). The reported short term hypophagia could be 
attributed to the influence of amphetamine induced stereotypy at higher dosages. 
Amphetamine-induced stereotypy predominantly occurs around dosages of 1.0 mg/kg 
(Wolgin, 2000), it is therefore possible that increases in stereotypic behaviour following 0.8 
and 1.2 mg/kg of amphetamine began to compete with consummatory behaviours, thus 
making it more behaviourally challenging for animals to eat food.  
Animals drank significantly less water following 0.8 and 1.2 mg/kg of amphetamine in 
comparison to the vehicle control, thus entering a hypodipsic state following 0.8 and 1.2 
mg/kg amphetamine in line with previous reports that acute dosages of amphetamine initially 
inhibits water intake (Stolerman & D’mello, 1978). Animals did not demonstrate an increase in 
water intake (hyperdipsia) within the one hour test session following acute amphetamine, 
suggesting that such compensatory hyperdipsia following the early hypodipsic affect of acute 
amphetamine do not occur within the first hour following amphetamine administration. 
Previous studies investigating hyperdipsia have measured water intake up to 7 hours following 
amphetamine administration (Rowland et al., 1981), it is therefore likely that the one hour test 
session employed in the current study only captured the initial hypodipsic effects of 
amphetamine. Furthermore, amphetamine-induced hyperdipsia has previously been reported 
following higher doses of amphetamine than those employed in the current study, ranging 
from 1- 10 mg/kg (Cioli, Caricati, & Nencini, 2000; Rowland et al., 1981; Stolerman & D’mello, 
1978). Furthermore, in light of the fact that higher doses of amphetamine are usually recruited 
in order to produce a disruptive effect upon drinking behaviour, it is probably not unsurprising 
that the employed dosages below 0.8 mg/ kg did not produce a significant effect on water 
intake.  
Acute amphetamine was found to lower body weight across all doses. Although post-hoc 
analyses failed to reveal significant differences between the body weights of the animals 
following the saline control treatment and any of the doses of amphetamine, there was a non-
significant trend for body weight to be reduced following administration of 1.2 mg/kg (p = 
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0.051). This suggests that following 0.8 mg/kg, amphetamine is beginning to rapidly alter 
mechanisms regulating body weight. Wolgin (1983) has previously reported weight loss in rats 
during 30 minute trials following 2 mg/kg of amphetamine, similarly supporting a fast acting 
effect of amphetamine upon body weight at high doses. Not surprisingly, food intake and body 
weight were found to highly correlate indicating that the observed reduction in body weight is 
related to the hypophagic effects of amphetamine. Furthermore, in consideration of the 
stimulatory effects of amphetamine on metabolism and stereotypy, it is plausible that acute 
amphetamine induced increases in gastric metabolism and motor activity alongside a 
reduction in food intake may have tipped animals into a negative energy balance causing a 
rapid reduction in weight loss. Doong et al. (1998) reported an increase in gastric emptying 
between 30 - 45 minutes following amphetamine dosages at and above 0.75 mg/kg. Similarly, 
amphetamine-induced increases in behavioural activity is initially exhibited within the first 
hour after 0.5 mg/kg amphetamine (Leith & Barrett, 1976). Thus, illustrating fast acting 
mechanisms that may cumulatively produce body weight loss during the first hour following 
acute amphetamine administration. 
Animals treated with 4-day amphetamine demonstrated hypophagia throughout drug 
treatment (Fig. 3.4). The magnitude of amphetamine induced hypophagia has previously been 
shown to be dose dependent (White et al., 2010; Wolgin & Hertz, 1995). For example, 1 and 2 
mg/kg of amphetamine have been shown to causing a greater reduction in food intake in 
comparison to 0.5 mg/kg (White et al., 2010) whilst 4 and 8 mg/kg cause a greater reduction in 
food intake than 1 and 2 mg/kg (Wolgin & Hertz, 1995). This suggests that as amphetamine 
doses increased during drug days within experiment 1a, the severity of hypophagia might have 
accordingly increased. Rats treated with 2.0 mg/kg amphetamine have previously been 
reported to display hypophagia for between 1 - 6 hours and resume eating between 7 - 12 
hours (White et al., 2007). During the administration schedule in experiment 1a there were 6 
hours between each daily injection of amphetamine with food intake measured 12 hours after 
the last daily amphetamine injection. In light of the possibility that from amphetamine 
administration at and above 2 mg/kg animals may have induced hypophagia for up to 6 hours, 
this would suggest that animals receiving amphetamine in experiment 1a might have only had 
approximately 6 hours (between 19- 24 hours following the last daily injection) within the 24 
hours food intake was measured to engage in normal feeding behaviour. The magnitude and 
time course of chronic amphetamine (2 mg/kg per day/ 24 days) induced hypophagia has also 
been shown to map onto chronic amphetamine induced stereotypy (Wolgin et al., 1987), 
suggesting that greater amphetamine induced stereotypy with rising amphetamine dosages 
might have also contributed towards inhibition of feeding. Furthermore, high doses of 
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amphetamine such as 4 and 8 mg/kg have been shown to reduce intraoral milk consumption 
as well as completely inhibiting intake of bottle milk (Wolgin & Hertz, 1995) suggesting that 
both consummatory behaviours and appetitive motivation might have been inhibiting feeding 
behaviour following administration of 5 mg/kg in experiment 1a during prolonged phases of 
hypophagia. 
Tolerance to amphetamine-induced hypophagia did not develop within the employed 4-day 
amphetamine regime. Tolerance has previously been reported to devlop at around seven days 
following repeated administration of a stabilised amphetamine dose (e.g. 2 mg/kg) (Carlton & 
Wolgin, 1971; Wolgin & Hertz, 1995; Wolgin, 2000). Due to the fact that amphetamine was 
administered across four days in experiment 1a, it is possible animals were not exposed to the 
hypophagic effects of amphetamine long enough to develop tolerance. Furthermore, it has 
previously been shown that tolerance does not develop to amphetamine-induced long-term 
hypophagia following an alternating dose regime of amphetamine (White et al., 2010). This 
would suggest that it is harder for animals to learn how to override amphetamine-induced 
hypophagia when the severity of drug induced hypophagia is unstable. Across drug days one 
and two in the current experiment animals were subjected to escalating doses of 
amphetamine three times a day. Thus, the employed unstable regime across drug days one 
and two may have inhibited tolerance from developing. This would leave only two days of a 
stable regime for animals to learn how to suppress amphetamine-induced hypophagia, which 
is likely to be too short a duration for animals to develop tolerance to amphetamine induced 
hypophagia.  
Following the termination of 4-day amphetamine treatment, animals continued to display 
hypophagia for up to 60 hours during amphetamine withdrawal, followed by normalisation of 
food intake by 84 hours after cessation of drug administration. These findings suggest that the 
employed amphetamine escalating-dose regime compromises motivation for food reward for 
up to 60 hours following the termination of amphetamine. Animals previously treated with the 
same 4-day amphetamine regime have been similarly reported to exhibit deficits in motivation 
for food reward for up to 60 hours. Specifically, animals treated with a similar 4-day escalating 
amphetamine regime to that employed in experiment 1a have been shown to display reduced 
break points to receive sucrose solution (Barr & Phillips, 1999) and greater negative contrast 
for sucrose reward for up to 60 hours following amphetamine termination (Barr & Phillips, 
2002). Brain reward thresholds are also elevated following the administration of the employed 
4-day amphetamine regime for up to 84 hours of amphetamine withdrawal indicating deficits 
in brain reward function during this period (Harrison, Liem, & Markou, 2001). It would appear, 
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therefore, that amphetamine withdrawal induced alterations of food intake normalises around 
24 hours earlier than amphetamine withdrawal induced dysphoria.  
Drug treatment effects persisted into withdrawal week two, as demonstrated by a significant 
withdrawal day x treatment group interaction during this later phase of withdrawal. However, 
post-hoc analysis of this interaction only revealed a trend towards an increase in food intake in 
amphetamine treated animals on day 13 relative to controls (p = 0.031 , bonferroni correction 
p = 0.007). This suggests that amphetamine treated might have been showing signs of feeding 
compensation during withdrawal week two following the earlier anorexic effects of 
amphetamine observed during amphetamine treatment and withdrawal week on. However, by 
withdrawal week three animals had normalised food intake to a comparable levels as saline 
controls, indicating that amphetamine treatment did not cause long-term changes in feeding 
behaviour. 
4-Day amphetamine administration did not affect water intake either during amphetamine 
administration or throughout amphetamine withdrawal. Whilst amphetamine is known to 
induce hyperdipsia following repeated administration, this has been observed following more 
maintained and longer durations of chronic amphetamine, such as 4mg/kg once a day for 30 
days (Rowland et al. 1981). In light of the fact amphetamine treated animals demonstrated no 
hyperdipsia following 4 days of a high dose amphetamine regime, this would suggest that a 
longer chronic regime is required to stimulate significant alterations to water intake. Camanni 
& Nencini (1994) previously reported amphetamine induced hypodipsia between 3 - 4 hours 
following 2 mg/kg of amphetamine but no difference in water intake at 24 hours following 
amphetamine administration, indicating that acute amphetamine induced alterations in water 
intake may shift the distribution of water intake without impacting the overall level of water 
intake measured across 24 hours. It is possible therefore that the employed 4-day 
amphetamine regime did affect water intake, however, due to the fact water intake was 
measured over a 24 hour period, acute alternations in water intake may have been 
compensated over the course of 24 hours and not captured in the current data set. The lack of 
effect of amphetamine upon water intake is particularly interesting in light of the severe 
hypophagia demonstrated across amphetamine administration and withdrawal. If animals are 
still able to engage in drinking behaviours, this would suggest that amphetamine treated 
animals were not completely inhibited by amphetamine-induced stereotypy. However, as 
Wolgin et al., (1998) demonstrated, the more complex the consummatory behaviour that is 
required to drink milk, e.g. drinking from milk bottle vs. from an intraoral cannula, the more 
likely behaviour is to be disrupted by the effects of amphetamine. will manifest upon food 
intake. Furthermore, the lack of effect of amphetamine on water intake alongside observed 
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hypophagia supports previous research demonstrating that amphetamine-induced hypophagia 
and hypodipsia are not related for the manifestation of each effect (Rowland et al., 1981). 
Amphetamine treated animals exhibited a significant reduction in body weight in comparison 
to saline treated animals during 4-day amphetamine treatment, in line with hypophagia 
observed in animals. Interestingly, the reduction in body weight throughout withdrawal week 
one was the longest residual effect of all variables measured, suggesting that amphetamine 
induced alterations in body weight were affected most significantly long-term. Amphetamine 
treated animals did not differ in body weight in comparison to saline throughout withdrawal 
week two and three, confirming that amphetamine treated animals had fully compensated the 
earlier anorexic effects of amphetamine on body weight. However, although non-significant, it 
is noteworthy that animals only regained body weight comparable to saline controls across 
withdrawal week two when there was a trend indicating that animals began to simultaneously 
consume more food (Fig. 3.4), suggesting that animals may have regained body weight by 
compensating with food intake.   
3.4.1 Key Findings 
The main findings from this study are that acute amphetamine at and above doses of 0.8 
mg/kg significantly reduce food intake and water intake, whilst more chronic 4-day 
amphetamine treatment significantly reduces food intake and body weight during drug 
treatment and withdrawal week one in comparison to controls in rats. These findings suggest 
that both acute and chronic regimes of amphetamine might impair primary motivation in rats. 
This study was conducted in order to assess how amphetamine regimes later employed in this 
thesis directly affect primary motivation in rats, with a view to considering how these changes 
might affect measures of response inhibition on the Go/No-go symmetrically reinforced task. 
Changes in food intake, water intake and body weight indicate that any amphetamine induced 
changes in impulsivity observed on this task should be interpreted in consideration of possible 
changes in primary motivation impinging on task performance. 
3.4.2 Limitations 
The main limitation in this study is that gross measures of food intake, water intake and body 
weight were employed. Firstly, measurement of all variables was conducted manually which 
increases the chance of error in data collection. For example, it would have been more reliable 
to measure food and water intake through using food and water dispensers. This would have 
enabled a more exact and accurate measurement of food consumed by rats during drug 
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treatment. Secondly, measurement of food intake, water intake and body weight were only 
measured over 24 hours periods. This means that any subtle changes in any of these measures 
may not have been captured when being measured over a period of 24 hour. In order to more 
accurately measure changes in food and water intake it would have been useful to employ 
food and water dispensers that log the displacement of food and water at specific time points. 
This would enable more precise measurement of any drug induced changes in these measures.  
3.4.3 Conclusions 
In conclusion, acute amphetamine leads to hyperphagia that can be triggered by amphetamine 
dosages at or above 0.8 mg/kg, whilst hypodipsia requires a slightly higher dosage of 1.2 
mg/kg. Body weight, similarly, appears to be more impacted by higher dosages of 
amphetamine at 1.2 mg/kg to produce an effect on weight change. Treatment with 4-day 
amphetamine similarly induced hypophagia and causing weight loss in rats, however no hypo-/ 
hyperdipsic effects were observed following this longer-term regime. 4-day amphetamine also 
induced long-term alterations in hypophagia for up to 60 hours of drug withdrawal and 
reduced body weight for up to 154 hours of withdrawal. However, no significant differences 
between amphetamine and controls were observed during withdrawal weeks two and three 
confirming that residual effects on hypophagia and body weight were restricted to withdrawal 
week one. Collectively, these findings indicate that treatment with acute and 4-day 
amphetamine can cause alterations in the motivation for food. 
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Chapter 4 The effects of a 4-day amphetamine binge on behavioural 
inhibition in rats 
4.1Introduction 
The acute effects of drugs in healthy subjects have been shown to alter impulsivity during 
measures of impulsive action, choice and reflection (Caswell et al., 2013; de Wit et al., 2000; 
Fillmore, Carscadden, & Vogel-Sprott, 1998; Fillmore et al., 2002, 2003; George et al., 2005; 
Ortner et al., 2003; Ramaekers & Kuypers, 2005; Reynolds, Richards, & de Wit, 2006). These 
effects typically increase impulsivity, however, stimulant drugs show a slightly more 
paradoxical profile on impulsivity and can reduce impulsive choice and action in healthy 
subjects when measured by delay discounting, SSRT and Go/No-Go performance (de Wit et al., 
2002). However, these effects were found in subjects with reduced inhibitory control at 
baseline, suggesting that the effects of amphetamine interact with baseline level of inhibitory 
control (de Wit et al., 2002). 
In addition to the acute effects of drugs on impulsivity, substance dependent subjects display 
increased levels of impulsivity. Opiate, cocaine, methamphetamine, nicotine and alcohol 
dependent users display poor inhibitory control (Verdejo-García et al. 2007; Kjome et al. 2010; 
Colzato et al. 2007; Moeller et al. 2002; Moeller et al. 2004; Lawrence et al. 2009; Monterosso 
et al. 2005) and discount delayed reward to a greater extent than healthy controls (Coffey et 
al., 2003; Hoffman et al., 2006; Kirby & Petry, 2004; Madden et al., 1997; Mitchell, 1999; Petry, 
2001; Vuchinich & Simpson, 1998). Reduced action restraint on the SST, reduced reflection on 
the IST and increased delay discounting have also all been observed in drug users during 
phases of short and long-term drug abstinence (Clark et al., 2006; Heil et al., 2006; Hoffman et 
al., 2006; Lee & Pau, 2002; Li et al., 2006; Petry, 2001) indicating that elevated impulsivity is 
associated with drug use and drug withdrawal. 
Consistent with human literature, the acute administration of drugs in rats alters impulsivity. 
Alcohol, amphetamine, cocaine, nicotine and morphine have been shown to acutely reduce 
behavioural inhibition in rats (Van Gaalen, Brueggeman, et al. 2006; Harrison et al. 1997; Pattij 
et al. 2007; Bizarro et al. 2004; Pattij et al. 2009; Paine & Olmstead 2004). Acute nicotine and 
morphine can also acutely increase delay discounting (Kolokotroni et al. 2011; Kieres et al. 
2004; Pitts & McKinney 2005) whilst stimulants including amphetamine and MPH produce 
contrasting effects that actually reduce delay discounting and improve impulse control in rats 
(Wade et al. 2000; van Gaalen et al. 2006b; Cardinal et al. 2000; Pitts & McKinney 2005). 
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Amphetamine induced reductions in delay discounting have however been shown to depend 
on the presence of light cues during the delay to reward (Cardinal et al., 2000). In addition, the 
effects of amphetamine in rats have also been shown to depend upon baseline levels of 
impulsive behaviour, for example, acute amphetamine does not affect impulsive choice on a 
cued delayed reward task in rats that are impulsive at baseline, but does increase impulsive 
choice in rats that are not impulsive at baseline (Hand, Fox, & Reilly, 2009). These data indicate 
that similar to human literature, the effects of amphetamine on impulsivity depends on both 
baseline levels of inhibitory control and the specific dimension of impulsivity measured.  
 
Chronic drug administration can also alter impulsivity during drug administration and 
withdrawal in rats. Studies utilising chronic drug administered non-contingently and through 
self-administration procedures have shown that cocaine, methamphetamine and nicotine can 
increase impulsive action, and or, impulsive choice during drug administration (Winstanley et 
al. 2009; Richards et al. 1999; Dallery & Locey 2005; Kolokotroni et al. 2012) and chronic 
cocaine, methamphetamine, nicotine and MDMA can increase impulsive action, and or, 
impulsive choice during drug withdrawal in rats (Dallery & Locey, 2005; Dalley et al., 2005; 
Dalley et al., 2007b; Winstanley et al., 2009).  
Interestingly, despite the acute effects of amphetamine reliably altering impulsive behaviour in 
rats (Pattij et al. 2007; Harrison et al. 1997; van Gaalen et al. 2006; van Gaalen et al. 2006b; 
Wade et al. 2000; Cardinal et al. 2000) long term amphetamine administration has only been 
found to directly increase impulsivity throughout drug administration and acute drug 
withdrawal within one study measuring the effects of amphetamine self-administration on an 
adjusting delay procedure (Gipson & Bardo, 2009). Additional studies investigating the 
relationship between long-term amphetamine treatment and impulsivity have found no 
effects of chronic amphetamine on long-term changes in impulsive choice measured by a 
delayed reward task (Slezak, Krebs, & Anderson, 2012; Stanis et al., 2008) and withdrawal from 
amphetamine self-administration does not affect behavioural inhibition on the 5CSRTT in rats 
(Dalley et al., 2005; Dalley et al., 2007b). However, the 5CSRTT primarily measures accuracy of 
attention in rats (Carli et al., 1983) and subsequently the index of impulsivity, assessed through 
the number of premature responses made before the presentation of a brief light stimulus, is 
intertwined with attentional demand. Consequently, if amphetamine does increase impulsivity 
during withdrawal this would make it difficult to assess within the 5CSRTT if attention is also 
disrupted, which it appears to be (Dalley et al., 2005; Dalley et al., 2007b). Within the Go/No-
go symmetrically reinforced task attentional demand is relatively low due to the continuous 
presentation of visual light cues guiding behaviour during Go and No-go trials. In addition, 
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failure to complete a correct No-go trial results in the direct loss of reward meaning the animal 
has an incentive to successfully inhibit behaviour in contrast to the 5CSRTT where reward for 
behavioural inhibition is intertwined with attentional accuracy and does not necessarily result 
in a loss of reward. In following, an investigation into the effects of chronic amphetamine on 
behavioural inhibition during drug treatment and subsequent drug withdrawal was conducted 
in rats using the symmetrically reinforced Go/No-go task. In consideration of the fact stimulant 
drugs, including amphetamine, are commonly administered in binge patterns, amphetamine 
was administered in a 4-day binge pattern. In addition, the long-term effects of amphetamine 
treatment on impulsivity were assessed through acute amphetamine challenges administered 
following prolonged drug withdrawal.  
4.1.1 Objectives 
In order to investigate the effects of a 4-day amphetamine binge on behavioural inhibition 
within the symmetrically reinforced Go/No-go task the objectives of Experiments 2a, b, c and d 
were: 
 
i) To determine the effects of a 4-day amphetamine binge on behavioural inhibition 
during drug treatment within the symmetrically reinforced Go/No-go task 
(Experiment 2a) 
ii) To determine the effects of spontaneous short-term drug withdrawal from a 4-day 
amphetamine binge on behavioural inhibition within the symmetrically reinforced 
Go/No-go task (Experiment 2b) 
iii) To determine the effects of long-term drug withdrawal from a 4-day amphetamine 
binge on behavioural inhibition within the symmetrically reinforced Go/No-go task 
(Experiment 2c) 
iv) To determine the effect of acute amphetamine challenges on behavioural inhibition 
within the symmetrically reinforced Go/No-go task following prolonged withdrawal 
from a 4-day amphetamine binge (Experiment 2d) 
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4.2Methods 
4.2.1 Subjects 
20 male Lister Hooded rats (Charles River, UK) were housed in pairs and maintained under a 12 
hour light/ dark cycle, in a temperature (21°C ± 2°C) and humidity (50% ± 5%) controlled 
environment. Throughout experimentation animals were maintained on a food restriction 
schedule of 18.6g per day (inclusive of food received during testing), maintaining animals at 
85% of their adult free feeding body weight. Water was available ad libitum and feeding took 
place in the morning after testing. All animals were treated in accordance with the UK Animals 
(Scientific Procedures) Act 1996. All procedures were covered by Home Office Project Licence 
No. PIL 40/2711 and Home Office Personal Licence No. 40/9836.  
4.2.2 Drugs 
d-Amphetamine sulphate (Sigma Aldrich, UK) was dissolved in 0.9% saline solution and was 
administered intraperioneally (i.p.) in a volume of 1 ml/kg body weight. 
4.2.3 Apparatus 
Behavioural testing took place in eight aluminium operant chambers (30.5 x 24.1 x 21 cm, Med 
Associates Inc., USA) placed inside sound attenuating and ventilated cubicles (63.5 x 49.1 x 
39.4 cm, Med Associates Inc., USA). Apparatus was controlled, and all data was recorded from 
chambers, using MED-PC IV software (Med Associates Inc., USA). For a more detailed 
description of all apparatus refer to Chapter 2, section 2.1.3, page 60.  
4.2.4 Behavioural Testing 
Behavioural disinhibition was assessed via the symmetrically reinforced go/no-go visual 
discrimination paradigm. Behavioural training took place for approximately 8 weeks until 
animals reached a total of 85% correct or more over seven consecutive training sessions. 
Following stable baseline performance, animals subsequently entered the experiment. All 
behavioural training and testing took place between 0700-0930 hours during the light phase of 
animals Light/ Dark cycle. For a detailed outline of the task refer to Chapter 2, section 2.1.4, 
page 61. 
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4.2.5 Design and Procedure 
A mixed design was employed to assess the effects of amphetamine treatment on behavioural 
disinhibition, with ‘drug treatment group’ (saline and amphetamine) acting as the between-
subjects factor and ‘test day’ acting as the within-subjects factor. Following stable 
performance, animals were assigned to groups receiving either systemic saline or 
amphetamine treatment. Groups were counterbalanced according to their baseline 
performance accuracy, programmed levers, and fast/ slow- Go/ No-go contingencies.  
4.2.6 Experiment 2a: The effects of a 4-day amphetamine binge on behavioural 
inhibition 
The chronic drug regime employed was a modified version to that of (Harrison et al. 2001). 
Animals were entered into two groups receiving amphetamine (n=9) or saline (n=10) 
treatment. Amphetamine was administered i.p. three times a day (0800 hrs/ 1400 hrs/ 2000 
hrs) over the course of four days in a rising dose regime. Dosages started at 1 mg/kg increasing 
up to and stabilising at 5 mg/ kg. A total of 50 mg/ kg of amphetamine was administered per 
animal in the following daily regimes; Day 1 (1, 2, 3 mg/kg), Day 2 (4, 5, 5 mg/kg), Day 3 (5, 5, 5 
mg/kg), Day 4 (5, 5, 5 mg/kg). Drug treatment started immediately after behavioural testing on 
baseline day 7. Control animals were administered with saline i.p. three times a day (0800 hrs/ 
1400 hrs/ 2000 hrs) over the course of four days, mimicking the administration regime of 
amphetamine treated animals. Behavioural testing took place prior to the first morning 
injection of amphetamine or saline, thus behavioural inhibition was measured during the 
treatment phase 12 hrs after the final amphetamine injection on the previous day. 
4.2.7 Experiment 2b and c: The effects of short- and long-term spontaneous 
amphetamine withdrawal on behavioural inhibition  
Spontaneous amphetamine withdrawal was initiated after the fourth day of amphetamine 
treatment. Animals were subsequently tested for the next 14 days to assess the effects of 
short- and long-term amphetamine withdrawal on behavioural inhibition. In order to more 
thoroughly examine behavioural disinhibition throughout acute amphetamine withdrawal, 
animals were tested at 12 and 18 hrs post drug termination; constituting two test sessions on 
day 1 of drug withdrawal. Animals were tested once per day across all remaining withdrawal 
days. Specifically, animals were tested at the following hours post drug treatment; 12, 18, 36, 
60, 84, 108, 132, 156 hrs (withdrawal week 1) (Experiment 2b), and across the following days 
post drug treatment; 8, 9, 10, 11, 12, 13, 14 (withdrawal week 2) (Experiment 2c).  
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4.2.8 Experiment 2d: The effects of acute amphetamine challenges on 
behavioural inhibition 
Following two weeks of drug withdrawal and when animals performance had returned to 
baseline levels (85% correct, +/- 5%), both amphetamine and saline treated animals received 
five acute amphetamine challenges (0, 0.2, 0.4, 0.8 and 1.2 mg/kg, i.p.) in a latin square design 
20 minutes before behavioural testing. The acute amphetamine dose range was chosen based 
on findings by Harrison et al., (pers. comm.). Animals were required to achieve a minimum of 
85% correct (+/- 5%) across two consecutive days between acute injections in order ensure 
that animals had returned to baseline levels in their performance before receiving their next 
amphetamine injection. A wash out period of a minimum of 72 hrs was employed between 
each drug injection. Performance had returned to baseline levels prior to all drug injections. 
4.2.9 Statistical Analysis 
All data was initially checked for normality through Shaprio-Wilk tests and was appropriately 
transformed via arcsine, log10, square root and reciprocal transformations following any 
violations to normality. Homogeneity of variance was checked via Mauchley’s test of Sphericity 
and following any significant violation of equal variances, the GLM degrees of freedom were 
adjusted using the Greenhouse- Geisser correction. For all employed ANCOVAs, homogeneity 
of the regression slope was assessed via testing the interaction between baseline performance 
and independent variables. Following a significant baseline x treatment group or baseline x 
test day interaction, the use of ANCOVA was considered no longer appropriate, and 
subsequently data was re-expressed a percentage of baseline performance and entered into 2 
x   mixed ANOVA (Field, 2005). The validity of using average baseline performance as a 
covariate was also assessed through checking that baseline performance yielded a main effect 
upon treatment groups within the ANCOVA model (Field et al., 2005). On the rare occasion 
that baseline performance was found to not significantly affect treatment groups, data was re-
expressed a percentage of baseline performance and entered into a 2 x   mixed ANOVA (Field, 
2005).  
In order to maintain power when conducting multiple post hoc comparisons the sidak 
correction was applied to all within-subjects post hoc tests (Field, 2005) and the Benjamini-
Hochberg correction was applied to between-subjects post hoc comparisons (Benjamini-
Hochberg, 1995). The sidak correction controls for false positivity in combination with 
increased power in comparison to traditional post hoc tests such as the bonferonni correction 
(Sidak, 1967; Liu et al, 2010), and the Benjamini-Hochberg test has been shown to enforce 
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stronger control over both type 1 and type 2 errors in comparison to traditional approaches 
controlling for familywise error rate when conducting multiple comparisons (Thissen et al, 
2002; Noble 2009). The Benjamini-Hochberg test achieves this control though conducting a 
test of ‘false discovery rate’ across all comparisons controlling for the chance of incorrectly 
accepting the null hypothesis as well as incorrectly rejecting the null hypothesis, as oppose to 
post hoc tests such as the bonferonni correction, controlling solely for the probability of 
making at least one incorrect rejection of the null hypothesis. Furthermore, through employing 
ANCOVA an additional proportion of the variance is accounted for within the analysis, 
enforcing further control over the variance analysed and subsequent p value generated. 
Unless otherwise stated α < 0.05 was employed. Subsequently, the following four sets of data 
analyses were performed: 
4.2.10 Assessment of Baseline Performance 
After checks of normality, the following transformations were performed before conducting 
baseline analysis: log₁₀ transformation (Go magazine latency). 
Baseline performance was analysed via 2 x 7 mixed ANO As with ‘drug treatment group’ 
entered as the between- subjects factor, and ‘baseline day’ entered as the within-subjects 
factor. Main effects of ‘baseline day’ were followed up via sidak corrected post hoc tests, and 
significant treatment group x baseline day interactions were deconstructed via simple effects 
analysis. Simple effects analysis was conducted in two steps. Firstly, two one-way repeated 
measures ANOVAs were performed for each treatment group to assess individual group 
within-subject effects, with subsequent significant main effects of ‘baseline day’ followed up 
via sidak corrected post hoc tests. Secondly, seven independent t-tests were performed to 
examine between-treatment group effects within individual baseline days (Benjamini-
Hochberg correction of α = (i/k)*0.05)1).  
4.2.11 The Effects of a 4-Day amphetamine binge, short- and long-term 
spontaneous amphetamine withdrawal on behavioural inhibition 
After checks of normality, the following transformations were applied across chronic drug and 
withdrawal data: log₁₀ transformation (Go trial response latency, Go trial magazine latency). 
Performance across amphetamine treatment, short- and long-term spontaneous 
amphetamine withdrawal was assessed via mixed ANCO As, with ‘drug treatment group’ 
                                                             
1
 “i” = Order of p values ranked from highest to lowest, “k” = number of tests 
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entered as the between-subjects factor and ‘test day’, ‘withdrawal hour’, or withdrawal day’ 
entered as the within-subjects factor. In summary, the following ANCOVAs were performed 
across all behavioural parameters; 2 x 4 mixed ANCOVA (drug treatment), 2 x 8 mixed ANCOVA 
(withdrawal week one), and 2 x 7 mixed ANCOVA (withdrawal week two). In order to control 
for within-subjects variation in behavioural performance, average baseline performance across 
baseline was entered as a covariate into the ANCOVA model. Further analysis of within-
subjects main effects was conducted via post hoc sidak corrected tests and significant 
interaction effects were deconstructed via post hoc simple effects analysis. Simple effects 
were performed using the pooled error term from the main ANCOVA model (Howell, 2010). 
However, under circumstances of violated sphericity, a separate error term for each simple 
effect was generated to avoid the use of an unreliable post-hoc F value generated from 
adjusted degrees of freedom (Boik, 1981; Howell, 2010). Simple effects were subsequently 
conducted in two steps as reported in section 4.2.10 with the addition of entering baseline 
performance as a covariate into both within- and between-subjects deconstruction analyses. 
Firstly, two one-way repeated measures ANCOVAs were performed for each treatment group 
to assess individual treatment group within-subjects effects, and secondly, univariate 
ANCOVAs were performed on each individual test day to assess between-group treatment 
effects at each level of ‘test day’/ ‘withdrawal hour’/ ‘withdrawal day’. Simple effects analysis 
revealing a significant main effect of ‘test day’/ ‘withdrawal hour’/ ‘withdrawal day’ were 
further analysed via post hoc sidak corrected multiple comparisons. P values of between-
groups simple effects analysis were corrected via the Benjamini-Hochberg correction (α = 
(i/k)*0.05) to control for increased false discovery rates following multiple between group 
comparisons (Benjamini and Hochbery, 1995).  
In addition, in order to identify the specific initiation and longevity of treatment effects in line 
with exploring experimental aims to examine the direct effects of amphetamine treatment on 
behavioural inhibition, all main effects of ‘treatment group’ were further investigated via 
conducting multiple between-group comparisons on individual test days (Benjamini-Hochbery 
correction of α = (i/k)*0.05)) along with one-way repeated measures ANCOVAs within each 
treatment group. This analysis aimed to specifically identify the development and extinction of 
between-group differences within the go/no-go task.   
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4.2.12 The effects of acute amphetamine challenges on behavioural 
disinhibition  
After checks of normality, the following transformations were performed before conducting 
analysis of acute amphetamine challenges: log₁₀ transformation (No-go trial response latency, 
Go trial magazine latency). 
The effect of acute amphetamine challenges upon behavioural disinhibition was assessed via 2 
x 5 repeated measures ANO As with ‘amphetamine dose’ entered as the within-subjects 
factor and ‘drug treatment group’ entered as the between-subjects factor. All main effects 
were followed up via post hoc Sidak corrected tests and significant interactions were 
deconstructed via simple effects analysis, whereby the pooled error term from the original 
ANOVA model was utilised to generate the post hoc F value, as described in section 4.2.11, 
page 85. 
  
95 
 
4.3Results  
Unless otherwise stated, for all of the following ANCOVAs homogeneity of regression was 
assumed (p > 0.05) and average baseline performance was found to significantly affect 
treatment groups (p < 0.05), reinforcing the need to control for within-subject variation. Due 
to data remaining abnormally distributed following transformations, the total percentage 
correct of Go trials, No-go trial response latencies and Go trial panel responses were re-
expressed as a percentage of baseline performance and analysed in ANOVA. During baseline 
these variables were analysed using non-parametric tests Friedman’s ANO A and Mann 
Whitney U tests. All values within graphs represent means and error bars represent the 
standard error of the mean (SEM). 
4.3.1 Experiment 2a: Pre-drug baseline performance 
4.3.1.1 Performance accuracy: 
No main effect of baseline day was revealed by the analysis of the total percentage correct of 
trials (F(6, 102) = 1.777, NS), the total percentage correct of Go trials (χ(6) = 6.559, NS) or the 
total percentage correct of No-go trials (F(6, 102) = 1.877, NS). Accuracy of performance also 
did not differ between treatment groups within the total percentage correct of all trials (F(1, 
17) = 0.068, NS), the total percentage correct of Go trials (all days U > 36, NS) and the total 
percentage correct of No-go trials (F(1, 17) = 0.180, NS). No significant baseline day x 
treatment group interactions were found within the total percentage correct of trials (F(6, 102) 
= 1.033, NS) or the total percentage correct of No-go trials (F(6, 102) = 1.143, NS) (Figs 4.1 - 
4.2). 
4.3.1.2 Speed of Responding: 
No main effect of baseline day was revealed by the analysis of Go trial response latencies (F(6, 
102) = 0.623, NS), No-go trial response latencies (F(6, 102) = 1.383, NS), Go trial magazine 
latencies (F(1, 17) = 0.170, NS) or No-go trial magazine latencies (F(3.659, 62.211) = 0.705, NS). 
No difference was found between drug treatment groups within the analysis of Go trial 
responses latencies (F(1, 17) = 1.730, NS), No-go trial response latencies (F(1, 17) = 0.098, NS), 
Go trial magazine latencies (F(1, 17) = 0.170, NS)  and No-go trial magazine latencies (F(1, 17) = 
0.046, NS). Furthermore, no significant baseline day x treatment group interactions were 
found by the analysis of Go trial response latencies (F(6, 102) = 0.777, NS), No-go trial response 
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latencies (F(6, 102) =1.370, NS), Go trial magazine latencies(F(3.220, 57.732) = 0.777, NS)  and 
No-go trial magazine latencies (F(63.659, 62.211) = 0.705, NS) (Table 4.1). 
4.3.1.3 Anticipatory Responding: 
No significant difference was revealed by the analysis of Go trial early responses (F(6, 102) = 
0.569, NS), No-go trial early responses (F(6, 102) = 0.595, NS), Go trial panel responses (χ(6) = 
4.622, NS) and No-go trial panel responses (F(6, 102) = 0.618, NS). Similarly, no differences 
were detected between treatment groups in the analysis of Go trial early responses (F(1, 17) = 
0.370, NS), No-go trial early responses (F(1, 17) = 0.829, NS), Go trial panel responses (all days 
U > 30, NS) and No-go trial panel responses (F(1, 17) = 0.031, NS). Furthermore, no significant 
baseline day x treatment group interactions were detected by the analysis of Go trial early 
responses (F(6, 102) = 2.042, NS), No-go trial early responses (F(6, 102) = 1.155, NS) and No-go 
trial panel responses (F(6, 102) = 0.937, NS)  (Table 4.2). 
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Behavioural Measure Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Go Trial 
Response 
Latency 
Saline 0.98 ± 0.16 0.91 ± 0.12 0.86 ± 0.14 0.96 ± 0.12 0.81 ± 0.13 1.05 ± 0.13 1.11 ± 0.17 
Amphetamine 0.77 ± 0.13 1.77 ± 0.09 0.70 ± 0.11 0.85 ± 0.14 0.75 ± 0.11 0.75 ± 0.14 0.73 ± 0.17 
No-go Trial 
Incorrect 
Response 
Latency 
Saline 1.95 ± 0.33  1.93 ± 0.25  1.80 ± 0.29  2.40 ± 0.36  2.81 ± 0.36  2.02 ± 0.27  1.88 ± 0.33  
Amphetamine 1.82 ± 0.22  1.97 ± 0.41  2.09 ± 0.29  1.78 ± 0.41  2.12 ± 0.23  2.34 ± 0.32  1.97 ± 0.38  
Go Trial 
Magazine 
Latency 
Saline 0.42 ± 0.08  0.40 ± 0.10  0.38 ± 0.06  0.40 ± 0.06  0.37 ± 0.05  0.38 ± 0.05  0.37 ± 0.04  
Amphetamine 0.42 ± 0.05  0.41 ± 0.04  0.40 ± 0.04  0.38 ± 0.03  0.39 ± 0.03  0.39 ± 0.04  0.38 ± 0.04  
No-go Trial 
Magazine 
Latency 
Saline 0.60 ± 0.13  0.66 ± 0.15  0.71 ± 0.17  0.73 ± 0.16  0.71 ± 0.12  0.69 ± 0.12  0.64 ± 0.13  
Amphetamine 0.64 ± 0.07  0.65 ± 0.07  0.67 ± 0.08  0.63 ± 0.09  0.60 ± 0.06  0.68 ± 0.07  0.65 ± 0.06  
 
Behavioural Measure Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Go Trial Early 
Response 
Saline 19.50 ± 2.54  20.30 ± 2.84  22.10 ± 3.01  19.60  ± 2.42  19.90 ± 2.06  18.00 ± 2.54  17.60  ± 1.86  
Amphetamine 22.22 ± 3.58  22.22 ± 2.90  20.78 ± 2.33  21.00 ± 2.95  20.67 ± 2.59  21.33 ± 2.88  23.78 ± 3.17  
No-go Trial 
Early 
Response 
Saline 10.10 ± 2.09  9.60 ± 2.07  9.80 ± 1.85  9.30 ± 1.63  8.10 ± 1.68  8.50 ± 1.68  9.40 ± 2.07  
Amphetamine 11.44 ± 1.89  11.89 ± 2.97  12.00 ± 1.50  11.89 ± 2.21  12.89 ± 1.87  11.11 ± 2.09  10.33 ± 2.15  
Go Trial Panel 
Response 
Saline 1.30 ± 0.45  1.90 ± 2.42  1.00 ± 0.30  1.00 ± 0.37  0.80 ± 0.20  0.90 ± 0.23  0.50 ± 0.17  
Amphetamine 1.11 ± 0.42  1.11 ± 0.48  0.44 ± 0.18  0.67 ± 0.33  0.78 ± 0.32  1.33 ± 0.75  0.67 ± 0.33  
No-go Trial 
Panel 
Response 
Saline 11.00  ± 2.31  10.30 ± 2.39  9.00 ± 2.23  9.50 ± 2.42  9.40 ± 2.27  8.00 ± 2.03  9.20 ± 2.32  
Amphetamine 10.22  ± 2.53  9.56 ± 2.64  10.56 ± 2.40  10.00 ± 1.97  9.22 ± 2.18  10.22 ± 3.02  10.56 ± 2.81  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4.2:Baseline: Anticipatory responding during baseline week. Values represent means and the SEM. 
 
Table 4.1: Baseline: Speed of responding during baseline week. Values represent means and the standard error or the mean (SEM). 
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Figure 4.1. Performance within the total percentage correct of all trials during baseline week, drug administration, withdrawal week one and 
withdrawal week two. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant difference between amphetamine and saline 
group. Values represent means and error bars represent the SEM. 
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Figure 4.2. Performance within the total percentage correct of Go and No-go trials during baseline week, drug administration, withdrawal 
week one and withdrawal week two. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant difference between 
amphetamine and saline group. Values represent means and error bars represent the SEM. 
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4.3.2   Experiment 2a: 4-day amphetamine treatment 
4.3.2.1 Performance accuracy: 
Analysis of the total percentage correct of trials revealed no main effect of drug day (F(2, 32) = 
2.398, p > 0.05, NS), however, a main effect of treatment group revealed that amphetamine 
treated animals had lower accuracy during drug treatment in comparison to saline controls 
(F(1, 16) = 23.117, p < 0.001). Further within-subjects analysis of this effect revealed that the 
total percentage of correctly completed trials was not affected between drug days amongst 
saline treated animals (F(1.237, 9.894) = 3.920, NS), however, amphetamine treated animals 
had reduced accuracy across drug days (F(2, 14) = 5.513, p < 0.05), specifically on drug day 3 in 
comparison to drug day 2 (p < 0.05) (Fig. 4.1). Further analysis of between-subjects effects 
revealed that amphetamine treated animals had lower accuracy in comparison to saline 
controls specifically on drug day 1 (F(1, 16) = 7.838, p < 0.05), day 2 (F(1, 16) = 6.205, p < 0.05) 
and day 3 (F(1, 16) = 14.965, p < 0.001) (Fig. 4.1) (Benjamini-Hochberg correction, α = p < 0.05 
– p < 0.016, see Appendix 1, Table 1a for specific F- and corrected p-values).  However, no drug 
day x treatment group interaction was detected within the total percentage correct of trials 
(F(2, 32) = 1.807, NS).  
Analysis of Go trials independently revealed no main effect of drug day (F(2, 34) = 0.039, NS), 
drug treatment (F(1, 17) = 0.096, NS) or day x treatment group interaction (F(2, 34) = 0.034, 
NS) (Fig. 4.2). Analysis of No-go trials also revealed no main effect of drug day on No-go trial 
accuracy (F(2, 32) = 1.957, NS), however, amphetamine treated animals had significantly lower 
accuracy within No-go trials in comparison to saline controls (F(1, 16) = 17.742, p < 0.001). 
Further within-subjects analysis of this effect revealed that the total percentage of correctly 
completed No-go trials was not affected between drug days amongst saline (F(1, 14) = 3.402, 
NS) or amphetamine treated animals (F(2, 16) = 3.228, NS). Further analysis of between-
subject effects revealed that amphetamine treated animals had lower accuracy within No-go 
trials in comparison to controls specifically on drug day 1 (F(1, 16) = 10.848, p < 0.05) and day 3 
(F(1, 16) = 11.253, p < 0.01) (Fig. 4.2) (Benjamini-Hochberg correction, α = p < 0.05 – p < 0.016, 
see Appendix 1, Table 1b for specific F- and corrected p-values).  No drug day x treatment 
group interaction was detected within No-go trial accuracy (F(2, 34) = 2.065, NS). 
4.3.2.2 Speed of Responding: 
Analysis of Go trial response latencies revealed no main effect of drug days (F(2, 32) = 2.570, 
NS), drug treatment group (F(1, 16) = 2.749, NS) or drug day x drug treatment group 
101 
 
interaction (F(2, 32)= 0.017, NS) (Table 4.3). Analysis of No-go trial response latencies also 
revealed no main effect of drug day (F(2, 32) = 0.044, NS) and drug treatment group (F(1, 16) = 
0.028, NS). A drug day x drug treatment group interaction was however detected within No-
go-trial response latencies (F(2, 32) = 2.695, p < 0.05). Within-subjects simple effects analysis 
of this interaction revealed that neither saline (F(16, 32) = 0.507, p > 0.05) or amphetamine 
treatment (F(14, 32) = 1.362, p > 0.05) affected the speed to make an incorrect response 
during No-go trials across drug days (Table 4.3). In addition, between-subjects simple effects 
analysis revealed no difference in the speed to make an incorrect response during No-go trials 
on drug day 1, day 2, or day 3 (df= 1, 48, all F ≤ 2.845, NS) (Table 4.3) (Benjamini-Hochberg 
correction, α = p < 0.05 – p < 0.016, see Appendix 1, Table 1c. for specific F- and corrected p-
values).  
Go trial magazine latencies were unaffected by drug days (F(2, 32) = 0.463, NS), drug 
treatment group (F(1, 16) = 0.199, NS), and no drug day x drug treatment group interaction 
was found (F(2, 32) = 0.263, NS) (Table 4.3). A main effect of drug day was detected within No-
go trial magazine latencies (F(2, 32) = 3.939, p < 0.05), however, post-hoc analysis of this main 
effect failed to identify a significant difference between individual drug days in the speed to 
collect the food reward during No-go trials (all p > 0.05) (Table 4.3). No-go trial magazine 
latencies were unaffected by drug treatment group (F(1, 16) = 3.412, NS) and no drug day x 
drug treatment group interaction was found (F(2, 32) = 2.529, NS) (Table 4.3). 
4.3.2.3 Anticipatory Responding:  
Go trial early responses were unaffected by drug day (F(2, 32) = 0.791, NS), drug treatment 
group (F(1, 16) = 0.109, NS) and no drug day x drug treatment group interaction was found 
(F(2, 32) = 1.623, NS) (Table 4.4). Similarly, No-go trial early responses were not affected by 
drug day (F(2, 32) = 2.095, NS), drug treatment group (F(1, 16) = 0.241, NS) and no drug day x 
drug treatment group interaction was found (F(2, 32) = 0.125, NS) (Table 4.4). Analysis of Go 
trial panel responses revealed no main effect of drug day (F(2, 34) = 2.120, NS), however, a 
main effect of drug treatment group revealed that amphetamine treated animals performed 
more Go trial panel responses in comparison to saline controls during drug treatment (F(1, 17) 
= 7.064, p < 0.05). Analysis of within-subject effects of amphetamine and saline groups 
independently revealed no main effect of amphetamine (F(2, 18) = 2.120, NS) or saline (F(2, 
16) = 2.698, NS) on Go trial panel responses between drug days. Further analysis of between-
group effects revealed that amphetamine treated animals made more Go trial panel responses 
specifically on drug day 3 (F(1, 17) = 12.140, p < 0.01) but not drug days 1 and 2 (df = 1, 17, all F 
≤ 3.059, NS) (Table 4.4) (Benjamini-Hochberg correction, α = p < 0.05 – p < 0.016, see Appendix 
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Behavioural Measure Day 1 Day 2 Day 3 
Go Trial 
Response 
Latency 
Saline 0.88 ± 0.13  0.91 ± 0.10  1.06 ± 0.09  
Amphetamine 0.84 ± 0.15  1.04 ±  0.20  1.13 ±  0.12  
No-go Trial 
Incorrect 
Response 
Latency 
Saline 2.52 ± 0.39  1.74 ± 0.29  1.97 ± 0.35  
Amphetamine 1.79 ± 0.28  2.23 ± 0.23  2.08 ± 0.38  
Go Trial 
Magazine 
Latency 
Saline 0.40 ± 0.11  0.41 ± 0.09  0.44 ± 0.11  
Amphetamine 0.41 ± 0.05  0.41 ± 0.04  0.40 ± 0.03  
No-go Trial 
Magazine 
Latency 
Saline 0.65 ± 0.15  0.65 ± 0.11  0.73 ± 0.13  
Amphetamine 0.64 ± 0.06  0.85 ± 0.09  0.71 ± 0.07  
 
Behavioural Measure Day 1 Day 2 Day 3 
Go Trial Early 
Response 
Saline 17.60 ± 2.39  21.3 ± 2.13  19.30 ± 1.76  
Amphetamine 21.89 ± 2.53  20.00 ± 2.93  19.00 ± 2.07  
No-go Trial 
Early 
Response 
Saline 8.70 ± 1.56  9.40 ± 1.92  11.2 ± 1.71  
Amphetamine 11.67 ± 2.07  12.33 ± 2.16  12.89 ± 2.49  
Go Trial Panel 
Response 
Saline 1.30 ± 0.40  1.00 ± 0.33  1.20 ± 0.42  
Amphetamine 1.44 ± 0.53  1.89 ± 0.59  2.77 ± 0.32  
No-go Trial 
Panel 
Response 
Saline 8.00 ± 2.23  8.90 ± 1.83  8.30 ± 2.27  
Amphetamine 11.44 ± 2.90  10.44 ± 2.17  9.44 ± 1.69  
 
1, Table 1d for specific F- and corrected p-values). No drug day x drug treatment group 
interaction was detected during Go trial panel responses (F(2, 34) = 2.698, NS) (Table 5). No-go 
trial panel responses were unaffected by drug day (F(1.475, 23.597) = 1.753, NS), drug 
treatment group (F(1, 16) = 2.152, NS) or drug day x drug treatment group interaction  
(F(1.475, 23.597) = 0.898, NS) (Table 4.4). 
 
 
 
 
 
  
Table 4.3: 4-Day Amphetamine: Speed of Responding during 
4-day amphetamine binge. Values represent means and SEM. 
Table 4.4: 4-Day Amphetamine: Anticipatory Responding 
during 4-day amphetamine binge. *p<0.05 and **p<0.01, 
***p<0.001 = significant difference between amphetamine and 
saline group. Values represent means and SEM. 
** 
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4.3.3 Experiment 2b: Amphetamine withdrawal week one 
4.3.3.1 Performance Accuracy: 
Analysis of the total percentage of correctly completed trials revealed no main effect 
withdrawal days (F(4.082, 65.305) = 2.007, NS), however, amphetamine treated animals were 
found to perform significantly less correct responses in comparison to controls (F(, 1, 16) = 
13.523, p < 0.01). Further within-subjects analysis of this effect revealed that performance was 
not affected between withdrawal days within either saline (F(1, 14) = 3.402, NS) or 
amphetamine (F(2, 16) = 3.228, NS) treated animals when analysed independently (Fig. 4.1). 
Further analysis of between-group effects revealed that amphetamine treated animals 
performed less correct responses specifically at 12 (F(1, 16) = 40.041, p < 0.001), 18 (F(1, 16) = 
7.694, p < 0.01), 36 (F(1, 16) = 12.921, p < 0.05), 132 (F(1, 16) = 5.67, p < 0.05) and 156 (F(1, 16)  
6.519, p < 0.05) hours of amphetamine withdrawal (Fig. 4.1) (Benjamini-Hochberg correction, 
α = p < 0.05 – p < 0.006, see Appendix 1, 1e for all specific F- and corrected p-values). No 
significant withdrawal day x drug treatment group interaction was detected by the analysis of 
the total percentage correct of correctly completed trials during withdrawal week one 
(F(4.082, 65.305) = 2.007, NS). 
Independent analysis of Go trials revealed no main effect of withdrawal day (F(3.733, 63.464) = 
0.677, NS), drug treatment group (F(1, 17) = 0.038, NS) or withdrawal day x drug treatment 
group interaction (F(3.733, 63.464) = 0.880, NS) on Go trial accuracy during withdrawal week 
one (Fig. 4.2). Independent analysis of No-go trials also revealed that withdrawal days did not 
affect No-go trial accuracy (F(7, 112) = 1.930, NS), however, amphetamine treated animals 
were found to perform significantly less correct No-go trials during withdrawal week one in 
comparison to controls (F(1, 16) = 12.397, p < 0.01). Further within-subjects analysis of this 
effect revealed that No-go trial performance was not affected between withdrawal days within 
either saline (F(2.959, 23.672) = 1.151, NS) or amphetamine (F(4, 49) = 1.708, NS) treated 
animals when analysed independently. Further analysis of drug treatment group effects, 
however, revealed that amphetamine treated animals made less correct No-go trials than 
controls specifically at 12 (F(1, 16) = 17.893, p < 0.001), 18 (F(1, 16) = 6.148, p < 0.01), 36 (F(1, 
16) = 15.368, p < 0.05) and 156 (F(1, 16) = 8.762, p < 0.05) hours of drug withdrawal (Fig. 4.2) 
(Benjamini-Hochberg correction, α = p < 0.05 – p < 0.006, see Appendix 1, Table 1f for all 
specific F- and corrected p-values). However, no significant withdrawal hour x drug treatment 
group interaction was found during No-go trial accuracy during withdrawal week one (F(7, 112) 
= 0.835, NS). 
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4.3.3.2 Speed of responding: 
Analysis of Go trial response latencies revealed no significant main effects of either withdrawal 
hour (F(4.319, 60.104) = 1.174, NS) or drug treatment group (F(1, 16) = 3.967, NS). However, a 
withdrawal hour x drug treatment group interaction was detected within the Go trial response 
latencies (F(4,319, 69.104) = 3.920, p < 0.01). Within-subjects simple effects analysis of this 
interaction revealed no effect of withdrawal hours on the speed of responding during Go trials 
within saline (F(7, 56) = 1.910, NS) or amphetamine treated animals (F(7, 49) = 1.186, NS), 
whilst between-subjects simple effects analysis revealed that amphetamine treated animals 
became significantly slower in their speed of responding during Go trials at 60 hours of drug 
withdrawal in comparison to controls (F(1, 16) = 10.298, p < 0.01) (Table 4.5). In addition, no 
significant between-group effects were detected at any other time points in withdrawal week 
one (df = 1, 16, all F ≤ 5.210, NS) (Table 4.5) (Benjamini-Hochberg correction, α = p < 0.05 – p < 
0.005, see Appendix 1, Table 1g for specific F- and corrected p-values). No-go trial response 
latencies were unaffected by withdrawal hour (F(4.241, 72.094) = 0.957, NS), drug treatment 
group (F(1, 17) = 0.970, NS) and no withdrawal hour x drug treatment group interaction was 
found (F(4.241, 72.094) = 1.476, NS). 
Go trial magazine latency was unaffected by withdrawal hour (F(3.716, 59.451) = 0.501, NS), 
drug treatment group (F(1, 16) = 0.515, NS), and no withdrawal hour x drug treatment 
interaction was detected (F(3.716, 59.451) = 0.887, NS) (Table 4.5). Analysis of No-go trial 
magazine latencies revealed no main effect of withdrawal hour (F(7, 112) = 1.026, NS) and by 
drug treatment group (F(1, 16) = 0.749, NS). However, a withdrawal hour x drug treatment 
interaction was detected in No-go trial magazine latency (F(7, 112) = 3.848, p < 0.001). Within-
subjects simple effects analysis of this interaction revealed that withdrawal hour significantly 
affected the speed to collect food reward during No-go trials in amphetamine treated animals 
(F(49, 122) = 1.475, p < 0.05) whilst the speed to collect food reward during No-go trials was 
unaffected by withdrawal hour in saline treated animals (F(56, 112) = 1.150, NS). The main 
effect of withdrawal hour on No-go trial magazine latencies within amphetamine treated 
animals, however, did not reveal any specific significant differences between individual 
withdrawal hours when analysed with post-hoc tests (all p > 0.05). Between-groups simple 
effects analysis also did not produce any significant difference in No-go trial magazine latencies 
between drug treatment groups at specific withdrawal hours (df = 1, 16, all F ≤ 6.953, NS), and 
only detected a trend towards a significant increase in No-go trial magazine latencies amongst 
amphetamine treated animals at 18 hours of drug withdrawal (F(1, 16) = 6.953, p = 0.009, NS) 
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(Table 4.5) (Benjamini-Hochberg correction, α = p < 0.05 – p < 0.006, see Appendix 1, 1h for 
specific F- and corrected p-values).   
4.3.3.3 Anticipatory Responding: 
Go trial early responses were unaffected by withdrawal hour (F(7, 112) = 0.549, NS), drug 
treatment group (F(1, 16) = 0.0035, NS) and no withdrawal hour x drug treatment group 
interaction was found during withdrawal week one (F(7, 112) = 1.637, NS) (Table 4.6). No-go 
trial early responses were similarly unaffected by withdrawal hour (F(7, 112) = 1.482, NS) and 
drug treatment group (F(1, 16) = 0.292, NS). A withdrawal hour x drug treatment group 
interaction was, however, detected within No-go trial early responses (F(7, 112) = 2.418, p < 
0.05). Within-subject simple effect analysis of this interaction identified a main effect of 
withdrawal hour on No-go trial early responses within amphetamine treated animals (F(49, 
112) = 1.475, p < 0.05) but not within saline treated animals (F(56, 112) = 1.150, NS). Post hoc 
analysis of this withdrawal hour effect within amphetamine treated animals, however, failed 
to produce any significant difference in the number of early responses made during No-go 
trials between individual withdrawal hours (all p > 0.05). Between-subjects simple effects 
analysis also revealed no significant difference between drug treatment groups at individual 
withdrawal hours measured during withdrawal week one (df = 1, 128, all F ≤ 3.081, NS) (Table 
4.6) (Benjamini-Hochberg correction, α = p < 0.05 – p < 0.006, see Appendix 1, 1i for specific F- 
and corrected p-values). 
A main effect of withdrawal hour was detected on Go trial panel responses during withdrawal 
week one (F(2.967, 50.433) = 5.079, p < 0.01). Post-hoc Sidak analysis of this effect, however, 
only revealed a trend towards a significant increase in Go trial panel responses at 12 hours vs. 
108 hrs of drug withdrawal (p = 0.069), and all remaining post-hoc comparisons were not 
significant (all p > 0.05) (Table 4.6). Go trial panel responses were unaffected by treatment 
group during withdrawal week one (F(1, 16) = 3.086, NS) and no withdrawal hour x drug 
treatment group interaction as detected (F(2.967, 50.433) = 2.579, NS) (Table). No-go trial 
panel responses were unaffected by withdrawal hour (F(7, 112) = 0.217, NS), drug treatment 
group (F(1, 16) = 1.881, NS) and no withdrawal hour x drug treatment group interaction was 
found (F(7, 112) = 0.600, NS) (Table 4.6). 
106 
 
Behavioural Measure 12 hrs 18 hrs 36 hrs  60 hrs 84 hrs 108 hrs 132 hrs 156 hrs 
Go Trial Early 
Response 
Saline 18.60 ± 2.50  19.90 ± 2.61  17.80 ± 2.63  18.70  ± 2.13  20.40 ± 2.15  17.30 ± 2.38  19.00  ± 2.39  18.80 ± 2.40  
Amphet 17.22 ± 2.24  18.33 ± 2.13  18.33 ± 2.36  20.78 ± 2.23  20.89 ± 2.53  22.22 ± 2.26  21.44 ± 2.41  22.67 ± 1.89  
No-go Trial 
Early 
Response 
Saline 8.90 ± 1.70  10.10 ± 2.08  8.50 ± 1.19  10.80 ± 1.85  8.00 ± 1.29  10.30 ± 1.58  9.10 ± 2.07  8.50  ± 2.07  
Amphet 13.11 ± 1.86  14.00 ± 1.81  12.78 ± 1.76  10.11 ± 1.59  10.89 ± 1.99  9.89 ± 1.33  11.44 ± 1.83  10.78 ± 1.87  
Go Trial 
Panel 
Response 
Saline 1.30 ± 0.56  1.70 ± 0.62  1.10 ± 0.23  0.60 ± 0.22  0.50 ± 0.22  0.60 ± 0.22  0.70 ± 0.21  0.50 ± 0.22  
Amphet 3.44 ± 0.88  2.44 ± 0.80  1.11 ± 0.54  1.33 ± 0.55  0.67 ± 0.29  0.33 ± 0.17  0.67 ± 0.24  1.11 ± 0.42  
No-go Trial 
Panel 
Response 
Saline 11.70  ± 2.66  12.00 ± 2.86  10.00 ± 2.87  10.70 ± 2.37  8.80 ± 2.25  9.70 ± 2.30  10.10 ± 2.27  10.60 ± 2.38  
Amphet 9.56  ± 1.89  10.00 ± 2.54  8.44 ± 1.59  7.89 ± 1.84  8.44 ± 2.36  8.44 ± 1.81  9.11 ± 2.28  8.11 ± 2.12  
 
Behavioural Measure 12 hrs 18 hrs 36 hrs  60 hrs 84 hrs 108 hrs 132 hrs 156 hrs 
Go Trial 
Response 
Latency  
Saline 0.97 ± 0.12  0.86 ± 0.16  1.10 ± 0.21  0.876  ± 0.15  1.12 ± 0.12  1.06 ± 0.19  0.99  ± 0.12  1.04 ± 0.12  
Amphet 1.18 ± 0.12  1.07 ± 0.14  1.11 ± 0.16  1.22 ± 0.17  0.83 ± 0.09  1.06 ± 0.14  1.03 ± 0.13  0.74 ± 0.07  
No-go Trial 
Incorrect 
Response 
Latency 
Saline 1.87 ± 0.26  2.08 ± 0.41  2.50 ± 0.29  1.96 ± 0.234  1.89 ± 0.27  2.11 ± 0.26  1.83 ± 0.18  2.22  ± 0.36  
Amphet 
2.51 ± 0.29  2.26 ± 0.32  2.19 ± 0.19  2.20 ± 0.27  2.33 ± 0.25  3.07 ± 0.37  1.92 ± 0.18  2.92 ± 0.41  
Go Trial 
Magazine 
Latency  
Saline 0.43 ± 0.09  0.45 ± 0.14  0.45 ± 0.12  0.42 ± 0.11  0.40 ± 0.10  0.40 ± 0.10  0.41 ± 0.10  0.38 ± 0.08  
Amphet 0.39 ± 0.03  0.36 ± 0.03  0.38 ± 0.04  0.40 ± 0.06  0.36 ± 0.04  0.39 ± 0.04  0.34 ± 0.02  0.38 ± 0.05  
No-go Trial 
Magazine 
Latency  
Saline 0.74  ± 0.17  0.64 ± 0.13  0.68 ± 0.15  0.69 ± 0.16  0.66 ± 0.11  0.61 ± 0.10  0.76 ± 0.13  0.78 ± 0.16  
Amphet 0.87  ± 0.09  0.88 ± 0.08  0.75 ± 0.07  0.83 ± 0.12  0.62 ± 0.07  0.71 ± 0.09  0.61 ± 0.05  0.59 ± 0.04  
 
Table 4.5: Withdrawal Week One: Speed of Responding during withdrawal week one. *p<0.05 and **p<0.01, ***p<0.001 = significant 
difference between amphetamine and saline group. Values represent means and SEM. 
Table 4.6: Withdrawal Week One: Anticipatory Responding during withdrawal week one. Values represent the mean and SEM. 
** 
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4.3.4  Experiment 2c: Withdrawal week two  
4.3.4.1 Performance Accuracy: 
Analysis of the total percentage of correctly completed trials during withdrawal week two 
revealed no main effect of  withdrawal day (F(6, 96) = 1.379, NS), however, a main effect of 
drug treatment group was detected (F(1, 16) = 4.983, p < 0.05) (Fig. 4.1). Further analysis of 
this main effect revealed no effect of withdrawal day on performance accuracy within saline 
(F(6, 48) = 2.029, NS) or amphetamine treated animals (F(6, 42) = 3.402, NS) when analysed 
independently, however, amphetamine treated animals performed less correct trials on 
withdrawal day 8 in comparison to saline controls (F(1, 16) = 16.958, p < 0.001) (Fig. 4.1). All 
remaining drug withdrawal days did not reveal any difference in performance accuracy 
between amphetamine and saline controls (df = 1, 16, all F ≤ 4.513) (Fig. 4.1) (Benjamini-
Hochberg correction, α = p < 0.05 – p < 0.007, see Appendix 1, Table 1j for specific F- and 
corrected p-values). A withdrawal day x drug treatment group interaction was not detected 
within the total percentage correct of trials (F(6, 96) = 1.379, NS). 
Independent analysis of Go trial accuracy revealed no main effect of withdrawal day (F(6, 102) 
= 1.554, NS), drug treatment group (F(1, 17) = 2.279, NS) or withdrawal day x drug treatment 
group interaction (F(6, 102) = 1.557, NS) (Fig. 4.2). Independent analysis of No-go trial accuracy 
also revealed no main effect of withdrawal day (F(6, 96) = 2.107, p = 0.059, NS), drug 
treatment group (F(1, 16) = 3.247, p = 0.090, NS) or withdrawal day x drug treatment group 
interaction (F(6, 96) = 2.053, NS) (Fig. 4.2). 
4.3.4.2 Speed of Responding: 
Analysis of Go trial response latencies were revealed no main effect of withdrawal day (F(6, 96) 
= 0.763, NS), drug treatment group (F(1, 16) = 0.145, NS), and no withdrawal day x drug 
treatment group interaction (F(6, 96) = 0.533, NS) (Table 4.7). Analysis of No-go trial response 
latencies were similarly unaffected by withdrawal day (F(4.108, 69.835) = 1.947, NS), drug 
treatment group (F(1, 17) = 0.041, NS), and no withdrawal day x drug treatment group 
interaction was detected (F(4.108, 69.835) = 2.356, NS) (Table 4.7). 
Analysis of Go trial magazine latencies also revealed no main effect of withdrawal day (F(6, 96) 
= 1.551, NS), drug treatment group (F(1, 16) = 0.904, NS) and no withdrawal day x drug 
treatment group interaction (F(6, 96) = 1.534, NS) (Table 4.7). Analysis of No-go trial magazine 
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latencies produced a main effect of withdrawal day (F(6, 96) = 2.766, p < 0.05), however, post 
hoc comparisons failed to identify any difference in the speed to collect food reward on 
individual withdrawal days during drug withdrawal week two (all p > 0.05) (Table 4.7). No main 
effect of drug treatment group (F(1, 16)= 0.904, NS) or withdrawal day x drug treatment group 
interaction (F(6, 96) = 1.242, NS) were additionally detected by the analysis of No-go trial 
magazine latencies during drug withdrawal week two (Table 4.7).  
4.3.4.3 Anticipatory Responding: 
Analysis of Go trial early responses revealed no main effect of withdrawal day (F(6, 96) = 0.585, 
NS), drug treatment group (F(1, 16) = 0.017, NS) and no withdrawal day x drug treatment 
group interaction was detected (F(6, 96) = 0.534, NS) (Table 4.8). Similarly, analysis of No-go 
trial early responses revealed no main effect of withdrawal day (F(6, 96) = 0.571, NS), drug 
treatment group (F(1, 16) = 0.946, NS), and no withdrawal day x drug treatment group 
interaction (F(6, 96) = 0.571, NS) (Table 4.8). 
Analysis of Go trial panel responses revealed no main effect of withdrawal day (F(3.091, 
52.541) = 2.731, p = 0.051, NS) and drug treatment group (F(1, 17) = 2.079, NS), and no 
withdrawal day x treatment group interaction (F(3.091, 52.541) = 2.532, NS) (Table 4.8). 
Analysis of No-go trial panel responses revealed no main effect of withdrawal day (F(6, 96) = 
0.916, NS) and drug treatment group (F(1, 16) = 0.028, NS), however, a significant withdrawal 
day x drug treatment group interaction was detected by the analysis of No-go trial panel 
responses during withdrawal week two (F(6, 96) = 2.924, p < 0.05). Within-subjects simple 
effects analysis of this interaction, however, failed to detect a significant effect of withdrawal 
day on No-go trial panel responses within saline (F(48, 96) = 0.877, NS) or amphetamine 
treated animals (F(42, 96) = 0.873, NS). Between-subjects simple effects analysis also failed to 
detect a difference in No-go trial panel responses between drug treatment groups at specific 
days during withdrawal week two (df = 1, 16, all F ≤ 2.265, NS) (Table 4.8) (Benjamini-Hochberg 
correction, α = p < 0.05 – p < 0.007, see Appendix 1, Table 1k for specific F- and corrected p-
values). 
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Behavioural Measure WD8  WD9  WD10  WD11  WD12  WD13  WD14 
Go Trial 
Response 
Latency  
Saline 0.77 ± 0.09  0.91 ± 0.15  0.81 ± 0.11  0.89  ± 0.13  0.93 ± 0.10  1.07 ± 0.18  0.92  ± 0.15  
Amphetamine 0.70 ± 0.10  0.81 ± 0.10  0.72 ± 0.11  0.94 ± 0.18  1.01 ± 0.18  0.85 ± 0.15  0.94 ± 0.15  
No-go Trial 
Incorrect 
Response 
Latency 
Saline 2.09 ± 0.29  1.94 ± 0.18  2.54 ± 0.45  1.72 ± 0.22  3.23 ± 0.34  2.25 ± 0.45  1.79 ± 0.27  
Amphetamine 2.45 ± 0.38  2.36 ± 0.32  1.57 ± 0.26  2.15 ± 0.30  2.06 ± 0.36  2.35 ± 0.23  2.01 ± 0.29  
Go Trial 
Magazine 
Latency  
Saline 0.43 ± 0.12  0.38 ± 0.11  0.39 ± 0.09  0.41 ± 0.09  0.41 ± 0.11  0.42 ± 0.11  0.44 ± 0.15  
Amphetamine 0.38 ± 0.05  0.37 ± 0.05  0.04 ± 0.06  0.32 ± 0.03  0.37 ± 0.04  0.38 ± 0.05  0.39 ± 0.05  
No-go Trial 
Magazine 
Latency  
Saline 0.75  ± 0.17  0.80 ± 0.14  0.68 ± 0.14  0.70 ± 0.15  0.78 ± 0.14  0.85 ± 0.20  0.68 ± 0.11  
Amphetamine 0.55  ± 0.06  0.61 ± 0.06  0.57 ± 0.07   0.67± 0.06  0.65 ± 0.07  0.72 ± 0.09  0.72 ± 0.09  
 
Behavioural Measure WD8  WD9  WD10  WD11  WD12  WD13  WD14 
Go Trial 
Early  
Responses  
Saline 19.10 ± 2.16  20.40 ± 2.34  21.20 ± 2.78  20.60  ± 2.23  19.20 ± 3.12  17.60 ± 3.31  18.70  ± 2.24  
Amphetamine 23.44 ± 2.62  21.56 ± 2.96  20.89 ± 3.13  21.56 ± 2.80  21.89 ± 2.24  22.11 ± 1.83  19.78 ± 2.36  
No-go Trial 
Early  
Responses 
Saline 9.90 ± 2.06  9.00 ± 2.11  9.40 ± 1.98  8.50 ± 2.12  9.10 ± 2.16  8.50 ± 2.23  9.50 ± 1.88  
Amphetamine 14.33 ± 1.78  11.56 ± 1.62  12.00 ± 2.12  11.44 ± 2.04  12.56 ± 1.95  13.11 ± 1.93  12.67 ± 1.94  
Go Trial Panel 
Responses  
Saline 1.10 ± 0.41  0.90 ± 0.31  0.80 ± 0.33  0.20 ± 0.13  0.30 ± 0.15  1.10 ± 0.31  0.30 ± 0.15  
Amphetamine 0.56 ± 0.24  1.89 ± 0.86  1.11 ± 0.26  0.33 ± 0.17  1.11 ± 0.39  0.67 ± 0.44  0.67 ± 0.24  
Trial Panel 
No-go 
responses  
Saline 10.10  ± 2.12  10.50 ± 2.04  9.30 ± 1.77  7.70 ± 1.40  8.10 ± 2.18  7.20 ± 1.61  7.60 ± 1.42  
Amphetamine 7.78  ± 2.03  8.11 ± 2.16  8.11 ± 2.38  8.56 ± 1.89  9.22 ± 1.77  10.22 ± 2.42  8.78 ± 2.39  
 
Table 4.7: Withdrawal Week Two: Speed of Responding during withdrawal week two. Values represent the mean and SEM. 
Table 4.8: Withdrawal Week Two: Anticipatory Responding during withdrawal week two. Values Represent the mean and SEM. 
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4.3.5  Experiment 2d: Acute amphetamine challenges 
4.3.5.1 Performance Accuracy 
Acute amphetamine had an effect on the total percentage of correctly completed trials in both 
amphetamine and saline treated animals (F(4, 68) = 23.258, p = 0.001). Post hoc analysis of this 
effect revealed that the total percentage of correctly completed trials decreased following 0.8 
and 1.2 mg/kg in comparison to 0 and 0.2 mg/kg amphetamine (p < 0.001), and following 1.2 
mg/kg in comparison to 0.4 mg/kg amphetamine (all p < 0.001) (Fig. 4.3). However, there was 
no main effect of previous drug histories (saline vs. amphetamine) (F(1, 17) = 2.0101, NS) and 
no interaction between amphetamine dose x treatment group was detected (F(4, 68) = 0.278, 
NS).  
Analysis of the percentage of correctly completed Go trials revealed no main effect of 
amphetamine dose (df = 4, X2 = 3.123, NS), however, animals that previously received 
amphetamine treatment were found to have higher Go trial accuracy than animals that 
previously received saline treatment following 1.2 mg/kg of amphetamine (MWU = 20, p < 
0.05) (Fig. 4.4). Analysis of the percentage of correctly completed No-go trials revealed a main 
effect of amphetamine dose (F(4, 68) = 25.462, p = 0.001). Post hoc analysis of this effect 
revealed that the total percentage correct of No-go trials decreased following 0.8 and 1.2 
mg/kg in comparison to 0 and 0.2 mg/kg amphetamine (p < 0.001), and following 1.2 mg/kg in 
comparison to 0.4 mg/kg amphetamine (all p < 0.001) (Fig. 4.5). However, there was no main 
effect of previous drug treatment on No-go trial accuracy F(1, 17) = 1.545, NS) and no 
amphetamine dose x drug treatment group interaction was detected (F(4, 68) = 0.306, NS). 
4.3.5.2 Speed of Responding 
Analysis of Go trial response latencies revealed a main effect of amphetamine dose (F(2.796, 
47.531) = 6.882, p = 0.001). Post hoc analysis of this effect revealed that animals produced 
increased response latencies during G trials following 1.2 mg/kg in comparison to 0.2 and 0.4 
mg/kg of amphetamine (p < 0.01) (Fig. 4.6). However, no main effect of previous drug history 
(amphetamine vs. saline) was found in the analysis of Go trial response latencies (F(1, 17) = 
0.780, NS) and no amphetamine dose x drug pre-treatment group interaction was detected 
(F(2.796, 47.531) = 1.969, NS). Analysis of No-go trial response latencies revealed no main 
effect of amphetamine dose (F(4, 68) = 0.559, NS) and previous drug treatment group (F(1, 17) 
= 0.007, NS) or dose x treatment group interaction (F(4, 68) = 1.298, NS) (Fig. 4.7).  
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Post hoc analysis of a significant main effect of amphetamine dose on Go trial magazine 
latencies  (F(2.137, 36.333) = 10.113, p < 0.001) revealed that animals became slower to collect 
the food reward during Go trials following 1.2 mg/kg in comparison to 0, 0.2 and 0.4 mg/kg 
amphetamine (all p < 0.05) (Fig. 4.8). However, analysis of Go trial magazine latencies revealed 
no main effect of drug treatment group (F(1, 17) = 0.411, NS) or dose x treatment group 
interaction (F(2.137, 36.666) = 1.468, NS). Analysis of No-go trial magazine latencies revealed 
no main effect of amphetamine dose (F(2.396, 40.740) = 1.979, NS), previous drug treatment 
group (F(1, 17) = 0.125, NS) and no dose x treatment group interaction (F(2.137, 36.666) = 
1.094, NS) (Fig. 4.9).  
4.3.5.3 Anticipatory Responding: 
Acute amphetamine produced a treatment effect on Go trial early responses (F(2.973, 50.546) 
= 7.081, p = 0.001). Post hoc analysis of this effect revealed a decrease in Go trial early 
responses following 1.2 mg/kg in comparison to 0, 0.2 and 0.4 m/kg amphetamine in both 
amphetamine and saline treated animals (all p < 0.05) (Fig. 4.10). However, Go trial early 
responses did not differ between previous drug groups following acute amphetamine (F(1, 17) 
= 1.296, NS) and no amphetamine dose x treatment group interaction was detected (F(2.973, 
50.546) = 1.400, NS) (Fig. 4.10). Acute amphetamine also produced a main effect on No-go trial 
early responses in animals (F(4, 68) = 3.665, p < 0.01). Post hoc analysis of this effect revealed 
a decrease in No-go trial early responses following 1.2 mg/kg in comparison to 0.2 mg/kg of 
amphetamine in both saline and amphetamine pre-treated animals (p < 0.05) (Fig. 4.11). 
However, no effect of previous drug treatment group was found on No-go trial early responses 
following acute amphetamine (F(1, 17) = 0.126, NS) and no dose x treatment group interaction 
was detected (F(4, 68) = 1.4892, NS) (Fig. 4.11).  
Analysis of Go trial panel responses revealed no main effect of amphetamine dose (F(4, 68) = 
2.342, p = 0.064, NS), previous drug treatment group (F(1, 17) = 0.239, NS) or dose x treatment 
group interaction (F(4, 68) = 0.625, NS) (Fig. 4.12). Similarly, the analysis of No-go trial panel 
responses revealed no main effect of amphetamine dose acute (F(2.761, 46.948) = 1.691, NS), 
previous drug treatment group (F(1, 17) = 0.197, NS) or dose x treatment group interaction 
(F(2.761, 49.948) = 0.865, NS) (Fig. 4.13). 
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 Figures 4.3-4.5: Performance 
Following acute amphetamine 
challenges upon (4.3) the total 
percentage correct of all trials, (4.4) 
the total percentage correct of Go 
trials, (4.5) the total percentage 
correct of No-Go trials. *p<0.05 and 
**p<0.01, ***p<0.001 vs saline dose. 
p<0.05 vs saline group. Values 
represent means and error bars 
represent the SEM. Fig. 4.5 
Fig. 4.3 Fig. 4.4  
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  Figures 4.6-4.9: Performance following acute amphetamine challenges on (4.6)Go trial 
response latency, (4.7)No-go trial incorrect response latency, (4.8) Go trial magazine latency, 
(4.9) No-go trial magazine latency. *p<0.05 and **p<0.01, ***p<0.001 vs saline dose. Values 
represent means and error bars represent the SEM. 
 
    Fig. 4.8     Fig. 4.9 
    Fig. 4.7      Fig. 4.6 
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 Figures 4.10-13: Performance following acute amphetamine challenges on (4.10) Go trial 
early responses, (4.11) No-go trial early responses, (4.12) Go trial inappropriate panel 
responses, (4.13) No-go trial inappropriate panel responses. *p<0.05 and **p<0.01, 
***p<0.001 vs saline dose. Values represent means and error bars represent the SEM. 
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4.4Discussion 
Amphetamine treatment decreased No-go trial accuracy during drug treatment with minimal 
effects detected on response latencies and anticipatory responding. Short-term withdrawal 
from amphetamine treatment also caused a reduction in No-go trial accuracy alongside slower 
correct response latencies and effects indicative of possible changes in motivation and 
anticipatory responding. Longer-term withdrawal from amphetamine treatment continued to 
cause a decrease in overall performance accuracy along with possible indications of changes in 
anticipatory responding during this phase. However, no change was observed in No-go 
accuracy amongst amphetamine treated animals in comparison to controls, suggesting that 
amphetamine induced elevations in impulsivity had recovered by this later stage of drug 
withdrawal. Subsequent amphetamine challenges revealed no changes in amphetamine 
induced impulsivity based on previous drug history. Collectively, these findings indicate that a 
4-day amphetamine binge reduces behavioural inhibition in rats both during binge 
administration and through short-term drug withdrawal. However, this drug induced 
impairment in behavioural inhibition is transient and recoverable by long-term drug 
withdrawal and produces no lasting effects on sensitivity to drug induced effects on impulsivity 
following 2 weeks post drug exposure. 
During amphetamine treatment deficits in No-go trial accuracy were observed alongside an 
increase in Go trial panel responses. It could be suggested that increased Go trial panel 
responses might represent amphetamine induced changes in attention, motor or motivational 
behaviour, given that amphetamine is known to disrupt these dimensions of behaviour in rats 
(Bardo, Valone, & Bevins, 1999; Barr & Markou, 2005; Dalley et al., 2007b; Dalley et al., 2005; 
Harrison et al., 1997; Pulvirenti & Koob, 1993; Schiørring, 1971; Segal & Mandell, 1974). 
However, in consideration of the fact no changes were observed in the accuracy of Go trials, 
the speed of responding during Go trials or the speed to collect food reward during all trials, it 
is unlikely that the observed increase in Go trial panel responses reflects drug induced changes 
in attention, motor and motivational behaviour, that would have noticeably affected these 
measures if such deficits were present. Furthermore, these null results indicate that reduced 
No-go trial accuracy during drug treatment is unlikely to be related to any drug induced deficit 
in attention, locomotor behaviour or motivation for food reward. Given that the most 
pronounced drug induced deficit during drug treatment was reduced No-go trial accuracy, 
indicting elevated impulsivity, the observed increase in Go trial panel responses might then 
represent drug induced increases in premature responding for food reward, in line with the 
clear deficits observed in behavioural inhibition. However, whilst this may be the case, given 
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that increased Go trial panel responses was the only measure of anticipatory responding to be 
affected by drug treatment, this suggests that any possible changes in premature responding 
for food reward was only a small change in anticipatory responding during drug treatment as 
otherwise this deficit would have been observed within more measures of anticipatory 
responding. 
There was also a significant interaction detected in No-go trial response latencies during drug 
treatment that continued to be non-significant following simple effects analysis. From visual 
inspection of latency means during No-go trials (Table 4.3) it appears that amphetamine 
treated animals are faster to make incorrect responses during No-go trials than controls on 
drug day 1 and subsequently slower than controls to make incorrect responses on drug days 2 
and 3. However, this pattern in the speed to make incorrect responses during No-go trials 
between amphetamine and saline treated animals is similar to that observed during the pre-
drug baseline week (Table 4.1) suggesting that amphetamine treated animals were not 
behaving unusually in their speed to make incorrect responses during drug treatment. 
Alongside the lack of any additional latency effects during drug treatment, this pattern of 
behaviour between amphetamine treated animals and controls suggests that latencies were 
unaffected by drug treatment.   
Withdrawal from the 4-day amphetamine binge lead to more latency effects than that 
observed during drug administration, consistent with the behavioural profile of amphetamine 
withdrawal in rats (Barr & Markou 2005). Amphetamine treated animals were slower to 
respond during Go trials at 60 hours of withdrawal, and there was a trend towards slower 
collection of food reward during No-go trials at 18 hours of withdrawal (p = 0.009, Benjamini-
Hochberg correction α = 0.006) (See Table 4.5 and Appendix 1, Table 1h). Reduced response 
speed during Go trials observed at 60 hours of amphetamine withdrawal is consistent with 
previous literature reporting a reduction in photobeam counts produced by rats at 56 hours of 
amphetamine withdrawal (Pulvirenti & Koob, 1993). In addition, the trend observed in reduced 
No-go trial magazine latencies at 18 hours of withdrawal is consistent with previous literature 
demonstrating that animals treated with the same 4-day amphetamine binge to that in the 
current experiment develop elevated reward thresholds for up to 108 hours of withdrawal 
(Harrison et al., 2001; Lin, Koob, & Markou, 1999), suggesting that animals might have been 
experiencing anhedonia during this phase of drug withdrawal making animals less motivated 
to gain food reward. In addition, binge amphetamine regimes similar to that employed in the 
current experiment have reported reduced motivation to earn food reward during acute 
amphetamine withdrawal (20 – 68  hours of withdrawal) (Barr & Phillips, 1999). Interestingly, 
from visual inspection of No-go trial magazine latencies (Table 4.5), the speed to collect food 
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reward amongst amphetamine treated animals appears to slow down during early drug 
withdrawal, and following 60 hours of withdrawal speed up to become slightly faster than 
controls. Although non-significant, this pattern in the speed to collect food reward during No-
go trials is consistent with the duration of decreased motivation to received food reward 
observed by Barr & Phillips, (1999). 
However, in consideration of the fact the trend in elevated No-go trial magazine latencies 
represents a possible reduction in motivation to gain food reward amongst amphetamine 
treated rats, it could be suggested that reduced No-go trial accuracy might be related to a loss 
of motivation to perform No-go trials correctly amongst these animals as opposed to increased 
impulsivity. However, given that amphetamine treated rats continued to produce a high level 
of performance during Go trials and no changes were observed between amphetamine and 
saline treated rats within Go trial magazine latencies or No-go trial latencies, this indicates that 
the trend in withdrawal induced effects on motivation was not substantial. In addition, from 
Table 4.5, it is clear that the effects detected within latency measures do not represent gross 
deficits in the speed of responding. It is therefore unlikely that increased response latencies, 
mainly increased No-go trial magazine latencies, would account for the substantial reduction 
observed within No-go trial accuracy.  
Furthermore, given that increased Go trial latencies and trends in elevated No-go trial 
magazine latencies indicate slowing down of response behaviour during short-term 
withdrawal, it is interesting that amphetamine treated animals were also more impulsive 
during this phase of withdrawal. This suggests that despite withdrawal induced effects that 
reduce the speed of responding in amphetamine treated animals, these animals continue to 
remain more impulsive through short-term drug withdrawal. Interestingly, acute amphetamine 
induced behavioural disinhibition in rats is often accompanied by faster response latencies 
(Harrison et al., 1997; Pattij et al., 2007) and withdrawal from pharmacologically similar drugs 
to amphetamine, including MA, MDMA and cocaine, that is accompanied by increased 
premature responding has been found not to overlap with increased response latencies during 
the same phases of drug withdrawal (Dalley et al., 2007b) or not to overlap at all (Dalley et al., 
2007b; Winstanley et al., 2009). The co-occurrence of both increased response latencies and 
behavioural disinhibition in the current experiment therefore demonstrates that greater 
behavioural activation is not always required for increased behavioural disinhibition. 
Despite reduced No-go trial accuracy throughout withdrawal week one, anticipatory 
responding remained relatively normal during this withdrawal phase. An interaction was 
detected within No-go trial early responses and an effect of withdrawal day was detected 
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within Go trial panel responses, however, post hoc analyses failed to detect a significant 
difference between treatment groups in No-go early responding at any specific withdrawal 
hour or significant difference in Go trial panel responses across drug days. Furthermore, from 
Table 4.6 it is clear that amphetamine treatment did not produce any substantial changes in 
the number of No-go trials with early responses or the number of Go trials with panel 
responses that would be indicative of changes in anticipatory responding during short-term 
amphetamine withdrawal. 
During withdrawal week two, amphetamine treated animals continued to show reduced 
overall performance on withdrawal day 8 relative to controls, however, no other significant 
effects were detected across all remaining variables during this withdrawal phase. This 
confirms that withdrawal induced reductions on behavioural inhibition and latencies observed 
during withdrawal week one had recovered by the second week of drug withdrawal. Possible 
changes in No-go trial magazine latencies and panel responses were indicated by an 
interaction and main effect of withdrawal day during this withdrawal phase, respectively. 
However, neither of these effects produced any significant post hoc effects, and from Table 
4.8, it does not appear that either amphetamine or saline treated animals behaved unusually 
during this late phase of drug withdrawal. In following, the effects of a 4-day amphetamine 
binge on impulsivity had recovered by two weeks of drug withdrawal. 
The increase in impulsivity observed during experiment 2a is the first to examine and identify 
reduced behavioural inhibition during the administration of an amphetamine binge in rats. 
Increased impulsivity observed during amphetamine treatment is consistent with previous 
studies that have reported elevated impulsivity during the administration phase with stimulant 
drugs (Winstanley et al., 2009; Richards, 1999; Paine et al., 2003; Gipson & Bardo 2009; 
Kolokotroni et al., 2012; Dallery and Locey, 2005). Chronic administration of stimulants that 
are pharmacologically similar to amphetamine, including, methamphetamine and cocaine 
increase impulsivity during adjusting delay and delayed reward procedures, respectively, 
(Richards et al., 1999; Paine et al., 2003) and long access (6 hrs) to amphetamine self-
administration increases impulsivity during an adjusting delay procedure (Gipson et al., 2009). 
This is the first study, however, to report reduced behavioural inhibition during amphetamine 
administration. Reduced behavioural inhibition observed during a 4-day amphetamine binge 
therefore expands on these studies by suggesting that multiple dimensions of impulsivity may 
be disrupted during phases of stimulant, and specifically, amphetamine use. 
Reductions in behavioural inhibition during chronic drug treatment have also been reported 
with other stimulant drugs including cocaine and nicotine (Winstanley et al. 2009; Kolokotroni 
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et al. 2012). Winstanley et al., (2009) found that rats became transiently more impulsive 
during the acquisition phase of cocaine self-administration with no simultaneous disruptions in 
accuracy or latency measures. Similarly, chronic nicotine administered through osmotic mini-
pumps reduces No-go trial accuracy in rats throughout this phase of drug administration 
(Kolokotroni et al., 2012). These studies therefore support that chronic stimulant 
administration can reduce behavioural inhibition during the phase of drug administration 
itself. Such reductions in behavioural control might then increase vulnerability to repeated 
drug use during phases of drug use. In particular, increased impulsivity observed during a 4-
day amphetamine binge suggests that reduced behavioural inhibition might play a role in 
fuelling the escalation of drug use during periods of binging.  
The persistence of elevated impulsivity during short-term drug withdrawal observed in 
experiment 2b is the first report that spontaneous withdrawal from an amphetamine binge 
can transiently reduce behavioural inhibition in rats. This findings differs from previous 
observations that rats repeatedly withdrawn from cycles of 5 day amphetamine self-
administration do not become impulsive on the 5CSRTT during amphetamine withdrawal 
(Dalley et al., 2005). Dalley et al., (2005) found that amphetamine withdrawal decreased 
accuracy, increased response latencies and increased omissions, indicative of a withdrawal 
induced deficit in attention, but did not differ in the number of premature responses made in 
comparison to controls in rats. In contrast, animals in experiment 2b did not demonstrate any 
obvious deficits in attention, as demonstrated by the high percentage correct observed within 
Go trial accuracy and a lack of gross deficits observed in either latencies or anticipatory 
responses (See Fig. 4.2 and Table 4.5 – 4.8), however, impulsive behaviour was found to 
increase. Differences between these results might relate to differences in the tasks employed 
to measure impulsivity. The 5CSRTT primarily measures accuracy of attention meaning that 
reward for impulsive behaviour is intertwined with attentional performance. In contrast, 
successful response inhibition during a No-go trial results in the direct gain of receiving food 
reward that is not dependent on a high level of attention, meaning the animal has an incentive 
to successfully inhibit behaviour coupled will relatively low attentional demands. Given that 
amphetamine withdrawal impairs accuracy of performance within the 5CSRTT (Dalley et al., 
2005; 2007b), the previous lack of withdrawal induced effects on impulsivity in the 5CSRTT 
compared to those observed in experiment 2b might then relate to differences in task 
sensitivity to attention and subsequent parameters to measure behavioural inhibition. 
Consequently, the withdrawal induced deficit in behavioural inhibition observed in experiment 
2b might then reflect a more fundamental loss of inhibitory control that is distinguishable from 
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deficits in attentional processes, of which premature responses within the 5CSRTT are much 
more related to.  
Interestingly, early responses within the Go/No-go symmetrically reinforced paradigm, that 
might be more comparable to premature responses on the 5CSRTT were not affected during 
withdrawal week one. Early responses within the Go/No-go symmetrically reinforced paradigm 
represent anticipatory responding in animals before gaining trial information from light cues 
whilst premature responses on the 5CSRTT represent anticipatory responses made before the 
illumination of a light stimulus to guide response behaviour. These measures might then be 
more comparable to premature responses on the 5CSRTT than No-go trial accuracy. 
Consistency between the lack of withdrawal induced effects on early responses within 
experiment 2b and premature responses within the 5CSRTT (Dalley et al., 2005) therefore 
supports that impulsivity measured by anticipatory responding that is more closely under the 
control of attentional processes than No-go trials are not disrupted during short or long term 
amphetamine withdrawal. 
Reduced impulsivity during drug withdrawal may also have occurred as a consequence of the 
dose and duration of amphetamine employed. Animals in experiment 2b were treated with 
higher amphetamine doses (up to 15 mg/kg per day) in a shorter period of time (4 days) than 
animals in the Dalley et al., (2005) study that could self administer up to 3.75 mg/kg during 
extended access self-administration over 5 days. This indicates that animals in experiment 2b 
received a more intense binge of amphetamine administration than animals treated with 
amphetamine in the study by Dalley et al., 2005. The intensity of amphetamine withdrawal 
measured though ICSS thresholds has been shown to change in relation to the duration (days) 
and severity (dose) of amphetamine pre-treatment, with the greatest increase in reward 
thresholds occurring following longer and more intense phases of amphetamine treatment (Lin 
et al., 1999). Animals treated with a 4-day amphetamine binge in experiment 2b might then 
have entered a more intense withdrawal period following spontaneous amphetamine 
termination, in line with a more intense phase of amphetamine treatment, than animals 
receiving a shorter duration and smaller amount of amphetamine (Dalley et al., 2005). If this 
was the case then impulsivity may have also been more substantially disrupted in rats in 
experiment 2b in comparison to rats withdrawal from less amphetamine self-administered 
over a longer period of time in Dalley et al., (2005).  
Withdrawal from chronic amphetamine treatment (21 days self-administration) has previously 
been found to increase MAD in rats during acute drug withdrawal (Gipson & Bardo, 2009). 
Reduced behavioural inhibition observed during short-term amphetamine withdrawal 
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therefore suggests that both impulsive choice and action might be transiently disrupted 
following chronic amphetamine use. However, rats treated with repeated amphetamine 
administration do not differ to saline controls in the acquisition of, or long-term performance, 
on a DRT (Slezak et al., 2012; Stanis et al., 2008). This suggests that transient reductions in 
reward discounting, but not delay discounting, alongside loss of behavioural inhibition might 
be residual short-term consequences of amphetamine use. 
Reduced behavioural inhibition observed through short-term amphetamine withdrawal also 
expands on previous literature similarly identifying that impulsivity increases following 
withdrawal from chronic drug administration. Chronic cocaine and nicotine administration 
have both been shown to produce elevations in impulsive action and choice procedures during 
drug withdrawal (Anderson & Diller, 2010; Dallery & Locey, 2005; Dalley et al., 2005; Mendez 
et al., 2010; Simon, Mendez, & Setlow, 2007; Winstanley et al., 2009). Reduced behavioural 
inhibition observed during a 4-day amphetamine binge therefore contributes towards this 
literature area by supporting that elevated impulsivity persists following sub-chronic drug use 
and can be a consequence of drug per se following drug termination.  
These results also expand upon previous literature that has identified specific periods of 
anhedonia during amphetamine withdrawal. Amphetamine induced anhedonia has been 
shown to last for up to 60- 108 hours of amphetamine withdrawal (Lin et al. 1999; Harrison et 
al. 2001; Barr & Phillips 1999; Barr & Phillips 2002). Animals in experiment 2b became 
transiently more impulsive for up to 36 hours of withdrawal and again at 156 hours of 
withdrawal (Fig. 4.2). Animals became the most impulsive during acute amphetamine 
withdrawal, as demonstrated by the greatest significance between groups occurring at 12 and 
18 hours of drug withdrawal. These findings therefore expand on this previous literature by 
additionally identifying that animals are also more impulsive through the same period of drug 
withdrawal that they are also experiencing anhedonia. The combination of these observations 
of during the same phase of acute amphetamine withdrawal, suggest that the combinations of 
that symptoms of withdrawal symptoms may persist into periods of heightened vulnerability 
to relapse.  
No long-term changes were observed in impulsivity amongst animals treated with 
amphetamine relative to controls following acute amphetamine challenges following two 
weeks of drug withdrawal. The only difference observed between pre-treatment drug groups 
at the stage was during Go trial accuracy, whereby amphetamine pre-treated animal displayed 
a slight greater tolerance to amphetamine induced disruptions of performance at 1.2 mg/kg 
(Fig. 4.4). However, from Figs. 4.3 – 4.13, it is clear that this tolerance is only a small difference 
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between drug treatment groups and given that there were no differences in performance 
across any other variables between pre-treatment groups, it can be concluded that treatment 
with a 4-day amphetamine binge did not produced any substantial long-term changes in 
performance of the Go/No-go task in comparison to controls. These findings are consistent 
with previous studies reporting no difference in impulsivity following acute amphetamine 
challenges tested at 6 weeks and 10 weeks post drug on DRT and DRL30 tasks, respectively 
(Hankosky & Gulley, 2012; Stanis et al., 2008). This finding supports literature indicating that 
prior amphetamine treatment does not alter amphetamine induced impulsivity following a 
protracted abstinence period. However, Dalley et al. (2005) did observe that rats repeatedly 
withdrawn from amphetamine self-administration displayed reduced premature responding in 
comparison to controls following an acute of 0.8 mg/kg at two months post amphetamine 
treatment (Dalley et al,. 2005). Differences in these findings might relate to differences in the 
duration of drug administration between studies. Animals in the study by Dalley et al. (2005) 
self-administered amphetamine for five days followed by nine days of withdrawal over the 
course of ten weeks, whereas Hankosky & Gulley (2012) and Stanis et al. (2008) administered 
amphetamine over 18 and 20 days, respectively. Differences in the duration of these 
administration regimes might suggest that longer exposure to amphetamine might produced 
greater long-term changes in amphetamine induced impulsivity. 
4.4.1 Key Findings 
The main findings from this study are that a 4-day amphetamine binge reduces response 
inhibition in rats both during phases of drug treatment and short-term withdrawal. These 
findings suggest that subchronic amphetamine exposure might directly impair response 
inhibition during phases of drug use where the propensity to escalate (drug treatment) and 
relapse (short-term withdrawal) are high. However, amphetamine induced reductions in 
response inhibition did not persist into withdrawal week two, and there was no indication that 
amphetamine treatment caused any changes in sensitivity to drug induced response 
disinhibition in rats. These additional findings suggest that a subchronic level of amphetamine 
exposure might not cause any enduring changes in neural systems mediating response 
inhibition. The main objective of this study was to further disentangle the relationship 
between amphetamine and impulsivity through assessing the effects of subchronic 
amphetamine on the Go/No-go symmetrically reinforced task. Observations that 4-day 
amphetamine can elevate impulsivity in rats helps to disentangle this relationship through, 
firstly, demonstrating that amphetamine use might increase impulsivity, and secondly, 
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indicating that the effects of amphetamine on impulsivity might occur at specific time points 
that facilitate the development and maintenance of addiction.  
4.4.2 Limitations 
Whilst this study has helped to establish the effects of subchronic amphetamine on response 
inhibition in rats, there are caveats in the study design that limit interpretations from these 
findings. One main limitation of this study is in the scalability of the main findings to human 
populations. The drug regime employed was non-contingent, meaning that rats had no control 
over drug administration. Contingent drug regimes (self-administration) are more comparable 
to human drug use since animals have control over administering the drug provided to them, 
more closely matching the control that humans have over drug use. Whilst non-contingent 
regimes can control dose exposure more closely than contingent regimes, experimental 
designs employing non-contingent drug regimes are not as reliable as contingent regimes for 
modelling human drug use. As a result of employing a non-contingent amphetamine regime in 
the current study, observations that a 4-day amphetamine binge reduces response inhibition 
in rats might not necessarily translate to how an amphetamine binge might affect response 
inhibition within a human population.  
Animals in this study were not screened for differences in trait impulsivity at baseline. The 
effects of amphetamine and ATS on impulsivity are known to relate to baseline levels of 
impulse control (de Wit, 2000; Eagle et al., 2007; Hand, Fox & Reilly, 2009) and highly 
impulsive rats show greater sensitivity to the effects of amphetamine than less impulsive rats 
(Yates et al., 2012). Increased impulsive behaviour is also associated with increased risk of 
engaging with drug use amongst humans and highly impulsive rats show increased 
vulnerability to key stages of addiction including drug acquisition, escalation and relapse 
(Broos et al., 2012b; Dalley et al., 2007; Diergaarde et al., 2009; Kollins, 2003; Perry, 2005; 
2008). These studies demonstrate a relationship, firstly, between trait impulsivity and the 
effects of amphetamine, and secondly, between trait impulsivity and drug addiction. As the 
current study did not screen rats for high and low levels of trait impulsivity at baseline, there 
are limitations to the main findings of this study in relation to how individual differences in 
impulsivity at baseline might have affected amphetamine induced effects on response 
inhibition and also the time points at which effects occurred.  
There were no neuroanatomical or neurochemical controls in this study, limiting 
interpretations into the possible neural mediators of amphetamine induced impulsivity 
observed. In order to consider the possible neuroanatomical regions mediating the effects of 
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amphetamine on impulsivity, it would have been useful to employ an additional group of rats 
with lesions to neural sites hypothesised to mediate impulsivity. The ventral striatum has been 
associated with impulsivity in drug addicts and lesions to the nucelus accumbens disrupt 
amphetamine induced impulsivity in rats when measured by the 5CSRTT (Lee et al., 2009; 
Murphy et al., 2008). Including an additional group of rats with accumbal lesions might have 
been useful in order to establish a possible anatomical location that amphetamine induced 
impulsivity is mediated. In order to address possible neurochemical mediation of 
amphetamine induced impulsivity that was observed, it would have been useful to employ an 
l-amphetamine group in addition to the d-amphetamine and saline control groups. As d-
amphetamine has a greater binding affinity for dopamine than l-amphetamine, this additional 
group would have created a neurochemical control to test the involvement of amphetamine 
induced changes in dopamine on impulsivity.  
A final limitation of this study is that rats were not assigned to drug treatment groups at 
random. Rats were assigned to treatment groups based on their baseline performance on the 
task. Assigning groups in this manner was conducted in attempt to counterbalance individual 
differences in performance at baseline between treatment groups. However, as a 
consequence of assigning groups in this manner it is possible that bias might have been 
introduced into the drug groups before experimental procedures began. 
4.4.3 Future Research 
Having established that subchronic amphetamine can reduce response inhibition in rats on the 
Go/No-go symmetrically reinforced task, future research investigating the effects of chronic 
amphetamine on response inhibition measured by this task will be useful for understanding 
how different levels of amphetamine exposure affects impulsivity. Alternatively, research 
exploring the affects of multiple binge regimes on response inhibition measured by the Go/No-
go task would be useful for establishing how chronic amphetamine exposure in an intermittent 
pattern affects impulsivity. These research directions will help to address how different 
patterns and levels of amphetamine exposure might affect impulsivity, and more broadly, 
contribute towards understanding the relationship between patterns of human drug use and 
impulsivity.  
Investigations into the neurobiological changes mediating subchronic amphetamine induced 
impulsivity will also be a useful future research direction. More specifically, it would be useful 
to investigate the involvement of the ventral striatum and the D2 receptors in mediating the 
effects of subchronic amphetamine on response inhibition that was observed. Previous 
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research has linked changes in D2 receptor function within the ventral striatum to impulsivity 
in drug addicts and in acute amphetamine induced impulsivity on the 5CSRTT in rats (Lee et al., 
2009; Pattij et al., 2007). It would therefore be useful to assess whether the D2 receptors 
within the ventral striatum are involved in mediating more chronic drug induced changes in 
impulsivity. Future research focused in this direction will be essential for establishing the 
contribution of drug use per se to neurochemical changes related to impulsivity observed 
amongst addicts. 
4.4.4 Conclusions 
In conclusion, these findings provide further insight into the complex and paradoxical 
relationship of amphetamine use and impulsivity. Whilst amphetamine is a highly addictive 
drug that has a relationship with impulsivity, evidenced through therapeutic benefits of 
amphetamine for alleviating ADHD symptoms, the effects of repeated and chronic 
amphetamine use per se on impulsivity remain elusive. Given recent conceptualisations of 
addiction proposing that the binge and withdrawal phases fuelling the addiction cycle become 
increasingly more intense and severe over the course of dependence (Koob & Le Moal, 2008), 
better understanding of how impulsivity may persist during phases of binging and withdrawal 
will give a wider understanding of psychological factors that may be treatable at these stages 
of the addiction cycle to reduce chronic relapse. Furthermore, given that amphetamine is a 
drug commonly administered in an intense binge pattern, observations of that behavioural 
inhibition is reduced during a 4-day binge and through short-term binge withdrawal in rats are 
useful for considering how behavioural control may change throughout phases of binging and 
drug withdrawal during amphetamine dependence. 
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Chapter 5 The effects of 11-day chronic amphetamine on behavioural 
inhibition in rats 
5.1Introduction 
Drug use can occur through a variety of different settings and administration patterns (Perry et 
al., 2008). Amphetamine is a drug that is abused in a number of different settings for different 
demands. For example, the performance enhancing effects of amphetamine are desirable for 
sustained alertness, energy and concentration for long periods of time, whilst the stimulant 
and euphoric effects of amphetamine are desirable for the recreational drug use (Davey, 
Richards, & Freeman, 2007; Degenhardt et al., 2007; Hall, Darke, Ross, & Wodak, 1993; Low & 
Gendaszek, 2002; McCabe et al., 2006; Riley et al., 2001; Teter et al., 2006). 
Different patterns of drug use are also associated with different levels of impulsivity. For 
example, MDMA users that report greater weekly use of cocaine and more years of cocaine 
and amphetamine use show greater reflection impulsivity than MDMA users with reports of 
lower weekly and yearly use of cocaine and amphetamine (Quednow et al., 2007). ‘Heavy’ 
(weekly) MDMA users also make more errors on the IMT/DMT in comparison to ‘light’ MDMA 
(less than weekly use) and non-drug using controls (Moeller et al., 2002), suggesting that 
patterns of MDMA use leading to greater frequency and consumption of MDMA are associated 
increased levels of behavioural disinhibition than patterns of less frequent and no MDMA use. 
Greater levels of cocaine consumption have also been shown to correlate with an increase in 
SSRT amongst recreational cocaine users (Colzato et al., 2007), suggesting that patterns of 
drug use leading to greater quantity of cocaine consumption might lead to higher behavioural 
disinhibition. In addition, subjects that smoke between 11-20 cigarettes per day show 
significantly longer SSRT than subjects that smoke below 10 cigarettes per day (Billieux et al., 
2010), again suggesting that patterns of drug use associated with greater consumption are 
associated with poorer behavioural inhibition capacity. 
In addition, current smokers (20 cigarettes plus per day) show greater discounting of 
hypothetical money rewards than ex-smokers and controls (Bickel et al., 1999) and ‘heavy’ 
smokers (over 40 cigarettes per day) also show steeper discounting of actual monetary reward 
in comparison to ‘chippers’ (less than 40 cigarettes per day) and controls (Heyman & Gibb, 
2006). This suggests that smoking patterns that are associated with greater nicotine 
consumption are associated with greater levels of impulsive choice. Similarly, amongst subjects 
that report illicit drug use, occasions of stimulant use over the previous month, year and 
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lifetime stimulant use has been found to correlate with disadvantageous decision making 
within the IGT (Hanson et al., 2008). Severity of dependence amongst alcoholics, crack cocaine 
and methamphetamine dependent subjects also correlates with disadvantageous decisions on 
the IGT, whereby subjects with greater severity scores for dependence make more bad 
decision on the IGT relative subjects lower severity of dependence scores (Bechara et al. 2001). 
This suggests that patterns of drug use that employ a greater frequency and greater quantity 
of drug use, might be associated with both increased levels of impulsive action and choice.  
Different patterns of repeated drug administration have also been shown to produce different 
effects on behavioural inhibition in rats. For example, rats that self-administer 0.5 mg/kg of 
cocaine (2 hr access, unlimited) over the course of four weeks become transiently more 
impulsive during cocaine withdrawal on the 5CSRTT (Winstanley et al., 2009), whilst rats self-
administering 0.25 mg/kg of cocaine (8 hr access, limit of 75 infusions) intermittently over the 
course of 8 weeks do not become more impulsive on the 5CSRTT during intermittent drug 
withdrawal from cocaine self-administration (Dalley et al., 2005b). This might suggest that 
animals receiving a more maintained and higher drug dose regime are more vulnerable to 
deficits in behavioural inhibition during drug withdrawal. However, rats intermittently 
withdrawn from long-access (8 hrs) amphetamine self-administration over 2-3 months and rats 
withdrawn following 21 days of long-access (8 hrs) amphetamine self-administration do not 
display any changes in behavioural inhibition during amphetamine withdrawal (Dalley et al., 
2005; Dalley et al., 2007b). This indicates that despite extending the duration of amphetamine 
exposure before animals entered drug withdrawal, there were no changes in behavioural 
inhibition in rats. This alternatively suggests that impulsivity might not be differentially 
affected by different patterns of amphetamine use. However, as previously discussed (Chapter 
4, section 4.1), the attentional parameters of the 5CSRTT might suggests that this lack of 
withdrawal induced effect on impulsivity following different patterns of amphetamine 
administration might only reflect a distinct dimension of attentional impulsivity.  
Interestingly, rats treated with a long-access (6 hrs) amphetamine self-administration regime 
for 21 days, similar therefore to the methodology employed by Dalley et al (2007b), have 
found that rats do become more impulsive during drug administration and acute drug 
withdrawal on an adjusting delay procedure (Gipson & Bardo, 2009). This further suggests that 
the effects of different patterns of drug use on impulsivity might relate to the specific aspect of 
impulsive behaviour being studied.  
In consideration of the results observed in experiments 2a and b (See Chapter 4, section 4.3) 
demonstrating that subchronic amphetamine treatment can lead to a transient reduction in 
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behavioural inhibition on the symmetrically reinforced Go/No-go task, the current chapter 
subsequently sought to investigate the effects of a longer term and more maintained pattern 
of amphetamine administration on impulsivity within this Go/No-go task. 
5.1.1 Objectives 
In order to investigate the effects of a long-term chronic amphetamine regime on behavioural 
inhibition measured by the symmetrically reinforced Go/No-go task, the objectives of Chapter 
5 were: 
i) To determine the effects of 11 day chronic amphetamine on behavioural inhibition 
during drug treatment within the symmetrically reinforced Go/No-go task 
(Experiment 3a) 
ii) To determine the effects of 11 day chronic amphetamine on behavioural inhibition 
throughout short term amphetamine withdrawal  within the symmetrically 
reinforced Go/No-go task (Experiment 3b) 
iii) To determine the effects of 11 day chronic amphetamine on behavioural inhibition 
throughout long-term amphetamine withdrawal within the symmetrically reinforced 
Go/No-go task (Experiment 3c) 
iv) To determine the effect of acute amphetamine challenges upon behavioural 
inhibition following prolonged withdrawal period from chronic (11 day) 
amphetamine within the symmetrically reinforced Go/No-go task (Experiment 3d) 
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5.2Methods 
5.2.1 Subjects 
19 male Lister Hooded rats (Charles River, UK) were housed in pairs and maintained under a 12 
hour light/ dark cycle (lights on 0700), in a temperature (21°C ± 2°C) and humidity (50% ± 5%) 
controlled environment. Throughout experimentation animals were maintained on a food 
restriction schedule of 18.6g per day (inclusive of food received during testing), maintaining 
animals at 85% of their adult free feeding body weight. Water was available ad libitum and 
feeding took place in the morning after testing. All animals were treated in accordance with 
the UK Animals (Scientific Procedures) Act 1996. All procedures were covered by Home Office 
Project Licence No. PIL 40/2711 and 40/3606, and Home Office Personal Licence No. 40/9836.  
5.2.2 Drugs 
d-Amphetamine sulphate (Sigma Aldrich, UK) was dissolved in 0.9% physiological saline 
solution and was administered intraperioneally (i.p.) in a volume of 1 ml/kg body weight. 
5.2.3 Apparatus 
Behavioural testing took place in eight aluminium operant chambers (30.5 x 24.1 x 21 cm, Med 
Associates Inc., USA) placed inside sound attenuating and ventilated cubicles (63.5 x 49.1 x 
39.4 cm, Med Associates Inc., USA). Apparatus was controlled, and all data was recorded from 
chambers, using MED-PC IV software (Med Associates Inc., USA). For a more detailed 
description of all apparatus refer to Chapter 2, section 2.1.3, page 60.  
 
5.2.4 Behavioural Testing 
Behavioural inhibition was assessed via the symmetrically reinforced go/no-go visual 
discrimination paradigm. Behavioural training took place for approximately 8 weeks until 
animals reached a total of 85% correct or more over seven consecutive training sessions. Upon 
stable baseline performance, animals were subsequently entered into the experiment. All 
behavioural training and testing took place at the same time each day, between 0700-0930, 
and prior to morning drug administrations. For a detailed outline of the task refer to Chapter 2, 
section 2.1.4, page 61. 
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5.2.5 Design and Procedure 
A mixed design was employed to assess the effects of 11-day chronic amphetamine upon 
behavioural disinhibition, with ‘drug treatment group’ (saline and amphetamine) acting as the 
between-subjects factor and ‘test day’ acting as the within-subjects factor. Following 7 days of 
stable performance, constituting the baseline week, animals were assigned to groups receiving 
either systemic amphetamine or saline treatment according to their baseline performance 
accuracy, programmed levers, and fast/ slow- Go/ No-go contingencies to ensure matched 
baseline performance of both groups prior to drug administration.  
5.2.6 Experiment 3a: The effects of 11-day chronic amphetamine on 
behavioural disinhibition 
Animals were entered into two groups receiving amphetamine (n=9) or saline (n=10) 
treatment. Amphetamine was administered i.p. twice a day (0800 hrs/2000 hrs) over the 
course of eleven days in an escalating dose regime. Dosages started at 1 mg/kg increasing up 
to and stabilising at 5mg/kg. A total of 100 mg/kg of amphetamine was administered per 
animal in the following daily regimes; Day 1 (1, 2 mg/kg), Day 2 (3, 4 mg/kg), Day 3 (5, 5 
mg/kg), Day 4 (5, 5 mg/kg), Day 5 (5, 5 mg/kg), Day 6 (5, 5 mg/kg), Day 7 (5, 5 mg/kg), Day 8 (6, 
5 mg/kg), Day 9 (5, 5 mg/kg), Day 10 (5, 5 mg/kg), Day 11 (5, 5 mg/kg). Day 1 of drug treatment 
began immediately after behavioural testing on baseline day 7, therefore impulsivity measured 
throughout the subsequent 10 drug days constituted the drug administration phase labelled 
on Figure and Figure. Saline treated animals were administered with physiological saline i.p. 
twice a day (0800 hrs/2000 hrs) over the course of eleven days, mimicking the administration 
regime of amphetamine treated animals. Dosages were based on the principle of doubling the 
total amount of amphetamine received in experiment 2a and extending the administration of 
drug over a more continuous, rather than binge, administration regime. Subsequently, 
amphetamine was administered twice daily instead of three times daily, in line with 
amphetamine regimes employed over a long administration period (Hankosky & Gulley, 2012; 
Slezak, Krebs, & Anderson, 2012; Stanis et al., 2008).  
5.2.7 Experiment 3b-c: The effects of short- and long-term spontaneous 
amphetamine withdrawal on behavioural disinhibition  
Spontaneous amphetamine withdrawal was initiated after the eleventh day of chronic 
amphetamine treatment. Animals were subsequently tested for the following 14 days to 
assess the effects of short- and long-term amphetamine withdrawal upon behavioural 
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disinhibition. In order to more thoroughly examine behavioural disinhibition throughout acute 
amphetamine withdrawal animals were tested at 12, 18, 36 and 42 hours post drug 
termination; constituting two test sessions on day 1 and day 2 of drug withdrawal. Animals 
were tested once per day across all remaining withdrawal days. Specifically, animals were 
tested at the following hours post drug treatment; 12, 18, 36, 42, 60, 84, 108, 132, 156 hrs 
(withdrawal week 1), and on the following days post drug treatment; 8, 9, 10, 11, 12, 13, 14 
(withdrawal week 2).  
5.2.8 Experiment 3d: The effects of acute amphetamine challenges on 
behavioural disinhibition 
Upon return to stable baseline performance on the Go/No-go task, both amphetamine and 
saline treated animals received five acute amphetamine challenges (0, 0.2, 0.4, 0.8 and 1.2 
mg/kg) in a latin square design. The acute amphetamine dose range was chosen based upon 
findings by Harrison et al. (unpublished data) demonstrating that 0.8 mg/kg of amphetamine 
reliably induces a decrease in behavioural inhibition as measured by the go/no-go task. Smaller 
and larger dosages of amphetamine relative to 0.8 mg/kg (0.2, 0.4 and 1.2 mg/kg) were 
incorporated into the dose range in order to detect any subtle changes in the sensitivity to this 
effect of amphetamine following chronic drug treatment. Animals were required to return to 
their baseline performance on the total percent correct of trials (+/- 5%) across two 
consecutive days between acute injections in order to ensure that task performance was 
stable before receiving the following acute amphetamine challenge. A wash out period of a 
minimum of 72 hours was employed between each drug challenge. 
5.2.9 Statistical Analysis 
All data was initially checked for normality through Shaprio-Wilk tests and was appropriately 
transformed via arcsine, log10, square root and reciprocal transformations following any 
violations to normality. Homogeneity of variance was checked via Mauchley’s test of Sphericity 
and following any significant violation of equal variances, the GLM degrees of freedom were 
adjusted using the Greenhouse- Geisser correction. For all employed ANCOVAs, homogeneity 
of the regression slope was assessed via testing the interaction between baseline performance 
and independent variables. Following a significant baseline x treatment group or baseline x 
test day interaction, the use of ANCOVA was considered no longer appropriate, and 
subsequently data was re-expressed a percentage of baseline performance and entered into 2 
x   mixed ANOVA (Field, 2005). The validity of using average baseline performance as a 
covariate was also assessed through checking that baseline performance yielded a main effect 
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upon treatment groups within the ANCOVA model (Field et al., 2005). Upon the rare occasion 
that baseline performance was found to not significantly affect treatment groups, data was re-
expressed a percentage of baseline performance and entered into a 2 x   mixed ANOVA (Field, 
2005).  
Unless otherwise stated α < 0.05 was employed. Subsequently, the following four sets of data 
analyses were performed: 
5.2.10 Assessment of baseline performance 
After checks of normality, the following transformations were performed before conducting 
baseline analysis: log₁₀ transformation (No-go trial incorrect response, Go trial magazine 
latency, No-go trial magazine latency, Go trials early responses). 
Baseline performance was analysed via 2 x 7 mixed ANO As with ‘drug treatment group’ 
entered as the between- subjects factor, and ‘baseline day’ entered as the within-subjects 
factor. Main effects of ‘baseline day’ were followed up via Sidak corrected post hoc tests, and 
significant treatment group x baseline day interactions were deconstructed via simple effects 
analysis. Simple effects analysis was conducted in two steps. Firstly, two one-way repeated 
measures ANOVAs were performed for each treatment group to assess individual group 
within-subject effects, with subsequent significant main effects of ‘baseline day’ followed up 
via Sidak corrected post hoc tests. Secondly, seven independent t-tests were performed to 
examine between-treatment group effects within individual baseline days (Benjamini-
Hochberg correction of α = (i/k)*0.05).  
5.2.11 The effects of 11-day chronic amphetamine, short- and long-term 
spontaneous amphetamine withdrawal on behavioural inhibition 
After checks of normality, the following transformations were applied across chronic drug and 
withdrawal data: log₁₀ transformation (Go trial response latency, No-go trial response latency, 
Go trial magazine latency, No-go trial magazine latency, Go trial early responses). 
Performance across 11-day chronic amphetamine, short- and long-term spontaneous 
amphetamine withdrawal was analysed via mixed ANCO As, with ‘drug treatment group’ 
entered as the between-subjects factor and ‘test day’, ‘withdrawal hour’, or ‘withdrawal day’ 
entered as the within-subjects factor. In summary, the following ANCOVAs were performed 
across all behavioural parameters with subjects average baseline performance entered as the 
covariate; 2 x 10 mixed ANCOVA (chronic drug), 2 x 9 mixed ANCOVA (withdrawal week one), 
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and 2 x 7 mixed ANCOVA (withdrawal week two). Further analysis of within-subjects main 
effects was conducted via post hoc Sidak corrected tests and significant interaction effects 
were deconstructed via post hoc simple effects analysis. Simple effects were performed 
according to that described in Chapter 4, section 4.2.11. 
In addition, in order to identify the specific initiation and duration of treatment effects, all 
main effects of ‘treatment group’ were further investigated via conducting multiple between-
group comparisons on individual test days (Benjamini-Hochbery correction of α = (i/k)*0.05)) 
along with one-way repeated measures ANCOVAs within each treatment group.  
5.2.12 The effects of acute amphetamine challenges on behavioural 
disinhibition  
After checks of normality, the following transformations were performed before conducting 
analysis of acute amphetamine challenges: log₁₀ transformation (Go trial response latency, Go 
trial magazine latency, No-go trial magazine latency, No-go trials panel responses). 
The effect of acute amphetamine challenges upon behavioural disinhibition was assessed via 2 
x 5 repeated measures ANO As with ‘amphetamine dose’ entered as the within-subjects 
factor and ‘drug treatment group’ entered as the between-subjects factor. All main effects 
were followed up via post hoc Sidak corrected tests and significant interactions were 
deconstructed via simple effects analysis, whereby the pooled error term from the original 
ANOVA model was utilised to generate the post hoc F value, as described in Chapter 4, Section 
4.2.11. 
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5.3Results 
Unless otherwise stated, for all of the following ANCOVAs homogeneity of regression was 
assumed (p > 0.05) and average baseline performance was found to significantly affect 
treatment groups (p < 0.05), reinforcing the need to control for within-subjects variation in 
behaviour. Due to data remaining abnormally distributed following transformations, the total 
percentage correct of Go trials, Go trial magazine latencies and Go trial panel responses were 
re-expressed as a percentage of average baseline performance and analysed in an ANOVA. This 
data was analysed using the non-parametric tests Friedman’s ANO A and Mann Whitney U 
Tests during baseline. Non-parametric tests were also run on Go trial magazine latencies 
during withdrawal week one and two due to data remaining abnormally distributed after re-
expression as a percentage of baseline performance.  
5.3.1 Experiment 3a: Pre-drug baseline performance 
5.3.1.1 Performance accuracy: 
No main effect of baseline day was found within the analysis of total percentage of correctly 
completed trials (F(6, 120) = 0.686, NS), the total percentage of correct Go trials (χ²(6) = 
10.696, NS), or the total percentage of correct No-Go trials (F(6, 120) = 1.268, NS). Analysis of 
the accuracy of performance also produced no main effect of drug treatment group within the 
total percentage of correctly completed trials (F(1, 17) = 0.334, NS), the total percentage of 
correct Go trials (all U ≥ 36, NS) and the total percentage of correct No-go trials (F(1,17) = 
0.501, NS). No significant baseline day x treatment group interactions were found within the 
analysis of the total percentage of correctly completed trials (F(6, 120) = 1.941, NS), or the 
total percentage of correct No-go trials (F(6, 120) = 0.476, NS) (Figs. 5.1 and 5.2). 
5.3.1.2 Speed of Responding: 
No main effect of baseline day was found within the analysis of Go trial response latencies 
(F(6, 102) = 1.416, NS), Go trial magazine latencies (χ²(6) = 3.284, NS), No-go trial incorrect 
response latencies (F(6, 102) = 0.307, NS) or No-go trial magazine latencies (F(6, 102) = 2.172, 
NS). In addition, no main effect of drug treatment group was found in the analysis of Go trial 
response latencies (F(1, 17) = 0.091, NS), No-go trial incorrect response latencies (F(1, 17) = 
0.010, NS), Go trial magazine latencies (all U ≥ 38, NS) and No-go trial magazine latencies (F(1, 
17) = 0.105, NS). Furthermore, no significant baseline day x treatment group interactions were 
found in the analysis of Go trial response latencies (F(6, 102) = 0.424, NS),  No-go trial incorrect 
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response latencies (F(6, 102) = 0.803, NS) and No-go trial magazine latencies (F(6, 102) = 1.312, 
NS) (Table 5.1). 
5.3.1.3 Anticipatory Responding: 
No significant difference was observed between baseline days within the analysis of Go trial 
early responses (F(6, 102) = 1.262, NS), Go trial panel responses (χ²(6) = 8.735, NS), No-go trial 
early responses (F(6, 102) = 0.547, NS), No-go trial panel responses (F(6, 102) = 0.999, NS). In 
addition, no difference was detected between treatment groups in the analysis of Go trial 
early responses (F(1, 17) = 0.757, NS), No-go trial early responses (F(1, 17) = 0.195, NS), Go trial 
panel responses (all U ≥ 34, NS) or No-go trial panel responses (F(1, 17) = 1.539, NS). 
Furthermore, no significant baseline day x treatment group interactions were detected in the 
analysis of Go trial early responses (F(6, 102) = 0.930, NS), No-go trial early responses (F(6, 
102) =1.261, NS) or No-go trial panel responses (F(6, 102) = 0.860, NS) (Table 5.2) 
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Behavioural Measure Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Go Trial Early 
Response 
Saline 13.10 ± 1.29 15.60 ± 1.99 14.80 ± 1.68 15.90 ± 2.32 16.40 ± 2.10 15.30 ± 1.40 17.60 ± 2.10 
Amphetamine 16.67 ± 2.59 16.89± 3.15 19.11 ± 2.56 18.00 ± 2.32 19.56 ± 2.84 18.78 ± 2.13 16.11 ± 2.12 
No-go Trial 
Early 
Response 
Saline 5.00 ± 1.18 4.7 ± 1.14 5.10 ± 1.03 5.40 ± 1.39 6.50 ± 1.19 6.60 ± 1.73 6.60 ± 1.53 
Amphetamine 6.11 ± 1.52 6.22 ± 1.66 6.89 ± 1.56 7.89 ± 2.19 5.33 ± 1.68 6.33 ± 1.22 6.11 ± 1.16 
Go Trial Panel 
Response 
Saline 1.30 ± 0.70 1.30 ± 0.40 1.20 ± 0.33 0.90 ± 0.31 1.50 ± 0.58 0.80 ± 0.33 0.40 ± 0.22 
Amphetamine 1.44 ± 0.44 1.33 ± 0.44 1.22 ± 0.36 1.56 ± 0.73 0.56 ± 0.24 0.67 ± 0.55 0.67 ± 0.33 
No-go Trial 
Panel 
Response 
Saline 12.20 ± 2.15 10.90 ± 2.34 11.60 ± 2.19 9.10 ± 2.06 11.70 ± 2.65 10.70 ± 2.27 9.60 ± 1.89 
Amphetamine 7.22 ± 2.27 8.22 ± 2.27 7.22 ± 2.48 7.56 ± 2.07 7.11 ± 1.87 7.22 ± 2.09 6.44 ± 1.75 
 
Behavioural Measure Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Go Trial 
Response 
Latency 
Saline 0.90 ± 0.32 0.95 ± 0.49 0.82 ± 0.33 0.94 ± 0.57 0.85 ± 0.37 0.86 ± 0.31 0.89 ± 0.42 
Amphetamine 0.98 ± 0.55 1.12 ± 0.67 0.82 ± 0.46 0.94 ± 0.50 0.88 ± 0.43 0.79 ± 0.43 1.04 ± 0.58 
No-go Trial 
Incorrect 
Response 
Latency 
Saline 2.42 ± 1.08 2.05 ± 1.10 2.43 ± 1.32 1.89 ± 1.08 2.21 ± 1.08 1.72 ± 0.97 1.68 ± 0.93 
Amphetamine 2.01 ± 1.63 2.55 ± 1.39 2.26 ± 2.33 2.67 ± 2.54 2.63 ± 2.22 2.49 ± 1.57 2.17 ± 1.62 
Go Trial 
Magazine 
Latency 
Saline 0.44 ± 0.44 0.50 ± 0.55 0.45 ± 0.48 0.47 ± 0.55 0.45 ± 0.51 0.41 ± 0.34 0.41 ± 0.34 
Amphetamine 0.35 ± 0.12 0.35 ± 0.17 0.32 ± 0.09 0.34 ± 0.11 0.34 ± 0.12 0.31 ± 0.10 0.35 ± 0.12 
No-go Trial 
Magazine 
Latency 
Saline 0.62 ± 0.30 0.58 ± 0.25 0.63 ± 0.27 0.66 ± 0.29 0.70 ± 0.25 0.66 ± 0.23 0.69 ± 0.26 
Amphetamine 0.74 ± 0.37 0.71 ± 0.46 0.67 ± 0.38 0.71 ± 0.32 0.69 ± 0.46 0.75 ± 0.41 0.78 ± 0.46 
 
 
Table 5.1: Baseline Week: Speed of responding during baseline week. Values represent means and SEM. 
Table 5.2: Baseline Week: Anticipatory responding during baseline week. Values represent means and SEM. 
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Figure5.1: Performance within the total percentage correct of all trials during baseline week, drug administration, withdrawal week one and 
withdrawal week two. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant difference between amphetamine and saline 
group. Values represent means and errors represent SEM. 
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Figure 5.2: Performance within the total percentage correct of Go and No-go trials during baseline week, drug administration, withdrawal week one and 
withdrawal week two. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = significant difference between amphetamine and saline group. 
Values represent means and errors represent SEM. 
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5.3.2      11-Day amphetamine treatment 
5.3.2.1 Performance accuracy: 
Analysis of the total percentage of correctly completed trials revealed no main effect of drug 
day (F(9, 144) = 0.494, NS), however, a main effect of drug treatment group (F(1, 16)= 14.676, 
p < 0.001) and drug day x drug treatment group interaction were detected (F(9, 144) = 2.071, p 
< 0.05). Within-subjects simple effects revealed no significant main effect of drug day within 
either saline (F(72, 144) = 0.01, NS) or amphetamine treated animals (F(63, 144) = 0.03, NS) 
when analysed independently. Between-subjects simple effects, however, revealed that 
amphetamine treated animals had lower accuracy in comparison to controls during drug day 3 
(F(1,16) = 4.343, p < 0.05), day 4 (F(1,16) = 8.045, p < 0.01), day 5 (F(1, 16) = 5.140, p < 0.05), 
day 6 (F(1, 16) = 6.420, P < 0.05), day 7 (F(1, 16) = 15.605, p < 0.001), day 8 (F(1, 16) = 11.733, p 
< 0.001), day 9 (F(1, 16) = 11.847, p < 0.001) and day 10 (F(1, 16) = 8.873, p < 0.01) (Fig. 5.1) 
(Benjamini-Hochberg correction, α = p < 0.04 - p < 0.005, see Appendix 2, Table 2a for specific 
corrected p-values).  
Analysis of the total percentage of correct Go trials revealed no significant main effect of drug 
day (F(4.027, 68.452) = 0.542, NS) or drug treatment group (F(1, 17) = 0.920, NS), and no 
significant drug day x drug treatment group interaction (F(4.027, 68.452) = 1.436, NS) (Fig. 5.2). 
Analysis of the total percentage of correct No-go trials also failed to a significant main effect of 
drug day (F(3.985, 63.275)  = 0.485) = 0.485, NS), however, amphetamine treated animals 
were found to have significantly lower No-go performance in comparison to controls (F(1, 16) 
= 9.041, p < 0.01). Further within-subjects analysis revealed that neither saline (F(3.650, 
29.201) = 1.427, NS) or amphetamine treated animals (F(1.913, 13.388) = 1.409, NS) 
performance within No-go trials altered across drug days when analysed independently, 
however, further between-subjects analysis revealed that amphetamine treated animals had 
lower No-go trial accuracy in comparison to controls on drug day 4 (F(1, 16) = 8.398, p < 0.01), 
day 7 (F(1,16) = 6.127, p < 0.05), day 8 (F(1,16) = 8.297, p < 0.05), day 9 (F(1,16) = 6.845, p < 
0.0) and day 10 (F(1,16) = 8.214, p < 0.05) (Fig. 5.2) (Benjamini-Hochberg correction, α = p < 
0.025 – p < 0.005, see Appendix 2, Table 2b for specific corrected p-values). No significant drug 
day x drug treatment group interaction was found (F(3.985, 63.275) = 1.492, NS). 
 
 
140 
 
5.3.2.2 Speed of Responding: 
Analysis of Go trial response latencies revealed no main effect of drug day (F(5.234, 83.751) = 
0.355, NS), however, amphetamine treated animals were slower in responding during Go trials 
in comparison to saline controls during drug treatment (F(1, 16) = 8.166, p < 0.05). Further 
with-subjects analysis revealed that neither saline (F(3.239, 25.909) = 0.451, NS) or 
amphetamine treated animals (F(3.871, 27.095) = 0.383, NS) differed in speed of responding 
during Go trials when analysed independently. Further between-subjects analysis also failed to 
produce any significant differences between saline and amphetamine treated animals on 
individual drug days (Table 5.3) (df = 1, 16, all F ≥ 0.076, Benjamini-Hochberg correction 
applied, see Appendix 2, Table 2c for specific F- and corrected p-values). In addition, no 
significant drug day x drug treatment group interaction was found within Go trial response 
latencies (F(5.234, 83.751) = 2.198, NS). Analysis of No-go trial incorrect response latencies 
also revealed no main effect of drug day (F(9, 144) = 1.280, NS), drug treatment group (F(1, 16) 
= 0.590, NS) or significant drug day x treatment group interaction (F(9, 144) = 0.881, NS) (Table 
5.3).  
Analysis of Go trial magazine latencies revealed no main effect of drug day (F(2.817, 48.894) = 
0.291, NS), drug treatment group (F(1, 17) = 0.001, NS) or drug day x drug treatment group 
interaction was detected (F(2.817, 48.894) = 0.590, NS) (Table 5.3). Analysis of No-go trial 
magazine latencies also revealed no main effect of drug day (F(4.848, 77.596) = 1.280, NS), 
however, amphetamine treated animals were slower to collect of the food reward within No-
go trials in comparison to controls during drug treatment (F(1, 16) = 6.638, p < 0.05). Further 
within-subjects analysis revealed that neither saline (F(4.593, 36.741) = 1.037, NS) nor 
amphetamine (F(3.275, 22.927) = 0.821, NS) treated animals differed across drug days in their 
speed to collect food following a correct No-go trial when analysed independently. However, 
further between-subjects analysis revealed that amphetamine treated animals were 
significantly slower to collect food reward within No-go trials relative to controls specifically on 
drug day 7 (F(1, 16) = 13.928, p < 0.01) and day 9 (F(1, 16) = 15.649, p < 0.01) (Table 5.3) 
(Benjamini-Hochberg correction, α = p < 0.05 – p < 0.005, see Appendix 2, Table 2d for specific 
F- and corrected p-values). 
5.3.2.3 Anticipatory Responding: 
 
Analysis of Go trial early responses revealed no main effect of drug day (F(9, 144) = 0.802, NS), 
however, amphetamine treated animals were found to perform less Go trial early response in 
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comparison to saline treated animals during drug treatment (F(1, 16) = 6.951, p < 0.05). 
Further within-subjects analysis revealed that neither saline (F(3.536, 28.291) = 0.523, NS) or 
amphetamine F(3.536, 28.291) = 0.523, NS) treated animals significantly differed in the 
number of Go trial early responses across drug days, however, further between-subjects 
analysis revealed that amphetamine treated animals performed less Go trial early responses in 
comparison to controls on drug day 7 (F(1, 16) = 11.341, p < 0.01) and drug day 9 (F(1, 16) = 
13.979, p < 0.01) (Table 5.4) (Benjamini-Hochberg correction, α = p < 0.05 – p < 0.005, see 
Appendix 2, Table 2e for specific F- and corrected p-values). No significant drug day x drug 
treatment group interaction was however detected with Go trial early responses (F(9, 144) = 
1.717, NS). Analysis of No-go trial early responses revealed no main effect of drug day (F(4.640, 
74.247) = 0.644, NS), drug treatment group (F(1, 16) = 0.028, NS) and no significant drug day x 
treatment group interaction (F(4.640, 74.247) = 0.945, NS) (Table 5.4). 
Analysis of Go trial panel responses revealed no main effect of drug day (F(9, 153) = 1.591, NS), 
however, amphetamine treated animals performed significantly more Go trial panel responses 
during drug administration in comparison to controls (F(1, 17) = 5.152, p < 0.05). Further 
within-subjects analysis demonstrated that neither amphetamine (F(4.380, 35.039) = 1.128, 
NS) nor saline (F(3.693, 33.234) = 0.835, NS) treated animals differed in the number of Go trials 
performed with panel responses during drug administration when analysed independently. 
Further between-subjects analysis also failed to produce any significant differences between 
drug treatment groups on individual drug days (df= 1, 16, all F ≥ 0.120, NS) (Table 5.4) 
(Benjamini-Hochberg correction, α = p < 0.05 – p < 0.005, see Appendix 2, Table 2f for specific 
F- and corrected p-values). Additionally, no significant drug day x drug treatment group 
interaction was found in the analysis of Go trial panel responses (F(9, 153) = 0.576, NS). No 
main effect of drug day (F(3.967, 63.469) = 0.340, NS), drug treatment group (F(1, 16) = 0.164, 
NS) and no significant drug day x drug treatment group interaction was found in the analysis of 
No-go trial panel responses during drug treatment (F(3.967, 63.469) (Table 5.4). 
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Behavioural Measure Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8  Day 9 Day 10 
Go Trial 
Response 
Latency 
Saline 0.89 ± 0.09 0.70 ± 0.12 0.75 ± 0.11 0.88 ± 0.14 0.86 ± 0.14 0.91 ± 0.12 0.70 ± 0.15 0.67 ± 0.08 0.76 ± 0.12 0.75 ± 0.13 
Amphet 0.95 ± 0.17 1.00 ± 0.24 1.10 ± 0.23 1.15 ± 0.24 1.18 ± 0.24 1.09 ± 0.22 1.32 ± 0.22 1.16 ± 0.26 1.55 ± 0.34 1.30 ± 0.23 
No-go Trial 
Incorrect 
Response 
Latency 
Saline 2.24 ± 0.29 1.68 ± 0.44 2.22 ± 0.35 1.84 ± 0.44 1.70 ± 0.23 1.63 ± 0.35 1.62 ± 0.59 2.25 ± 0.43 2.23 ± 0.50 1.53 ± 0.32 
Amphet 2.02 ± 0.50 2.51 ± 0.50 1.90 ± 0.27 2.34 ± 0.29 1.93 ± 0.39 2.29 ± 0.38 2.22 ± 0.25 2.35 ± 0.32 2.23 ± 0.32 2.53 ± 0.39 
Go Trial 
Magazine 
Latency 
Saline 0.38 ± 0.09 0.36 ± 0.08 0.37 ± 0.10 0.40 ± 0.12 0.41 ± 0.14 0.43 ± 0.15 0.45 ± 0.17 0.44 ± 0.17 0.44 ± 0.18 0.42 ± 0.16 
Amphet 0.34 ± 0.04 0.34 ± 0.04 0.35 ± 0.03 0.33 ± 0.0. 0.32 ± 0.03 0.32 ± 0.02 0.31 ± 0.02 0.33 ± 0.02 0.34 ± 0.02 0.36 ± 0.02 
No-go Trial 
Magazine 
Latency 
Saline 0.60 ± 0.07 0.62 ± 0.09 0.65 ± 0.09 0.71 ± 0.07 0.66 ± 0.10 0.67 ± 0.12 0.54 ± 0.06 0.63 ± 0.08 0.59 ± 0.06 0.62 ± 0.07 
Amphet 0.76 ± 0.14 0.78 ± 0.16 0.82 ± 0.15 0.79 ± 0.13 0.78 ± 0.12 0.78 ± 0.14 0.86 ± 0.14 0.81 ± 0.14 0.92 ± 0.16 0.88 ± 0.13 
◊ 
◊ ** ** 
 
Behavioural Measure Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8  Day 9 Day 10 
Go Trial 
Early 
Response 
Saline 18.70 ± 2.31 18.50 ± 2.52 18.30 ± 2.85 16.50 ± 2.53 17.10 ± 2.07 16.90 ± 1.83 17.90 ± 1.90 17.10 ± 2.08 17.30 ± 2.13 17.20 ± 2.25 
Amphet 18.79 ± 2.23 18.44 ± 2.21 14.78 ± 2.32 17.22 ± 2.44 16.44 ± 2.33 17.56 ± 2.29 14.11 ± 2.19 16.67 ± 2.25 14.11 ± 3.04 15.22 ± 2.48 
No-go Trial 
Early 
Response 
Saline 5.90 ± 1.86 8.20 ± 2.02 6.60 ± 1.45 4.70 ± 1.41 6.80 ± 1.65 6.50 ± 1.42 15.90 ± 1.52 6.30 ± 1.34 6.30 ± 1.44 6.30 ± 1.51 
Amphet 6.78 ± 1.16 7.33 ± 1.71 5.67 ± 1.29 6.67 ± 1.01 7.22 ± 1.36 8.00 ± 1.40 7.67 ± 1.40 7.67 ± 1.49 6.00 ± 1.34 7.11 ± 1.56 
Go Trial 
Panel 
Response 
Saline 0.70 ± 0.26 0.30 ± 0.21 0.60 ± 0.22 1.10 ± 0.67 1.10 ± 0.43 0.80 ± 0.20 0.50 ± 0.31 1.16 ± 0.58 1.16 ± 0.52 1.00 ± 0.37 
Amphet 1.22 ± 0.66 1.11 ± 0.48 1.00 ± 0.33 0.56 ± 0.47. 2.20 ± 0.85 0.89 ± 0.26 0.33 ± 0.50 1.78 ± 0.55 3.00 ± 0.85 1.11 ± 0.26 
No-go Trial 
Panel 
Response 
Saline 9.40 ± 1.48 11.30 ± 2.73 10.80 ± 2.56 11.30 ± 2.80 10.20 ± 2.76 10.70 ± 2.40 10.90 ± 2.42 12.20 ± 2.43 10.90 ± 2.28 10.30 ± 2.49 
Amphet 7.78 ± 2.09 7.22 ± 2.25 7.28 ± 2.31 6.33 ± 1.99 8.11 ± 1.84 9.00 ± 2.32 7.11 ± 2.00 8.11 ± 2.04 8.67 ± 2.07 6.78 ± 2.90 
◊ 
◊ 
** ** 
Table 5.4: Chronic Amphetamine: Anticipatory responding during amphetamine treatment. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = 
significant difference between amphetamine and saline group. Values represent means and SEM. 
 
Table 5.3: Chronic Amphetamine: Speed of responding during amphetamine treatment. ◊ = main effect of group. *p<0.05 and **p<0.01, ***p<0.001 = 
significant difference between amphetamine and saline group. Values represent means and SEM. 
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5.3.3 Experiment 3b: Withdrawal week one 
5.3.3.1 Performance accuracy: 
Analysis of the total percentage of correctly completed trials revealed no main effect of 
withdrawal hour (F(4.580) = 0.455, NS). However, amphetamine treated animals were found to 
have significantly lower overall accuracy in comparison to controls during withdrawal week 
one (F(1, 16) = 18.516, p < 0.001). Further analysis of this effect revealed that saline (F(8, 64) = 
0.621, NS) and amphetamine treated animals (F(2,832, 19,763) = 0.440, NS) did not differ in 
performance between withdrawal hours during withdrawal week one when analysed 
independently, however, further between-subjects comparisons at specific hours of 
withdrawal demonstrated that amphetamine treated animals had lower overall accuracy in 
comparison to controls at 12 hrs (F(1, 16) = 14.694, p < 0.001), 18 hrs (F(1, 16) = 8.868, p < 
0.01), 36 hrs (F(1, 16) = 8.716, p < 0.01), 42 hrs (F(1, 16) = 12.217, p < 0.01), 60 hrs (F(1, 16) = 
9.793, p < 0.01), 84 hrs (F(1, 16) = 5.123, p < 0.05) and 108 hrs of drug withdrawal (F(1, 16) = 
6.880, p < 0.05) (Fig. 5.1) (Benjamini-Hochberg correction, α. = p < 0.039 – p < 0.005, see 
Appendix 2, Table 2g for specific corrected p-values).  
Analysis of Go trial performance during withdrawal week one revealed no main effect of 
withdrawal hour (F(2.826, 48.039) = 2.123, NS), drug treatment group (F(1, 17) = 2.953, NS) or 
withdrawal day x drug treatment group interaction (F(2.826, 48.039) = 2.503, NS) (Fig. 5.2). 
Analysis of No-go trial performance during withdrawal week one revealed no significant main 
effect of withdrawal hour (F(4.320, 69.113) = 0.536, NS), however, amphetamine treated 
animals did have lower No-go trial accuracy during withdrawal week one (F(1, 16) = 12.352, p <  
0.01). Further analysis of this treatment group effect revealed no significant difference in No-
go trial performance between withdrawal hours amongst either saline (F(8, 64) = 0.612, NS) or 
amphetamine treated animals (F(2.664, 18.668) = 0.698, NS) when analysed independently. 
And further analysis of between-subjects effects also revealed no significant difference 
between saline and amphetamine treated animals performance within No-go trials throughout 
withdrawal week one (df = 1, 16, all F ≥ 0.021. NS) (Fig. 5.2) (Benjamini-Hochberg correction, 
see Appendix 2, Table 2h for specific F- and corrected p-values). No significant withdrawal hour 
x treatment group effect was found (F(4.320, 69.112) = 0.536, NS). 
144 
 
5.3.3.2 Speed of Responding: 
Analysis of Go trial response latencies revealed no main effect of withdrawal hour (F(8, 128) = 
1.313, NS), however, amphetamine treated animals were significantly slower to respond 
during Go trials in comparison to controls (F(1, 16) = 5.491, p < 0.05). Further within-subjects 
analysis revealed that neither saline (F(2.807, 22.459) = 0.926, NS) nor amphetamine (F(3.826, 
26.780) = 0.702, NS) treated animals differed across withdrawal hours in their speed to 
respond within Go trials when analysed independently. Further between-groups analysis also 
revealed no significant differences between saline and amphetamine treated animals in the 
speed of responding within Go trials at specific hours of withdrawal (df = 1, 16, all F ≥ 0.127, 
NS) (Table 5.5) (Benjamini-Hochberg correction, see Appendix 2, Table 2i for specific F- and 
corrected p-values). Analysis of No-go trial incorrect response latencies revealed no main 
effect of withdrawal hour (F(4.779, 76.780) = 0.970, NS), drug treatment group (F(1, 16) = 
0.018, NS) or significant withdrawal hour x drug treatment group interaction (F(4.779, 76.780) 
= 0.1644, NS) (Table 5.5).  
Analysis of Go trial magazine latencies revealed that the speed to collect the food reward did 
not change across withdrawal hours (χ²(8) = 6.517, NS) and between-subjects analysis of Go 
trial magazine latencies also revealed that amphetamine and saline treated animals did not 
differ in the speed to collect food reward within Go trials during withdrawal week one (all U ≥ 
28, NS) (Table 5.5). Analysis No-go trial magazine latencies also revealed no main effect of 
withdrawal hour (F(8, 128) = 0.593, NS), however, amphetamine treated animals were slower 
to collect the food reward during No-go trial trials in comparison to controls during withdrawal 
week one (F(1, 16) = 8.767, p < 0.01). Further within-subjects analysis revealed that neither 
saline (F(4.367, 34.934) = 0.681, NS) nor amphetamine (F(3.029, 21.200) = 1.483, NS) treated 
animals significantly differed in the speed to collect food reward following successful No-go 
trials when analysed independently, however, multiple comparisons of between-subjects 
effects revealed that amphetamine treated animals were significantly  slower to collect food 
reward during No-go trials at 18 hours of withdrawal (F(1, 16) = 13.718, p < 0.01) (Table 5.5) 
(Benjamini-Hochberg correction, α =  p < 0.05 – p< 0.006, see Appendix 2. Table 2j for specific 
F- and corrected p-values). No significant withdrawal hour x drug treatment group interaction 
was detected in the analysis of No-go trial magazine latencies (F(8, 128) = 1.659, NS). 
5.3.3.3 Anticipatory Responding: 
Analysis of Go trial early responses revealed no main effect of withdrawal hour (F(3.629, 
58.062) = 0.976, NS), however, amphetamine treated animals performed significantly less Go 
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trial early responses  during withdrawal week one in comparison to controls (F(1, 16) = 8.258, p 
< 0.05). Further within-subjects analysis revealed that there was no significant difference 
between withdrawal hours within either saline (F(8, 64) = 1.357, NS) or amphetamine treated 
animals (F(2.588, 18.113) = 1.615, NS) during withdrawal week one when analysed 
independently. Further between-subjects analysis also failed to identify a significant difference 
between treatment groups at specific hours of withdrawal (df = 1, 16, all F ≥ 0.015, NS) (Table 
5.6) (Benjamini-Hochberg correction, see Appendix 2, Table 2k for specific F- and corrected p-
values). In addition, no significant withdrawal hour x drug treatment group interaction was 
found (F(3.629, 58.062) = 0.967, NS). Analysis of No-go trial early responses revealed no main 
effect of withdrawal hour (4.029, 64.463) = 1.138, NS), drug treatment group (F(1, 16) = 0.024, 
NS) and no withdrawal hour x drug treatment group interaction was detected during 
withdrawal week one (F(4.029, 64.463) = 0.793, NS) (Table 5.6).  
Analysis of Go trial panel responses revealed no main effect of withdrawal hour (F(4.221, 
71.756) = 1.214, NS), drug treatment group (F(1, 17) = 0.540, NS) and no significant withdrawal 
hour x drug treatment group interaction (F(4.221, 71.756) = 0.835, NS) (Fig. 5.6). Similarly, the 
analysis of No-go trial panel responses revealed no main effect of withdrawal hour (F(4.729, 
75.662), drug treatment group (F(1, 16) = 1.121, NS) and no withdrawal hour x drug treatment 
group interaction (F(4.729, 75.662) = 0.603, NS) (Table 5.6).  
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Behavioural Measure 12 hrs 18 hrs 36 hrs 42 hrs  60 hrs 84 hrs 108 hrs 132 hrs 156 hrs 
Go Trial   
Response 
Latency 
Saline 0.79 ± 0.12 0.71 ± 0.08 0.69 ± 0.09 0.86 ± 0.10 0.77 ± 0.11 0.71 ± 0.09 0.78 ± 0.18 0.68 ± 0.08 0.80 ± 0.16 
Amphet 1.40 ± 0.28 1.11 ± 0.15 1.02 ± 0.21 1.12 ± 0.24 1.23 ± 0.28 0.93 ± 0.17 0.93 ± 0.17 0.86 ± 0.13 0.86 ± 0.19 
No-go Trial  
Incorrect 
Response 
Latency 
Saline 2.09 ± 0.31 1.89 ± 0.24 1.59 ± 0.38 2.16 ± 0.35 1.78 ± 0.35 1.59 ± 0.30 1.75 ± 0.39 1.53 ± 0.26 1.15 ± 0.26 
Amphet 2.63 ± 0.35 2.10 ± 0.37 2.12 ± 0.41 1.41 ± 0.36 1.43 ± 0.30 1.65 ± 0.27 1.70 ± 0.37 2.00 ± 0.43 2.19 ± 0.63 
Go Trial 
Magazine 
Latency 
Saline 0.42 ± 0.16 0.43 ± 0.16 0.50 ± 0.24 0.46 ± 0.19 0.51 ± 0.20 0.46 ± 0.20 0.43 ± 0.15 0.44 ± 0.17 0.49 ± 0.18 
Amphet 0.38 ± 0.04 0.38 ± 0.67 0.37 ± 0.07 0.37 ± 0.07 0.37 ± 0.07 0.43 ± 0.13 0.44 ± 0.14 0.43 ± 0.51 0.37 ± 0.07 
No-go Trial 
Magazine 
Latency 
Saline 0.68 ± 0.11 0.58 ± 0.08 0.63 ± 0.09 0.62 ± 0.08 0.64 ± 0.08 0.63 ± 0.09 0.58 ± 0.07 0.67 ± 0.08 0.74 ± 0.09 
Amphet 0.95 ± 0.17 1.02 ± 0.20 0.77 ± 0.14 0.87 ± 0.20 0.87 ± 0.19 0.80 ± 0.12 0.82 ± 0.17 0.83 ± 0.17 0.82 ± 0.21 
◊ 
◊ ** 
 
Behavioural Measure 12 hrs 18 hrs 36 hrs 42 hrs  60 hrs 84 hrs 108 hrs 132 hrs 156 hrs 
Go Trial   
Early 
Response 
Saline 18.60 ± 2.84 17.70 ± 2.37 17.90 ± 1.96 15.80 ± 2.17 19.80 ± 2.18 19.50 ± 2.53 20.00 ± 2.87 18.60 ± 2.33 18.90 ± 2.18 
Amphet 14.22 ± 2.53 16.22 ± 1.96 14.44 ± 2.13 14.67 ± 1.98 16.33 ± 2.97 18.00 ± 2.70 19.78 ± 2.18 18.11 ± 2.81 19.22 ± 2.49 
No-go Trial 
Early 
Response 
Saline 5.10 ± 0.96 7.90 ± 2.00 6.10 ± 1.73 5.70 ± 1.35 5.00 ± 1.67 4.70 ± 1.67 5.50 ± 2.09 6.00 ± 1.45 6.40 ± 2.00 
Amphet 7.78 ± 1.42 7.67 ± 1.47 6.33 ± 1.68 6.00 ± 1.11 5.56 ± 1.29 5.78 ± 1.06 7.11 ± 1.34 5.67 ± 1.54 6.56 ± 1.42 
Go Trial 
Panel 
Response 
Saline 1.30 ± 0.40 1.30 ± 0.45 0.70 ± 0.30 1.11 ± 0.46 0.90 ± 0.53 1.20 ± 0.39 1.00 ± 0.37 0.80 ± 0.36 1.30 ± 0.42 
Amphet 1.00 ± 0.29 1.78 ± 0.64 0.89 ± 0.77 2.44 ± 1.26 1.33 ± 0.75 1.11 ± 0.75 1.44 ± 0.87 1.44 ± 0.58 1.11 ± 0.75 
No-go Trial   
Panel 
Response 
Saline 9.10 ± 1.77 10.90 ± 2.01 10.60 ± 2.60 10.60 ± 2.78 9.70 ± 2.21 10.30 ± 2.23 10.30 ± 2.74 9.30 ± 2.78 9.90 ± 2.54 
Amphet 10.00 ± 2.89 8.44 ± 2.58 7.78 ± 2.74 8.67 ± 2.51 7.67 ± 2.13 9.00 ± 2.64 8.00 ± 2.33 6.78 ± 2.07 7.44 ± 3.06 
◊ 
Table 5.5: Withdrawal Week One: Speed of responding during withdrawal week one. ◊ = main effect of group. *p<0.05 and **p<0.01, 
***p<0.001 = significant difference between amphetamine and saline group. Values represent means and SEM. 
Table 5.6: Withdrawal Week One: Anticipatory responding during withdrawal week one. ◊ = main effect of group. *p<0.05 and **p<0.01, 
***p<0.001 = significant difference between amphetamine and saline group. Values represent means and SEM. 
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5.3.4  Experiment 3c: Withdrawal week two 
5.3.4.1 Performance accuracy: 
Analysis of the total percentage of correctly completed trials during withdrawal week two 
revealed no main effect of withdrawal day (F(6, 96) = 0.558, NS), drug treatment group (F(1, 
16) = 0.203, NS) or significant withdrawal day x treatment group interaction (F(6, 96) = 0.558, 
NS) (Fig. 5.1). Analysis of the total percentage of correct Go trials also revealed no main effect 
of withdrawal day (F(3.450, 58.654) = 1.060, NS), drug treatment group (F(1, 17) = 0.782, NS) 
or withdrawal day x treatment group interaction (F(3.450, 58.654) = 0.391, NS) (Fig. 5.2). 
Analysis of the total percentage of correct No-go trial further revealed no main effect of 
withdrawal day (F(6, 96) = 0.834, NS), drug treatment group (F(1, 16) = 0.162, NS) or 
withdrawal day x treatment group interaction (F(6, 96) = 1.280, NS) (Fig. 5.2). 
5.3.4.2 Speed of Responding: 
Analysis of Go trial response latencies revealed no main effect of withdrawal day(F(6, 96) = 
0.547, NS), drug treatment group (F(1, 16) = 1.725, NS) or withdrawal day x drug treatment 
group interaction during withdrawal week one (F(6, 96) = 0.802, NS) (Table 5.7). Analysis of 
No-go trial incorrect response latencies also revealed no main effect of withdrawal day (F(6, 
96) = 1.520, NS), drug treatment group (F(1, 16) = 0.175, NS) or withdrawal day x drug 
treatment group interaction during withdrawal week two (F(6, 96) = 0.670, NS) (Table 5.7). 
Analysis of Go trial magazine latencies also revealed that the speed to collect the food reward 
during correct Go trials did not differ across days during withdrawal week two (χ²(6) = 4.99, 
NS) and did not differ between drug treatment groups (all U ≥ 40, NS) (Table 5.7). Analysis of 
No-go trial magazine latencies further revealed no main effect of withdrawal day (F(3.431, 
54.899) = 2.069, NS), drug treatment group (F(1, 16) = 0.589, NS) or withdrawal day x drug 
treatment group interaction (F3.431, 54.899) = 2.250, NS) (Table 5.7).     
5.3.4.3 Anticipatory Responding: 
Analysis of Go trial early response revealed no main effect of withdrawal day (F(2.927, 46.832) 
= 0.748, NS), drug treatment group (F(1, 16) = 0.333), NS) or withdrawal day x drug treatment 
group interaction during withdrawal week two (F(2.927, 46.832) = 0.520, NS) (Table 5.8). 
Analysis of No-go trial early responses also revealed no main effect of withdrawal day (F(6, 96) 
= 0.210, NS), drug treatment group (F(1, 16) = 1.406, NS) and no withdrawal day x drug 
treatment group interaction (6, 96) = 0.539, NS) (Table 5.8). Analysis of Go trial panel 
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responses revealed no main effect of withdrawal day (F(6, 102) = 1.131, NS), drug treatment 
group(F(1, 17) = 1.113, NS) or withdrawal day x drug treatment group interaction during 
withdrawal week two (F(6, 102) = 1.028, NS) (Table 5.8). Analysis of No-go trial panel 
responses also revealed no main effect of withdrawal day (F(6, 96) = 0.182, NS), drug 
treatment group (F(1, 16) = 0.325, NS or withdrawal day x drug treatment group interaction 
during withdrawal week two (F(6, 96) = 0.229, NS) (Table 5.8). 
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Behavioural Measure WD8 WD9 WD10 WD11 WD12 WD13 WD14 
Go Trial  
Early  
Response 
Saline 18.50 ± 2.37 20.0 ± 3.35 18.60 ± 2.99 19.00 ± 2.93 19.20 ± 3.15 19.80 ± 3.00 16.80 ± 2.86 
Amphet 18.56 ± 1.65 19.67 ± 2.22 20.89 ± 2.68 19.56 ± 2.36 19.44 ± 2.04 17.67 ± 2.63 17.33 ± 2.72 
No-go Trial 
Early  
Response 
Saline 6.50 ± 2.03 6.90 ± 21.95 7.20 ± 1.99 6.40 ± 2.00 7.60 ± 2.49 7.30 ± 2.22 7.44 ± 1.88 
Amphet 4.22 ± 1.22 5.22 ± 1.39 5.11 ± 1.09 5.22 ± 1.32 5.11 ± 1.51 6.44 ± 1.34 7.00 ± 1.62 
Go Trial   
Panel 
Response 
Saline 1.80 ± 0.51 0.90 ± 0.31 0.70 ± 0.30 0.80 ± 0.29 0.10 ± 0.26 0.70 ± 0.21 0.80 ± 0.29 
Amphet 1.78 ± 1.42 1.56 ± 0.96 1.67 ± 1.08 1.22 ± 0.80 1.33 ± 0.75 1.33 ± 0.58 1.33 ± 0.65 
No-go Trial 
Panel 
Response 
Saline 10.50 ± 2.38 11.00 ± 2.84 9.90 ± 2.47 11.00 ± 2.37 10.90 ± 2.35 10.00 ± 2.11 9.80 ± 2.17 
Amphet 6.22 ± 2.25 7.11 ± 2.34 5.56 ± 1.58 6.44 ± 2.00 6.56 ± 2.27 5.33 ± 1.62 6.56 ± 2.57 
 
Behavioural Measure WD8 WD9 WD10 WD11 WD12 WD13 WD14 
Go Trial 
Response 
Latency 
Saline 0.83 ± 0.13 0.68 ± 0.11 0.65 ± 0.10 0.66 ± 0.10 0.67 ± 0.13 0.80 ± 0.13 0.82 ± 0.11 
Amphet 0.96 ± 0.16 1.00 ± 0.23 0.83 ± 0.17 0.97 ± 0.23 1.01 ± 0.24 0.93 ± 0.21 0.83 ± 0.17 
No-go Trial 
Incorrect 
Response 
Latency 
Saline 1.74 ± 0.33 1.73 ± 0.31 1.41 ± 0.27 1.54 ± 0.31 1.96 ± 0.51 1.09 ± 0.20 1.85 ± 0.37 
Amphet 1.36 ± 0.24 1.60 ± 0.21 1.43 ± 0.35 1.75 ± 0.38 1.58 ± 0.57 2.02 ± 0.55 1.80 ± 0.46 
Go Trial 
Magazine 
Latency 
Saline 0.49 ± 0.19 0.55 ± 0.23 0.43 ± 0.16 0.41 ± 0.12 0.48 ± 0.11 0.40 ± 0.12 0.40 ± 0.10 
Amphet 0.47 ± 0.18 0.46 ± 0.17 0.45 ± 0.15 0.45 ± 0.15 0.37 ± 0.10 0.40 ± 0.13 0.41 ± 0.12 
No-go Trial 
Magazine 
Latency 
Saline 0.69 ± 0.09 0.66 ± 0.09 0.62 ± 0.07 0.74 ± 0.12 0.65 ± 0.08 0.70 ± 0.14 0.45 ± 0.08 
Amphet 0.83 ± 0.19 0.92 ± 0.21 0.84 ± 0.16 0.70 ± 0.13 0.82 ± 0.17 0.72 ± 0.17 0.72 ± 0.13 
 
  
Table 5.7: Withdrawal Week Two: Speed of responding during withdrawal week two during withdrawal week one. Values 
represent means and SEM. 
Table 5.8: Withdrawal Week Two: Anticipatory responding during withdrawal week two during withdrawal week one. Values 
represent means and SEM. 
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5.3.5 Experiment 3d:  Acute amphetamine challenges 
5.3.5.1 Performance accuracy: 
Acute amphetamine challenges produced a treatment effect on the total percentage of 
correctly completed trials (F(2.444, 41.554) = 18.504, p < 0.001). Post hoc analysis revealed 
that the total percentage of correctly completed trials decreased in both amphetamine and 
saline pre-treated animals following administration of 0.8 and 1.2 mg/kg amphetamine in 
comparison to the saline control treatment, 0.2 (p < 0.001) and 0.4 mg/kg amphetamine (p < 
0.05) (Fig. 5.3). However, there was no main effect of previous drug history (saline vs. 
amphetamine) (F(1, 17) = 0.762, NS) and no amphetamine dose x drug treatment group 
interaction was detected (F(2.444, 41.554) = 0.007, NS) (Fig. 5.3).  
Independent analysis of the percentage of correctly completed Go trials revealed no main 
effect of amphetamine dose (χ²(4) = 2.169, NS), however, animals with a previous history of 
chronic amphetamine treatment were found to have reduced Go trial accuracy in comparison 
to animals previously treated with saline following 1.2 mg/kg amphetamine (U = 20, p < 0.01), 
however, smaller dose challenges of amphetamine did not differentially effect the 
performance of animals with previous exposure to saline or amphetamine (all U ≥ 40, NS) (Fig. 
5.4). Independent analysis of No-go trial accuracy revealed a main effect of amphetamine dose 
(F(2.382, 40.486) = 17.628, p < 0.001). Post hoc analysis of this effect revealed that the total 
percentage of correctly completed No-go trials decreased following 0.8 and 1.2 mg/kg 
amphetamine in comparison to saline control treatment and 0.2 mg/kg amphetamine (p < 
0.001), and 1.2 mg/kg also reduced No-go trial accuracy in comparison to 0.4 mg/kg (p < 0.05) 
(Fig. 5.5). However, there was no main effect of previous drug treatment group (F(1, 17) = 
0.001, NS) and no dose x drug treatment group interaction was found within the analysis of 
No-go trial accuracy (F(2.382, 40.486) = 0.685, NS) (Fig. 5.5). 
5.3.5.2 Speed of Responding: 
Analysis of Go trial response latencies revealed no main effect of amphetamine dose (F(4, 68) 
= 0.225, NS), previous drug treatment group (F(1, 17) = 1.941, NS) and no significant dose x 
drug treatment group interaction (F(4, 68) = 0.616. NS) (Fig. 5.6). Analysis of No-go trial 
response latencies revealed a trend towards an increase in speed to make incorrect responses 
during No-go trials (F(4, 68) = 2.2400, p = 0.057, NS), however, previous drug treatment group 
had no effect on No-go trial incorrect response latencies (F(1, 17) = 0.254, NS), and no 
significant dose x drug treatment group interaction was detected (F(4, 68) = 1.489, NS) (Fig. 
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5.7). Analysis of Go trial magazine latencies revealed no main effect of amphetamine dose 
(F(4.937, 32.924) = 0.724, NS), previous drug treatment group (F(1, 17) = 0.05, NS) or 
significant dose x drug treatment group interaction (F(4.937, 32.924) = 0.622, NS) (Fig. 5.8). In 
addition, no main effect of amphetamine dose (F(2.252, 38.277) = 0.336, NS), previous drug 
treatment group (F(1, 17) = 0.332, NS) and no significant dose x drug treatment group 
interaction was detected in the analysis of No-go trial magazine latencies (F(2.252, 38.277) = 
0.185, NS) (Fig. 5.9). 
5.3.5.3 Anticipatory Responding: 
Analysis of Go trial early responses revealed no main effect of amphetamine dose (F(2.584, 
43.933) = 0.571, NS), previous drug treatment group  (F(1, 17) = 0.064, NS) and no dose x drug 
treatment group was detected (F(2.584, 43.933) = 0.264, NS) (Fig. 5.10). In addition, analysis of 
No-go trial early responses revealed no main effect of amphetamine dose (F(1.955, 33.235) = 
2.706, NS), previous drug treatment group (F(1, 17) = 0.168, NS) and no significant dose x drug 
treatment group interaction (F(2.584, 43.933) = 0.295, NS) (Fig. 5.11). Analysis of Go trial panel 
responses also revealed no main effect of amphetamine dose (χ²(4) = 3.233, NS) or previous 
drug treatment group (all U ≥ 28.5, NS) (Fig. 5.12). No main effect of amphetamine dose was 
detected in the analysis of No-go trial panel responses (F(1.745, 29.663) = 1.442, NS), however, 
animals previously treated with amphetamine performed significantly less No-go trials with a 
panel response following all acute amphetamine challenges in comparison to animals with a 
previous history of saline treatment (F(1, 17) = 6.404, p < 0.05) (Fig. 5.13). However, no dose x 
previous drug treatment group interaction was found in the analysis of No-go trial panel 
responses (F(1.754, 26.663) = 0.457, NS) (Fig. 5.13). 
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Figures 5.3-5.13: Performance following 
acute amphetamine challenges within (5.3) 
the total percent correct of all trials, (5.4) 
the total percent correct Go trials, (5.5) the 
total percent correct No-go trials,(5.6) Go 
trial latency, (5.7) No-go trial response 
latency,(5.8) Go trial magazine response 
latency, (5.9) No-go trial magazine latency, 
(5.10) Go trial early responses, (5.11) No-go 
trial early response, (5.12) Go trial panel 
response and (5.13) No-go trial panel 
response. ◊ = main effect of group. 
*p<0.05, **p<0.01 and ***p<0.001 vs 
saline dose. § p<0.05, §§ p<0.01 and 
§§§<0.001 vs saline group. Values 
represent means and error bars represent 
SEM. 
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5.4Discussion 
Results revealed that treatment with 11 day chronic amphetamine caused an increase in 
impulsivity during drug treatment that was coupled with slower response speed during Go 
trials and in the speed to collect food reward during No-go trials. In addition, increased 
impulsivity was coupled with less early but more panel responses during Go trials during drug 
treatment. This pattern of behavioural deficits continued into withdrawal week one, where 
amphetamine treated animals remained more impulsive than controls and displayed slower 
response speed during Go trials and in the speed collect food reward during No-go trials. In 
addition, amphetamine treated animals continued to perform less early responses during Go 
trials relative to controls. This pattern of behaviour terminated by withdrawal week two where 
there was no difference observed between amphetamine treated animals and controls on all 
behavioural measures, indicating that drug induced changes in behavioural inhibition, speed of 
responding and anticipatory responding had recovered by two weeks following drug 
termination. Acute drug challenges revealed that animals with a history of chronic 
amphetamine treatment displayed an increase in sensitivity to amphetamine induced 
performance effects during Go trials at the highest dose of acute amphetamine in comparison 
to rats with a history of saline treatment. However, no differences were observed in 
impulsivity on the Go/No-go task in relation to previous drug history, indicating that 11 day 
chronic amphetamine did not cause any long term changes in drug induced impulsivity.   
Increased Go trial responses latencies amongst amphetamine treated animals during drug 
treatment indicates that animals became slower in their speed of responding during drug 
treatment. However, the speed with which amphetamine treated animals collected food 
reward following correct Go trials was similar to the saline treated animals. Interestingly, 
amphetamine treated animals also became slower to collect the food reward during No-go 
trials during drug treatment. Given that the first active response during a correct No-go trial is 
the collection of the food reward, this change in behaviour may not reflect a change in the 
motivation for the food reward, but rather a general slowing of responding in amphetamine 
treated rats during drug treatment. This is supported by results indicating that amphetamine 
treated animals performed less Go trial early responses at the same time as increased No-go 
trial magazine latencies were observed (days 7 and 9 of treatment, see Table 5.3 and 5.4).  
Furthermore, although analysis of Go trial panel responses revealed a significant main effect of 
treatment group during this phase of the study, with amphetamine treated animals 
performing more panel responses, closer examination of Table 5.4 indicates that on days 4 and 
7 amphetamine treated animals actually performed less panel responses than the saline 
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treated animals. Therefore, eleven day amphetamine treatment appears to produce a robust 
increase in impulsive behaviour as indicated by reduced no-go trial performance accuracy, and 
transiently slows response behaviour, at the same time as reducing anticipatory responding. 
These data are interesting because increases in impulsive behaviour are often accompanied by 
faster response speeds and increased response frequency (Harrison et al., 1997; Pattij et al., 
1997). The findings in the data therefore indicate that the inability to withhold responding is 
not directly related to speeding of responding.   
General slowing of response behaviour observed during the drug treatment phase of this 
experiment is consistent with reduced locomotor activity is observed during spontaneous 
amphetamine withdrawal following contingent and non-contingent chronic (10 days – 6 
weeks, respectively) amphetamine administration (Paulson & Robinson, 1996; Pulvirenti & 
Koob, 1993) and is considered a marker of amphetamine withdrawal (Barr & Markou, 2005). A 
possible interpretation of slower response behaviour observed during drug treatment might 
then be that amphetamine treated animals were entering an early phase of drug withdrawal 
when tested at 12 hours following the preceding amphetamine injection. Interestingly, 
however, rats tested at 16 hours following 6 hour amphetamine self-administration do  not 
differ in latencies to respond during forced choice trials on an adjusting delay procedure, 
although variance in latencies was high in this study (Gipson & Bardo 2009).  
During withdrawal week one the pattern of behavioural deficits was consistent with that 
during drug administration. Amphetamine treated animals continued to display lower No-go 
trial accuracy relative to controls, indicative of a continuation in reduced behavioural inhibition 
relative into short-term drug withdrawal. Similarly, amphetamine treated animals continued to 
display slower response speed during Go trials and in collection of food reward during No-go 
trials. As discussed above, this profile of behaviour coupled with unaffected Go trial magazine 
latencies suggests that animals were slower in response behaviour whilst also continuing to be 
motivated to gain food reward. The combination of these results again indicates that despite 
slowing down in response behaviour and maintained motivation to gain food reward, 
amphetamine treated animals remained more impulsive relative to controls during withdrawal 
week one. Furthermore, the similarity in the behavioural profile of amphetamine treated 
animals during amphetamine treatment and withdrawal week one support the possibility that 
animals might have entered early drug withdrawal during chronic amphetamine treatment.  
Slower speed of responding during amphetamine withdrawal coincides with previous 
literature reporting slower speed of responding to visual targets by rats in amphetamine 
withdrawal on the 5CSRTT (Dalley et al., 2005; Dalley et al., 2007b) and literature 
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demonstrating that rats display reduced locomotor activity during amphetamine withdrawal 
(Paulson & Robinson, 1996; Pulvirenti & Koob, 1993). Slower response speed during stimulant 
withdrawal has previously been suggested to represent withdrawal induced deficits on 
attentional processes (Dalley et al., 2005), which could be suggested to underlay observations 
of reduced response speed in this study. However, stable performance during Go trials 
indicates that amphetamine treated animals sustained accuracy in response selection and 
discrimination of visual targets throughout short term drug withdrawal. During this period the 
Go trial magazine latencies of amphetamine and saline treated animals were similar indicating 
that motivational processes were matched between treatment groups. It is unlikely, therefore, 
that increased Go trial response latencies and No-go trial magazine latencies represent a gross 
deficit in attention, and further, that such deficits may underlay decreased No-go trial 
performance.  
Amphetamine treated animals also continued to performed less early responses during Go 
trials relative to controls during withdrawal week one. However, as previously discussed, given 
that animals became slower to respond during the same phase as these reductions in early 
responses, it is likely that this reduction is related to the slower response behaviour during Go 
trials rather than withdrawal induced changes in anticipatory responding relating to 
impulsivity. Interestingly, the only drug effect that did not continue into withdrawal week one 
was amphetamine induced increases in Go trial panel responses. The prevalence of this effect 
solely to drug administration and not withdrawal further supports that the drug induced effect 
on Go trial panel responses was both mild and transient during drug administration.  
Although during most of week one of withdrawal amphetamine treated animals performed 
significantly less accurately than saline treated animals, as indicated by reduced total 
percentage of correctly completed trials, analysis of the significant main effect of group 
identified in the analysis of No-go trial accuracy failed to identify any individual day when the 
performance of amphetamine treated animals was less than that of saline treated animals. 
This additional analysis run on drug treatment effects is therefore useful for elucidating the 
specific time course over which impulsivity was affected by 11-day chronic amphetamine 
treatment. The significant group effect detected alongside non-significant post hoc tests 
therefore indicates that whilst impulsivity was transiently elevated amongst amphetamine 
treated animals relative to controls during amphetamine withdrawal, the difference in 
impulsivity relative to controls was only slight throughout drug withdrawal in comparison to 
during drug administration, as demonstrated by the lack of significant between group 
differences at any specific withdrawal day. Consequently, these findings indicate that the most 
severe amphetamine induced deficits on impulsivity following 11 day chronic amphetamine 
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occur during amphetamine administration rather than short-term drug withdrawal. 
Interestingly, this pattern of results is similar to that reported by (Gipson & Bardo, 2009) that 
identified greater levels of impulsive choice throughout 21 days of amphetamine self-
administration and for three days into amphetamine withdrawal.  
The observed elevations in impulsive behaviour during drug treatment are the first to identify 
that chronic amphetamine can reduce behavioural inhibition in rats during drug 
administration. These findings therefore provide a new insight into the relationship between 
chronic amphetamine use and impulsivity. The only other study to measure impulsivity during 
a long-term amphetamine regime is Gipson & Bardo (2009) that assessed MAD during 21 days 
of amphetamine self-administration. Within this study animals that both escalated and did not 
escalate amphetamine self-administration became more impulsive during drug administration 
Gipson & Bardo (2009). Interestingly this suggests that escalation of amphetamine is not 
required to affect impulsivity, and in fact maintained self-administration can disrupt 
impulsivity to a comparable level of animals that escalate drug use. Animal within the Gipson & 
Bardo (2009) study that displayed a maintained pattern of self-administration also self-
administered on average 8- 13 mg/kg amphetamine daily, indicating that the range of daily 
amphetamine administration was not dissimilar between Gipson & Bardo (2009) and 
experiment 3a. Whilst the route of administration between Gipson & Bardo (2009) and that 
employed within experiment 3a are different (contingent vs. non-contingent), and may in itself 
contribute towards the effects observed in both experiments, the fact that both sets of 
animals became more impulsive during long-term maintained amphetamine treatment 
supports that this pattern of chronic amphetamine use can increase impulsive behaviour, and 
furthermore, that this elevation can occur within distinct dimensions of impulsivity. 
Elevated impulsivity during amphetamine administration also relates to previous literature 
demonstrating increased reflection impulsivity amongst current amphetamine users (Clarke et 
al., 2006), further supporting a relationship between chronic amphetamine exposure and 
altered impulse control. However, amphetamine users have also been shown to exhibit 
comparable levels of perseverative responding to healthy controls, suggesting that some forms 
of impulse control remain normal following chronic amphetamine exposure (Ersche et al., 
2008). The decrease in behavioural inhibition observed in experiment 3a and b therefore 
expands upon previous literature by identifying alternative dimensions of impulsivity that may 
be disrupted as a consequence of repeated amphetamine exposure. Furthermore, in 
consideration of elevated reflection impulsivity amongst amphetamine users (Clark et al., 
2006) the reported reduction in behavioural inhibition again suggests that multiple systems 
mediating inhibitory control may be altered during chronic amphetamine use.  
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Increased impulsivity during chronic amphetamine treatment also relates to literature 
reporting reduced behavioural inhibition amongst users of pharmacologically similar drugs 
such as cocaine (Colzato et al., 2007; Fillmore & Rush, 2002) and MDMA (Morgan, 1998; 
Quednow et al., 2007), and contributes towards substance abuse literature by clarifying that 
repeated amphetamine use alone can lead to significant alterations in behavioural control. 
These findings are useful in consideration of factors underlying the transition from recreational 
to maintained use of amphetamine, both alone or in combination with other psychostimulant 
use, by demonstrating that repeated exposure to high dosages of amphetamine per se can 
reduce behavioural control that may lower inhibitory control over repeated and maintained 
drug use. 
The observed elevation in impulsivity that continued into drug withdrawal are the first to 
identify that withdrawal from chronic amphetamine can reduce behavioural inhibition in rats. 
Studies that have previously administered chronic non-contingent amphetamine have found 
that chronic amphetamine produces no long term effects on impulsive choice (Slezak et al., 
2012; Stanis et al., 2008). However, both of these studies employed lower doses to that in 
experiment 3a and Slezak et al. (2012) did not measure impulsivity through short-term drug 
withdrawal. In contrast, sub-chronic amphetamine regimes consisting of 5 mg/kg for 5 days 
have been shown to cause an increase in premature responding within DRL procedures 
(Peterson, Wolf, & White, 2003) supporting that withdrawal from non-contingent daily 
administration of amphetamine can reduce behavioural inhibition. In addition (Gipson & 
Bardo, 2009) also found that amphetamine treated animals remain more impulsive than 
controls for three days following amphetamine cessation, supporting the prevalence of 
residual amphetamine induced effects on impulsivity during drug withdrawal. 
However, other studies employing long-term (21 day) amphetamine self-administration in rats 
have found that no changes in impulsivity measured by premature responding during 
amphetamine withdrawal (Dalley et al., 2007b). Differences in doses administered by animals 
and the route of drug administration (contingent vs. non-contingent) may account for the 
observed differences in amphetamine withdrawal effects on impulsivity, however, given that 
(Gipson & Bardo, 2009) employed a similar self-administration methodology to (Dalley et al., 
2007b) and observed increased impulsive choice through acute drug withdrawal, this suggests 
that differences in withdrawal induced impulsivity observed between (Dalley et al., 2007b) and 
experiment 3a might relate to differences between the 5CSRTT and Go/No-go symmetrically 
reinforced paradigm. As previously discussed the 5CSRTT is sensitive to changes in attention 
capacity. Differences in the effects of amphetamine withdrawal on impulsivity might then be 
likely to reflect differences in task sensitivity to behavioural inhibition vs. attentional 
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processes. However, what is consistent between studies that have identified amphetamine 
withdrawal induced effects on cognitive processes is that these effects are transient during 
short-term amphetamine withdrawal (Dalley et al., 2005; Dalley et al., 2007b; Gipson & Bardo, 
2009).  
Further confirmation that amphetamine induced effects on impulsivity were transient was 
observed by a lack of effect of previous drug history on acute amphetamine challenges within 
performance measures of behavioural inhibition. Amphetamine treated animals did show a 
slight increase in sensitivity to amphetamine induced reductions of Go trial performance 
accuracy at 1.2 mg/kg amphetamine relative to controls, suggesting that chronic amphetamine 
leads to some residual changes in sensitivity to the disruptive performance effects by 
amphetamine. Although analysis of No-go trial panel responses revealed a main effect of 
previous drug history, there was no interaction with amphetamine dose. Thus animals 
previously treated with saline performed more no-go trial with panel responses than 
amphetamine treated animals at all doses including 0 mg/kg amphetamine. Therefore this 
result does not indicate differential sensitivity to amphetamine challenges between the two 
groups of animals. In addition, due to the fact no other between group differences were 
observed within any other variable, and no difference in No-go trial accuracy was observed in 
relation to previous amphetamine exposure, this indicates that previous amphetamine 
exposure did not lead to any substantial change in response to amphetamine induced effects 
on the Go/No-go symmetrically reinforced paradigm. Furthermore, the lack of difference 
between drug treatment groups during No-go trials suggests that no long term neural 
adaptations occurred in amphetamine treated animals that might render these animals more 
or less sensitive to the disinhibitory effects of amphetamine. These effects are consistent with 
previous literature reporting that chronic amphetamine treatment does not produce any long-
term sensitivity or tolerance to amphetamine induced impulsivity (Slezak et al., 2012; Stanis et 
al., 2008).  
5.4.1 Key Findings 
The main findings from this study are that 11-day amphetamine treatment reduces response 
inhibition in rats during drug treatment and short-term drug withdrawal. These findings 
suggest that a chronic level of amphetamine exposure might directly reduce response 
inhibition during phases where drug use is maintained (chronic treatment) and vulnerability to 
relapse is high (short-term withdrawal). However, response inhibition returned to comparable 
levels in withdrawal week two and no changes in sensitivity to drug induced response 
disinhibition was observed in rats previously exposed to chronic amphetamine relative to 
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saline treated animals. This suggests that chronic amphetamine treatment did not lead to any 
longer term changes in response inhibition or neural systems mediating response inhibition. 
The main objective of this study was to assess how chronic amphetamine treatment affects 
response inhibition in rats, with a broader objective of disentangling the relationship between 
amphetamine use and impulsivity. Evidence that chronic amphetamine can impinge on 
response inhibition consequently helps to disentangle this relationship by, firstly, confirming 
that chronic amphetamine exposure can directly increases impulsive responding, and 
secondly, indicating that these drug induced effects on impulsivity may occur at specific time 
periods during which heightened impulsivity can contribute towards maintaining drug use and 
relapse. 
5.4.2 Limitations 
As discussed in Chapter 4, section 4.4.2, page 121, a limitation of using non-contingent drug 
administration is that there is less scalability to human drug use. The effects of non-contingent 
chronic amphetamine in rats on response inhibition may not reflect the effects of chronic 
voluntary administration of amphetamine in human drug users on response inhibition. In 
addition, amphetamine was administered in a high and frequent dose pattern. Amphetamine 
is typically binged amongst human users and is unlikely to be abused in a frequent pattern 
similar to that employed in the current study. The main findings from this study suggesting 
that chronic amphetamine use affects response inhibition should therefore be treated with 
caution when considering what the effects of human voluntary drug use and patterns of 
human drug use might be on impulsivity. 
Similar to that discussed in Chapter 4, section 4.4.2, page 121, this study did not screen rats for 
high and low levels of trait impulsivity at baseline. This means that any possible effects of 
individual differences on amphetamine on response inhibition, and the time points at which 
this effect was prevalent, cannot be inferred. Consequently, this study does not account for 
how individual differences in rats might have been involved in the effects of amphetamine 
observed on impulsivity. In addition, this study did not employ neuroanatomical or 
neurochemical control groups that would have helped elucidate the possible neurobiological 
changes involved in chronic amphetamine induced impulsivity observed. It would have been 
useful to employ an additional lesion group or drug group to account for possible neural sites 
and neurochemical changes mediating chronic amphetamine induced impulsivity (see Chapter 
4, section 4.4.2, page 121). 
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Finally, it should also be noted that rats were not randomly assigned to drug treatment groups. 
Rats were assigned to treatment groups based on their overall accuracy of performance on the 
Go/No-go task at baseline. This was done in order to counterbalance baseline differences in 
the accuracy of performance between drug treatment groups. However, through assigning rats 
in this manner, bias may have been introduced to drug treatment groups.   
5.4.3 Future Research 
In order to address the limitation of the scalability to human drug use, future research 
investigating the effects of chronic amphetamine self-administration on impulsivity measured 
by the Go/No-go symmetrically task would be useful. This would help determine whether 
there is a difference in the effects of contingent and non-contingent chronic amphetamine 
administration on impulsivity measured by the Go/No-go symmetrically reinforced task. Such 
investigations would help elucidate whether high dose and frequency amphetamine exposure 
per se affects response inhibition, regardless of whether this is voluntary or not, and would 
subsequently help elucidate what the consequence of chronic amphetamine use might be on 
impulsivity amongst human populations.  
It would also be useful to determine whether the effects of chronic amphetamine on response 
inhibition are related to individual differences in impulsive behaviour. In order to do this a 
screening method that identifies high and low levels of trait impulsivity on the Go/No-go 
symmetrically reinforced task would need to be developed. Splitting animals into these groups 
would help to establish whether particular groups within the general population (high and low 
impulsivity) are differentially affected by chronic drug exposure. In addition, future research 
aimed at elucidating the neurochemical changes involved in chronic amphetamine induced 
impulsivity on the Go/No-go task will be useful for establishing the neurochemical pathology of 
impulsivity that is a direct consequence of long-term drug exposure. As there are indications 
that changes in ventral striatal D2 receptors are linked to impulsivity observed in drug addicts, 
it would be useful to explore D2 receptor mediation of chronic amphetamine induced 
impulsivity on the Go/No-go symmetrically reinforced task via intra-nucleus accumbens 
infusions of D2 receptor ligands alongside chronic amphetamine treatment. This would help to 
elucidate how possible drug induced changes in key sub-receptors and neural sites associated 
with impulsivity amongst addicts might develop as a consequence of chronic drug use. 
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5.4.4 Conclusions 
In conclusion, the observed elevations in impulsivity during chronic amphetamine treatment 
and withdrawal extend upon previous animal and human literature investigating the 
relationship between amphetamine use and impulsivity by identifying that chronic 
amphetamine use can cause a transient reduction in behavioural inhibition both during drug 
use and short-term drug withdrawal. Interestingly, elevated impulsivity was most pronounced 
during chronic amphetamine treatment, consistent with previous studies identifying chronic 
amphetamine induced impulsivity (Gipson & Bardo, 2009). This suggests that along with 
phases of drug withdrawal following complete drug cessation that act as periods of heightened 
vulnerability to relapse, drug induced changes in inhibitory control during drug use, possibly 
during phases of early withdrawal, might also constitute a period of significant vulnerability to 
repeated drug use as a consequence of drug induced reductions in behavioural control. Such 
elevations in behavioural disinhibition during drug use might then increase the chance of 
escalating drug use during maintained use, or alternatively might contribute towards 
maintaining drug use through lowering behavioural control during chronic maintained drug 
use.  
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Chapter 6 The effects of Dopamine D2 receptor antagonism within the 
NAcb core on behavioural inhibition and amphetamine induced 
behavioural disinhibition in rats 
6.1Introduction 
Stimulant users display higher levels of impulsivity than controls (Fillmore & Rush, 2002; 
Hoffman et al., 2006; Lee et al., 2009; Monterosso et al., 2005). Alongside this elevation in 
impulsivity they also show changes in the structure of fronto-striatal regions associated with 
impulsivity (Ersche et al., 2012) and changes in dopamine function and D2 receptor availability 
in the striatum(Martinez et al., 2004, 2009; Nora D Volkow et al., 1993; Nora D Volkow, Chang, 
Wang, Fowler, Ding, et al., 2001). Changes in D2 receptor availability in the ventral striatum 
also correlates with trait impulsivity in methamphetamine users (Lee et al., 2009) linking 
ventral striatal D2 receptors directly with elevated impulsivity in observed amongst stimulant 
users. Collectively these findings have led to the recent proposition that the D2 receptors 
within the striatum are a biomarker of impulsivity in drug addiction (Trifilieff & Martinez, 
2013).  
Investigations into the role of the dopamine sub-receptors in impulsivity and stimulant 
induced impulsivity in animal models have found contrasting involvement of the D1 and D2 sub-
receptors that appear to depend on the dimension of impulsivity measured. Systemic 
administration of the D1/2 receptor antagonist cis-flupenthixol does not affect modafinil or 
MPH induced reductions in SSRT (Eagle et al., 2007) suggesting that D1 and D2 receptors are 
not involved in stimulant induced changes in behavioural inhibition in the form of action 
cancellation (‘stopping’). However, the D1 and D2 receptors have been associated with 
behavioural inhibition in the form of ‘waiting’ behaviour. Systemic administration of the D1 
receptor antagonist SCH 23390 reduces premature responding on the 5CSRTT and increases 
delay discounting within a DRT when administered alone, but does not reverse amphetamine 
induced premature responding or reductions in delay discounting when administered in 
combination with amphetamine (van Gaalen, et al., 2006; van Gaalen et al., 2006b). In 
contrast, systemic administration of the D2 receptor antagonist eticlopride does not produce 
any changes in premature responses when administered alone, but does reverse 
amphetamine, cocaine and nicotine induced premature responding on the 5CSRTT when 
administered in combination with these stimulants (van Gaalen et al., 2006) and attenuated 
amphetamine induced reductions in impulsive choice on a DRT (van Gaalen et al., 2006b). 
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These findings therefore suggest a specific role for the D1 receptors in the mediation of 
impulsivity, and the D2 receptors in the mediation of stimulant induced changes in impulsivity 
on the 5CSRTT and DRT. 
However, an opposing pattern of results has been observed when impulsivity is measured 
using a symmetrically reinforced Go/No-go task. Acute amphetamine and nicotine both reduce 
No-go trial accuracy on the Go/No-go task indicating increased behavioural disinhibition 
similar to that observed in the 5CSRTT (Kolokotroni et al., 2011; Harrison et al., In prep). 
However, in contrast to the results observed on the 5CSRTT, systemic SCH 23390 does not 
affect No-go trial accuracy when administered alone, but does reverse amphetamine and 
nicotine reductions in No-go trial accuracy (Harrison et al., In prep). In contrast, systemic 
administration of eticlopride impairs active responding on the Go/No-go task and 
consequently produces unclear effects on impulsivity when combined with amphetamine 
(Harrison et al., In prep).  
The differences in results between the 5CSRTT and the Go/No-go symmetrically reinforced 
task present a contrasting picture of D1 vs D2 involvement in behavioural inhibition considering 
that both of these tasks attempt to measure the same ‘waiting’ dimension of behavioural 
inhibition. The differences in D1 and D2 receptor mediation of impulsivity and drug induced 
impulsivity may relate to differences in the reinforcement of behavioural inhibition between 
the 5CSRTT and the symmetrically reinforced Go/No-go task, and in following, the motivational 
significance of behavioural inhibition between these two tasks. Rats that receive systemic SCH 
23390 before performing the 5CSRTT produce reductions in premature responses alongside 
increases in omissions on this task (van Gaalen et al., 2006) indicating more extensive 
disruption to performance of the task that might be indicative of motivational changes 
following D1 receptor antagonism. In contrast, administration of SCH 23390 on the 
symmetrically reinforced Go/No-go task produces no change in magazine latencies or 
omissions, indicating that no changes in motivation occur following D1 antagonism on this task 
(Harrison et al., In prep). This suggests that SCH 23390 induced reductions in premature 
responding on the 5CSRTT might reflect motivational changes in rats that were only detected 
on the 5CSRTT, and not the Go/No-go task, possibly because the outcome of behavioural 
inhibition is less motivationally significant on the 5CSRTT than the Go/No-go task. In following, 
SCH 23390 reversal of amphetamine induced impulsivity on the Go/No-go task suggests that 
the D1 receptors are involved in stimulant induced behavioural inhibition when this behaviour 
is more directly associated with reinforcement.  
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In contrast, systemic eticlopride produces general performance and motivation deficits on the 
Go/No-go task that are not observed following systemic eticlopride on the 5CSRTT (Harrison et 
al., In prep; van Gaalen et al., 2006; Pattij et al., 2007), suggesting the converse to that 
observed with the D1 receptors, that D2 meditated reversal of amphetamine induced 
impulsivity on the 5CSRTT might only be prevalent when there is less motivational significance 
to behavioural inhibition. Given that systemic administration of D1 and D2 antagonists, 
including SCH 23390 and eticlopride, can lower motivation to earn food reward (Salamone et 
al., 2002; Sink et al., 2008), such differences in the reinforcement value of behavioural 
inhibition between the 5CSRTT and Go/No-go task might be particularly important in dictating 
the effects of D1 and D2 receptor antagonism on behavioural inhibition in these tasks. 
Collectively, systemic investigations into the involvement of dopamine sub-receptors in 
impulsivity within animal models have identified distinct roles for the D1 and D2 receptors in 
impulsivity and drug induced impulsivity, however the specific role of these sub-receptors 
might relate to differences in the performance and motivational parameters of behavioural 
inhibition set out by the task employed.  
Central investigations into the role of the D1 and D2 receptors in impulsivity and drug induced 
impulsivity have also been conducted through infusions of SCH 23390 and eticlopride into the 
NAcb core and shell alone and in combination with amphetamine. Similar to systemic SCH 
23390 administration on the 5CSRTT, infusions of SCH 23390 into the NAcb core and shell 
reduces premature responding when administered alone, but does not fully reverse 
amphetamine induced premature responding when infused into either sites in combination 
with systemic amphetamine (Pattij et al., 2007).  
In contrast, infusions of eticlopride alone into the NAcb core and shell do not affect premature 
responding on the 5CSRTT, but eticlopride infusions into the NAcb core in combination with 
systemic amphetamine produces full reversal of amphetamine induced premature responding, 
an effect that is not observed following eticlopride infusions into the shell in combination with 
systemic amphetamine (Pattij et al., 2007). However, eticlopride mediated reversal of 
amphetamine induced premature responding on the 5CSRRT was also reported alongside 
eticlopride mediated reversal of amphetamine induced deficits in accuracy and faster response 
latencies (Pattij et al., 2007) indicating extensive changes in performance on 5CSRTT that might 
contribute towards the observation of eticlopride mediated reversal of amphetamine induced 
impulsivity on this task. In addition, when eticlopride is infused into the NAcb core alone, a 
significant increase in omissions and response latencies has been reported (Pattij et al., 2007), 
suggesting the possibility of additive changes in motivation that might account for eticlopride 
induced reversal of amphetamine induced impulsivity on the 5CSRTT. 
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Central investigations into the role of the dopamine sub-receptors in mediating impulsivity and 
drug induced impulsivity has therefore, similar to systemic studies, indicated distinct roles for 
the D1 and D2 receptors, with a specific role for the D2 receptors within the NAcb core in 
mediating amphetamine induced impulsivity. However, there also continues to be indications 
from central investigations that treatment induced changes in premature responding observed 
on the 5CSRTT might relate to changes in attention or motivation processes. This further 
indicates that differences in the reinforcement parameters of the behavioural inhibition might 
be significant to the effects of D1 and D2 antagonists on impulsivity observed. 
In addition to evidence that the D1 and D2 receptors have distinct roles in relation to 
impulsivity, the NAcb core and shell have also been shown to have distinct functions in relation 
to drug induced impulsivity. Lesions to the NAcb core and shell have been shown to produce 
opponent effects on amphetamine induced impulsivity, with core lesions potentiating and 
shell lesions attenuating amphetamine induced premature responding in rats (Murphy et al., 
2008). These findings, along with the evidence that lesions to the NAcb core lesions disrupt 
processing of effortful and adaptive behavioural output (Galtress & Kirkpatrick, 2010; Ghods-
Sharifi & Floresco, 2010) whilst NAcb shell lesions disrupt the processing of acute drug 
reinforcement and hyperactivity (Parkinson et al., 1999), support a role for the NAcb core in 
processing inhibited behaviour and the NAcb shell in processing disinhibited behaviour.  
In summary, a large amount of evidence has implicated changes in D2 receptor availability in 
the striatum with stimulant use and impulsivity (Lee et al., 2009; Martinez et al., 2004, 2009; 
Volkow et al., 1993; Volkow et al., 2001). Evidence from animal models to date have also 
indicated a specific role for the D2 receptors within the NAcb core in mediating amphetamine 
induced impulsivity (Pattij et al., 2007) and the NAcb core in processing inhibitory control over 
amphetamine induced impulsivity (Murphy et al., 2008). However, these effects have only 
been observed in the 5CSRTT, and given the differences observed between systemic D1 and D2 
receptor antagonism on impulsivity measured by the 5CSRTT and Go/No-go task discussed, it is 
possible that the involvement of the D2 receptor within the NAcb core in impulsivity and 
amphetamine induced impulsivity might relate to the reinforcement parameters of 
behavioural inhibition employed. In following, the current chapter sought to investigate the 
role of the D2 receptors within the NAcb core on behavioural inhibition and amphetamine 
induced behavioural inhibition using a symmetrically reinforced Go/No-go task. 
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6.1.1 Objectives 
In order to investigate the role of the D2 receptors within the NAcb core in impulsivity and 
amphetamine induced impulsivity on the Go/No-go symmetrically reinforced task, the 
objectives were: 
i) To examine the effects of D2 receptor antagonism within the NAcb core on 
behavioural inhibition measured by the Go/No-go symmetrically reinforced task 
(Experiment 4) 
 
ii) To examine the effects of D2 receptor antagonism within the NAcb core on 
amphetamine induced behavioural disinhibition measured by the Go/No-go 
symmetrically reinforced paradigm (Experiment 5) 
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6.2Methods 
6.2.1 Subjects 
17 male Lister Hooded rats (Charles River, UK) were housed in pairs upon arrival into Leeds 
Behavioural Neuroscience Laboratory and maintained under a 12 hour light/dark cycle (lights 
on 0700 hours), in a temperature (21°C ± 2°C) and humidity (50% ± 5%) controlled 
environment. Throughout behavioural experimentation animals were placed on a food 
restriction schedule of 18.6g per day, maintaining animals above 85% of their adult free 
feeding body weight. Water was available ad libitum in home cages and feeding took place in 
the morning after behavioural testing. All animals were treated in accordance with the UK 
Animals (Scientific Procedures) Act 1996. All procedures were covered by Home Office Project 
Licence No. PIL 40/3606 and Home Office Personal Licence No. 40/1989.  
6.2.2 Drugs 
D-Amphetamine sulphate (Sigma Aldrich, UK) was dissolved in 0.9% physiological saline 
solution and was administered intraperioneally (i.p.) in a volume of 1 ml/kg body weight. S-(-)-
Eticlopride hydrochloride (Sigma Aldrich, UK) was dissolved in a vehicle of 0.9% NaCl and was 
administered via intracerebral infusion into the NAcb core in a volume of 0.5 μl per 
hemisphere. Both amphetamine and eticlopride were weighed out and prepared in solution on 
the morning of test sessions. Eticlopride was occasionally stored over night at a temperature of 
4°c. Stored eticlopride was used within 3 days (Sigma-Aldrich UK guidelines). The dosages 
employed in experiments 4 and 5 were selected from previous literature eg. (Pattij et al., 
2007). 
6.2.3 Apparatus 
Behavioural testing took place in eight aluminium operant chambers (30.5 x 24.1 x 21 cm, Med 
Associates Inc., USA) placed inside sound attenuating and ventilated cubicles (63.5 x 49.1 x 
39.4 cm, Med Associates Inc., USA). Chambers were controlled, and all data was recorded from 
chambers, using MED-PC IV software (Med Associates Inc., USA). Administration of 
intracerebral drug infusions was performed using an infusion pump (KDS101 Infusion pump, 
KD Scientific Inc., USA). For a more detailed description of test chambers refer to Chapter 2 
section 2.1.3, page 60. 
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6.2.4 Behavioural Testing 
Behavioural disinhibition was assessed via the symmetrically reinforced go/no-go visual 
discrimination paradigm. Behavioural training took place for approximately 8 weeks until 
animals reached stable performance of 85% total percent correct (+/-5%). Following stable 
baseline performance animals were entered into the experiment. All behavioural training and 
testing took place between 0700-1030 hours during the light phase of animals Light/Dark 
cycle. For a detailed outline of the task refer to Chapter 2 section 2.1.4, page 61. 
6.2.5 Surgery 
Once behavioural performance was stable at the minimum criteria of 85% total percent 
correct (+/-5%), animals receiving surgery were removed from daily test sessions and placed 
on a free-feeding schedule for a minimum of 3 days prior to receiving surgery and 
approximately 12 hours before surgery all food was removed. Rats were anaesthetised using a 
combination of 4% isoflurane gas and oxygen (flow rate 3 l/min) before being placed into a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) continuing to deliver 4% 
isoflurane gas and oxygen. Rats were secured into flat skull position via ear bars and a nose 
clamp with the incisor bar set to -3.3 - -5.0, depending on flat skull measurements from each 
rat. 22 gauge bilateral guide cannulae (centre-to-centre distance between each cannula: 3.8 
mm; pedestal height: 10.41 mm; stainless steel length below pedestal: 7 mm; pedestal 
diameter: 6.12 mm; Plastics One Inc., USA) were positioned 2 mm above the NAcb core via the 
following stereotaxic coordinates: +1.5 mm anterior to bregma (AP), +/- 1.9 mm lateral to 
midline (ML), -5.2 mm ventral to skull surface (DV) calculated from Paxinos and Watson (1998). 
Co-ordinates were selected via a literature review identifying studies targeting the NAcb core 
in the administration of intracerebral drug infusions. Cannulas were fixed to the skull via dental 
cement (Kemdent Dental Cement, Associated Dental Products Ltd, UK) and three stainless 
steel screws (Plastics One Inc., USA) drilled posterior to the cannula. 29 gauge stylets extending 
1mm below the guide cannula and sitting 1 mm above the NAcb core were inserted following 
secure placement of the guide cannula to the skull. Animals subsequently remained in their 
home cages on a free-feeding schedule for a minimum of 7 days post surgery. Following the 
demonstration of surgical recovery via weight gain and healing of the scalp wound surrounding 
the guide cannulae, animals were reintroduced to their original cage mate and were re-housed 
in pairs. On occasion animals continued to be singly housed following surgery due to failure to 
re-habituate to their cage mates. Following surgical recovery, animals were placed back on a 
food restriction schedule of 18.6g per day and behavioural training recommenced.  
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6.2.6 Microinfusion Procedure 
Eticlopride dosages were infused in a volume of 0.5 µl/ side over a period of 30s (rate 1µl/min) 
via a 25µl Hamilton syringe driven by an infusion pump. To infuse, stylets were removed from 
bilateral guide cannulae and a 28 gauge bilateral internal injector (centre-to-centre distance, 
3.8 mm; injector length from top of pedestal, 11 mm; Plastics One Inc., Roanoke, VA, USA) 
extending 2mm ventral to the tip of the guide cannulae was inserted delivering eticlopride into 
the NAcb core. Injectors were inserted 1 minute pre-drug infusion and were left in place for a 
further 1 minute post-drug infusion to allow for the diffusion of drug solutions. After drug 
infusions, stylets were replaced into the guide cannula. This infusion procedure was based on 
previous literature administering dopamine antagonists into the NAcb core (Besson et al., 
2009; Pattij et al., 2007). 
6.2.7 Design and Procedure 
Following recovery from surgery and the return of stable baseline task performance, animals 
were assigned to either experiment 4 or 5. These groups were counterbalanced according to 
their baseline performance accuracy, programmed levers, and stimulus-response 
contingencies. A within subject design was employed in both experiment 4 and 5.  
6.2.7.1 Experiment 4: The effects of eticlopride infusions into the NAcb core on 
behavioural disinhibition  
Animals (N=9) received intracerebral (i.c.) infusions of (0 µg, 0.1 µg, 0.3 µg and 1.0 µg/ 0.5 µl/ 
side) eticlopride into the NAcb core 10 minutes before behavioural testing according to a Latin 
square design, with a minimum of 72 hours between each drug infusion to encourage site 
preservation between intracerebral injections. Prior to all drug treatments animal’s task 
performance had returned to post-surgery baseline levels. 
6.2.7.2 Experiment 5: The effects of eticlopride pre-treatment into the NAcb core 
on amphetamine induced behavioural inhibition  
Animals (N=9) received the following combination treatments of eticlopride (i.c., 10 minutes 
prior to testing) immediately followed by amphetamine (i.p.); 0 µg + 0 mg/kg, 0 µg + 0.8 
mg/kg, 0.1 µg + 0.8 mg/kg, 0.3 µg + 0.8 mg/kg, 1.0 µg/ 0.5 µl + 0.8 mg/kg. A minimum of 72 
hours was employed between each drug infusion to encourage site preservation between 
intracerebral injections and to allow for a 3 day wash out period of amphetamine between 
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subsequent amphetamine administrations. Animals were also required to re-stabilise 
behavioural performance between intracerebral infusions to a criteria of +/-10% of their 
average baseline performance following surgery. All drug treatments were administered in a 
latin-square design. 
6.2.8 Assessment of Cannulae Placement 
Following completion of experimental procedures animals were administered i.p. with a lethal 
dose of pentobaribital sodium solution (Animal Health Ltd, Essex, UK). Conscious 
responsiveness was checked via assessment of the pedal withdrawal and corneal reflex. Upon 
termination of respiration, the heart was perfused via injection of 100ml of 0.9% NaCl into the 
left ventricle of the heart, followed by 400ml of 4% paraformaldehyde (Sigma Aldrich, UK) in a 
0.2M phosphate buffer. The brain was immediately removed and stored in 4% 
paraformaldehyde solution at 4°C. Brains were transferred into 25% sucrose solution 48 hours 
before slicing. Rat brains were sliced in 40 µm coronal sections using a cryostat (Bright OTF 
5000; Bright Instruments, Cambridge, UK). Slices were subsequently mounted onto microscope 
slides and stained using working cresyl violet solution to determine cannula placements. 
6.2.9 Statistical Analysis 
All data was initially checked for normality through Shaprio-Wilk tests and was appropriately 
transformed via arcsine and log₁₀ transformations following violations to normality. 
Homogeneity of variance was checked via Mauchley’s test of Sphericity and following any 
significant violation of equal variances, degrees of freedom in the GLM were adjusted using 
the Greenhouse- Geisser correction. All data were analysed via one-way repeated measures 
ANO As with ‘drug dose’ entered as the within-subjects factor. The effects of eticlopride 
infusions into the NAcb core on behavioural inhibition was assessed via 1 X 4 repeated 
measures ANOVAs across all behavioural parameters. The effects of eticlopride pre-treatment 
within the NAcb core on amphetamine induced behavioural disinhibition were assessed via 1 X 
5 repeated measures ANOVAs. Significant main effects of drug treatment were further 
analysed using Sidak corrected post-hoc analyses. Unless otherwise stated α < 0.05 was 
employed across all statistical analysis.  
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6.3Results 
After checks of normality, the following transformations were performed: Experiment 4: Log₁₀ 
(No-go trial incorrect latency, No-go magazine latency; Go trial panel responses); Experiment 5: 
Log₁₀ (No-go trial incorrect latency, No-go trial magazine latency, No-go trial early responses; 
Go trial panel responses). Due to Go trial accuracy remaining abnormally distributed following 
transformations within experiment 5, the total percentage correct of Go trials within 
experiment 5 was analysed using a non-parametric Friedman Test.  
6.3.1 Histology 
17 animals completed behavioural testing and were perfused (n = 8 eticlopride; n = 9 
eticlopride and amphetamine). Animals with one injector tip located minimally dorsal to the 
NAcb core border and one injector tip hitting the NAcb core were included in analysis. Animals 
with one or both injector tips located ventral to the NAcb core boarder, and therefore hitting 
the NAcb shell, were removed from analysis. After visual inspection of cannula placements, 
one animal was removed from the analysis of experiment 4 due to both the left and right 
hemisphere injector tips hitting the NAcb shell, and one animal was removed from experiment 
5 due to the right hemisphere injector tip hitting the NAcb shell. Subsequently, data from 15 
animals was used in statistical analysis (n = 7 experiment 4; n = 8 experiment 5). Figure 6.1 
shows the location of injector tips amongst animals treated with eticlopride (experiment 4), 
and eticlopride in combination with systemic amphetamine (experiment 5). Photographs 
showing the location of injector tips from an animal in experiment 4 and an animal in 
experiment 5 are shown in Figures 6.2 - 6.5. For photographs showing the location of injector 
tips for each animal in experiments 4 and 5, see Appendices 3 and 4.  
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Fig. 6.1: Schematic illustrations of the rat brain taken from Paxinos and Watson Atlas (1998) 
demonstrating the location of injector tips relative to bregma in experiments 4 and 5.  
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6.3.2 Experiment 4: The effects of eticlopride infusions into the NAcb core on 
behavioural inhibition 
6.3.2.1 Performance Accuracy 
Accuracy was not affected by eticlopride infusions. The total percentage of correctly 
completed trials (F(3, 18) = 0.263, NS), total percentage of correct Go trials (F(3, 18) = 0.980, 
NS) and the total percentage of correct No-go trials (F(3, 18) = 0.423, NS) did not significantly 
differ in comparison to the saline control following eticlopride infusions into the NAcb core 
(Figs. 6.6 – 6.8).  
Figures 6.2-6.5: Example pictures of brain slices taken during histology to confirm the location of 
injector tips in the Nucleus Accumbens core. Pictures are taken from an animal treated with 
eticlopride (6.2: left hemisphere; 6.3: right hemisphere), and an animal treated with eticlopride 
and systemic amphetamine (6.4: left hemisphere; 6.5: right hemisphere). 
Fig. 6.2 
Fig. 6.5 Fig. 6.4 
Fig. 6.3 
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6.3.2.2 Speed of Responding 
The speed of responding was also not affected by eticlopride infusions. Go trial latency (F(3, 
18) = 1.465, NS), No-go trial incorrect response latency (F(3, 18) = 0.302, NS), Go trial magazine 
latency (F(1.273, 7.738) = 0.902, NS) and No-go trial magazine latency (F(3, 18) = 2.675, NS) did 
not significantly differ in comparison to the saline control following infusions of eticlopride into 
the NAcb core (Figs. 6.12 – 6.15).  
6.3.2.3 Anticipatory Responding 
Anticipatory responding was also not affected by eticlopride infusions. Go trial early responses 
(F(3, 18) = 2.644, NS), No-go trial early responses (F(3, 18) = 0.292, NS), Go trial inappropriate 
panel responses (F(3, 18) = 1.961, NS) and No-go trial inappropriate panel responses (F(3, 18) = 
1,961, NS) did not significantly differ in comparison to the saline control following eticlopride 
infusions into the NAcb core (Figs. 6.20 – 6.23). 
6.3.3 Experiment 5: The effects of eticlopride pre-treatment into the NAcb 
core on systemic amphetamine induced behavioural disinhibition 
6.3.3.1 Performance Accuracy 
Eticlopride and systemic amphetamine produced to a main treatment effect in the total 
percentage correct of trials (F(4, 28) = 10.779, p < 0.01). Post hoc analysis of this main effect 
revealed a significant reduction in the total percentage of correctly completed trials following 
vehicle infusion + systemic amphetamine (p = 0.002) and 0.1 µg eticlopride + systemic 
amphetamine (p = 0.038) in comparison to vehicle infusion + systemic saline. A significant 
increase in the total percentage of correctly completed trials was found following 1.0 µg 
eticlopride + systemic amphetamine in comparison to vehicle infusion + systemic 
amphetamine (p = 0.020) (Fig. 6.9). A trend towards a significant increase in the total percent 
correct was detected following 0.3 µg eticlopride + systemic amphetamine in comparison to 
vehicle infusion + systemic amphetamine (p = 0.075). There was no significant difference 
between the percentage of correctly completed trials following administration of either 1.0 µg 
eticlopride + systemic amphetamine, or 0.3 µg eticlopride + systemic amphetamine (p > 0.05), 
in comparison to vehicle infusion + systemic saline (Fig. 6.9).  Analysis of Go trials revealed no 
main effect of eticlopride and amphetamine treatment (χ(4) = 5.818, NS) (Fig. 6.10). Analysis of 
No-go trials produced a main effect of eticlopride and amphetamine treatment (F(4, 28) = 
10.228, p < 0.001). Post hoc analysis of this main effect revealed a reduction in No-go trial 
176 
 
accuracy following vehicle infusion + systemic amphetamine in comparison to vehicle infusion 
+ systemic saline (p = 0.003), and an increase in No-go trial accuracy following 1.0 µg 
eticlopride + systemic amphetamine in comparison to the vehicle infusion + systemic 
amphetamine (p = 0.014) (Fig. 6.11). A non-significant trend towards reduced No-go trial 
accuracy was found following 0.1 µg eticlopride + systemic amphetamine in comparison to the 
vehicle infusion + systemic saline (p = 0.057), and a non-significant trend towards increased 
No-go trial accuracy was found following 0.3 µg eticlopride + systemic amphetamine in 
comparison to the vehicle infusion + systemic amphetamine (p = 0.076) (Fig 6.11). 
6.3.3.2 Speed of Responding 
A main effect of eticlopride + systemic amphetamine treatment was found in Go trial response 
latencies (F(4, 28) = 2.972, p < 0.05), however, post hoc tests failed to detect any significant 
difference in response speed during Go trials between specific combination dosages (all p > 
0.05) (Fig. 6.16). No-go trial response latencies did not differ following eticlopride + 
amphetamine combinations in comparison to the vehicle infusion + systemic saline 
combination (F(4, 28) = 1.144, NS) (Fig. 6.17).  Go trial (F(4, 28) = 0.683, NS) and No-go trial 
magazine latencies (F(4, 28) = 1.084, NS) were also unaffected by eticlopride + systemic 
amphetamine treatment (Figs. 6.18 and 6.19). 
6.3.3.3 Anticipatory Responding 
Analysis of Go trial early responses produced a main effect of eticlopride + systemic 
amphetamine treatment (F(4, 28) = 3.131, p < 0.05), however, post hoc tests only detected a 
trend towards a significant increase in Go trial early responses following the vehicle infusion + 
systemic amphetamine in comparison to the vehicle infusion + systemic saline (p = 0.09) (Fig 
6.24). Analysis of No-go trial early responses also produced a main effect of drug treatment 
(F(4, 28) = 9.313, p < 0.001). Post hoc analysis revealed that animals made significantly more 
early responses within No-go trials following either the vehicle infusion + systemic 
amphetamine (p = 0.003) or the 0.1µg eticlopride + systemic amphetamine (p = 0.012) 
treatment in comparison to the vehicle infusion + systemic saline. A trend towards a significant 
reduction in No-go trial early responses was detected following 1.0 µg eticlopride + systemic 
amphetamine in comparison to vehicle infusion + systemic amphetamine (p = 0.085). No-go 
trial early responses did not significantly differ between 1.0 µg eticlopride + systemic 
amphetamine and the vehicle infusion + systemic saline combination (p > 0.05) (Fig. 6.25). Go 
trial (F(4, 28) = 2.223, NS) and No-go trial inappropriate panel responses were unaffected by 
the eticlopride + systemic amphetamine treatments (F(4, 28) = 1.338, NS) (Figs. 6.26 and 6.27). 
177 
 
  
Eticlopride 
 Fig. 7a 
Eticlopride + Amphetamine 
 Fig. 7b 
 Fig. 7c 
 Fig. 7a 
 Fig. 7b 
 Fig. 7c 
Figures 6.6- 6.27: Performance following eticlopride infusions into the NAcb core on (6.6) the total 
percent correct of all trials, (6.7) the total percent correct Go trials, (6.8) the total percent correct No-
go trials, (6.12) go trial latency, (6.13) No-go trial latency, (6.14) go trial magazine latency, (6.15) no-
go trial magazine latency, (6.20) go trial early responses, (6.21) no-go trial early response, (6.22) go 
trial panel response and (6.23) no-go trial panel response. Performance following eticlopride 
infusions into the NAcb core and systemic amphetamine on (6.9) the total percent correct of all trials, 
(6.10) the total percent correct Go trials, (6.11) the total percent correct No-go trials, (6.16) go trial 
latency, (6.17) no-go trial latency, (6.18) go trial magazine latency, (6.19) no-go trial magazine 
latency, (6.24) go trial early responses, (6.25) no-go trial early response, (6.26) go trial panel response 
and (6.27) no-go trial panel response. *p<0.05, **p<0.01 and ***p<0.001 vs vehicle infusion + 
systemic saline combination. †p<0.05 vs vehicle infusion + systemic amphetamine combination. ‘S’ 
represents the vehicle infusion + systemic saline control combination. Values represent means and 
error bars represent the SEM. 
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6.4Discussion 
Eticlopride infused into the NAcb core alone did not disrupt any performance measures, 
indicating that D2 receptors within the core do not mediate behavioural inhibition, speed of 
responding or anticipatory responding within a symmetrically reinforced Go/No-go task. 
Treatment with systemic amphetamine increased impulsivity in rats, demonstrated by reduced 
No-go trial accuracy and increased No-go trial early responses. Amphetamine induced 
reductions of No-go trial accuracy were reversed following 1.0 µg of eticlopride and increases 
in No-go trial early responses were partially reversed following 1.0 μg of eticlopride. Go trial 
accuracy, speed of responding and magazine latencies during Go and No-go trials were 
unaffected by eticlopride + systemic amphetamine treatment.  
6.4.1 The effects of eticlopride infusions into the NAcb core on behavioural 
inhibition 
Eticlopride infusions did not disrupt the speed of responding during either go or no-go trials, 
indicating that central infusions of the D2 antagonist had no affect on the animals general 
motor performance on the task. D2 receptor antagonism of the NAcb core via eticlopride and 
raclopride infusions has previously been shown to reduce locomotor activity in rats (Baldo et 
al., 2002; Boye, Grant, & Clarke, 2001) and increase response latencies on choice reaction time 
tasks (Pattij et al., 2007; Pezze, Dalley, & Robbins, 2006). However, dopamine depletion within 
the NAcb core via 6-hydroxdopamine infusions does not affect speed of responding within 
simple reaction time tasks where animals have limited response selection (Amalric & Koob, 
1987) similar to that on the Go/No-go task. This suggests NAcb core D2 mediated changes in 
locomotor activity might not be detected in tasks where behavioural responding is more 
controlled than locomotor (photobeam) measures and the 5CSRTT. Furthermore, the NAcb 
shell has been shown to have a preferential role in mediating locomotor activity in comparison 
to the core (Moreno et al., 2013; Parkinson et al., 1999) and D2/3 agonists infused into the 
NAcb core have been shown to induce no effects on locomotion or rearing in rats (Ikemoto, 
2002).  
Dopaminergic innervation of the basal ganglia and systemic administration of D2 antagonists 
have previously been associated with changes in timing perception in rats (Harrington, 
Haaland, & Hermanowitz, 1998;  Jones et al., 2008; Meck, 1986). The lack of change in the 
speed of responding therefore additionally indicates that any D2 mediated changes in time 
perception in rats did not significantly affect the speed of responding. Furthermore, 6-
hydroxydopamine infusions into the NAcb core and shell do not change the temporal dynamics 
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of responding in rats performing a ‘peak procedure’ task designed to measure changes in the 
speed of the ‘internal clock’ in rats, whilst 6-hydroxydopamine infusions into the caudate-
putamen complex does lead to a loss of temporal control (Meck, 2006), indicating that changes 
in timing perception might be located in more dorsal regions of the striatum than the NAcb 
core.  
Systemic administration of eticlopride, however, has been shown to produce a reduction in the 
speed of responding in rats performing the Go/No-go task (Harrison et al., In prep) indicating 
that this task is sensitive to D2 mediated changes in the speed of responding. The lack of 
change in response speed following eticlopride into the NAcb core, along with evidence for 
greater involvement of the NAcb shell in locomotor activity and the dorsal striatum in changes 
in time perception, therefore suggests that these systemic effects might have been produced 
though changes in D2 mediated dopamine transmission in striatal sites outside the NAcb core.  
Eticlopride infusions also did not disrupt the speed to collect food reward during either go or 
no-go trials, indicating that central infusions of the D2 antagonist had no affect on the animals 
general motivation to perform the task. These findings are consistent with previous literature 
demonstrating that eticlopride induced changes in motivation occur following infusions of 2.0 
μg eticlopride into the NAcb core, but not following 1.0 μg (Farrar et al., 2010), that was the 
highest dose in this study. However, these results contrast with the results of Pattij et al., 
(2007) that report increased omissions at all eticlopride doses infused into the core, the same 
doses to that employed in the current study, and increased response latencies following the 
highest (1.0 μg) dose. The differences in these results might relate to the fact that in the 
5CSRTT there is much higher attentional demand than the Go/No-go task, meaning that D2 
mediated changes in motivation might be detected at earlier doses on the 5CSRTT than on the 
Go/No-go task.  
Systemic administration of eticlopride does, however, cause an increase in No-go trial 
magazine latencies on the Go/No-go task (Harrison et al., In prep) indicating that this task is 
sensitive to D2 mediated changes in motivation. The fact these changes were not observed in 
the NAcb core, alongside literature indicating that a dose above 2.0 μg eticlopride is required 
to significantly change motivation suggests that this dose range of eticlopride might not have 
been large enough to replicate the highest doses of systemic eticlopride that changes No-go 
magazine latencies. However, D2 receptor antagonism within the NAcb shell has also been 
shown to induce motivational changes in rats (Farrar et al., 2010) also indicating that 
alternative neural targets of eticlopride might have caused this systemic effect.   
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The lack of effect of eticlopride infusions on performance accuracy demonstrates that the D2 
receptors within the core do not mediate behavioural inhibition measured by a symmetrically 
reinforced Go/No-go task. This is consistent with previous studies reporting that D2 receptor 
antagonism within the core does not affect behavioural inhibition measured by premature 
responding on the 5CSRTT and action cancellation on the SST in rats (Eagle et al., 2011; Pattij 
et al., 2007). This is also in line with previous systemic and central literature reporting systemic 
D1 but not D2 receptor mediation of premature responding (Van Gaalen et al., 2006) and D1 but 
not D2 receptor antagonism of the core and shell reducing premature responding in rats 
performing the 5CSRTT (Pattij et al., 2007a). However, systemic eticlopride administration on 
the symmetrically reinforced Go/No-go task produces a reduction in Go trial accuracy 
indicative of disruptive performance effects following eticlopride on this task (Harrison et al., 
In prep). The lack of eticlopride effects on performance measures of the Go/No-go task 
observed following eticlopride infusions into the NAcb core therefore indicates that these 
systemic effects may be mediated through neural targets outside of the NAcb core. In 
consideration of the lack of NAcb core D2 mediated changes on the 5CSRTT and SSRT (Eagle et 
al., 2011; Pattij et al., 2007) and further on the symmetrically reinforced Go/No-go task, this 
collectively suggests that D2 receptors within the core are not involved in the expression of 
behavioural inhibition or action cancellation. Results from the Go/No-go task further add to 
this literature by demonstrating that the D2 receptors might not be involved in behavioural 
inhibition even when this behaviour is directly reinforced.  
6.4.2 The effects of eticlopride on amphetamine induced behavioural 
disinhibition 
The combination of eticlopride and amphetamine treatment led to a main effect on Go trial 
response latencies. Although post hocs did not reveal any significant differences between 
specific doses, following amphetamine treatment Go trial response latencies were faster in 
comparison to the control treatment (Fig 6.16). This is generally consistent with previous 
literature reporting that acute amphetamine reduces response latencies on the 5CSRTT 
(Harrison et al., 1997; Pattij et al., 2007) and acutely increases locomotor behaviour in rat 
(Kuczenski & Segal, 2001). However, as post hoc tests were not significant in the analysis of Go 
trial response latencies, this suggests that changes in the speed of responding were not a 
substantial. The lack of change in Go trial response latencies between any eticlopride doses 
supports that eticlopride infusions did not cause any significant change in slowing response 
speed that might account for the reversal observed at the highest eticlopride infusion. 
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Amphetamine can acutely alter timing perception in rats through speeding of the ‘internal 
clock’ (Çevik, 2003; Maricq, Roberts, & Church, 1981; Meck, 1983; Taylor, Horvitz, & Balsam, 
2007) that might be proposed to underlay reduced No-go trial accuracy as a consequence of 
miscalculation of the time period in which behavioural responding must occur. The lack of 
significant changes in the speed of responding and magazine latencies, however, indicates that 
any amphetamine induced speeding of time perception did not significantly affect the speed of 
response behaviour in rats. The lack of such changes might relate to the fact that there is low 
demand on the ‘internal clock’ on the Go/No-go task due to the continual presentation of Go 
and No-go cues. Continual visual cues guiding the correct response behaviour for food reward 
therefore reduced demand on the ‘internal clock’ to track the time period when responding 
must occur. Consequently, any amphetamine or eticlopride induced changes in timing 
perception do not appear to have disrupted response behaviour, and are therefore unlikely to 
account for No-go trial performance. 
In addition no changes were observed in magazine latencies indicating that amphetamine did 
not produce any significant change in the animal’s motivation to gain food reward. Systemic 
amphetamine treatment within a similar dose range to that employed in the current 
experiment (0.75 mg/kg) has been shown to acutely increase motivation for food reward 
indexed via greater engagement in high effort high reward behaviours in rats following 
systemic amphetamine (Bardgett et al., 2009). Changes in motivation following amphetamine 
may not have occurred on the Go/No-go task due to that fact behaviour is controlled to one of 
two trials and there is not a high element of choice over behaviour involved, meaning that 
subtle changes in motivation that might affect differences in choice behaviour are less likely to 
be detected on the Go/No-go task where behaviour is more controlled.  
In addition, the lack of change in magazine latencies following eticlopride infusions in 
combination with systemic amphetamine indicates that motivational changes are unlikely to 
account for the eticlopride reversal of amphetamine induced No-go trial deficits. This is 
consistent with the lack of eticlopride induced change in magazine latencies when infused into 
the NAcb core alone, confirming that the dose range of eticlopride employed into the NAcb 
core does not affect motivation to perform the Go/No-go task, and previous literature 
indicating that a dose of 2.0 μg is required to affect motivation (Farrar et al., 2010).  
Collectively, the combination of speed and anticipatory responding results confirm that 
changes in impulsivity and eticlopride mediated reversal of amphetamine induced impulsivity 
cannot be easily accounted for by any substantial locomotor, timing or motivational changes in 
behaviour caused by amphetamine and eticlopride combination treatments. 
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The reversal of amphetamine induced No-go trial accuracy deficits by intra-NAcb core 
eticlopride is consistent with NAcb core eticlopride mediated reversal of amphetamine 
induced premature responding in rats performing the 5CSRTT (Pattij et al., 2007). These 
findings therefore collectively support a role for the D2 receptors within the NAcb core in the 
meditation of amphetamine induced behavioural disinhibition. The consistency in these results 
is interesting in light of the difference in effects observed following systemic D1 and D2 
receptor antagonism on the 5CSRTT and the Go/No-go task (van Gaalen et al., 2006; Harrison 
et al., In prep). Evidence that amphetamine induced impulsivity on both tasks can be reversed 
by D2 core antagonism therefore indicates that despite differences in overall system changes in 
D1 and D2 receptor activity on the 5CSRTT and Go/No-go tasks, changes at the D2 receptors 
within the NAcb core is a shared neural substrate of amphetamine induced impulsivity on both 
tasks. 
However, differences were observed in the results in the current experiment and (Pattij et al., 
2007). In the current experiment only the highest dose of eticlopride (1.0 μg) produced full 
behavioural reversal of reduced No-go trial accuracy following amphetamine, whereas 0.3 μg 
of eticlopride produced full behavioural reversal of premature responding on the 5CSRTT 
(Pattij et al., 2007). Differences in the dose at which eticlopride reversed amphetamine 
induced impulsivity might relate to the fact that impulsive behaviour is more controlled by 
food reinforcement and visual cues within the symmetrically reinforced Go/No-go task than 
the 5CSRTT, meaning that higher doses of eticlopride might be required on the Go/No-go task 
to produce similar effects to that on the 5CSRTT.  
Interestingly, amphetamine not only decreased No-go trial accuracy but also increased No-go 
trial early responses, which may be more comparable with premature responses during the 
5CSRTT. Both measures indicate early inappropriate responding. Although pre-treatment with 
eticlopride into the NAcb core did not fully reverse this effect, there was evidence of a partial 
reversal at the highest doses of eticlopride where no significant difference was detected in No-
go trial early responses following 1.0 and 0.3 μg eticlopride in comparison to control 
treatment, but both doses did not significantly differ from early responses performed 
following the amphetamine and vehicle combination and amphetamine and 0.1 μg eticlopride 
combination. These results therefore illustrate consistency in the role of the D2 receptors 
within the core in mediating behavioural disinhibition in situations of attentional demand.  
The lack of eticlopride induced effects on impulsivity on the Go/No-go task, in combination 
with eticlopride reversal of amphetamine induced impulsivity on this task, are also collectively 
interesting in relation to the role of the D2 receptors within the NAcb core and impulsivity. The 
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lack of eticlopride induced effects on impulsivity when infused into the NAcb core alone, in 
contrast the reversal observed in combination with amphetamine, suggests that the D2 
receptors are only involved in the mediation of impulsive behaviour during Go/No-go task 
following increased activation. This is also consistent with recent evidence that highly 
impulsive animals on the 5CSRTT have supersensitive D2 receptors within the NAcb core 
(Moreno et al., 2013). The D2 receptors within the NAcb core might then only be detrimental in 
the expression of behavioural inhibition when they are over stimulated, either via drug 
induced hyperactivity or predisposing supersensitivity of the receptor.  
However, it is also noteworthy that eticlopride also has an affinity for the D3 receptors (IC₅₀ 
(nM) =  113), although this is lower than eticlopride affinity for the D2 sub-receptor (IC₅₀ (nM) =  
1.0), consequently it is possible that blockade of the D3 receptors within the NAcb core might 
have contributed to the reversal of amphetamine induced impulsivity. Upregulation of the D3 
receptors has been observed in methamphetamine dependent subjects (Boileau et al., 2012), 
however, this has only been found in D3 rich and not D2 rich areas, as is the NAcb core  (Le 
Moine & Bloch, 1996). In addition, systemic D3 specific antagonists do not reverse 
amphetamine induced impulsivity on the 5CSRTT (van Gaalen et al., 2009) and increased 
impulsivity in rats performing the 5CSRTT following intra NAcb core infusions of the D2 specific 
agonist quiniprole is not reversed by pretreatment with the preferential D3 antagonist 
nafadotride (Moreno et al., 2013). These studies therefore support a more specific role for the 
D2 receptors, and D2 receptors within the NAcb core, in high levels of impulsivity in rats.  
Within the NAcb core, the D2 receptors exert inhibitory actions on cells via activation of G 
proteins that inhibit adenylate cyclase to hyperpolarise the cell membrane (Stoof & Kebabian, 
1984). In contrast, the D1 receptors exert an excitatory action on cells via activating G proteins 
that activate adenylate cyclase to activate local depolarisation of the cell membrane (Stoof & 
Kebabian, 1984). The inhibitory and excitatory actions of the D2 and D1 receptors, respectively, 
can therefore exert an inhibitory or excitatory influence over afferent connections innervation 
the NAcb core and efferent connections leaving the NAcb core.  
The D2 receptors within the ventral striatum are located presynaptically on glutamate 
terminals innervating the NAcb core and postsynaptically on GABAergic medium spiny neurons 
that project from the NAcb core to descending structures (Albin, Young, & Penney, 1989; Goto 
& Grace, 2005; Kawaguchi, 1993; Surmeier et al., 2007). The D2 receptors can therefore exert 
inhibitory control over excitatory prefrontal and limbic glutamatergic afferents innervating the 
NAcb core and GABAergic efferents leaving the NAcb core. This means that changes in D2 
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receptor function within the NAcb core might consequently disrupt the integration of fronto-
striatal activity, and or, disrupt the activity of descending GABAergic activity.  
The NAcb core and shell connect to descending anatomical targets via GABA mediated direct 
and indirect ventral striato-pallidal pathways (See Chapter 1, Fig. 1.4). The direct ventral 
striato-pallidal pathway projects directly back to the VTA and substantia nigra (SN) and 
predominantly expresses D1 receptors, whilst the indirect pathway projects indirectly to 
subthalamic and thalamic nuclei via the ventral pallidum, dorsomedial subthalamic nucleus, 
internal globus pallidum and substantia nigra pars reticular, and predominantly expresses D2 
receptors. GABAergic MSNs descending from the NAcb core and shell therefore modulate 
fronto-striatal activity through midbrain connections that ultimately influence the activation or 
deactivation of the thalamus (Feil et al., 2010; Carlezon & Thomas, 2009). Amphetamine 
induced activation of the inhibitory D2 receptors within the NAcb core might therefore cause 
subsequent inhibition of the indirect pathway projecting from the NAcb core that, along with 
the indirect pathway, modulate the fronto-striatal activity through ventral striato-pallido-
thalamic circuits (Bonelli & Cummings, 2007; Feil et al., 2010). 
6.4.3 Key Findings 
The main findings from this study are that infusions of the D2 receptor antagonist eticlopride 
into the nucelus accumbens core do not affect response inhibition, but do reverse 
amphetamine induced response disinhibition in rats. The combination of these findings 
suggests that the D2 receptors within the nucleus accumbens core are not involved in baseline 
expressions of response inhibition, but are involved in the expression of drug induced response 
disinhibition. The main aims of this study were to determine the role of the D2 receptors within 
the nucelus accumbens core in mediating response inhibition and amphetamine induced 
response disinhibition on the Go/No-go task. These aims were established from broader 
objectives to elucidate how pathological changes in the D2 receptors within the ventral 
striatum might contribute towards impulsive behaviour observed in addicts. Observations that 
the D2 receptors within the nucleus accumbens core are specifically involved in mediating 
amphetamine induced response disinhibition, but not baseline levels of response inhibition, 
consequently addresses this broader objective by demonstrating that drug induced activation 
of the D2 receptors within the nucleus accumbens core region of the ventral striatum can 
directly increase impulsive behaviour. 
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6.4.4 Limitations 
One limitation of this study is that only the D2 receptors within the nucleus accumbens core 
were investigated. It would have been useful to also investigate the role of the D2 receptors in 
the nucleus accumbens shell to gain a broader neuroanatomical understanding of D2 receptor 
function within the nucleus accumbens as a functional anatomical unit in relation to 
impulsivity and drug induced impulsivity. This study also did not investigate the role of the D1 
receptors within the nucleus accumbens core in impulsivity and amphetamine induced 
impulsivity on the Go/No-go symmetrically reinforced task. This consequently limits broader 
interpretations into roles of different dopamine sub-receptors within the ventral striatum in 
impulsivity and drug induced impulsivity.  
An additional limitation of this study is that the role of the D2 receptors within the nucleus 
accumbens was only investigated in relation to acute amphetamine induced impulsivity. Whilst 
these findings are useful for providing an initial indication of how the D2 receptors might 
function in relation to drug induced impulsivity, they do not necessarily extend to explain how 
the D2 receptors might be involved in impulsivity observed amongst addicts with a chronic 
history of drug use. The main findings of this study are therefore limited in terms of direct 
scalability to the role of the D2 receptors within the ventral striatum in relation to impulsivity 
observed amongst drug addicts. 
6.4.5 Future Research 
In order to address the limitations of this study in regards to neuroanatomy, it would be useful 
for future research to investigate the role of the D2 receptors within the nucleus accumbens 
shell in impulsivity and amphetamine induced impulsivity on the Go/No-go task. Previous 
research has suggested that the core and shell regions of the nucleus accumbens opponently 
modulate amphetamine induced impulsivity and that the D2/3 receptors within the nucleus 
accumbens core and shell might have dissociable effects on impulsivity in the 5CSRTT (Besson 
et al., 2009; Murphy et al., 2008). Establishing the role of the D2 receptors within the nucleus 
accumbens core and shell on accuracy, and drug induced changes in accuracy, within the 
Go/No-go symmetrically reinforced task will help to build a broader behavioural understanding 
of D2 receptor function in regards to impulsivity.  
In addition to investigating the D2 receptors within the nucleus accumbens core, it would be 
useful for future research to explore the role of the D1 receptors within the nucleus accumbens 
core and shell in impulsivity and drug induced impulsivity measured by the Go/No-go 
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symmetrically reinforced task. As discussed in the introduction of this chapter (pages 163 - 
166) there are indications from systemic studies that the D1 and D2 receptors might have 
different effects on impulsivity measured by the 5CSRTT and Go/No-go symmetrically 
reinforced task (Harrison et al., In prep; van Gallen et al., 2006; 2006b). Considering that the 
results from this study found a similar role for the D2 receptors within the nucleus accumbens 
core in amphetamine induced impulsivity, as has previously been reported by studies 
employing the 5CSRTT (Pattij et al., 2007), it would be useful to continue this line of research 
to fully establish the role of the D1 and D2 receptors in the core and shell on impulsivity 
measured by the Go/No-go symmetrically reinforced task. Further investigations into the role 
of the D1 and D2 receptors in response inhibition and drug induced response disinhibition 
measured by the Go/No-go task will help to build a more comprehensive picture of how the D1 
and D2 receptors might be involved in the expression of impulsivity and drug induced 
impulsivity.  
In order to address scalability limitations of this study to human addicts, it would be useful to 
explore the role of the D2 receptors in drug induced impulsivity during, and following, more 
chronic self-administration drug regimes in rats.  Future research employing a reliable animal 
model of human drug use alongside intra-nucleus accumbens D2 receptor manipulation would 
help to elucidate how long-term drug exposure affects D2 receptor function in relation to 
impulsive behaviour, and further, how such changes in receptor function might contribute 
towards elevated levels of impulsive behaviour observed amongst addicts. In addition, given 
that the D2 receptors within the ventral striatum have been linked to trait impulsivity in drug 
addicts (Lee et al., 2009), it would be useful to examine whether animals screened for high and 
low levels of trait impulsivity at baseline, are differentially affected by D2 antagonism within 
the nucleus accumbens core and shell on baseline levels of impulsivity, and drug induced 
impulsivity, measured by the Go/No-go symmetrically reinforced task. This would help to 
elucidate how the D2 receptors within the ventral striatum function in relation to both trait 
and drug induced impulsivity.  
In regards to future research directions concerned with the neurocircuitry of impulsivity and 
addiction, the next steps for elucidating how changes at the level of the D2 receptors within 
the nucleus accumbens core might be involved in higher level circuit changes mediating 
impulse control, will be to explore how changes in D2 receptor function affects the activity of 
neural targets in connection with the nucleus accumbens core, such as the ventral pallidum, 
prefrontal and orbitofrontal cortex. For example, it would be useful to measure GABA 
concentration in the ventral pallidum following D2 receptor antagonism to establish how 
changes in accumbens core D2 function affects the activity of descending neuroanatomical 
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sites. Alternatively, it would be useful to examine glutamate concentration in nucleus 
accumbens core following D2 antagonism in order to indentify how amphetamine induced D2 
receptor activation affects glutamate afferents innervating the nucleus accumbens core. This 
would be useful for considering how changes in D2 receptor activity might affect prefrontal 
glutamatergic afferents innervating the nucelus accumbens core, and thus help to further 
elucidate how changes in D2 receptor activity more specifically disrupt fronto-striatal 
connections. 
6.4.6 Conclusions 
In summary, eticlopride infused into the NAcb core alone produced no effects on behaviour 
whilst eticlopride infused into the NAcb core in combination with systemic amphetamine led 
to reversal of amphetamine induced impulsivity. These finding further implicate the 
involvement the D2 receptors within the NAcb core in amphetamine induced behavioural 
disinhibition and collectively suggest that stimulation of the D2 receptors can lead to 
behavioural disinhibition. These findings expand on previous animal literature implicating the 
D2 receptors within the NAcb core in amphetamine induced impulsivity (Pattij et al., 2007) by 
further identifying that the D2 receptors within the NAcb core also mediate amphetamine 
induced impulsivity on a symmetrically reinforced Go/No-go task. Furthermore, these findings 
also contribute towards existing literature implicating a role for the D2 receptors within the 
ventral striatum with impulsivity in stimulant addicts by further confirming that stimulant 
induced changes at the D2 receptor within the NAcb core can increase impulsivity. 
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Chapter 7 The effects of NAcb GABAA agonism on behavioural 
inhibition and amphetamine induced behavioural disinhibition 
7.1Introduction 
GABA is the brains major inhibitory neurotransmitter that is prevalent at approximately 40% of 
all synapses within the brain (Leonard, 2005). GABA transmission is modulated by three GABA 
sub-receptors: GABAA, GABAB and GABAC. The GABAA and GABAC receptors are ionotropic 
receptors meaning that activation of these receptors directly opens plasma membrane 
chloride (Cl⁻) channels, causing an increase in internal Cl⁻ and hyperpolarizing the cell (Chebib 
& Johnston, 1999). GABAB receptors are alternatively metabotropic G-protein coupled 
receptors that activate potassium (K⁺) and inhibit calcium (Ca²⁺) channels leading to 
hyperpolarization of the cell (Chebib & Johnston, 1999). The GABAA and GABAC receptors both 
produce fast inhibition whilst the GABAB receptors produce show inhibition (Nicoll, Malenka, & 
Kauer, 1990). Out of the three GABA sub-receptors the GABAA receptor is the most widely 
distributed throughout the brain (Young & Snyder, 1974).  
GABA transmission has been indirectly associated with a number of behavioural dimensions of 
impulsivity. Benzodiazepines that target sites of the GABAA receptor reduce impulsive 
aggression and behavioural dyscontrol in subjects with bipolar disorder (Cowdry & Gardner, 
1988; Hollander et al., 2003) and benzodiazepines can also be prescribed as a second line 
treatment for ADHD (Nair & Mahadevan, 2009; Popper, 2000; Silva, Munoz, & Alpert, 1996). 
More recently, studies directly assessing the relationship between GABA and impulsivity have 
found a relationship between cerebrospinal fluid GABA concentration and trait impulsivity in 
humans (Lee, Petty, & Coccaro, 2009). GABA concentration within prefrontal regions of the 
brain can also predict rash impulsivity (Boy et al., 2011), distractibility and motor decision 
speed within healthy adults (Sumner et al., 2010). Additionally, children with ADHD have 
reduced GABA concentration within the cerebral cortex (Edden et al., 2012), indicating that 
hypoactive GABA circulation is prevalent in deficits of inhibitory control.  
Investigation into the relationship between GABA and impulsivity using animal models has 
identified a role for GABA within the prefrontal cortex and behavioural inhibition in rats. 
Inhibition of GABA production within the PFC (infralimbic and prelimbic cortices) via infusion of 
the glutamate decarboxylase (GAD) inhibitor L-allylglycine increases premature responding in 
rats without producing any changes in accuracy of attention, response latencies or omissions 
(Asinof & Paine, 2012). Infusion of the GABAA agonist muscimol into the infralimbic cortex, but 
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not prelimbic cortex, also increases premature responding within the 5CSRTT in rats  (Murphy 
et al., 2012). Infusions of muscimol into the infralimbic cortex also produced some changes in 
accuracy, response latencies and omissions, however, only changes in premature responding 
were found to be site specific changes following muscimol (Murphy et al., 2012). In addition, 
highly impulsive rats on the 5CSRTT show reduced GABAA receptor availability within the ACC 
in comparison to less impulsive rats (Jupp et al., 2013) indicating that changes in GABA 
transmission via the GABAA sub-receptor within the ACC is associated with trait impulsivity in 
rats. Although only a small number of studies have investigated the effects of central GABA 
manipulation on impulsivity, these studies collectively confirm a relationship between GABA 
transmission and animal models of impulsivity.  
The NAcb core has been identified as a neural mediator of impulsivity and amphetamine 
induced impulsivity (Cardinal et al., 2001; Murphy et a., 2008; Pattij et al., 2007). The principle 
neurons within the NAcb core are GABAergic medium spiny projection neurons and aspiny 
GABAergic interneurons (Groenewegen & Trimble, 2007; Meredith, 1999), meaning that the 
convergence of prefrontal, limbic and midbrain afferent signals within the NAcb core is 
modulated by GABAergic cells, and furthermore, that the output of cortical, limbic and 
midbrain integration within the NAcb core is transmitted to descending anatomical targets of 
the NAcb core via GABAergic signalling. In addition, the NAcb core also receives GABAergic 
afferents from the ventral pallidum and VTA (Churchill & Kalivas, 1994; Van Bockstaele & 
Pickel, 1995), consequently placing the NAcb core anatomically within an inhibitory GABAergic 
network.   
Efferent GABA projections leaving the NAcb core constitute the direct and indirect ventral 
striato-pallidal pathways that through different anatomical midbrain connections ultimately 
influence the activation or deactivation of the thalamus (Carlezon & Thomas, 2009) (See 
Chapter 1, Fig 1.4). The direct ventral striato-pallidal pathway predominantly expresses D1 
receptors, whilst the indirect pathway predominantly expresses D2 receptors, that exert 
excitatory and inhibitory actions, respectively (Albin, Young, & Penney, 1989; Surmeier et al., 
2007). In consideration of evidence implicating changes at the D2 receptors within the NAcb 
core in amphetamine induced impulsivity (Pattij et al., 2007; Chapter 6, section 6.3), this 
suggests that D2 mediated changes in GABA release though the indirect pathway descending 
from the NAcb core might be an important neuropathology of drug induced impulsivity.  
In summary, emerging evidence has indicated that changes in GABA transmission can affect 
impulsivity in humans and animal models of impulsivity. In addition, changes at the D2 
receptors within the NAcb core that can influence the activation or deactivation of GABAergic 
192 
 
cells within the NAcb core have been implicated in amphetamine induced impulsivity (Pattij et 
al., 2007; Chapter 6, Section 6.3), suggesting that changes in GABA transmission at the level of 
the NAcb core might be involved in impulsivity. The following set of experiments therefore 
sought to investigate the effects of direct GABA manipulation within the NAcb core on 
impulsivity and amphetamine induced impulsivity in rats using the symmetrically reinforced 
Go/No-go task. Given that the GABAA sub-receptor is the most predominant GABA sub-
receptor within the rat brain (Young & Snyder, 1974), and that there are more GABAA type 
receptors within the NAcb than GABAB (Bowery, Hudson, & Price, 1987), the effects of GABAA 
inhibition within the NAcb core in impulsivity and amphetamine induced impulsivity on the 
symmetrically reinforced Go/No-go task was investigated.  
7.1.1 Objectives 
In order to investigate the involvement of GABA within the NAcb core on behavioural 
inhibition and amphetamine induced behavioural disinhibition, the following objectives of 
Chapter 7 were: 
i) To determine the effects of GABAA agonism within the NAcb core on behavioural 
disinhibition measured by a symmetrically reinforced Go/No-go task (Experiment 6) 
 
ii) To determine the effects of GABAA agonism within the NAcb core on amphetamine 
induced behavioural disinhibition measured by a symmetrically reinforced Go/No-go 
task (Experiment 7) 
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7.2Methods 
7.2.1 Subjects 
18 male Lister Hooded rats (Charles River, UK) were housed in pairs upon arrival into Leeds 
Behavioural Neuroscience Laboratory and were maintained under a 12 hour light/dark cycle 
(lights on 0700 hours), in a temperature (21°C ± 2°C) and humidity (50% ± 5%) controlled 
environment. Throughout behavioural experimentation animals were placed on a food 
restriction schedule of 18.6g per day, maintaining animals above 85% of their adult free 
feeding body weight. Water was available ad libitum in home cages and feeding took place in 
the morning after behavioural testing. All animals were treated in accordance with the UK 
Animals (Scientific Procedures) Act 1996. All procedures were covered by Home Office Project 
Licence No. PIL 40/3606 and Home Office Personal Licence No. 40/1989.  
7.2.2 Drugs 
D-Amphetamine sulphate (Sigma Aldrich, UK) was dissolved in 0.9% physiological saline and 
was administered i.p. in a volume of 1 ml/kg body weight. D-amphetamine was weighed out 
and prepared in solution on the morning of test days. Muscimol (Tocris, UK) was dissolved in 
Dulbecco’s phosphate buffered saline (Sigma Aldrich, UK) and was administered via 
intracerebral infusion into the NAcb core in a volume of 0.5 μl per hemisphere. Muscimol 
solutions were weighed out and prepared in solution upon the morning of test days. On 
occasion muscimol solutions were stored at ~-20°C until use (Tocris, UK storage guidelines).On 
test days, muscimol solutions were removed from freezing and left to sit at room temperature 
to defrost before use. Musicmol solutions stored overnight only underwent one freezing and 
de-frosting cycle; no solutions were re-frozen after experimental use. Muscimol dose were 
selected by literature review targeting studies administering solely muscimol into the brain, in 
combination with operant testing. Following assessment of the literature collected, a dose 
range of 30 ng (0.003μg) -1000ng (1.0μg) muscimol was documented (Cain, Denehy, & Bardo, 
2007; Corbit & Balleine, 2011; Hodge, Chappelle, & Samson, 1995; Lê Dzung et al., 2008; 
Murphy et al., 2012; Yoon et al., 2009). 
7.2.3 Apparatus 
Behavioural testing took place in eight aluminium operant chambers (30.5 x 24.1 x 21 cm, Med 
Associates Inc., USA) placed inside sound attenuating and ventilated cubicles (63.5 x 49.1 x 
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39.4 cm, Med Associates Inc., USA). Chambers were controlled, and all data was recorded from 
chambers, using MED-PC IV software (Med Associates Inc., USA). Administration of 
intracerebral drug infusions was performed using an infusion pump (KD Scientific, model 200). 
For a more detailed description of test chambers refer to Chapter 2 section 2.1.3, page 60.  
7.2.4 Behavioural Testing 
Behavioural inhibition was assessed via the symmetrically reinforced go/no-go visual 
discrimination paradigm. Behavioural training took place for approximately 8 weeks until 
animals reached stable performance of 85% total percent correct (+/-5%). Upon stable 
baseline performance animals were entered into the experiment. All behavioural training and 
testing took place between 0700-1030 hours during the light phase of animals Light/Dark 
cycle. For a detailed outline of the task refer to Chapter 2 section 2.1.4, page 61. 
7.2.5 Surgery 
Once behavioural performance was stable at the minimum criteria of 85% total percent 
correct (+/-5%), animals were removed from daily test sessions and placed on a free-feeding 
schedule for a minimum of 3 days prior to receiving surgery. Rats were anaesthetised using a 
combination of 4% isoflurane gas and oxygen (flow rate 3 l/min) before being placed into a 
stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) continuing to deliver 4% 
isoflurane gas and oxygen. Rats were secured into flat skull position via ear bars and a nose 
clamp with the incisor bar set to -3.3 - -4.7, depending on flat skull measurements from each 
rat. 22 gauge bilateral guide cannulae (centre-to-centre distance between each cannula: 3.8 
mm; pedestal height: 10.41 mm; stainless steel length below pedestal: 7 mm; pedestal 
diameter: 6.12 mm; Plastics One Inc., USA) were positioned 2 mm above the NAcb core via the 
following stereotaxic coordinates: +1.5 mm anterior to bregma (AP), +/- 1.9 mm lateral to 
midline (ML), -5.2 mm ventral to skull surface (DV) calculated from Paxinos and Watson (1998). 
Co-ordinates were selected via a literature review identifying studies targeting the NAcb core 
in the administration of intracerebral drug infusions. Cannulas were fixed to the skull via dental 
cement (Kemdent Dental Cement, Associated Dental Products Ltd, UK) and three stainless 
steel screws (Plastics One Inc., USA) were fixed to the skull posterior to the cannula. 29 gauge 
stylets extending 1 mm below the guide cannula and sitting 1 mm above the NAcb core were 
inserted following secure placement of the guide cannula to the skull. Prior to removing 
animals from the stereotaxic frame, rats received a 0.2 ml intramuscular injection of 
buprenorphine (Vetergesic, Animal Health Ltd, Essex) to alleviate post-operative pain. 
Buprenorphine dosages were selected based upon previous literature reviewing the effects of 
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buprenorphine upon food and water consumption when administered post-operatively (Liles 
& Flecknell, 1992). Animals subsequently remained in their home cages on a free-feeding 
schedule for a minimum of 7 days post surgery. Following the demonstration of surgical 
recovery via weight gain and healing of the scalp wound surrounding the guide cannulae, 
animals were reintroduced to their original cage mate and were re-housed in pairs. On 
occasion animals continued to be singly housed following surgery due to failure to re-habituate 
to their cage mates. Following surgical recovery, animals were placed back on a food 
restriction schedule of 18.6 g per day and behavioural training recommenced.  
7.2.6 Microinfusion Procedure 
Muscimol dosages were infused in a volume of 0.5 µl/ side over a period of 1 minute (rate 0.5 
µl/min) via a 25µl Hamilton syringe driven by an infusion pump (KD Scientific, model 200). To 
infuse, stylets were removed from guide cannulae and a 28 gauge internal injector (centre-to-
centre distance, 3.8 mm; injector length from top of pedestal, 11 mm; Plastics One Inc., 
Roanoke, VA, USA) extending 2mm ventral to the tip of the guide cannulae was inserted 
delivering muscimol into the NAcb core. Injectors were inserted 1 minute pre-drug infusion 
and were left in place for a further 1 minute post-drug infusion to allow for the diffusion of 
liquid. The infusion rate, infusion volume per hemisphere, pre- and post-injection times were 
based upon previous literature administering intracerebral muscimol infusions (Murphy et al., 
2012; Yoon et al., 2009). After drug infusions, stylets were replaced and animals in experiment 
7 were immediately administered with either systemic amphetamine or saline. Animals were 
subsequently tested 10 minutes later. Pre-treatment time was based on previous findings that 
intracerebral infusions of muscimol take approximately 5 minutes to manifest behaviourally 
(Cain, Denehy, & Bardo, 2007; Spanis et al., 1999). 
7.2.7 Design and Procedure 
Following recovery from surgery and the return of stable baseline task performance, animals 
were assigned to either experiment 6 or 7. These groups were counterbalanced according to 
their baseline performance accuracy, programmed levers, and stimulus-response 
contingencies. A within subject design was employed in both experiment 6 and 7.  
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7.2.8 Experiment 6: The effects of muscimol infusions into the NAcb core on 
behavioural inhibition  
Animals (N=8) received i.c. infusions of (0ng, 120ng, 240ng, 480ng and 960ng/ 0.5μl/ side) 
muscimol into the NAcb core 10 minutes before behavioural testing according to a Latin 
square design, with a minimum of 72 hours between each drug infusion to encourage site 
preservation between intracerebral injections. Prior to all drug treatments animal’s task 
performance had returned to post-surgery baseline levels. 
7.2.9 Experiment 7: The effects of pre-treatment of muscimol infusions into 
the NAcb core upon   amphetamine induced behavioural disinhibition  
Animals (N=10) received the following dosages of muscimol (i.c. 10 minutes prior to testing) 
immediately followed by amphetamine (i.p.); 0 ng + 0 mg/kg, 0ng + 0.8 mg/kg, 120ng + 0.8 
mg/kg, 240 ng + 0.8 mg/kg, 480 ng + 0.8 mg/kg and 960 ng + 0.8 mg/kg (ng/0.5 µl). A minimum 
of 72 hours was employed between each drug infusion to encourage site preservation 
between intracerebral injections and to allow for a 3 day wash out period of amphetamine 
between subsequent amphetamine administrations. Animals were also required to re-stabilise 
behavioural performance between intracerebral infusions to a criteria of +/-10% of their 
average baseline performance following surgery. All drug treatments were administered in a 
latin-square design. 
7.2.10 Assessment of Cannulae Placement 
Following completion of experimental procedures animals were administered i.p. with a lethal 
dose of pentobaribital sodium solution (Animal Health Ltd, Essex, UK). Conscious 
responsiveness was checked via assessment of the pedal withdrawal and corneal reflex. Upon 
termination of respiration, the heart was subsequently perfused via injection of 100ml of 0.9% 
NaCl into the left ventricle of the heart, followed by 400ml of 4% paraformaldehyde (Sigma 
Aldrich, UK) in 0.2M phosphate buffer. Brains were immediately removed and stored in 4% 
paraformaldehyde solution at 4°C. Brains were transferred into 25% sucrose solution 48 hours 
prior to slicing. Rat brains were sliced in 40 µm coronal sections using a cryostat (Bright OTF 
5000). Slices were mounted onto microscope slides and stained using working cresyl violet 
solution to determine the location of cannulae placements. Cresyl violet solution was mixed 
into a working solution within Leeds Behavioural Neuroscience Laboratory using cresyl violet 
acetate salt (Sigma Aldrich, UK). 
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7.2.11 Statistical Analysis 
All data was initially checked for normality through Shaprio-Wilk tests and was appropriately 
transformed via arcsine, log10, square root and reciprocal transformations following any 
violations to normality. Homogeneity of variance was checked via Mauchley’s test of Sphericity 
and following any significant violation of equal variances, the GLM degrees of freedom were 
adjusted using the Greenhouse- Geisser correction. All data was analysed via one-way 
repeated measures ANO As with ‘drug treatment’ entered as the within-subjects factor. The 
effects of muscimol infusions into the NAcb core upon behavioural disinhibition was assessed 
via 1 X 5 repeated measures ANOVAs across all behavioural parameters. The effects of 
muscimol pre-treatment within the NAcb core upon amphetamine induced behavioural 
disinhibition were assessed via 1 X 6 repeated measures ANOVAs across all behavioural 
parameters. Significant main effects of drug dose were followed up with Sidak post-hoc 
analyses. α < 0.05 was employed across all statistical analysis.  
7.2.12 Histology 
18 animals completed behavioural testing and were perfused (n = 8 muscimol; n = 10 
muscimol and amphetamine). Animals with both injector tips located dorsal to the NAcb core 
border were removed from analysis. Animals with one injector tip located minimally dorsal to 
the NAcb core border and one injector tip hitting the NAcb core were included in analysis. 
After visual inspection of cannula placements, one animal was removed from the analysis of 
experiment 6 due to a loss of histological data following an unsuccessful perfusion, and one 
animal was removed from experiment 7 due to both the left and right hemisphere injector tips 
falling dorsal to the NAcb core border. No injector tips were found to cross the ventral border 
of the NAcb core into the NAcb shell. Subsequently, the data from 16 animals was used in 
statistical analysis (n = 7 experiment 6; n = 9 experiment 7). Figure 7.1 shows the location of 
injector tips amongst animals treated with muscimol (experiment 6), and muscimol in 
combination with systemic amphetamine (experiment 7). Photographs showing the location of 
injector tips from an animal in experiment 6 and an animal in experiment 7 are shown in 
Figures 7.2 – 7.5. For photographs showing the location of injector tips for each animal in 
experiments 6 and 7, see Appendices 5 and 6.  
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7.3Results 
After checks of normality, the following transformations were performed: Experiment 6: Log₁₀ 
(Go trial latency, No-go trial incorrect latency, Go trial panel responses); Experiment 7: Log₁₀ 
(Go trial latency, No-go trial incorrect latency, Go trial magazine latency, No-go trial magazine 
latency, Go trial panel responses, No-go trial panel responses). In order to transform Go trials 
to a normal distribution, the total percentage correct of Go trials was analysed as a percentage 
change of the previous test day (baseline). 
7.3.1 Experiment 6: The effects of muscimol infusions into the NAcb core on 
behavioural inhibition 
7.3.1.1 Performance Accuracy 
Accuracy was not affected by muscimol infusions. The total percentage correct (F(1.800, 
10.798) = 0.738, NS), total percentage correct of Go trials (F(4, 24) = 1.518, NS) and the total 
percentage correct of No-go trials (F(4, 24) = 0.718, NS) did not significantly differ following 
muscimol infusions into the NAcb core (Figs. 7.6 – 7.8). 
7.3.1.2 Speed of Responding 
The speed of responding was not affected by muscimol infusions. Go trial response latency 
(F(4, 24) = 2.404, NS), No-go trial incorrect response latency (F(2, 24) = 0.958, NS), Go trial 
magazine latency (F(2, 24) = 1.787, NS) and No-go trial magazine latency (F(2,24) = 0.710, NS) 
did not significantly differ following infusions of muscimol into the NAcb core (Figs. 7.12 – 
7.15).  
7.3.1.3 Anticipatory Responding 
Anticipatory responding was also not affected by muscimol infusions. Go trial early responses 
(F(4, 24) = 0.473, NS), No-go trial early responses (F(1.414, 8.484) = 1.175, NS), Go trial 
inappropriate panel responses (F(2, 24) = 1.402, NS), and No-go trial inappropriate panel 
responses (F(1.553, 9.319) = 0.264, NS) did not significantly differ following infusions of 
muscimol into the NAcb core (Figs. 7.20 – 7.23). 
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7.3.2 Experiment 7: The effects of muscimol pre-treatment into the NAcb core 
on systemic amphetamine induced behavioural disinhibition  
7.3.2.1 Performance Accuracy 
Muscimol and systemic amphetamine treatment produced a main effect of drug treatment on 
the total percent of correctly completed trials (F(5, 40) = 7.213, p =0.001). Post hoc analysis 
revealed a reduction in the total percent of correctly completed trials following vehicle 
infusion + systemic amphetamine in comparison to the control treatment (0 ng + 0 mg/kg 
amphetamine) (p < 0.05) and a non-significant trend towards an increase in accuracy was 
found following 960 ng muscimol + systemic amphetamine in comparison to vehicle infusion + 
systemic amphetamine (p = 0.07) and in comparison to 120 ng muscimol + systemic 
amphetamine (p = 0.08). No significant differences in the total percent of correctly completed 
trials were detected between remaining muscimol + systemic amphetamine treatment 
combinations (all p > 0.05) (Fig. 7.9). Independent analysis of Go trials revealed no main effect 
of drug treatment (F(5, 40) = 1.269, NS) (Fig. 7.10), however, independent analysis of No-go 
trials did reveal a significant main effect of drug treatment (F(5, 40) = 7.182, p =0.001). Post 
hoc analysis subsequently revealed a reduction in No-go trial accuracy following vehicle 
infusion + systemic amphetamine in comparison to control treatment (p < 0.01), and a non-
significant trend towards a significant increase in No-go trial accuracy following 960 ng 
muscimol + systemic amphetamine in comparison to 120 ng muscimol + systemic 
amphetamine treatment was detected (p = 0.07) (Fig. 7.11). No significant differences in No-go 
trial accuracy were detected between remaining muscimol + systemic amphetamine treatment 
combinations (all p > 0.05). 
7.3.2.2 Speed of Responding 
Muscimol and systemic amphetamine treatment produced a main effect of drug treatment on 
Go trial response latencies (F(5, 40) = 3.016, p < 0.05) (Fig. 7.16), however, post hoc tests failed 
to reveal any significant differences in the speed of responding during Go trials between 
specific muscimol + systemic amphetamine treatment combinations (all p > 0.05). Analysis of 
No-go trial response latencies (F(5, 40) = 1.771, NS), Go trial magazine latencies (F(1.765, 
14.118) = 1.653, NS) and No-go trial magazine latencies (F(1.700, 13.598) = 0.483, NS) all 
revealed no main effect of drug treatment (Figs. 7.17 – 7.19). 
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7.3.2.3 Anticipatory Responding 
Analysis of Go trial early responses revealed no main effect of drug treatment (F(5, 40) = 1.435, 
NS) (Fig. 7.24). Analysis of No-go trial early responses, however, produced a main effect of 
muscimol and systemic amphetamine treatment (F(5, 40) = 5.229, p = 0.001), however,  post 
hoc analysis of this effect only detected a trend towards a significance increase in No-go trial 
early responding following 0 ng muscimol + systemic amphetamine in comparison to control 
treatment (p = 0.08) and a trend towards a reduction in No-go trial early responses following 
960 ng muscimol + systemic amphetamine in comparison to vehicle infusion + systemic 
amphetamine treatment (p = 0.07) (Fig. 7.25). No-go trial early responses did not significantly 
differ between any remaining muscimol + systemic amphetamine treatment combinations (all 
p > 0.05). Analysis of Go trial inappropriate panel responses (F(1.560, 12.478) = 0.987, NS) and 
No-go trial inappropriate panel responses revealed no main effect of drug treatment (F(5, 40) 
= 0.883, NS) (Figs. 7.26 – 7.27). 
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Figure 7.1: Schematic illustrations of the rat brain taken from Paxinos and Watson Atlas (1998) 
demonstrating the location of injector tips relative to bregma in experiments 6 and 7. 
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 Fig. 7.2 Fig. 7.3 
Fig. 7.4  Fig. 7.5 
Figures 7.2 – 7.5: Example pictures of brain slices taken during histology to confirm the location 
of injector tips in the Nucleus Accumbens core. Pictures are taken from an animal treated with 
muscimol (7.2: left hemisphere; 7.3: right hemisphere), and an animal treated with muscimol 
and systemic amphetamine (7.4 left hemisphere; 7.5: right hemisphere). 
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Figures 7.6 – 7.11: Performance following muscimol infusions into the NAcb core on (7.6) the total 
percent correct of trials, (7.7) the total percent correct Go trials, (7.8) the total percent correct No-go 
trials, (7.12) Go trial latency, (7.13) No-go trial latency, (7.14) Go trial magazine latency, (7.15) No-go 
trial magazine latency, (7.20) Go trial early responses, (7.21) No-go trial early response, (7.22) Go trial 
panel response and (7.23) No-go trial panel response. Performance following muscimol infusions into 
the NAcb core and systemic amphetamine on (7.9) the total percent correct of all trials,  (7.10) the 
total percent correct Go trials, (7.11) the total percent correct No-go trials, (7.16) go trial latency, 
(7.17) no-go trial latency, (7.18) go trial magazine latency, (7.19) no-go trial magazine latency, (7.24) 
go trial early responses, (7.25)no-go trial early response,  (7.26) go trial panel response and (7.27) no-
go trial panel response. *p<0.05, **p<0.01 and ***p<0.001 vs vehicle infusion + systemic saline 
combination. ‘S’ represents the vehicle infusion + systemic saline control combination. Values 
represent means and error bars represent SEM. 
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7.4Discussion 
Intra-NAcb core muscimol infusions did not disrupt accuracy, speed or anticipatory responding, 
indicating that under basal conditions, stimulation of the GABAA receptors within the NAcb 
core does not mediate behavioural inhibition measured by the Go/No-go symmetrically 
reinforced task. Treatment with vehicle infusion and systemic amphetamine led to a reduction 
in No-go trial accuracy in comparison to control treatment, indicating that animals became 
acutely more impulsive following systemic amphetamine. No-go trial accuracy did not differ 
from control treatment following intra-NAcb core muscimol infusions in combination with 
systemic amphetamine, indicating that activation of the GABAA receptors within the NAcb core 
led to partial reversal of amphetamine induced impulsivity on the symmetrically reinforced 
Go/No-go task.  
7.4.1 The effects of muscimol infusions into the NAcb core on behavioural 
inhibition 
Although systemic administration of muscimol can produce sedative (sleep inducing) effects in 
rats (DeFeudis, 1980; Lancel, Crönlein, & Faulhaber, 1996; Scheel-Krüger, Christensen, & Arnt, 
1978) no changes were observed in response latencies following intra-NAcb core infusions of 
muscimol. This suggests that activation of the GABAA receptors within the NAcb core does not 
lead to sedation in rats performing a symmetrically reinforced Go/No-go task. Considering that 
the sedative effects of GABAergic drugs has been located to activation of the GABAA receptors 
(Reynolds et al., 2003; Rowlett, Platt, Lelas, Atack, & Dawson, 2005; Rudolph et al., 1999; 
Vinkers et al., 2009) the lack of change in response latencies following GABAA receptor 
activation might appear surprising. However, despite the role of the GABAA receptors in 
sedation, there is little direct evidence linking the GABAA receptors within the NAcb core 
specifically to the sedative effects of muscimol. Sedation via GABAA receptor activation has 
rather been neurally located to anatomical regions constituting sleep pathways, such as the 
tuberomammillary nucelus in the hypothalamus (Nelson et al., 2002). In following, the lack of 
sedation observed in rats following intra-NAcb core infusions of muscimol might relate to the 
fact the NAcb core is not anatomically connected with neural sleep pathways. 
Infusions of muscimol (100 ng) and GABA (33 ng) into the NAcb has, however, previously been 
shown to reduce locomotor activity in rats, measured by photobeam counts (Andén, 
Grabowska‐Andén, & Wachtel, 1979; Jones, Mogenson, & Wu, 1981), and these effects have 
been assumed to reflect GABA induced inhibition of dopamine mediated locomotor behaviour 
(Arnt, Christensen, & Scheel-Krüger, 1978; Jones et al., 1981; Scheel-Krüger et al., 1978). In 
Muscimol 
 Fig. 10h  Fig. 11h 
 Fig. 10i  Fig. 11i 
   Fig. 10j  Fig. 11j 
Fig. 10k  Fig. 11k 
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addition, intra-NAcb core muscimol-baclofen (GABAB agonist) infusions (combined dose 75 ng) 
can lead to slower response speed in rats performing operant behavioural tasks (Floresco et 
al., 2006; Ghods-Sharifi & Floresco, 2010). These studies therefore contrarily suggest that 
muscimol infusions into the NAcb core might be expected to produce some reduction of motor 
activity as a consequence of GABA-dopamine interactions within the NAcb that mediate 
locomotor activity in rats (Arnt et al., 1978; Jones et al., 1981). In addition, considering that the 
dose range employed in the current study was much higher than the doses employed by these 
studies, this further suggests that the lack of changes in response latencies following muscimol 
infusions into the NAcb core appear surprising.  
However, intra-NAcb infusions of a high muscimol dose (500 ng), comparable to the 480 ng 
dose in this study, does not change active or inactive lever responding in rats performing a FR1 
schedule of food reinforcement (Yoon et al., 2009) indicating that high doses of muscimol 
infused into the NAcb does not necessarily lead to a changes in motor behaviour that might 
affect operant performance. Furthermore, infusions of the GABAB agonist baclofen into the 
NAcb have been shown to significantly suppress locomotor behaviour, whist infusion of GABAA 
agonists into the NAcb do not significantly change locomotor activity (Wong, Eshel, Dreher, 
Ong, & Jackson, 1991). Such differences in GABAA vs GABAB receptor mediation of locomotor 
activity within the NAcb core might then explain why muscimol-baclofen infusions into the 
NAcb core can produce changes in response latencies on behavioural tasks (Floresco et al., 
2006; Ghods-Sharifi & Floresco, 2010) but muscimol infusions alone into the NAcb core did not 
affect response latencies in the current experiment. In addition, Floresco et al (2006) detected 
slower response latencies in rats during a maze based task whereby changes in locomotor 
activity would be more easily detected than on the Go/No-go task as trial completion on this 
task requires greater locomotor activity than trial completion on the Go/No-go task. In 
addition, slower response latencies reported by Ghods-Sharifi & Floresco (2010) were 
identified in an effort discounting task where animals could make choices in the magnitude of 
effort engaged in to obtain reward. This type of task enables a greater level of individual 
difference in response behaviour between rats than the Go/No-go task, and therefore changes 
in locomotor activity might be more easily detected on this task than on the Go/No-go task 
where animals do not have a choice in the behaviour they must employ to on each trial.  
In following, whilst there is literature to suggest that increasing, or mimicking, GABA activity 
within the NAcb core might lead to changes in locomotor activity (Jones et al., 1981), changes 
in the speed of responding following GABA agonists into the NAcb core has only been 
observed alongside GABAB agonism and on tasks where there is greater motor activity 
required and greater sensitivity to individual differences in animal behaviour than on the 
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Go/No-go task employed in the current set of experiments. Consequently, changes in GABAA 
activation within the NAcb core on the Go/No-go symmetrically reinforced task, where 
behavioural responding is relatively controlled, would not necessarily be expected to produce 
the same behavioural effects as these studies.  
The lack of drug induced changes of magazine latencies observed following muscimol infusions 
into the NAcb core is also indicative that muscimol did not produce any changes in motivation 
for food reward. These effects are generally consistent with previous literature that has 
implicated GABA activity within the NAcb shell, but not the core, in the motivation to earn 
food reward on progression ratio tasks (Basso & Kelley, 1999; Stratford & Kelley, 1997; Zhang, 
Balmadrid, & Kelley, 2003). 
Increased variance at higher muscimol doses was observed in No-go trial accuracy (Fig. 7.8). 
The decrease in No-go trial accuracy and increase in variance observed as muscimol doses 
increase is representative of one animal in the group displaying decreased No-go trial accuracy 
as muscimol doses were increased. This change in No-go trial accuracy was, however, only 
observed in one animal. When this animal’s placement was checked it was found to fall within 
the boundaries of the NAcb core (injector tips: +1.20 anterior to bregma left and right 
hemispheres) therefore the animal remained in the inclusion of data analysis. This visual 
change in No-go trial accuracy and increase in variance is therefore a consequence of the 
variance contributed by one animal that displayed decreased No-go trial accuracy following 
muscimol infusions. 
In summary, the lack of change in any performance measures following muscimol infusions 
into the NAcb core on the symmetrically reinforced Go/No-go task indicates that GABAA 
receptor agonism within the NAcb core does not affect impulsivity, response speed or 
motivation to perform the task. Whilst the lack of effects on this task might initially appear 
surprising, considering that previous studies have found behavioural effects at lower doses to 
that employed in the current study, on closer analysis of these studies the specific role for the 
NAcb core vs. shell and GABAA vs GABAB in the mediation of sedative, locomotor and 
motivational effects can account for some of the differences in results between studies. 
Consequently, the current findings expand on previous literature by demonstrating that a wide 
range of muscimol doses infused into the NAcb core does not affect impulsivity, response 
speed or motivation for food reward in rats.  
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7.4.2 The effects of muscimol infusions into the NAcb core on amphetamine 
induced behavioural disinhibition 
The combination of intra-NAcb core muscimol infusions and systemic amphetamine treatment 
was found to significantly affect Go trial response latencies. Although no significant post hoc 
effects were detected following this main effect, Go trial response latencies were faster 
following vehicle infusion and systemic amphetamine than the control treatment (Fig. 7.16). 
This is consistent with faster response latencies reported following systemic amphetamine on 
the 5CSRTT in rats (Harrison, Everitt, & Robbins, 1997; Pattij et al., 2007). However, the lack of 
significant difference between individual treatment combinations indicates that any changes in 
the speed of responding were not substantial. The lack of significant change in the speed of 
responding following drug treatment also indicate that any amphetamine induced changes in 
timing perception in rats (Meck, 1996) appear not to have affected the timing of response 
behaviour on the Go/No-go task. Consequently, amphetamine induced changes in locomotor 
activity or timing perception do not appear to have substantially affected response behaviour 
in rats performing the Go/No-go task. As such, changes in motor activity and timing perception 
are unlikely to account for amphetamine induced impulsivity observed, or for the apparent 
muscimol induced partial reversal of amphetamine induced impulsivity.  
Considering that GABA-dopamine interactions within the NAcb have been found to mediate 
locomotor activity in rats (Jones et al., 1981) the lack of change in response latencies might 
appear surprising. Muscimol infusions into the NAcb core have previously been shown to 
reduce stimulant (cocaine, methylphenidate) induced increases in locomotor activity (Scheel-
Krüger et al., 1978). However, indications of amphetamine induced changes in the speed of 
responding were subtle in the current experiment as no post hoc differences in the speed of 
responding were found on Go trial response latencies (Fig. 7.16). This might suggest that any 
GABA attenuating effects on amphetamine induced effects on motor behaviour were 
subsequently less likely to be detected due to the fact amphetamine only subtly changed the 
speed of responding in rats. In following, although previous studies have implicated GABA-
dopamine interactions within the NAcb on stimulant induced motor activity (Arnt et al., 1978; 
Jones et al., 1981; Scheel-Krüger et al., 1978) such effects might not have been detected in the 
current experiment due to the fact that any amphetamine induced changes in locomotor 
activity did not significantly change the speed of responding between doses in rats on the 
Go/No-go task.  
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The lack of drug effects on the speed to collect the food reward also indicates that animals 
remained motivated to perform the Go/No-go task and receive food reward following intra-
NAcb core muscimol infusions and systemic amphetamine treatment. Although amphetamine 
can increase motivation to earn food reward in rats (Bardgett et al., 2009) suggesting that 
magazine latencies might have been expected to increase following systemic amphetamine, 
the lack of change between intra-NAcb core muscimol and systemic amphetamine 
combination treatments is consistent with GABAergic activity NAcb shell, and not core, in 
mediating  motivation to earn food reward (Basso & Kelley, 1999; Stratford & Kelley, 1997; M. 
Zhang et al., 2003). Unaffected magazine latencies therefore additionally indicate that intra-
NAcb core muscimol infusions in combination with systemic amphetamine did not caused any 
changes in motivation that can account for the muscimol induced changes in No-go trial 
accuracy. 
Intra-NAcb core muscimol infusions and systemic amphetamine treatment was found to 
significantly affect No-go trial early responses (Fig. 7.25). Although post hoc tests failed to 
produce any significant findings, a non-significant trend towards a significant increase in No-go 
trial early responses following vehicle infusion and systemic amphetamine in comparison to 
control treatment (p = 0.08) and non-significant trend towards a reduction following 960 ng 
muscimol and amphetamine in comparison to the vehicle infusion and amphetamine (p = 0.07) 
were detected. These p-values indicate trends towards amphetamine induced impulsivity and 
muscimol (960 ng) induced reversal of impulsivity, when measured by anticipatory responding. 
These trends are therefore consistent with amphetamine induced impulsivity observed on No-
go trials and muscimol induced partial reversal of amphetamine induced impulsivity measured 
by No-go trial accuracy. 
Partial reversal of amphetamine induced impulsivity via activation of the GABAA receptors 
within the NAcb core presents novel findings in relation to the neural substrates mediating 
amphetamine induced impulsivity. These findings are the first to indicate that changes in GABA 
transmission within the NAcb core is involved in drug induced impulsivity, and specifically 
amphetamine induced impulsivity. A relationship between GABA and impulsivity is consistent 
with recent research identifying that changes in GABA in the rat prefrontal cortex is involved in 
impulsivity on the 5CSRTT, and that the expression of the GABAA receptor within regions of the 
frontal cortex (ACC) is associated with highly impulsive rats on the 5CSRTT (Asinof & Paine, 
2012; Jupp et al., 2013; Murphy et al., 2012). Evidence that GABA activity within the NAcb core 
plays a role in mediating drug induced impulsivity consequently builds on this previous 
literature by indicating that GABA transmission within ventral regions of the striatum is 
involved in mediating drug induced impulsivity.  
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Full behavioural reversal of amphetamine induced impulsivity, however, was not detected in 
the analysis of No-go trial accuracy, and interestingly, no approaching significance was 
detected between any muscimol dose in combination with systemic amphetamine in 
comparison to vehicle infusion and systemic amphetamine. Despite the overall mean for the 
highest muscimol (960 ng) and systemic amphetamine dose visually appearing to fully reverse 
(Fig. 7.11), from closer inspection of the data presented in experiment 7, four out of the nine 
rats that received muscimol and systemic amphetamine treatment did not fully reverse 
following the highest muscimol dose and systemic amphetamine (range: 7.5 – 35 % lower than 
No-go trial accuracy following control combination), and out of the five animals that did 
display full behavioural reversal, performance following 960 ng muscimol and systemic 
amphetamine tended to surpass No-go trial accuracy following control treatment (range: + 7.5 
– 32.5 % higher than No-go trial accuracy following control combination) (See Appendix 7). 
This means that although the average of No-go trial accuracy following 960 ng muscimol and 
systemic amphetamine visually appears to have produced full behavioural reversal, only five 
out of the nine rats actually displayed this ‘full’ profile of reversal, whilst a convincing number 
of the animals tested did not fully reverse. This level of variance at the 960 ng muscimol dose 
consequently explains why, despite this effect visually appearing to have produced full 
behavioural reversal, this is not statistically close to significance.  
However, despite the high variation in No-go trial accuracy at the highest muscimol doses, all 
rats did demonstrate higher No-go trial accuracy at higher muscimol doses in combination with 
systemic amphetamine (480, 960 ng) than vehicle infusion and lower muscimol doses in 
combination with systemic amphetamine (120, 240 ng) (Fig. 7.11), supporting that higher 
doses of muscimol treatment did induce some reversal of amphetamine induced impulsivity. In 
addition, the lack of significant difference between all muscimol doses and systemic 
amphetamine in comparison control treatment indicates that muscimol did cause some 
reversal from vehicle infusion and systemic amphetamine treatment.  
The GABAA receptors are located both presynaptically on dopamine terminals innervating the 
NAcb and postsynaptically on medium spiny projection neurons and aspiny interneurons 
within the NAcb (Ferraro et al., 1996; Krebs, Kemel, Gauchy, Desban, & Glowinski, 1993; 
Ronken, Mulder, & Schoffelmeer, 1993; Schwarzer et al., 2001). It is most likely that the 
muscimol induced changes in No-go trial accuracy represent a presynaptic action of muscimol 
at the GABAA receptors located on dopaminergic nerve terminals innervating the NAcb core. 
This location of muscimol action would consequently cause an increase in presynaptic GABAA 
mediated inhibition over dopamine release into the NAcb core. Given that dopamine activity 
within the NAcb core has been found to mediate amphetamine induced impulsivity (Pattij et 
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al., 2007; Chapter 6, Section 6.3) this location of muscimol action within the NAcb core fits 
with the existing neurochemical framework within the NAcb core that is assumed to mediate 
amphetamine induced impulsivity. Muscimol infusions into the NAcb of anesthetised rats has 
previously been found to reduce dopamine concentration, whilst the GABAA antagonist 
bicuculline increases dopamine concentration in the NAcb in both anesthetized and freely 
moving rats (Ferraro et al., 1996; Yan, 1999). These findings therefore indicate that the GABAA 
receptors within the NAcb exert an inhibitory role over dopamine innervation into the NAcb, 
consistent with an inhibitory influence of muscimol over NAcb core dopamine induced 
impulsivity.  
However, opposing effects of muscimol on dopamine concentration within the NAcb have 
been reported when muscimol is infused into the NAcb of freely moving rats. Aono et al., 
(2008) found that muscimol produces an increase in basal dopamine flux within the NAcb in 
freely moving rats, contrarily suggesting the possibility that muscimol infused into the NAcb 
might bind to postsynaptic GABAA receptors located on inhibitory interneurons, consequently 
inhibiting the release of GABA at dopamine terminal innervating the core, leading to an 
increase in dopamine release. However, it is also noteworthy that Aono et al., (2008) report 
that the GABAA antagonist bicuculline also increase basal dopamine flux within the NAcb.  
Although animals in the Aono et al., (2008) study are comparable to the animals in the current 
study because they were freely moving rats, a postsynaptic action of muscimol within the 
NAcb core is unlikely to explain muscimol induced changes in No-go trial accuracy as a 
muscimol induced increase in dopamine within the NAcb core would mimic the actions of 
amphetamine in the core, and would therefore be expected to potentiate amphetamine 
induced impulsivity. A postsynaptic action of muscimol within the NAcb core is therefore at 
odds with muscimol induced increases in No-go trial accuracy. In addition, the infusion of 
muscimol by Aono et al., (2008) is much lower (25- 200 pmol) than that employed in the 
current study (120 – 960 ng), indicating that the action of muscimol within the NAcb reported 
by Aono et al., (2008) and the current study might not be comparable.  
In following, given that an action of muscimol within the NAcb core at the GABAA receptors 
located on GABAergic interneurons is at odds with muscimol induced increases in No-go trial 
accuracy, alongside the fact that much higher doses were employed in the current study to 
Aono et al., (2008), this suggest that changes in amphetamine induced impulsivity in the 
current study is more likely to reflect a presynaptic action of muscimol at the GABAA receptors 
located on the terminal of dopamine neurons innervating the NAcb core. If muscimol did 
produce the apparent partial reversal of amphetamine induced impulsivity through   
presynaptic activation of the GABAA receptors located on dopamine terminals innervating the 
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NAcb core, this might subsequently suggests muscimol indirectly reduced the effects of 
amphetamine induced dopamine activity at the D2 receptors within the NAcb core that are 
known to mediate amphetamine induced impulsivity in rats (Pattij et al., 2007; Chapter 6, 
Section 6.3). 
Interestingly, however, the data set did produce some indications of muscimol induced 
potentiation of amphetamine induced impulsivity at the lowest (120 ng) doses in a subset of 
animals (See Appendix 7). Although these effects were non-significant, this suggests that lower 
doses of muscimol might have acted at different GABAA receptor locations (presynaptic vs 
postsynaptic) within the NAcb core than higher muscimol doses in some animals. These non-
significant changes in the data set are generally consistent with previous observations that 
intra-NAcb muscimol infusions can produce biphasic effects on behaviour in rats (Scheel-
Krüger et al., 1980) possibly in relation to different pre-synaptic and post-synaptic GABAA 
targets within the NAcb.  
7.4.3 Key Findings 
The main findings from this study are that infusion of the GABAA agonist muscimol into the 
nucleus accumbens core does not affect baseline levels of response inhibition but can partially 
reverse amphetamine induced response disinhibition in rats. These findings suggest that 
changes to GABA function within the nucelus accumbens core might be involved in drug 
induced impulsivity. The main aim of the current study was to assess the involvement of GABA 
in response inhibition and amphetamine induced response disinhibition on the Go/No-go 
symmetrically reinforced task. These aims attempted to address broader objectives into the 
neurochemical mediators of impulsivity and drug induced impulsivity within the ventral 
striatum. The observation that muscimol partially revered amphetamine induced impulsivity, 
but did not affect baseline levels of response inhibition, consequently addresses these 
objectives by confirming that GABA activity might be specifically involved in drug induced 
impulsivity. 
7.4.4 Limitations 
The main limitation in the design of this study is that through administering muscimol to test 
GABAergic involvement in response inhibition and amphetamine induced response 
disinhibition, the partial reversal of amphetamine induced impulsivity observed may reflect 
either a pharmacological effect involving the GABAA receptors, or a GABA induced reversible 
lesion of the nucelus accumbens core. It is therefore difficult to interpret whether the GABAA 
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receptors are specifically involved in mediating amphetamine induced impulsivity or whether 
through inhibiting the nucelus accumbens as an entire site was responsible for partial reversal 
of impulsivity. It should therefore be noted that the current study does not confirm GABAergic 
involvement in drug induced impulsivity exclusively but might instead represent more general 
nucleus accumbens core site involvement in amphetamine induced impulsivity. 
7.4.5 Future Research 
Having established that mimicking GABAergic activity within the nucleus accumbens core can 
partially reverse amphetamine induced response disinhibition on the Go/No-go task, it would 
be useful for future research to more directly assess the role of the GABAA and GABAB 
receptors within the nucleus accumbens core and shell in response disinhibition. Such research 
efforts would help to elucidate whether specific changes in GABA sub-receptors are involved in 
the ventral striatal neuropathology linked to impulsivity and drug addiction. In addition, it 
would be useful for future research to investigate involvement of GABAergic activity within 
regions of the prefrontal cortex in response inhibition measured by the Go/No-go task. 
Changes in GABA concentration in regions of the prefrontal cortex have been linked to trait 
impulsivity in human subjects and direct manipulation of GABA in the infralimbic cortex of rats 
has been found to affect premature responding in rats (Boy et al., 2011; Murphy et al., 2012). 
It would therefore be useful to further investigate the role of GABA in response inhibition in on 
the Go/No-go task which can more directly ascertain response inhibition than the 5CSRTT. 
Further research aiming to further elucidate the relationship between GABAergic changes and 
impulsivity will be useful for considering how different neurochemical pathways may 
contribute towards impulsivity and addiction. Subsequently, understanding this relationship 
better will help give insight into potential novel pharmacological approaches for the treatment 
of drug addiction.  
7.4.6 Conclusions 
In conclusion, the lack of effects observed following GABAA activation within the NAcb core on 
impulsivity, alongside NAcb core GABAA mediated partial reversal of amphetamine induced 
impulsivity, implicates a role for GABA transmission within the NAcb core in amphetamine 
induced impulsivity. These findings consequently expand on previous animal and human 
literature implicating a role for GABA transmission in impulsive behaviour (Asinof & Paine, 
2012; Boy et al., 2011; Edden et al., 2012; Jupp et al., 2013; Murphy et al., 2012) by identifying 
a novel anatomical location whereby changes in GABA activity can reduce drug induced 
impulsivity in rats. These findings also expand on previous literature that has implicated 
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dopamine activity within the NAcb core in amphetamine induced impulsivity in rats (Pattij et 
al., 2007; Chapter 6, Section 6.3) by indicating that changes in both dopamine and GABA 
activity within the NAcb core might be involved in the neurochemical pathology of 
amphetamine induced impulsivity in rats. These findings therefore provide novel findings into 
the neural substrates mediating amphetamine induced impulsivity in rats. 
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Chapter 8 General Discussion 
 
The current sets of experiments provide evidence that sub-chronic and chronic amphetamine 
treatment can cause transient reductions in behavioural inhibition in rats measured by a 
symmetrically reinforced Go/No-go task. In addition, the D2 receptors, and to a lesser extent 
GABAA receptors, within the NAcb core were identified as neural substrates mediating 
amphetamine induced impulsivity on the Go/No-go task. These results therefore present novel 
findings on the relationship between subchronic and chronic amphetamine use and impulsivity 
and on the neural substrates of amphetamine induced impulsivity. These findings will be 
discussed below. 
8.1Subchronic and chronic amphetamine and impulsivity 
8.1.1 Feeding behaviour and impulsivity observed during 4-day amphetamine 
treatment and amphetamine withdrawal  
Reduced food intake observed during 4-day amphetamine treatment and for up to 60 hours of 
amphetamine withdrawal suggests that this amphetamine regime might cause some 
alterations in the motivation for food in rats. Interestingly, however, no significant changes in 
magazine latencies were detected amongst rats treated with the 4-day amphetamine regime 
in comparison to controls, either during amphetamine treatment or during withdrawal from 
amphetamine. This suggests that animals treated with 4-day amphetamine conversely 
remained active and motivated to gain food reward during drug treatment and withdrawal. 
The combination of these findings therefore suggests that whilst 4-day amphetamine 
treatment might produce some motivational effects on food intake in rats, any such changes 
did not appear to affect motivation to receive food reward on the Go/No-go task. These 
differences might relate to differences in the baseline motivational state of animals between 
studies (eg. free-feeding vs. food-restricted). The lack of change in magazine latencies amongst 
animals that were food restricted might suggest that the effects of 4-day amphetamine on 
motivation for food were less disruptive to these animals than animals on a free-feeding 
schedule that had access to food at any time. The combination of these results suggests that 
the food restriction schedule employed in Chapter 4 might prevent significant treatment 
induced changes in feeding motivation that might disrupt performance on the Go/No-go task.  
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8.1.2 Patterns of amphetamine use and impulsivity 
Treatment with a 4-day amphetamine binge and 11-day chronic amphetamine regime both 
reduced behavioural inhibition in rats during drug treatment. The combination of these results 
demonstrates that amphetamine can increase impulsivity during different patterns of use. 
Amphetamine can be abused in a variety of different settings and for different purposes 
(Davey, Richards, & Freeman, 2007; Degenhardt et al., 2007; Hall, Darke, Ross, & Wodak, 1993; 
McCabe, Teter, & Boyd, 2006; Riley, James et al., 2001; Teter et al., 2006) meaning that these 
findings are particularly useful for elucidating how different patterns of amphetamine use per 
se might affect impulsivity amongst amphetamine users.  
Different patterns of drug use can occur at different stages of addiction (Perry, 2008). In 
following, the 4-day and 11-day amphetamine regimes can be broadly mapped onto different 
stages of addiction. For example, the binge regime most closely maps onto a stage of 
escalating drug use, whilst the longer-term 11-day treatment more closely maps onto a stage 
of maintained drug use. Amphetamine induced impulsivity during both of these regimes 
therefore supports that behavioural inhibition might change as a consequence of the pattern 
of drug use employed during distinct stages of addiction. Increased impulsivity during 
escalation and maintenance of amphetamine use might then increase the chance of 
subsequent drug use as a consequence of reduced inhibitory control. In addition elevated 
impulsivity might reduce inhibitory control over other risk factors for addiction during phases 
of escalation and maintenance. For example, stress can facilitate escalation and maintenance 
of stimulant use in rats (Miczek et al., 2004; Piazza & Le Moal, 1996) and is a prominent risk 
factor for escalating drug use in humans (Sinha, 2008). Drug induced reductions in behavioural 
inhibition might then reduce inhibitory control over concurrent risk factors for addiction, such 
as stress, rendering drug users more vulnerable to developing, and or maintaining, drug 
addiction. 
Interestingly, previous investigations into the relationship between impulsivity and phases of 
escalation and maintenance have found that greater levels of trait impulsivity can increase 
escalation but not the maintenance of stimulant use in rats (Anker et al., 2009; Belin et al., 
2008; Dalley et al., 2007; Perry et al., 2005; Perry, Nelson, & Carroll, 2008). When considered 
with the present findings, this might suggest that greater levels of trait impulsivity can 
differentially affect the vulnerability to distinct stages of addiction, whilst the direct effects of 
stimulant use may produce common effects in elevating impulsivity during distinct stages of 
addiction. However, as the effects of amphetamine on impulsivity interact with baseline levels 
of inhibitory control in animals and humans, and stimulants can in fact improve inhibitory 
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control in highly impulsive subjects (Dalley, Fryer, et al., 2007; de Wit et al., 2002), 
amphetamine induced deficits in behavioural inhibition observed amongst animals in the 
current set of experiments might more accurately represent the causal effects of 
amphetamine on impulsivity in a population that display an existing level of inhibitory control 
at baseline.  
Whilst the 4-day and 11-day amphetamine regimes both produced a common outcome of 
increased impulsivity during drug use, the time course of which these effects developed was 
different. During treatment with the 4-day amphetamine binge a significant reduction in 
behavioural inhibition was observed following a cumulative dose of 6 mg/kg (day 1: 1, 2, 3 
mg/kg) (See Figs. 4.1 - 4.2). In contrast, during treatment with the 11-day amphetamine 
regime, reductions in behavioural inhibition occurred following a cumulative dose of 30 mg/kg 
(days 1 – 4: 1, 2; 3, 4; 5, 5; 5, 5 mg/kg) (See Figs. 5.1 – 5.2). The combination of these findings 
presents an interesting difference in amphetamine dose vs. pattern effects on impulsivity and 
suggests that a small cumulative amount of amphetamine administered in a short period of 
time can cause faster changes in behavioural inhibition than a larger cumulative amount of 
amphetamine administered over a longer period of time. The 4-day amphetamine regime 
therefore appears to be more detrimental to behavioural inhibition than the 11-day regime, 
based on the observation that this regime induced earlier reductions in behavioural inhibition 
and at a lower cumulative dose of amphetamine than the 11-day regime. Intense periods of 
binge intoxication are a hallmark feature of addiction and represent a phase of uncontrolled 
drug use (Koob & Le Moal, 2008; Perry et al., 2008), whilst more maintained patterns of drug 
use do not necessarily indicate phases of drug use that is out of control (Perry et al., 2008). The 
present findings therefore support that impulsivity might have a preferential relationship with, 
or be more detrimental to, periods of fast and frequent drug use (binge) relative to more 
maintained patterns of drug use (Perry et al., 2008). 
To date, previous investigations into the relationship between binge drug use and impulsivity 
have found that trait impulsivity can predict binge patterns of drug use in humans (Carlson et 
al., 2010; Semple, Zians, Grant, & Patterson, 2005) therefore suggesting that the direction of 
this relationship exists with impulsivity acting as a predictive cause of bingeing and not 
necessarily a consequence of drug use itself. The present findings therefore expand on this 
literature by demonstrating that not only might reduced inhibitory control increase the chance 
of engaging in an escalating and uncontrolled pattern of drug use, but this pattern of use might 
in itself also produce greater deficits in inhibitory control relative less intense patterns of use.  
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8.1.3 Patterns of amphetamine on short-term withdrawal induced impulsivity 
Both the 4-day and 11-day amphetamine regimes increased impulsivity during short-term 
amphetamine withdrawal (withdrawal week one) indicating an overall similarity in the 
duration of elevated impulsivity following the termination of two different patterns of 
amphetamine administration. However, further analysis of the specific duration of these 
effects demonstrated that treatment with the 4-day amphetamine regime caused a longer 
duration of increased impulsivity (12 -36 hrs, and 156 hrs of withdrawal) than that observed by 
11-day amphetamine treatment (See Figs. 4.2 and 5.2). These differences in withdrawal 
induced impulsivity are therefore useful for considering how different patterns of 
amphetamine use, and possibly stages of addiction, might affect impulsivity during early 
phases of drug withdrawal where vulnerability to relapse is high. 
Greater withdrawal induced impulsivity following 4-day amphetamine in comparison to 11-day 
amphetamine suggests that treatment with the 4-day amphetamine binge was more 
detrimental to behavioural inhibition than the 11-day amphetamine regime during short-term 
amphetamine withdrawal. Reduced behavioural inhibition during the first two days of 
withdrawal (up to 36 hrs withdrawal) following 4-day amphetamine treatment only, is 
particularly interesting for considering how inhibitory control between these two patterns of 
amphetamine use might affect impulsive urges to seek and take drugs during acute drug 
withdrawal. Acute drug withdrawal marks a period of heightened vulnerability to relapse 
(Koob & Le Moal, 2008) during which sensitivity to drug related cues and cue-elicited craving 
are thought to play a significant role in drug seeking and relapse (Childress et al., 1993; Myers 
& Carlezon Jr, 2010; Robinson & Berridge, 1993; Rohsenow et al., 1991; Wise, 1988). The lack 
of significant difference between amphetamine treated animals and controls during the first 
two days (up to 36 hrs withdrawal) of 11-day amphetamine withdrawal suggests that animals 
moving into this phase of acute withdrawal following treatment with a relatively maintained 
pattern of amphetamine use might be able to exert stronger inhibitory control over risk factors 
for relapse during this phase, such as sensitivity to drug cues. Reduced behavioural inhibition 
observed by animals treated with the 4-day amphetamine binge alternatively indicates that 
this pattern of amphetamine use might lead to a state of compromised inhibitory control over 
acute withdrawal symptoms, consequently increasing the vulnerability of relapse. This 
suggests that a binge pattern of amphetamine use might lead to a greater chance of 
subsequence drug use than a more maintained pattern of amphetamine use as a consequence 
of greater deficits in inhibitory control over risk factors for drug seeking and relapse, such as 
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increased sensitivity to drug cues and craving (Robinson & Berridge, 1993), during short-term 
amphetamine withdrawal.  
Collectively, observations that 4-day amphetamine treatment is more detrimental to 
behavioural inhibition than 11-day amphetamine during drug treatment, alongside greater 
inhibitory deficits during withdrawal from 4-day amphetamine to that observed by 11-day 
amphetamine, suggests that binge use of amphetamine causes quicker and longer lasting 
deficits in behavioural inhibition in comparison to longer-term and more maintained use of 
amphetamine. Consequently, this pattern of use might render amphetamine users more 
vulnerable to repeated drug use both throughout escalating patterns of use, consequently 
fuelling prolonged binge intoxication, or through increasing the chance of relapse during short-
term drug withdrawal, fuelling the transition into dependence and/or maintaining 
dependence. 
The differences observed in the onset and duration of impulsivity as a consequence of 4-day or 
11-day amphetamine treatment might relate to differences in the neurochemical changes 
induced by these different patterns of amphetamine treatment. The main differences in 4-day 
and 11-day amphetamine treatment was the frequency of administration per day and the 
duration of amphetamine treatment, both of which factors are known to influence 
neurochemical changes in dopamine during amphetamine withdrawal (Paulson & Robinson, 
1995; Robinson & Becker, 1986; Robinson & Berridge, 1993). Amphetamine withdrawal is 
associated with reduced dopamine concentration within the striatum and ventral striatum 
(Paulson & Robinson, 1996; Rossetti, Hmaidan, & Gessa, 1992) and partial dopamine agonists 
can reverse withdrawal induced reductions in motivational deficits (Orsini et al., 2001). These 
findings indicate that changes in dopamine functioning within striatal regions are concomitant 
with amphetamine withdrawal. Changes in dopamine functioning within the ventral striatum 
are thought to be associated with amphetamine induced behavioural inhibition in rats (Pattij 
et al., 2007) and in Chapter 6 changes in dopamine activity within the ventral striatum is 
shown to be associated with amphetamine induced behavioural inhibition measured by the 
symmetrically reinforced Go/No-go task. When considered together these findings may 
suggest that the differential changes in dopamine function in withdrawal relate to the 
differences observed in the significance of withdrawal induced deficits in behavioural 
inhibition between amphetamine treatment regimes.  
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8.1.4 Patterns of amphetamine on long-term withdrawal and impulsivity 
Neither 4-day amphetamine nor 11-day amphetamine caused any long-term changes in 
behavioural inhibition in rats. The combination of these results indicates that increased 
impulsivity following subchronic and chronic amphetamine is a transient effect that is 
recoverable long-term. Different patterns of amphetamine use might then only pose 
differential effects on impulsivity, and subsequently differential effects on the vulnerability to 
addiction/ maintenance of addiction, during periods of drug use and short-term withdrawal.  
In addition, neither regime caused any changes in long-term sensitivity to the acute effects of 
amphetamine on impulsivity. Given that more intermittent patterns of amphetamine 
administration are usually required to induced sensitisation to the acute effects of 
amphetamine (Robinson & Becker, 1986; Robinson & Berridge, 1993) these findings are 
generally consistent with previous literature. Furthermore, amphetamine regimes that 
produce sensitisation to the stereotypic effects of amphetamine in rats have also been shown 
not to affect sensitisation to the impulsive effects of amphetamine (Stanis et al., 2008) 
indicating that regimes that typically induce sensitisation to locomotor behaviour may not 
produce similar effects on impulsive behaviour.  
However, contrasting effects were observed during Go trial performance following 4-day and 
11-day amphetamine treatment (See Figs. 4.4 - 5.4). Animals treated with 4-day amphetamine 
showed tolerance to disruptive performance effects following 1.2 mg/kg amphetamine in 
comparison to animals treated with saline, whilst animals treated for 11-days with 
amphetamine showed sensitivity to these effects, performing Go trials less accurately than 
controls following 1.2 mg/kg. These differences might relate to the fact that during the 4-day 
regime there was less time (6 hrs/ 12 hrs) between each injection than the 11-day (12 hrs). 
Given that tolerance is usually observed following continuous drug regimes whilst sensitisation 
is usually observed following intermittent drug regimes (Post, 1980), the smaller duration 
between amphetamine injections during 4-day amphetamine treatment might then explain 
why these animals displayed some evidence of tolerance in response to acute amphetamine, 
whilst animals with a longer duration between injections displayed some evidence of 
sensitisation.  
8.1.5  Conclusions and Future Research 
In conclusion, the results presented demonstrate that both subchronic and chronic 
amphetamine treatment can reduce behavioural inhibition in rats both during drug treatment 
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and short-term drug withdrawal when measured by a symmetrically reinforced Go/No-go task. 
In addition, more specific analysis of these effects indicates that the pattern of amphetamine 
administration can affect both the onset and duration of drug induced impulsivity, with 
indications that subchronic high frequency regimes (binge) leading to earlier and more long-
term effects on impulsivity than chronic low frequency regimes. These findings therefore 
present novel findings in the relationship between to subchronic and chronic amphetamine 
administration and impulsivity in rats. The prevalence of both subchronic and chronic 
amphetamine induced deficits on behavioural inhibition during drug treatment and withdrawal 
therefore warrants future research into how such withdrawal induced deficits in behavioural 
inhibition might relate to relapse in animal models. Furthermore, given that much research has 
implicated changes in the D2 receptors in stimulant addicts during phases of abstinence (Lee et 
al., 2009) and impulsivity (Van Gaalen et al., 2009; Van Gaalen et al., 2006; Van Gaalen et al., 
2006b) future research investigating the role of the D2 sub-receptors in withdrawal induced 
impulsivity would be useful for elucidating possible neurochemical changes driving impulsivity 
that occur as a consequence of stimulant use. 
8.2Central Dopamine and GABA manipulations and Impulsivity 
Investigation into the neural substrates of impulsivity and amphetamine induced impulsivity 
revealed that the D2 and GABAA receptors within the NAcb core are involved in the expression 
of amphetamine induced disinhibition, but not behavioural inhibition, in rats performing a 
symmetrically reinforced Go/No-go task. Whilst the D2 receptors with the NAcb core have 
previously been found to mediate amphetamine induced impulsivity on the 5CSRTT (Pattij et 
al., 2007), this is the first study to identify that the D2 receptors within the NAcb core mediate 
drug induced impulsivity that is associated with a direct loss of reward, consequently 
implicating this receptor in the mediation of a motivationally significant loss of inhibitory of 
control. Similarly, no previous literature to date has investigated the involvement of the GABAA 
receptors within the NAcb core in impulsivity or amphetamine induced impulsivity in rats. The 
combination of these studies therefore presents novel findings into the behavioural profile of 
behavioural disinhibition that is mediated by the D2 and GABAA receptors within the NAcb 
core, and more broadly, into the neurochemical systems within the NAcb core that mediate 
drug induced disinhibited behaviour in rats. 
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8.2.1 Neural substrates of impulsivity 
Infusions of eticlopride and muscimol into the NAcb core both produced no effects on any 
measures of the Go/No-go task, indicating that dopamine neurotransmission at the D2 
receptors and exogenous activation of the GABAA receptors within the NAcb core does not 
disrupt baseline performance on the Go/No-go task. D2 receptors are located presynaptically 
on dopamine nerve terminals forming inhibitory autoreceptors (Benoit-Marand, Borrelli, & 
Gonon, 2001; Zhang & Sulzer, 2012) and within the ventral striatum the D2 receptors are also 
located postsynaptically on medium spiny projection neurons and cholinergic interneurons, 
and there are also evidence that the D2 receptors are located presynaptically on glutamate 
terminals innervating the NAcb (Albin, Young, & Penney, 1989; Goto & Grace, 2005; 
Kawaguchi, 1993; Surmeier et al., 2007). The lack of effect eticlopride produced on baseline 
performance of behaviour inhibition therefore indicates that the blockade of the D2 receptors 
at any of these potential sites of action might not change the expression of baseline 
behavioural inhibition on the Go/No-go task. Infusion of eticlopride into the NAcb core has 
previously been shown to facilitate prefrontal glutamate input into the NAcb core (Goto & 
Grace, 2005) suggesting that these results might reflect a lack of involvement in of presynaptic  
D2 receptors located on glutamate terminals innervating the NAcb core. However, Goto & 
Grace, (2005) infused much higher eticlopride doses (20 μM) to that in the current these (0.1 - 
1.0 μg), therefore, the site of action of eticlopride might not necessarily be comparable 
between these two studies. 
This lack of eticlopride induced effects on baseline behavioural inhibition is consistent with 
previous literature that has demonstrated a role for the D1 but not D2 receptors within the 
NAcb core in the mediation of baseline behavioural inhibition on the 5CSRTT (Pattij et al., 
2007b). In addition, the D1 receptors within the NAcb core have been shown to produce 
greater deficits in the processing of pavlovian cues that influence instrumental responding 
(PIT) than the D2 receptors within the NAcb core (Lex & Hauber, 2008), suggesting that the D1 
receptors within the NAcb core might be more preferentially involved in the mediation of cue 
elicited behavioural activation than the D2 receptors. The Go/No-go task requires intact 
associations between the introceptive value of Go and No-go cues with active and passive 
response behaviour. When considered together, this might suggest that intact D1 receptor 
functioning following eticlopride infusions enabled normal processing of the introceptive 
values of Go and No-go visual cues in relation to reward. 
The GABAA receptors are located postsynaptically on medium spiny projection neurons and 
aspiny interneurons, and presynaptically on dopamine terminals innervating the NAcb core 
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(Ferraro et al., 1996; Krebs et al., 1993; Ronken et al., 1993; Schwarzer et al., 2001). The lack of 
muscimol induced effects on baseline behavioural inhibition on the Go/No-go task therefore 
suggests that activation of the GABAA receptors at any of these potential sites of action might 
not affect baseline behavioural inhibition on the Go/No-go task. Muscimol infused into the 
NAcb has previously been shown to exert effects that are reflective of both a presynaptic 
action on dopamine terminals and postsynaptic action on medium spiny and aspiny neurons 
(Aono et al., 2008; Ferraro et al., 1996; R. Mitchell, 1980; Yan, 1999). Consequently, the lack of 
effects of muscimol might reflect a lack of GABAA receptor involvement at any or all of these 
sites. 
Aside from dopamine and GABA systems within NAcb core, there are multiple neurochemical 
systems that innervate the NAcb core that might potentially be involved in the processing of 
behavioural inhibition under baseline conditions. The NAcb core is heavily innervated by 
prefrontal, limbic and thalamic glutamate afferents (DeFrance et al., 1985; Fuller, Russchen, & 
Price, 1987; McDonald, 1991), and as such, these afferent projections might affect processing 
of behavioural inhibition within the NAcb core on the Go/No-go task. AMPA and NMDA 
receptor antagonism within the NAcb core and shell has recently been shown to increase 
behavioural disinhibition, measured by the ratio of responding to non-rewarded auditory 
stimuli in rats (Ambroggi et al., 2011). Interestingly, AMPA and NMDA antagonism within the 
NAcb core, but not shell, additionally led to a significant reduction in the correct discrimination 
of an auditory tone signalling reward (Ambroggi et al., 2011), consistent with a specific role for 
the NAcb core in processing the incentive value of cues in rats (Parkinson et al., 1999). These 
findings therefore suggest that glutamate activity within NAcb core might mediate behavioural 
inhibition through processing the incentive value of stimuli that guides appropriate 
behavioural activation and inhibition for reward. Consequently, if glutamate signalling 
remained intact following infusions of eticlopride and muscimol into the NAcb core, then the 
incentive value of Go and No-go trial visual cues would remain intact, guiding the correct 
response behaviour to receive reward. 
Another neurochemical system that might have been unaffected by eticlopride and muscimol 
infusions and that might plausibly mediate behavioural inhibition within the NAcb core on the 
Go/No-go task is serotonin. Antagonism of the 5-HT2a and 5-HT2c sub-receptors have both been 
found to mediate changes in premature responding on the 5CSRTT (Robinson et al., 2007). 
Although antagonism of NAcb 5-HT2a and 5-HT2c receptors on the 5CSRTT might not be directly 
comparable to the role of serotonin within the NAcb on the Go/No-go task, especially since 
differences in omissions were observed between these effects (Robinson et al., 2007), these 
findings are useful in considering how changes in alternative systems within the NAcb core 
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might mediate behavioural inhibition. Furthermore, central serotonin depletion in rats has 
previously been shown to impair the acquisition of, and performance on, the symmetrically 
reinforced Go/No-go task employed in the current thesis (Harrison et al., 1999) indicating that 
changes in 5-HT function within the NAcb core might a potential neurochemical substrate of 
behavioural inhibition on the Go/No-go task. 
Noradrenalin terminals also innervate the NAcb, suggesting the possibility that this 
neurotransmitter might also play a role in behavioural inhibition. However, it is probably 
unlikely that noradrenalin represents a potential neurochemical system outside of dopamine 
and GABA within the NAcb core that mediates behavioural inhibition on the Go/No-go task, as 
firstly, immunoreactivity for the noradrenalin enzyme dopamine β-hydroxylase is much greater 
in the NAcb shell than NAcb core (Berridge et al., 1997), and secondly, infusions of the 
selective noradrenalin reuptake inhibitor atomoxetine has recently been shown to only affect 
premature responding in rats when infused into the NAcb shell, and not the core (Economidou 
et al., 2012). However, without investigation into the direct effects of noradrenalin 
manipulation within the NAcb core on the Go/No-go task, it remains possible this noradrenalin 
might additionally play a role in the neurochemical mediation of behavioural inhibition on the 
Go/No-go task that might not have been affected following eticlopride and muscimol infusions 
into the NAcb core. 
8.2.2 Neural substrates of amphetamine induced impulsivity 
Eticlopride mediated reversal of amphetamine induced impulsivity on the Go/No-go task 
demonstrates that amphetamine induced activation of the D2 receptors within the NAcb core 
is involved in the expression of amphetamine induced disinhibition on this task. It is well 
known that acute amphetamine causes an increase in dopamine flux within the NAcb (Carboni 
et al., 1989) and that acute amphetamine reduces behavioural inhibition in rats (Cole & 
Robbins, 1989; Harrison et al., 1997; Harrison et al., In prep; Murphy et al., 2008; Pattij et al., 
2007). These findings therefore help to elucidate how amphetamine induced elevations in 
dopamine release within the core sub-region of the NAcb might contribute towards the 
expression of acute disinhibition observed following systemic amphetamine in rats. These 
findings are consistent with a role for the D2 receptors within the NAcb core in the mediation 
of amphetamine induced premature responding on the 5CSRTT (Pattij et al., 2007) and 
additionally contribute towards elucidating the behavioural profile of disinhibited behaviour 
mediated by the D2 receptors within the NAcb core by implicating amphetamine induced 
activation of the D2 receptors in a the loss of behavioural inhibition that costs the loss of 
reward. Taken together these findings provide consistent evidence for changes at the D2 
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receptors within the NAcb core mediating the expression of amphetamine induced 
disinhibition, and indicate that changes at the D2 receptors can lead to disinhibited behaviour 
despite associated negative outcomes, consistent with the behavioural profile of impulsivity 
observed in drug users. 
Muscimol induced partial reversal of amphetamine induced impulsivity additionally indicates 
that activation of the GABAA receptors within the NAcb core can reduce the expression of 
amphetamine induced behavioural inhibition on Go/No-go task. These findings elucidate the 
involvement of potential neurochemical systems other than dopamine within the NAcb core 
that acute amphetamine might alter, either directly or indirectly, and that contribute towards 
acute changes in behavioural inhibition following amphetamine. When considered with the 
results observed with eticlopride, collectively these findings indicate that both dopamine and 
GABA systems within the NAcb core are involved in amphetamine induced behavioural 
disinhibition on the Go/No-go task.  
Interestingly, both eticlopride and muscimol infusions into the NAcb core produced a similar 
pattern of behavioural effects on the Go/No-go task. The only difference between the effects 
of eticlopride and muscimol infusions on Go/No-go performance was in the significance of full 
behavioural reversal at the highest dose of each drug. The similarities in these results might 
reflect the fact that eticlopride and muscimol both ultimately targeted dopamine activity 
within the NAcb core, meaning that both drugs shared a common pharmacological outcome of 
reducing dopaminergic action within the NAcb core that is responsible for disinhibited 
behaviour (Pattij et al., 2007). However, the differences in full behavioural reversal might 
reflect the fact that this common action of eticlopride and muscimol on dopamine was 
produced via different direct and indirect actions, respectively. Eticlopride directly blocks 
dopamine at the D2 receptors where as muscimol indirectly reduces dopamine by activation of 
inhibitory GABAA receptors (Ferraro et al., 1996; Köhler, Hall, & Gawell, 1986; Yan, 1999). 
Differences in the direct and indirect actions of eticlopride and muscimol might then explain 
why muscimol produced a similar pattern and direction of reversal to that observed with 
eticlopride, and consequently why this was not as significant as the effects of eticlopride. In 
addition, the similar pattern of results between eticlopride and muscimol infusions might also 
suggest that muscimol indirectly inhibited dopamine action at the D2 receptors. However, 
without knowing whether the D1 receptors within the NAcb core are involved in amphetamine 
induced  disinhibition on the Go/No-go task, muscimol induced reductions on dopamine might 
have affected the action of dopamine at both the D1 and D2 receptors within the NAcb core, 
along with the subsequent effects both receptors might play in behavioural disinhibition.  
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As previously mentioned, the D2 receptors are located both pre and postsynaptically on cells 
within the NAcb (Albin, Young, & Penney, 1989; Goto & Grace, 2005; Kawaguchi, 1993; 
Surmeier et al., 2007). Hypothetically, eticlopride induced antagonism of the D2 receptors 
within the NAcb core could reduce amphetamine induced disinhibition either through a 
presynaptic action on PFC NAcb-projecting glutamatergic neurons innervating the core, or 
through a postsynaptic action on GABAergic medium spiny neurons projecting to the ventral 
pallidum from the NAcb core (See Fig 1.4). Both of these locations would theoretically block 
the effects of amphetamine induced elevations of dopamine release on inhibitory D2 receptors 
that can attenuate PFC input (Goto & Grace, 2005) and attenuate the activation of medium 
spiny projection neurons through the indirect ventral striato-pallidal pathway (Albin et al., 
1989; Surmeier et al., 2007; West & Grace, 2002).  
As previously mentioned, the GABAA receptors are located presynaptically on dopamine 
terminals innervating the NAcb core and postsynaptically on medium spiny projection neurons 
and aspiny interneurons (Ferraro et al., 1996; Krebs et al., 1993; Ronken et al., 1993; 
Schwarzer et al., 2001). Theoretically, a presynaptic effect of muscimol would be expected to 
reduce amphetamine induced disinhibition though presynaptic dopamine inhibition, whilst a 
postsynaptic effect would be expected to potentiate amphetamine induced disinhibition 
through mimicking the actions of dopamine at inhibitory D2 receptors.  
The fact that muscimol did not potentiate the effects of amphetamine induced disinhibition on 
the Go/No-go task is therefore useful for considering whether changes on the post-synaptic 
membrane of MSNs, and subsequently changes in ventral striato-pallidal activity, are in 
involved in amphetamine induced disinhibition. The lack of potentiation in amphetamine 
induced disinhibition following muscimol might then suggest that changes in the activation of 
the indirect ventral striato-pallidal pathway are not involved in mediating amphetamine 
induced disinhibition. When considered with the eticlopride study, this might suggest that 
eticlopride induced reversal is more likely to reflect blockade of amphetamine induced 
increases in the activation of inhibitory D2 receptors located on PFC glutamate afferents as 
opposed to a postsynaptic D2 receptors on MSNs, consistent with previous literature indicating 
that activation/ inactivation of the D2 receptors can attenuate/ facilitate PFC glutamate release 
into the NAcb core (Goto & Grace, 2005) and that glutamate release in the NAcb core is 
required for behavioural inhibition in rats (Ambroggi et al., 2011). However, it is also possible 
that muscimol did not bind to the GABAA receptors located on medium spiny projection 
neurons but rather preferentially bound to presynaptic GABAA receptors on dopamine 
terminals (Ferraro et al., 1996; Yan, 1999) leaving open the possibility that indirect changes in 
the activation of the ventral striato-pallidal pathway, through a presynaptic inhibition of 
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dopamine by muscimol and direct blockade of the D2 receptors on MSNs by eticlopride, might 
be involved in reductions/ reversal the amphetamine induced disinhibition observed.  
8.2.3 Summary and Future Research 
In summary, in terms of the neural circuits that might mediate amphetamine induced 
disinhibition on the symmetrically reinforced Go/No-go task, the effects of eticlopride and 
muscimol on amphetamine induced impulsivity collectively support the involvement of circuits 
innervating and projecting from the NAcb core in the mediation of amphetamine induced 
disinhibition, and might specifically support VTA dopamine release causing a shift from top-
down frontal processing to bottom up dopamine modulated processing via disconnection of 
PFC glutamate input into the NAcb core. However, due to the fact that a presynaptic action of 
muscimol on dopamine receptors cannot be ruled out, it remains possible that changes in 
ventral striato-pallidal signalling from the NAcb core might also contribute toward 
amphetamine induced behavioural disinhibition. 
In order to better elucidate the specific involvement of prefrontal and ventral striato-pallidal 
circuits in amphetamine induced impulsivity, future research into the functional involvement 
of prefrontal and subcortical targets of the NAcb core, such as the ventral pallidum, are 
required with the Go/No-go task. Given that the NAcb core receives glutamatergic afferents 
from dorsal prelimbic and lateral orbitofrontal areas, it would be particularly useful to 
investigate the role of glutamate antagonism within these areas to establish whether inhibiting 
descending prefrontal networks to the NAcb core affects behavioural inhibition on the Go/No-
go task. Alternatively, given that the D2 receptors within the NAcb core exert an inhibitory role 
over medium spiny projection neurons to the ventral pallidum, it would be particularly 
interesting to investigate the involvement of GABA function within the ventral pallidum during 
amphetamine induced impulsivity, in order to establish whether changes in the descending 
processing from the NAcb core through ventral striato-pallidal circuits might also contribute 
towards amphetamine induced behavioural disinhibition. Furthermore, given that emerging 
evidence has implicated a specific role for the D2 mediated indirect pathway leaving the NAcb 
core in the development of disinhibited drug seeking in rats (Bock et al., 2013), it would be 
interesting to establish the role of this pathway, either through glutamatergic activation within 
the NAcb core or GABAergic manipulation within the ventral pallidum in animal models of 
impulsivity.  
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8.2.4 Conclusions 
In conclusion, the effects of eticlopride and muscimol infusions into the NAcb core on 
impulsivity measured by the symmetrically reinforced Go/No-go task have suggested that 
baseline expression of behavioural inhibition on this task is not mediated activity at the D2 or 
GABAA receptors. In contrast, amphetamine induced impulsivity on this task appears to be 
mediated by stimulation of the D2 receptors within the NAcb core, suggesting that 
amphetamine induced elevations in dopamine activity at the D2 receptors within the NAcb 
core is involved in the manifestation of acute disinhibition of response behaviour following 
amphetamine. In addition, evidence that stimulation of the GABAA receptors within the NAcb 
core can reduce amphetamine induced impulsivity is indicative of both dopamine and GABA 
systems within the NAcb core contributing towards the expression of amphetamine induced 
impulsivity on the symmetrically reinforced Go/No-go task. The combination of these effects 
lends support to a break down in fronto-striatal connectivity in the manifestation of drug 
induced impulsivity (Dalley, Everitt, & Robbins, 2011; Jentsch & Taylor, 1999) but also implicate 
possible changes in the activation of descending ventral striato-pallidal pathways projecting 
from the NAcb core in amphetamine induced disinhibition. These findings consequently 
present novel findings in the neural substrates of amphetamine induced impulsivity and 
warrant future research into the role of different dopamine and GABA sub-receptors within 
the NAcb core in drug induced impulsivity, and research into fronto-striatal and ventral striato-
pallidal circuits in the involvement of drug induced impulsivity.  
8.3Thesis Limitations 
One of the major limitations of this thesis, which has been discussed in experimental chapters, 
is that no animal models of addiction were employed. Non-contingent drug administration was 
employed within all experimental procedures, and as such, there are scalability limitations of 
the results in this thesis to human populations. In order to overcome this limitation in future 
research, it would be useful to employ non-contingent self-administration regimes alongside 
measuring performance the Go/No-go task. This would, firstly, enable a more transferable 
method of examining impulsive behaviour and addiction in rats to human populations, and 
secondly, allow a more direct assessment of specific phases of addiction, such as, escalation, 
maintenance and relapse. Whilst this thesis employed non-contingent regimes that broadly 
map onto patterns of drug use within specific phases of addiction, eg. 4-day binge (escalation) 
and 11-day chronic (maintenance), these regimes do not directly model these phases of 
addiction. It would therefore be useful for future research to employ self-administration 
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regimes that model escalation and maintenance phases of addiction whilst measuring 
impulsivity on the Go/No-go task during these treatment phases and subsequent short and 
long-term withdrawal. These alternations would give a greater level of scalability in the data 
collected and would therefore be more useful for considering how changes in impulse control 
might facilitate drug addiction in humans.  
The research presented in this thesis has only investigated the effects of amphetamine on one 
dimension of impulsivity in rats, limiting broad interpretations from results in relation to 
impulsivity as a multi-dimensional construct. Sub-dimensions of impulsivity have been 
suggested to be both distinct (Broos et al., 2012b; Reynolds, 2006) and related (Robinson et al., 
2009). It would have been useful, therefore, to examine whether the drug regimes employed 
in this thesis produced similar or differential effects on different behavioural measures of 
impulsivity. In order to address this limitation in future research, it would be useful to employ 
models of both impulsive action and choice in combination with chronic drug treatment. This 
would help to identify whether different dimensions of impulsivity are similarly or differentially 
affected by a specific set of dosing parameters employed within one study.  
Rats were not split into groups of high and low levels of trait impulsivity in this thesis. There is 
a well established relationship exists between trait impulsivity and the effects of amphetamine 
(de Wit, 2000; Eagle et al., 2007; Hand, Fox & Reilly, 2009) and between trait impulsivity and 
drug addiction (Broos et al., 2012; Dalley et al., 2007; Diergaarde et al., 2009; Kollins, 2003; 
Perry, 2005; 2008). Consequently, a limitation of this thesis is that it does not account for how 
individual differences might contribute the effects of amphetamine on impulsivity observed. It 
would have been useful to consider a method of screening trait impulsivity in rats on the 
Go/No-go task, and subsequently to include groups expressing high and low trait impulsivity in 
the studies conducted. In order to avoid this limitation in future research it will be important 
to develop a screening method to detect high and low levels of trait impulsivity on the Go/No-
go symmetrically reinforced task. Previous research investigating the relationship between 
trait response disinhibition and addiction has largely been conducted with the 5CSRTT. In 
consideration of main differences discussed between the 5CSRTT and the Go/No-go task (see 
pages 57-58), once a screening method for detecting trait impulsivity on the Go/No-go 
symmetrically reinforced task has been established, it will be useful to compare how highly 
impulsive rats on this task respond to self-administration models of acquisition, escalation, 
maintenance and relapse. This will help to consider how trait impulsivity on a more direct 
animal model of response inhibition in comparison to the 5CSRTT affects vulnerability to 
distinct stages of addiction.  
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Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 2 4.479 0.050 0.050  
2 Day 3 10.848 0.005 0.033 * 
3 Day 1 11.253 0.004 0.017 * 
 
Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 2 6.206 0.024 0.050 * 
2 Day 1 7.838 0.013 0.033 * 
3 Day 3 14.965 0.001 0.017 ** 
 
Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 1 2.846 0.098 0.050  
2 Day 3 0.289 0.593 0.033  
3 Day 2 2.287 0.137 0.017  
 
Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 1 0.269 0.611 0.050  
2 Day 2 3.059 0.098 0.033  
3 Day 3 12.140 0.003 0.017 ** 
 
Appendix 1: Chapter 4: 4-Day Amphetamine: Corrected p-values using 
the Benjamini-Hochberg correction 
 
Experiment 2a: 4 – Day Amphetamine 
Performance Accuracy 
 
 
 
 
 
 
Speed of responding 
 
 
 
Anticipatory Responding 
 
 
 
  
Table 1b: Total percent correct No-go trials 
Table 1a: Total percent correct  
Table 1c: No-go trial incorrect response latency  
Table 1d: Go trial panel responses  
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Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 60 hrs 0.671 0.425 0.050  
2 108 hrs 0.858 0.368 0.044  
3 84 hrs 4.925 0.041 0.038  
4 132 hrs 5.671 0.030 0.031 * 
5 156 hrs 6.519 0.021 0.025 * 
6 18 hrs 7.694 0.014 0.019 * 
7 36 hrs 12.920 0.002 0.013 ** 
8 12 hrs 40.014 0.000 0.006 *** 
 
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 60 hrs 0.952 0.344 0.050  
2 108 hrs 1.043 0.322 0.044  
3 84 hrs 4.231 0.056 0.038  
4 132 hrs 5.228 0.036 0.031  
5 18 hrs 6.148 0.025 0.025 * 
6 156 hrs 8.762 0.009 0.019 ** 
7 36 hrs 15.368 0.001 0.013 ** 
8 12 hrs 17.893 0.001 0.006 *** 
 
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 108 hrs 0.493 0.493 0.050  
2 84 hrs 1.432 0.249 0.044  
3 132 hrs 1.637 0.219 0.038  
4 156 hrs 2.120 0.165 0.031  
5 36 hrs 4.407 0.052 0.025  
6 12 hrs 5.175 0.037 0.019  
7 18 hrs 5.211 0.036 0.013  
8 60 hrs 10.298 0.005 0.006 ** 
 
Experiment 2b: Withdrawal week one 
Performance Accuracy 
  
 
 
 
 
 
 
 
 
 
Speed of Responding 
 
 
 
 
 
  
Table 1e: Total percent correct. * p < 0.05, ** p< 0.01, *** p < 0.001 
Table 1f: Total percent correct No-go trials. * p < 0.05, ** p< 0.01, *** p < 0.001 
Table 1g: Go trial correct response latency. * p < 0.05, ** p< 0.01, *** p < 0.001 
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Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 12 hrs 2.735 0.101 0.050  
2 84 hrs 0.081 0.777 0.044  
3 36 hrs 0.945 0.333 0.038  
4 108 hrs 1.059 0.305 0.031  
5 132 hrs 1.543 0.216 0.025  
6 60 hrs 2.877 0.092 0.019  
7 156 hrs 2.950 0.088 0.013  
8 18 hrs 6.953 0.009 0.006  
 
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 132 hrs 0.000 0.990 0.050  
2 156 hrs 0.011 0.917 0.044  
3 84 hrs 0.535 0.466 0.038  
4 18 hrs 1.273 0.261 0.031  
5 108 hrs 1.781 0.184 0.025  
6 60 hrs 2.343 0.128 0.019  
7 12 hrs 3.081 0.082 0.013  
8 36 hrs 3.496 0.064 0.006  
 
Index Withdrawal 
Day 
F-Value P-Value Benjamini-Hochberg Correction 
1  Day 10 0.260 0.617 0.050  
2 Day 14 0.469 0.503 0.043  
3 Day 11 1.449 0.246 0.036  
4 Day 9 1.894 0.188 0.029  
5 Day 12 4.070 0.061 0.021  
6 Day 13 4.514 0.050 0.014  
7 Day 8 16.958 0.001 0.007 *** 
 
 
 
 
 
 
Anticipatory Responding 
 
 
 
 
 
Experiment 2c: Withdrawal week two 
Performance Accuracy 
 
 
 
 
 
  
Table 1h: No-go trial magazine latency 
Table 1i: No-go trial early responses 
Table 1j: Total percent correct. * p < 0.05, ** p< 0.01, *** p < 0.001 
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Index Withdrawal 
Day 
F-Value P-Value Benjamini-Hochberg Correction 
1 Day 11 0.086 0.769 0.050  
2 Day 12 0.166 0.685 0.043  
3 Day 14 0.242 0.624 0.036  
4 Day 10 0.718 0.399 0.029  
5 Day 13 1.975 0.163 0.021  
6 Day 8 2.212 0.140 0.014  
7 Day 9 2.265 0.135 0.007  
      
 
Anticipatory Responding  
 
 
 
 
 
  
Table 1k: No-go trial panel responses 
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Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 1 0.007 0.932 0.050  
2 Day 2 0.154 0.696 0.045  
3 Day 3 4.343 0.039 0.040  * 
4 Day 5  5.140 0.025 0.035  * 
5 Day 6 6.420 0.012 0.030  * 
6 Day 4 8.054 0.005 0.025  ** 
7 Day 10 8.873 0.003 0.020  ** 
8 Day 8 11.733 0.001 0.015 *** 
9 Day 9  11.847 0.001 0.010  *** 
10 Day 7 15.605 0.000 0.005  *** 
 
Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 2 0.679 0.422 0.050  
2 Day 1 1.322 0.267 0.045  
3 Day 5 3.362 0.085 0.040   
4 Day 6  3.645 0.074 0.035   
5 Day 3 4.473 0.050 0.030   
6 Day 7 6.127 0.024 0.025  * 
7 Day 9 6.845 0.018 0.020  * 
8 Day 10 8.214 0.011 0.015 * 
9 Day 8  8.297 0.011 0.010  * 
10 Day 4 8.398 0.010 0.005  ** 
 
Appendix 2: Chapter 5: 11-Day Amphetamine: Corrected p-values 
using the Benjamini-Hochberg correction 
 
Experiment  3a:  11 – Day Amphetamine 
Performance Accuracy  
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2a: Total percent correct. * p < 0.05, ** p< 0.01, *** p < 0.001 
Table 2b: Total percent correct No-go trials. * p < 0.05, ** p< 0.01, *** p < 0.001 
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Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 1 0.077 0.786 0.050  
2 Day 6 0.647 0.433 0.045  
3 Day 2 0.826 0.377 0.040   
4 Day 4  2.072 0.169 0.035   
5 Day 5 2.561 0.129 0.030   
6 Day 3 2.654 0.123 0.025   
7 Day 8 5.048 0.039 0.020   
8 Day 9 7.031 0.017 0.015  
9 Day 10  7.078 0.017 0.010   
10 Day 7 7.838 0.013 0.005   
 
Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 4 0.005 0.944 0.050  
2 Day 6 0.193 0.667 0.045  
3 Day 2 0.957 0.343 0.040   
4 Day 3 1.794 0.199 0.035   
5 Day 1 1.958 0.181 0.030   
6 Day 5 2.074 0.169 0.025   
7 Day 10 2.956 0.105 0.020   
8 Day 8 3.316 0.087 0.015  
9 Day 7  13.982 0.002 0.010  ** 
10 Day 9 15.649 0.001 0.005  *** 
 
Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 4 0.098 0.758 0.050  
2 Day 1 0.516 0.483 0.045  
3 Day 6 0.751 0.399 0.040   
4 Day 2 0.922 0.351 0.035   
5 Day 8 1.353 0.262 0.030   
6 Day 5 1.572 0.228 0.025   
7 Day 10 2.162 0.161 0.020   
8 Day 3 5.116 0.038 0.015  
9 Day 7 11.341 0.004 0.010  ** 
10 Day 9 13.973 0.002 0.005  *** 
 
Speed of Responding  
 
 
 
 
 
 
 
 
 
 
 
 
Anticipatory Responding 
 
 
 
 
 
 
 
Table 2c: Go trial correct response latency. 
Table 2d: No-go trial magazine latency. * p < 0.05, ** p< 0.01, *** p < 0.001 
Table 2e: Go trial early responses. * p < 0.05, ** p< 0.01, *** p < 0.001 
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Index Drug Day F-Value P-Value Benjamini-Hochberg Correction 
1 Day 6 0.120 0.733 0.050  
2 Day 10 0.200 0.660 0.045  
3 Day 8 0.219 0.646 0.040   
4 Day 1 0.232 0.636 0.035   
5 Day 3 0.701 0.414 0.030   
6 Day 2 1.652 0.216 0.025   
7 Day 4 1.788 0.199 0.020   
8 Day 5 1.840 0.193 0.015  
9 Day 7 2.419 0.138 0.010   
10 Day 9 4.685 0.044 0.005   
 
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 132 hrs 0.039 0.845 0.050  
2 156 hrs 1.285 0.274 0.044  
3 84 hrs 5.123 0.038 0.039  * 
4 108 hrs  6.880 0.018 0.033  * 
5 36 hrs 8.716 0.009 0.028  ** 
6 18 hrs 8.868 0.007 0.022  ** 
7 60 hrs 9.793 0.006 0.017  ** 
8 42 hrs 12.217 0.003 0.011 ** 
9 12 hrs 14.694 0.001 0.006  *** 
 
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 132 hrs 0.021 0.886 0.050  
2 156 hrs 1.656 0.217 0.044  
3 108 hrs 3.603 0.076 0.039   
4 84 hrs  3.729 0.071 0.033   
5 60 hrs 4.641 0.047 0.028   
6 42 hrs 4.667 0.046 0.022   
7 18 hrs 6.340 0.023 0.017   
8 36 hrs 7.856 0.013 0.011  
9 12 hrs 9.103 0.008 0.006   
 
 
 
 
 
 
 
 
Experiment 3b: Withdrawal week one 
Performance Accuracy 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2f: Go trial panel responses. 
Table 2g: Total percent correct. * p < 0.05, ** p< 0.01, *** p < 0.001 
Table 2h: Total percent correct No-go trials. * p < 0.05, ** p< 0.01, *** p < 0.001 
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Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 156 hrs 0.127 0.727 0.050  
2 42 hrs 0.767 0.934 0.044  
3 108 hrs 1.214 0.287 0.039  
4 84 hrs 2.063 0.170 0.033  
5 132 hrs 2.526 0.132 0.028  
6 36 hrs 3.946 0.064 0.022  
7 60 hrs 4.302 0.055 0.017  
8 18 hrs 5.903 0.027 0.011  
9 12 hrs 6.207 0.024 0.006  
 
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 156 hrs 0.397 0.539 0.050  
2 132 hrs 0.538 0.474 0.044  
3 36 hrs 0.694 0.417 0.039  
4 12 hrs 2.293 0.149 0.033  
5 60 hrs 2.516 0.132 0.028  
6 42 hrs 2.668 0.122 0.022  
7 84 hrs 2.743 0.117 0.017  
8 108 hrs 7.042 0.017 0.011  
9 18 hrs 13.718 0.002 0.006 ** 
 
Speed of Responding 
 
  
 
 
 
 
 
 
 
 
 
 
Anticipatory Responding 
 
 
  
Index Withdrawal 
Hour 
F-Value P-Value Benjamini-Hochberg Correction 
1 108 hrs 0.151 0.703 0.050  
2 156 hrs 1.067 0.317 0.044  
3 18 hrs 1.159 0.298 0.039  
4 42 hrs 2.268 0.152 0.033  
5 132 hrs 2.230 0.147 0.028  
6 84 hrs 3.453 0.082 0.022  
7 60 hrs 4.675 0.046 0.017  
8 36 hrs 5.268 0.036 0.011  
9 12 hrs 6.821 0.019 0.006  
 
Table 2i: Go trial correct response latency. 
Table 2j: No-go trial incorrect response latency. * p < 0.05, ** p< 0.01, *** p < 0.001 
Table 2k: Go trial early responses. 
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Animal Left Hemisphere LH 
Location 
(mm) 
Right Hemisphere RH 
Location 
(mm) 
1 
 
+ 1.56 
 
1.44 
2 
 
+ 2.28 
 
2.52 
3 
 
+ 1.32 
 
1.56 
4 
 
+ 1.68 
 
1.80 
5 
 
+ 1.56 
 
1.56 
Appendix 3: Experiment 4: Photographs of cannlue placements 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3: Photographs showing the location of injector tips (mm from bregma) for each 
animal treated with eticlopride infusions into the NAcb core. 
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Animal Left Hemisphere LH 
Location 
(mm) 
Right Hemisphere RH 
Location 
(mm) 
1 
 
+ 1.92 
 
+ 2.04 
2 
 
+ 1.68h 
 
+ 1.68 -     
1.56 
3 
 
+ 1.08 -
0.96 
 
+ 1.08 
4 
 
+ 1.68 
 
+ 1.80 
5 
 
+ 1.68 
 
+ 1.56 
Appendix 4: Experiment 5: Photographs of cannlue placements 
 
 
 
 
 
  
Table 4: Photographs showing the location of injector tips (mm from bregma) for each animal 
treated with eticlopride infusions into the NAcb core with systemic amphetamine. 
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+ 1.56 
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+ 1.08 
 
+ 1.32 
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+ 1.44 
 
+ 1.44 
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Animal Left Hemisphere LH 
Location 
Right Hemisphere RH 
Location 
1 
 
+2.28 
 
+2.04 
2 
 
+1.20 
 
 
 
 
 
 
+1.20 
3 
 
+1.44 
 
 
 
 
 
+1.56 
4 
 
+2.04 
 
 
 
 
 
+2.24 
5 
 
+1.44-1.32 
 
 
 
 
+1.56-1.44 
6 
 
+1.68 
 
+1.68 
7 
 
+1.92 
 
 
+2.16 
Appendix 5: Experiment 6: Photographs of cannlue placements 
 
 
  
Table 5: Photographs showing the location of injector tips (mm from bregma) for each 
animal treated with muscimol infusions into the NAcb core. 
 
285 
 
Animal Left Hemisphere LH  
Location 
Right Hemisphere RH  
Location 
1 
 
+2.04 
 
+2.04 
2 
 
+1.68 
 
+1.56 
3 
 
+1.20 
 
+1.44 
4 
 
+1.80 
 
+1.92 
5 
 
+2.28 
 
+1.92 
6 
 
+2.16 
 
+2.28 
Appendix 6: Experiment 7: Photographs of cannlue placements 
 
 
 
 
Table 6: Photographs showing the location of injector tips (mm from bregma) for each animal 
treated with muscimol infusions into the NAcb core with systemic amphetamine. 
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+1.68 
 
+1.68 
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Appendix 7: Experiment 7: No-go trial accuracy following muscimol 
and systemic amphetamine treatment  
 
 Figures 7a: No-go trial accuracy in (n = 4) rat that did not display full behavioural reversal of 
amphetamine induced impulsivity. Figure 7b: No-go trial accuracy in (n = 5) rats that did 
display full behavioural reversal of amphetamine induced impulsivity. 
Fig. 7a Fig. 7b 
